<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6EC9A5B6-77FE-4FBD-9788-DE00A59CE4EB"><gtr:id>6EC9A5B6-77FE-4FBD-9788-DE00A59CE4EB</gtr:id><gtr:name>University Hospital Vall d'Hebron</gtr:name><gtr:address><gtr:line1>Passeig Vall d'Hebron</gtr:line1><gtr:line2>119-129</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/199BD811-2A70-46C2-A63C-2AB1DE931BBE"><gtr:id>199BD811-2A70-46C2-A63C-2AB1DE931BBE</gtr:id><gtr:name>British Transplantation Society (BTS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/28DF10CD-6250-442A-804C-A8710CF218D1"><gtr:id>28DF10CD-6250-442A-804C-A8710CF218D1</gtr:id><gtr:name>University of Bern</gtr:name><gtr:address><gtr:line1>Universitat Bern</gtr:line1><gtr:line2>Sidlerstrasse 5</gtr:line2><gtr:line4>Bern</gtr:line4><gtr:line5>CH-3012</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/76EDEF55-C6B3-41B8-967E-AAAE9C2BD373"><gtr:id>76EDEF55-C6B3-41B8-967E-AAAE9C2BD373</gtr:id><gtr:name>Chemocentryx</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/42B56A32-9194-468C-A790-BE55133838A6"><gtr:id>42B56A32-9194-468C-A790-BE55133838A6</gtr:id><gtr:name>University of Hamburg</gtr:name><gtr:address><gtr:line1>ZMK</gtr:line1><gtr:line2>Blunderstrasse</gtr:line2><gtr:line4>Hamburg</gtr:line4><gtr:line5>20146</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8"><gtr:id>3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8</gtr:id><gtr:name>Stanford University</gtr:name><gtr:address><gtr:line1>450 Serra Mall</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B2EE12FB-8E49-4F6A-8073-DF35FAF50581"><gtr:id>B2EE12FB-8E49-4F6A-8073-DF35FAF50581</gtr:id><gtr:name>Emory University</gtr:name><gtr:address><gtr:line1>201 Dowman Drive</gtr:line1><gtr:line4>Atlanta</gtr:line4><gtr:line5>Ga 30322</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E20F47CA-8AB4-4F4D-A90D-A290834C65FF"><gtr:id>E20F47CA-8AB4-4F4D-A90D-A290834C65FF</gtr:id><gtr:name>University Hospital Coventry NHS Trust</gtr:name><gtr:address><gtr:line1>Clifford Bridge Road</gtr:line1><gtr:line2>Walsgrave</gtr:line2><gtr:postCode>CV2 2DX</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E37A18E2-1E33-4ACE-BCFA-7DAD0DAF1261"><gtr:id>E37A18E2-1E33-4ACE-BCFA-7DAD0DAF1261</gtr:id><gtr:name>University of Regensburg</gtr:name><gtr:address><gtr:line1>University of Regensburg</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB"><gtr:id>AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB</gtr:id><gtr:name>Oxford University Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Churchill Site</gtr:line1><gtr:line2>Old Road</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX3 7LJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/337901E4-D9A7-438B-B275-0631F5F384A3"><gtr:id>337901E4-D9A7-438B-B275-0631F5F384A3</gtr:id><gtr:name>Royal Liverpool and Broadgreen University Hospital NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/94FB5AD0-A6E5-4A49-8022-359A689D4259"><gtr:id>94FB5AD0-A6E5-4A49-8022-359A689D4259</gtr:id><gtr:name>Washington University in St Louis</gtr:name><gtr:address><gtr:line1>Washington University in St Louis</gtr:line1><gtr:line2>One Brookings Drive</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A2F7FAD2-C83C-401F-93E2-B03C73D0101F"><gtr:id>A2F7FAD2-C83C-401F-93E2-B03C73D0101F</gtr:id><gtr:name>Pure Protein LLC</gtr:name><gtr:address><gtr:line1>c/o Emergent Technologies, Inc., Manager</gtr:line1><gtr:line2>11412 Bee Caves Road</gtr:line2><gtr:line3>Suite 300</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/60EC89C3-5A8E-40B6-8030-7D2502D8A36A"><gtr:id>60EC89C3-5A8E-40B6-8030-7D2502D8A36A</gtr:id><gtr:name>Epsom and St Helier University Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E832F6A6-3277-4F25-9336-6E314913CB23"><gtr:id>E832F6A6-3277-4F25-9336-6E314913CB23</gtr:id><gtr:name>Hull and East Yorkshire Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/91363DD3-3DEA-4D93-93B7-7A44176DADCE"><gtr:id>91363DD3-3DEA-4D93-93B7-7A44176DADCE</gtr:id><gtr:name>Catholic University of Louvain</gtr:name><gtr:address><gtr:line1>3 Place L Pasteur</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9E90A72A-4A7B-4D2D-854B-4DE60094219A"><gtr:id>9E90A72A-4A7B-4D2D-854B-4DE60094219A</gtr:id><gtr:name>St James's University Hospital (Jimmy's)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AB59C39C-D551-4BCF-9AA1-1C32080BEFD5"><gtr:id>AB59C39C-D551-4BCF-9AA1-1C32080BEFD5</gtr:id><gtr:name>Zhejiang University</gtr:name><gtr:address><gtr:line1>388 Yuhangtang Road</gtr:line1><gtr:postCode>310058</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5A8E328E-8A10-45F8-9C51-6BD66C215CC0"><gtr:id>5A8E328E-8A10-45F8-9C51-6BD66C215CC0</gtr:id><gtr:name>Nottingham University Hospital NHS Trust</gtr:name><gtr:address><gtr:line1>Nottingham University HospitalMedical Physics and clinical engineeringQMC Campus</gtr:line1><gtr:city>Nottingham</gtr:city><gtr:postCode>NG7 2UH</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FEC5FE7D-C329-4D18-9A3A-FAC03968DF93"><gtr:id>FEC5FE7D-C329-4D18-9A3A-FAC03968DF93</gtr:id><gtr:name>San Francisco University</gtr:name><gtr:address><gtr:line1>2130 Fulton Street</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9218106A-E8CE-46A5-AABC-B4C8ED148690"><gtr:id>9218106A-E8CE-46A5-AABC-B4C8ED148690</gtr:id><gtr:name>University of Amsterdam</gtr:name><gtr:address><gtr:line1>Liaison Office</gtr:line1><gtr:line2>PO Box 19268</gtr:line2><gtr:line4>Amsterdam</gtr:line4><gtr:line5>Amsterdam</gtr:line5><gtr:postCode>1000 GG</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AB000219-B681-4861-853A-EB9CDE05AEB3"><gtr:id>AB000219-B681-4861-853A-EB9CDE05AEB3</gtr:id><gtr:name>Belfast Health and Social Care Trust</gtr:name><gtr:address><gtr:line1>A Floor Belfast City Hospital
Lisburn Road</gtr:line1><gtr:city>Belfast</gtr:city><gtr:postCode>BT12 6BA</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2070F714-C13B-417D-B059-44B511471FF2"><gtr:id>2070F714-C13B-417D-B059-44B511471FF2</gtr:id><gtr:name>Institute for Clinical and Experimental Medicine (IKEM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C"><gtr:id>7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C</gtr:id><gtr:name>Academic Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DAEB2B76-3CE2-4F67-BE52-859227BD2B8F"><gtr:id>DAEB2B76-3CE2-4F67-BE52-859227BD2B8F</gtr:id><gtr:name>Great Ormond Street Hospital (GOSH)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8BFE03FB-6AF2-46C4-942E-1262EFD09774"><gtr:id>8BFE03FB-6AF2-46C4-942E-1262EFD09774</gtr:id><gtr:name>Royal Free London NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Pond Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW3 2QG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0CAFBCA9-D47B-49C7-836E-E7F61BB6F4DE"><gtr:id>0CAFBCA9-D47B-49C7-836E-E7F61BB6F4DE</gtr:id><gtr:name>Nantes University Hospital - CHU Nantes</gtr:name><gtr:address><gtr:line1>5 allee de l'ile Gloriette</gtr:line1><gtr:postCode>44093</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BCD05341-5D48-43F1-A505-C169496883A1"><gtr:id>BCD05341-5D48-43F1-A505-C169496883A1</gtr:id><gtr:name>University of Hong Kong</gtr:name><gtr:address><gtr:line1>Pok Fu Lam Road</gtr:line1><gtr:line4>Hong Kong</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Hong Kong</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F463A0E1-E89E-406B-B803-760625885B6C"><gtr:id>F463A0E1-E89E-406B-B803-760625885B6C</gtr:id><gtr:name>Hospital Universitario La Paz</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A06FED91-B1C2-4601-A8BC-7FDF7DF5EF3D"><gtr:id>A06FED91-B1C2-4601-A8BC-7FDF7DF5EF3D</gtr:id><gtr:name>University Libre Bruxelles (Universit? Libre de Bruxelles ULB)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5ABCC373-8D79-4794-9EAD-C1BAFAA2F5D7"><gtr:id>5ABCC373-8D79-4794-9EAD-C1BAFAA2F5D7</gtr:id><gtr:name>Milenia Biotec GmbH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/59D738F7-A1E5-4C15-AD09-3275AB1D723B"><gtr:id>59D738F7-A1E5-4C15-AD09-3275AB1D723B</gtr:id><gtr:name>University of Lubeck</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BE7A2CDE-C041-4244-A92D-C4DC327E14B7"><gtr:id>BE7A2CDE-C041-4244-A92D-C4DC327E14B7</gtr:id><gtr:name>Cambridge University Hospitals</gtr:name><gtr:address><gtr:line1>Addenbrooke's Hospital
Hills Road</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB2 0QQ</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2C1C85FB-77AC-4019-9363-4A2E4A909E16"><gtr:id>2C1C85FB-77AC-4019-9363-4A2E4A909E16</gtr:id><gtr:name>Cardiff &amp; Vale University Health Board</gtr:name><gtr:address><gtr:line1>Heath Park</gtr:line1><gtr:line4>Cardiff</gtr:line4><gtr:postCode>CF14 4XW</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/273BA583-03B3-4054-9371-E37F72293F80"><gtr:id>273BA583-03B3-4054-9371-E37F72293F80</gtr:id><gtr:name>Apellis Pharmaceutical</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B0AEF9E8-9618-4AAB-B886-EF5B5109840B"><gtr:id>B0AEF9E8-9618-4AAB-B886-EF5B5109840B</gtr:id><gtr:name>Royal Society of Edinburgh (RSE)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C5F5DCA-59E7-4987-AE32-A75A36944391"><gtr:id>9C5F5DCA-59E7-4987-AE32-A75A36944391</gtr:id><gtr:name>Nantes University</gtr:name><gtr:address><gtr:line1>Nantes University</gtr:line1><gtr:line2>1 Quai de Tourville</gtr:line2><gtr:line3>BP 13522</gtr:line3><gtr:line4>Nantes</gtr:line4><gtr:line5>F-44035</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A9426E3-7F35-48FC-BD72-3776C8F90A4A"><gtr:id>4A9426E3-7F35-48FC-BD72-3776C8F90A4A</gtr:id><gtr:name>Grants Admin Office</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9F389987-5CF8-4C31-B2E6-C5EE5CA19D4E"><gtr:id>9F389987-5CF8-4C31-B2E6-C5EE5CA19D4E</gtr:id><gtr:name>St George's Healthcare NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A"><gtr:id>9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A</gtr:id><gtr:name>Guy's and St Thomas' NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Westminster Bridge Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 7EH</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B97171FF-E5B1-44D2-983C-E83E607CCC7E"><gtr:id>B97171FF-E5B1-44D2-983C-E83E607CCC7E</gtr:id><gtr:name>Rigel Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A19A6372-A1A2-4F0D-AED7-7110E0A05C9B"><gtr:id>A19A6372-A1A2-4F0D-AED7-7110E0A05C9B</gtr:id><gtr:name>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EDC7316F-A897-4CBC-BA1F-30CE73C9FEFD"><gtr:id>EDC7316F-A897-4CBC-BA1F-30CE73C9FEFD</gtr:id><gtr:name>Astellas Pharma</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8B7C8B1B-87E1-482C-B0C7-5C9D4EEE8355"><gtr:id>8B7C8B1B-87E1-482C-B0C7-5C9D4EEE8355</gtr:id><gtr:name>European Cooperation in Science and Technology (COST)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D121F2E-1C43-4CFF-ABC0-A0117386CF3F"><gtr:id>5D121F2E-1C43-4CFF-ABC0-A0117386CF3F</gtr:id><gtr:name>Opsona Therapeutics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F7F8EA22-4A18-4B69-AA3D-A0E9C0B0EE7C"><gtr:id>F7F8EA22-4A18-4B69-AA3D-A0E9C0B0EE7C</gtr:id><gtr:name>ALTA</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F5569A12-0A1B-4474-B608-84BB0C44B3A7"><gtr:id>F5569A12-0A1B-4474-B608-84BB0C44B3A7</gtr:id><gtr:name>University of Minnesota</gtr:name><gtr:address><gtr:line1>127 Vincent Hall</gtr:line1><gtr:line2>206 Church St. S.E</gtr:line2><gtr:line4>Minneapolis</gtr:line4><gtr:line5>MN 55455</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D545C73D-780E-4D1A-B5CD-1D6630A8CCCA"><gtr:id>D545C73D-780E-4D1A-B5CD-1D6630A8CCCA</gtr:id><gtr:name>Royal London Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68EDC425-4126-4E27-958A-9A2DE10729BF"><gtr:id>68EDC425-4126-4E27-958A-9A2DE10729BF</gtr:id><gtr:name>Immune Tolerance Network</gtr:name><gtr:address><gtr:line1>Suite 430 - 3333 California St</gtr:line1><gtr:postCode>CA 94118</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E68BE577-6C17-48CE-B65C-24C477BB8AE9"><gtr:id>E68BE577-6C17-48CE-B65C-24C477BB8AE9</gtr:id><gtr:name>Yeshiva University</gtr:name><gtr:address><gtr:line1>500 West 185th Street</gtr:line1><gtr:postCode>10033</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E2174C7-CECC-4A37-9ED0-C16D5B6A585B"><gtr:id>4E2174C7-CECC-4A37-9ED0-C16D5B6A585B</gtr:id><gtr:name>NHS England</gtr:name><gtr:address><gtr:line1>NHS South of England</gtr:line1><gtr:line2>NHS Commissioning Board</gtr:line2><gtr:line3>PO Box 16728</gtr:line3><gtr:postCode>B97 9PT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C3992259-C19F-4FE5-9C01-210C819D7264"><gtr:id>C3992259-C19F-4FE5-9C01-210C819D7264</gtr:id><gtr:name>Yale University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/88C5F7F9-8DCC-41C9-BC4F-F37DA01075C7"><gtr:id>88C5F7F9-8DCC-41C9-BC4F-F37DA01075C7</gtr:id><gtr:name>University of East Anglia</gtr:name><gtr:address><gtr:line1>Earlham Road</gtr:line1><gtr:line4>Norwich</gtr:line4><gtr:line5>Norfolk</gtr:line5><gtr:postCode>NR4 7TJ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A01FD660-9141-46EE-9FFB-9236CE7FBFB4"><gtr:id>A01FD660-9141-46EE-9FFB-9236CE7FBFB4</gtr:id><gtr:name>University of Colorado (Denver)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6442075B-9FCD-4065-8EE0-56534DEAC1A5"><gtr:id>6442075B-9FCD-4065-8EE0-56534DEAC1A5</gtr:id><gtr:name>Genome Identification Diagnostics GmbH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E4F6BEA-8E66-490E-B61F-8CBB33116179"><gtr:id>5E4F6BEA-8E66-490E-B61F-8CBB33116179</gtr:id><gtr:name>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5364C2EA-5FF7-4563-AB28-F5ECD736CBFC"><gtr:id>5364C2EA-5FF7-4563-AB28-F5ECD736CBFC</gtr:id><gtr:name>University of Mons</gtr:name><gtr:address><gtr:line1>20 Place du Parc</gtr:line1><gtr:line4>Mons</gtr:line4><gtr:postCode>B7000</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/13613115-E290-45AC-BAA6-83D88728749C"><gtr:id>13613115-E290-45AC-BAA6-83D88728749C</gtr:id><gtr:name>Xian Jiaotong University</gtr:name><gtr:address><gtr:line1>28 Xianningxi West Road</gtr:line1><gtr:line2>710049</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF8EDD94-E846-412E-B59C-51D4D000D9E2"><gtr:id>EF8EDD94-E846-412E-B59C-51D4D000D9E2</gtr:id><gtr:name>Nagoya University</gtr:name><gtr:address><gtr:line1>Furo-cho</gtr:line1><gtr:line2>Chikusa-ku</gtr:line2><gtr:line4>Nagoya City</gtr:line4><gtr:line5>Aichi Prefecture</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF46D1B5-9EE9-459F-8D6D-68C3987370BD"><gtr:id>EF46D1B5-9EE9-459F-8D6D-68C3987370BD</gtr:id><gtr:name>University Hospitals of Leicester NHS</gtr:name><gtr:address><gtr:line1>Leicester Royal Infirmary</gtr:line1><gtr:line2>Infirmary Square</gtr:line2><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 5WW</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BF06ABFB-9547-484C-84F9-4110ED8759B7"><gtr:id>BF06ABFB-9547-484C-84F9-4110ED8759B7</gtr:id><gtr:name>Manchester University NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Central Manchester University Hospitals NHS Foundation Trust,Manchester Royal Infirmary,Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9WL</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1B0161A9-9EC7-4A57-AC51-97057219C9DC"><gtr:id>1B0161A9-9EC7-4A57-AC51-97057219C9DC</gtr:id><gtr:name>Plymouth Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D9E99D31-A5B6-43CF-83F5-20D97EBEC1D1"><gtr:id>D9E99D31-A5B6-43CF-83F5-20D97EBEC1D1</gtr:id><gtr:name>Cellogic GmbH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D3D8A940-2BB9-4960-A5F6-1F54554C34FA"><gtr:id>D3D8A940-2BB9-4960-A5F6-1F54554C34FA</gtr:id><gtr:name>Portsmouth Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E9DEFAE4-A354-4213-AB9D-FAA2047387F6"><gtr:id>E9DEFAE4-A354-4213-AB9D-FAA2047387F6</gtr:id><gtr:name>NHS Health Scotland</gtr:name><gtr:address><gtr:line1>NHS Health Scotland</gtr:line1><gtr:line2>Canaan Lane</gtr:line2><gtr:postCode>EH10 4SG</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7C3729AA-933E-4E5E-A502-0DFA7E6E98AD"><gtr:id>7C3729AA-933E-4E5E-A502-0DFA7E6E98AD</gtr:id><gtr:name>Alexion Pharmaceuticals</gtr:name><gtr:address><gtr:line1>352 Knotter Drive</gtr:line1><gtr:postCode>CT 06410</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3545CDC8-076D-4BD8-B370-8E558F9D46EE"><gtr:id>3545CDC8-076D-4BD8-B370-8E558F9D46EE</gtr:id><gtr:name>Leeds Teaching Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Beckett Street</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS9 7TF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2718B5D3-B880-4C4C-A4A3-0E639BDA800E"><gtr:id>2718B5D3-B880-4C4C-A4A3-0E639BDA800E</gtr:id><gtr:name>BMI The Beaumont Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/47F25582-F481-4297-B1C4-6C1BCF70818B"><gtr:id>47F25582-F481-4297-B1C4-6C1BCF70818B</gtr:id><gtr:name>Beth Israel Deaconess Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E777F7E-8B7E-406A-87FB-39A7026F891F"><gtr:id>4E777F7E-8B7E-406A-87FB-39A7026F891F</gtr:id><gtr:name>Uppsala University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0792034E-7B08-4D03-A4E1-0F2F89D82900"><gtr:id>0792034E-7B08-4D03-A4E1-0F2F89D82900</gtr:id><gtr:name>Immunotech S.A.S.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C705F4C9-3E9D-4C2A-90B0-49C636E962EE"><gtr:id>C705F4C9-3E9D-4C2A-90B0-49C636E962EE</gtr:id><gtr:name>Barts Health NHS Trust</gtr:name><gtr:address><gtr:line1>9 Prescot Street
Aldgate</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>E1 8PR</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/134B8A7B-4AA2-4DC1-91FC-0A4D338606E8"><gtr:id>134B8A7B-4AA2-4DC1-91FC-0A4D338606E8</gtr:id><gtr:name>University of Dresden</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82"><gtr:id>9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82</gtr:id><gtr:name>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F8ECC47E-FF10-432B-A5B1-38D2BD36EEF4"><gtr:id>F8ECC47E-FF10-432B-A5B1-38D2BD36EEF4</gtr:id><gtr:name>Great North Children's Hospital (GNCH)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BF056F42-5CA1-4C02-A8D3-AF6A9AA1A2FD"><gtr:id>BF056F42-5CA1-4C02-A8D3-AF6A9AA1A2FD</gtr:id><gtr:name>Salford Royal NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Cleveland House
Salford</gtr:line1><gtr:city>Greater Manchester</gtr:city><gtr:postCode>M6 8AL</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3BB202F-E9D1-4FB6-B29C-A98ED2C9AECF"><gtr:id>E3BB202F-E9D1-4FB6-B29C-A98ED2C9AECF</gtr:id><gtr:name>University of Seville</gtr:name><gtr:address><gtr:line1>Avda</gtr:line1><gtr:line2>Reina Mercedes, S/n</gtr:line2><gtr:line4>E-41012 Seville</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B"><gtr:id>46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B</gtr:id><gtr:name>Bristol-Myers Squibb</gtr:name><gtr:address><gtr:line1>Bristol-Myers Squibb</gtr:line1><gtr:line2>311 Pennington Rocky Hill Road</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD21B8FC-26A6-4A3A-9A23-207B6667CB41"><gtr:id>DD21B8FC-26A6-4A3A-9A23-207B6667CB41</gtr:id><gtr:name>University of Pittsburgh</gtr:name><gtr:address><gtr:line1>University of Pittsburgh</gtr:line1><gtr:line4>Pittsburgh</gtr:line4><gtr:line5>Pennsylvania</gtr:line5><gtr:postCode>PA 15260</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8FEA6C69-4633-4CAE-B920-88F6F7F57AA7"><gtr:id>8FEA6C69-4633-4CAE-B920-88F6F7F57AA7</gtr:id><gtr:name>Chelsea Therapeutics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DAFB4671-B85C-4383-B20F-8699CB229939"><gtr:id>DAFB4671-B85C-4383-B20F-8699CB229939</gtr:id><gtr:name>Catalan Health Institute (ICS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/53DD51C1-ACB9-4626-9BD6-81674D63471B"><gtr:id>53DD51C1-ACB9-4626-9BD6-81674D63471B</gtr:id><gtr:name>TcLand Expression</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37D03EDF-A585-4D7B-8E46-7A48F11DA5DC"><gtr:id>37D03EDF-A585-4D7B-8E46-7A48F11DA5DC</gtr:id><gtr:name>University Hospital Regensburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6ED98605-E2D0-401D-A73F-A9923F6C5D9D"><gtr:id>6ED98605-E2D0-401D-A73F-A9923F6C5D9D</gtr:id><gtr:name>East Kent Hospitals University NHS Foundation Trust</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Transplantation Immunology &amp; Mucosal Bio</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6EC9A5B6-77FE-4FBD-9788-DE00A59CE4EB"><gtr:id>6EC9A5B6-77FE-4FBD-9788-DE00A59CE4EB</gtr:id><gtr:name>University Hospital Vall d'Hebron</gtr:name><gtr:address><gtr:line1>Passeig Vall d'Hebron</gtr:line1><gtr:line2>119-129</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/199BD811-2A70-46C2-A63C-2AB1DE931BBE"><gtr:id>199BD811-2A70-46C2-A63C-2AB1DE931BBE</gtr:id><gtr:name>British Transplantation Society (BTS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/28DF10CD-6250-442A-804C-A8710CF218D1"><gtr:id>28DF10CD-6250-442A-804C-A8710CF218D1</gtr:id><gtr:name>University of Bern</gtr:name><gtr:address><gtr:line1>Universitat Bern</gtr:line1><gtr:line2>Sidlerstrasse 5</gtr:line2><gtr:line4>Bern</gtr:line4><gtr:line5>CH-3012</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/76EDEF55-C6B3-41B8-967E-AAAE9C2BD373"><gtr:id>76EDEF55-C6B3-41B8-967E-AAAE9C2BD373</gtr:id><gtr:name>Chemocentryx</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/42B56A32-9194-468C-A790-BE55133838A6"><gtr:id>42B56A32-9194-468C-A790-BE55133838A6</gtr:id><gtr:name>University of Hamburg</gtr:name><gtr:address><gtr:line1>ZMK</gtr:line1><gtr:line2>Blunderstrasse</gtr:line2><gtr:line4>Hamburg</gtr:line4><gtr:line5>20146</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8"><gtr:id>3DF2F8DD-33A5-44A1-81D7-347A6C2FBDC8</gtr:id><gtr:name>Stanford University</gtr:name><gtr:address><gtr:line1>450 Serra Mall</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B2EE12FB-8E49-4F6A-8073-DF35FAF50581"><gtr:id>B2EE12FB-8E49-4F6A-8073-DF35FAF50581</gtr:id><gtr:name>Emory University</gtr:name><gtr:address><gtr:line1>201 Dowman Drive</gtr:line1><gtr:line4>Atlanta</gtr:line4><gtr:line5>Ga 30322</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E20F47CA-8AB4-4F4D-A90D-A290834C65FF"><gtr:id>E20F47CA-8AB4-4F4D-A90D-A290834C65FF</gtr:id><gtr:name>University Hospital Coventry NHS Trust</gtr:name><gtr:address><gtr:line1>Clifford Bridge Road</gtr:line1><gtr:line2>Walsgrave</gtr:line2><gtr:postCode>CV2 2DX</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E37A18E2-1E33-4ACE-BCFA-7DAD0DAF1261"><gtr:id>E37A18E2-1E33-4ACE-BCFA-7DAD0DAF1261</gtr:id><gtr:name>University of Regensburg</gtr:name><gtr:address><gtr:line1>University of Regensburg</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB"><gtr:id>AE6EAB1A-CC2F-4FDB-A57F-41E76D78ACAB</gtr:id><gtr:name>Oxford University Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Churchill Site</gtr:line1><gtr:line2>Old Road</gtr:line2><gtr:line3>Headington</gtr:line3><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX3 7LJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/337901E4-D9A7-438B-B275-0631F5F384A3"><gtr:id>337901E4-D9A7-438B-B275-0631F5F384A3</gtr:id><gtr:name>Royal Liverpool and Broadgreen University Hospital NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/94FB5AD0-A6E5-4A49-8022-359A689D4259"><gtr:id>94FB5AD0-A6E5-4A49-8022-359A689D4259</gtr:id><gtr:name>Washington University in St Louis</gtr:name><gtr:address><gtr:line1>Washington University in St Louis</gtr:line1><gtr:line2>One Brookings Drive</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A2F7FAD2-C83C-401F-93E2-B03C73D0101F"><gtr:id>A2F7FAD2-C83C-401F-93E2-B03C73D0101F</gtr:id><gtr:name>Pure Protein LLC</gtr:name><gtr:address><gtr:line1>c/o Emergent Technologies, Inc., Manager</gtr:line1><gtr:line2>11412 Bee Caves Road</gtr:line2><gtr:line3>Suite 300</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/60EC89C3-5A8E-40B6-8030-7D2502D8A36A"><gtr:id>60EC89C3-5A8E-40B6-8030-7D2502D8A36A</gtr:id><gtr:name>Epsom and St Helier University Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E832F6A6-3277-4F25-9336-6E314913CB23"><gtr:id>E832F6A6-3277-4F25-9336-6E314913CB23</gtr:id><gtr:name>Hull and East Yorkshire Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/91363DD3-3DEA-4D93-93B7-7A44176DADCE"><gtr:id>91363DD3-3DEA-4D93-93B7-7A44176DADCE</gtr:id><gtr:name>Catholic University of Louvain</gtr:name><gtr:address><gtr:line1>3 Place L Pasteur</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9E90A72A-4A7B-4D2D-854B-4DE60094219A"><gtr:id>9E90A72A-4A7B-4D2D-854B-4DE60094219A</gtr:id><gtr:name>St James's University Hospital (Jimmy's)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB59C39C-D551-4BCF-9AA1-1C32080BEFD5"><gtr:id>AB59C39C-D551-4BCF-9AA1-1C32080BEFD5</gtr:id><gtr:name>Zhejiang University</gtr:name><gtr:address><gtr:line1>388 Yuhangtang Road</gtr:line1><gtr:postCode>310058</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A8E328E-8A10-45F8-9C51-6BD66C215CC0"><gtr:id>5A8E328E-8A10-45F8-9C51-6BD66C215CC0</gtr:id><gtr:name>Nottingham University Hospital NHS Trust</gtr:name><gtr:address><gtr:line1>Nottingham University HospitalMedical Physics and clinical engineeringQMC Campus</gtr:line1><gtr:city>Nottingham</gtr:city><gtr:postCode>NG7 2UH</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FEC5FE7D-C329-4D18-9A3A-FAC03968DF93"><gtr:id>FEC5FE7D-C329-4D18-9A3A-FAC03968DF93</gtr:id><gtr:name>San Francisco University</gtr:name><gtr:address><gtr:line1>2130 Fulton Street</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9218106A-E8CE-46A5-AABC-B4C8ED148690"><gtr:id>9218106A-E8CE-46A5-AABC-B4C8ED148690</gtr:id><gtr:name>University of Amsterdam</gtr:name><gtr:address><gtr:line1>Liaison Office</gtr:line1><gtr:line2>PO Box 19268</gtr:line2><gtr:line4>Amsterdam</gtr:line4><gtr:line5>Amsterdam</gtr:line5><gtr:postCode>1000 GG</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB000219-B681-4861-853A-EB9CDE05AEB3"><gtr:id>AB000219-B681-4861-853A-EB9CDE05AEB3</gtr:id><gtr:name>Belfast Health and Social Care Trust</gtr:name><gtr:address><gtr:line1>A Floor Belfast City Hospital
Lisburn Road</gtr:line1><gtr:city>Belfast</gtr:city><gtr:postCode>BT12 6BA</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2070F714-C13B-417D-B059-44B511471FF2"><gtr:id>2070F714-C13B-417D-B059-44B511471FF2</gtr:id><gtr:name>Institute for Clinical and Experimental Medicine (IKEM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C"><gtr:id>7B5B059B-D11D-4216-BAC4-CBFF7E5E3C2C</gtr:id><gtr:name>Academic Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DAEB2B76-3CE2-4F67-BE52-859227BD2B8F"><gtr:id>DAEB2B76-3CE2-4F67-BE52-859227BD2B8F</gtr:id><gtr:name>Great Ormond Street Hospital (GOSH)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8BFE03FB-6AF2-46C4-942E-1262EFD09774"><gtr:id>8BFE03FB-6AF2-46C4-942E-1262EFD09774</gtr:id><gtr:name>Royal Free London NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Pond Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW3 2QG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0CAFBCA9-D47B-49C7-836E-E7F61BB6F4DE"><gtr:id>0CAFBCA9-D47B-49C7-836E-E7F61BB6F4DE</gtr:id><gtr:name>Nantes University Hospital - CHU Nantes</gtr:name><gtr:address><gtr:line1>5 allee de l'ile Gloriette</gtr:line1><gtr:postCode>44093</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BCD05341-5D48-43F1-A505-C169496883A1"><gtr:id>BCD05341-5D48-43F1-A505-C169496883A1</gtr:id><gtr:name>University of Hong Kong</gtr:name><gtr:address><gtr:line1>Pok Fu Lam Road</gtr:line1><gtr:line4>Hong Kong</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Hong Kong</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F463A0E1-E89E-406B-B803-760625885B6C"><gtr:id>F463A0E1-E89E-406B-B803-760625885B6C</gtr:id><gtr:name>Hospital Universitario La Paz</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A06FED91-B1C2-4601-A8BC-7FDF7DF5EF3D"><gtr:id>A06FED91-B1C2-4601-A8BC-7FDF7DF5EF3D</gtr:id><gtr:name>University Libre Bruxelles (Universit? Libre de Bruxelles ULB)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5ABCC373-8D79-4794-9EAD-C1BAFAA2F5D7"><gtr:id>5ABCC373-8D79-4794-9EAD-C1BAFAA2F5D7</gtr:id><gtr:name>Milenia Biotec GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/59D738F7-A1E5-4C15-AD09-3275AB1D723B"><gtr:id>59D738F7-A1E5-4C15-AD09-3275AB1D723B</gtr:id><gtr:name>University of Lubeck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BE7A2CDE-C041-4244-A92D-C4DC327E14B7"><gtr:id>BE7A2CDE-C041-4244-A92D-C4DC327E14B7</gtr:id><gtr:name>Cambridge University Hospitals</gtr:name><gtr:address><gtr:line1>Addenbrooke's Hospital
Hills Road</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB2 0QQ</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C1C85FB-77AC-4019-9363-4A2E4A909E16"><gtr:id>2C1C85FB-77AC-4019-9363-4A2E4A909E16</gtr:id><gtr:name>Cardiff &amp; Vale University Health Board</gtr:name><gtr:address><gtr:line1>Heath Park</gtr:line1><gtr:line4>Cardiff</gtr:line4><gtr:postCode>CF14 4XW</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/273BA583-03B3-4054-9371-E37F72293F80"><gtr:id>273BA583-03B3-4054-9371-E37F72293F80</gtr:id><gtr:name>Apellis Pharmaceutical</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B0AEF9E8-9618-4AAB-B886-EF5B5109840B"><gtr:id>B0AEF9E8-9618-4AAB-B886-EF5B5109840B</gtr:id><gtr:name>Royal Society of Edinburgh (RSE)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C5F5DCA-59E7-4987-AE32-A75A36944391"><gtr:id>9C5F5DCA-59E7-4987-AE32-A75A36944391</gtr:id><gtr:name>Nantes University</gtr:name><gtr:address><gtr:line1>Nantes University</gtr:line1><gtr:line2>1 Quai de Tourville</gtr:line2><gtr:line3>BP 13522</gtr:line3><gtr:line4>Nantes</gtr:line4><gtr:line5>F-44035</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A9426E3-7F35-48FC-BD72-3776C8F90A4A"><gtr:id>4A9426E3-7F35-48FC-BD72-3776C8F90A4A</gtr:id><gtr:name>Grants Admin Office</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9F389987-5CF8-4C31-B2E6-C5EE5CA19D4E"><gtr:id>9F389987-5CF8-4C31-B2E6-C5EE5CA19D4E</gtr:id><gtr:name>St George's Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A"><gtr:id>9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A</gtr:id><gtr:name>Guy's and St Thomas' NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Westminster Bridge Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 7EH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B97171FF-E5B1-44D2-983C-E83E607CCC7E"><gtr:id>B97171FF-E5B1-44D2-983C-E83E607CCC7E</gtr:id><gtr:name>Rigel Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A19A6372-A1A2-4F0D-AED7-7110E0A05C9B"><gtr:id>A19A6372-A1A2-4F0D-AED7-7110E0A05C9B</gtr:id><gtr:name>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EDC7316F-A897-4CBC-BA1F-30CE73C9FEFD"><gtr:id>EDC7316F-A897-4CBC-BA1F-30CE73C9FEFD</gtr:id><gtr:name>Astellas Pharma</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8B7C8B1B-87E1-482C-B0C7-5C9D4EEE8355"><gtr:id>8B7C8B1B-87E1-482C-B0C7-5C9D4EEE8355</gtr:id><gtr:name>European Cooperation in Science and Technology (COST)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D121F2E-1C43-4CFF-ABC0-A0117386CF3F"><gtr:id>5D121F2E-1C43-4CFF-ABC0-A0117386CF3F</gtr:id><gtr:name>Opsona Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F7F8EA22-4A18-4B69-AA3D-A0E9C0B0EE7C"><gtr:id>F7F8EA22-4A18-4B69-AA3D-A0E9C0B0EE7C</gtr:id><gtr:name>ALTA</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3B1E5961-8677-4A32-B15C-12FB968FA163"><gtr:id>3B1E5961-8677-4A32-B15C-12FB968FA163</gtr:id><gtr:name>University of Pennsylvania</gtr:name><gtr:address><gtr:line1>3451 Walnut Street,</gtr:line1><gtr:line2>Suite P-221</gtr:line2><gtr:line3>Franklin Building</gtr:line3><gtr:line4>Philadelphia</gtr:line4><gtr:postCode>PA 19104</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F5569A12-0A1B-4474-B608-84BB0C44B3A7"><gtr:id>F5569A12-0A1B-4474-B608-84BB0C44B3A7</gtr:id><gtr:name>University of Minnesota</gtr:name><gtr:address><gtr:line1>127 Vincent Hall</gtr:line1><gtr:line2>206 Church St. S.E</gtr:line2><gtr:line4>Minneapolis</gtr:line4><gtr:line5>MN 55455</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D545C73D-780E-4D1A-B5CD-1D6630A8CCCA"><gtr:id>D545C73D-780E-4D1A-B5CD-1D6630A8CCCA</gtr:id><gtr:name>Royal London Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68EDC425-4126-4E27-958A-9A2DE10729BF"><gtr:id>68EDC425-4126-4E27-958A-9A2DE10729BF</gtr:id><gtr:name>Immune Tolerance Network</gtr:name><gtr:address><gtr:line1>Suite 430 - 3333 California St</gtr:line1><gtr:postCode>CA 94118</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E68BE577-6C17-48CE-B65C-24C477BB8AE9"><gtr:id>E68BE577-6C17-48CE-B65C-24C477BB8AE9</gtr:id><gtr:name>Yeshiva University</gtr:name><gtr:address><gtr:line1>500 West 185th Street</gtr:line1><gtr:postCode>10033</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E2174C7-CECC-4A37-9ED0-C16D5B6A585B"><gtr:id>4E2174C7-CECC-4A37-9ED0-C16D5B6A585B</gtr:id><gtr:name>NHS England</gtr:name><gtr:address><gtr:line1>NHS South of England</gtr:line1><gtr:line2>NHS Commissioning Board</gtr:line2><gtr:line3>PO Box 16728</gtr:line3><gtr:postCode>B97 9PT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C3992259-C19F-4FE5-9C01-210C819D7264"><gtr:id>C3992259-C19F-4FE5-9C01-210C819D7264</gtr:id><gtr:name>Yale University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/88C5F7F9-8DCC-41C9-BC4F-F37DA01075C7"><gtr:id>88C5F7F9-8DCC-41C9-BC4F-F37DA01075C7</gtr:id><gtr:name>University of East Anglia</gtr:name><gtr:address><gtr:line1>Earlham Road</gtr:line1><gtr:line4>Norwich</gtr:line4><gtr:line5>Norfolk</gtr:line5><gtr:postCode>NR4 7TJ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A01FD660-9141-46EE-9FFB-9236CE7FBFB4"><gtr:id>A01FD660-9141-46EE-9FFB-9236CE7FBFB4</gtr:id><gtr:name>University of Colorado (Denver)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6442075B-9FCD-4065-8EE0-56534DEAC1A5"><gtr:id>6442075B-9FCD-4065-8EE0-56534DEAC1A5</gtr:id><gtr:name>Genome Identification Diagnostics GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E4F6BEA-8E66-490E-B61F-8CBB33116179"><gtr:id>5E4F6BEA-8E66-490E-B61F-8CBB33116179</gtr:id><gtr:name>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5364C2EA-5FF7-4563-AB28-F5ECD736CBFC"><gtr:id>5364C2EA-5FF7-4563-AB28-F5ECD736CBFC</gtr:id><gtr:name>University of Mons</gtr:name><gtr:address><gtr:line1>20 Place du Parc</gtr:line1><gtr:line4>Mons</gtr:line4><gtr:postCode>B7000</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/13613115-E290-45AC-BAA6-83D88728749C"><gtr:id>13613115-E290-45AC-BAA6-83D88728749C</gtr:id><gtr:name>Xian Jiaotong University</gtr:name><gtr:address><gtr:line1>28 Xianningxi West Road</gtr:line1><gtr:line2>710049</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF8EDD94-E846-412E-B59C-51D4D000D9E2"><gtr:id>EF8EDD94-E846-412E-B59C-51D4D000D9E2</gtr:id><gtr:name>Nagoya University</gtr:name><gtr:address><gtr:line1>Furo-cho</gtr:line1><gtr:line2>Chikusa-ku</gtr:line2><gtr:line4>Nagoya City</gtr:line4><gtr:line5>Aichi Prefecture</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF46D1B5-9EE9-459F-8D6D-68C3987370BD"><gtr:id>EF46D1B5-9EE9-459F-8D6D-68C3987370BD</gtr:id><gtr:name>University Hospitals of Leicester NHS</gtr:name><gtr:address><gtr:line1>Leicester Royal Infirmary</gtr:line1><gtr:line2>Infirmary Square</gtr:line2><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 5WW</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BF06ABFB-9547-484C-84F9-4110ED8759B7"><gtr:id>BF06ABFB-9547-484C-84F9-4110ED8759B7</gtr:id><gtr:name>Manchester University NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Central Manchester University Hospitals NHS Foundation Trust,Manchester Royal Infirmary,Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9WL</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1B0161A9-9EC7-4A57-AC51-97057219C9DC"><gtr:id>1B0161A9-9EC7-4A57-AC51-97057219C9DC</gtr:id><gtr:name>Plymouth Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D9E99D31-A5B6-43CF-83F5-20D97EBEC1D1"><gtr:id>D9E99D31-A5B6-43CF-83F5-20D97EBEC1D1</gtr:id><gtr:name>Cellogic GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D3D8A940-2BB9-4960-A5F6-1F54554C34FA"><gtr:id>D3D8A940-2BB9-4960-A5F6-1F54554C34FA</gtr:id><gtr:name>Portsmouth Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E9DEFAE4-A354-4213-AB9D-FAA2047387F6"><gtr:id>E9DEFAE4-A354-4213-AB9D-FAA2047387F6</gtr:id><gtr:name>NHS Health Scotland</gtr:name><gtr:address><gtr:line1>NHS Health Scotland</gtr:line1><gtr:line2>Canaan Lane</gtr:line2><gtr:postCode>EH10 4SG</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7C3729AA-933E-4E5E-A502-0DFA7E6E98AD"><gtr:id>7C3729AA-933E-4E5E-A502-0DFA7E6E98AD</gtr:id><gtr:name>Alexion Pharmaceuticals</gtr:name><gtr:address><gtr:line1>352 Knotter Drive</gtr:line1><gtr:postCode>CT 06410</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3545CDC8-076D-4BD8-B370-8E558F9D46EE"><gtr:id>3545CDC8-076D-4BD8-B370-8E558F9D46EE</gtr:id><gtr:name>Leeds Teaching Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Beckett Street</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS9 7TF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2718B5D3-B880-4C4C-A4A3-0E639BDA800E"><gtr:id>2718B5D3-B880-4C4C-A4A3-0E639BDA800E</gtr:id><gtr:name>BMI The Beaumont Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/47F25582-F481-4297-B1C4-6C1BCF70818B"><gtr:id>47F25582-F481-4297-B1C4-6C1BCF70818B</gtr:id><gtr:name>Beth Israel Deaconess Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E777F7E-8B7E-406A-87FB-39A7026F891F"><gtr:id>4E777F7E-8B7E-406A-87FB-39A7026F891F</gtr:id><gtr:name>Uppsala University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0792034E-7B08-4D03-A4E1-0F2F89D82900"><gtr:id>0792034E-7B08-4D03-A4E1-0F2F89D82900</gtr:id><gtr:name>Immunotech S.A.S.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C705F4C9-3E9D-4C2A-90B0-49C636E962EE"><gtr:id>C705F4C9-3E9D-4C2A-90B0-49C636E962EE</gtr:id><gtr:name>Barts Health NHS Trust</gtr:name><gtr:address><gtr:line1>9 Prescot Street
Aldgate</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>E1 8PR</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/134B8A7B-4AA2-4DC1-91FC-0A4D338606E8"><gtr:id>134B8A7B-4AA2-4DC1-91FC-0A4D338606E8</gtr:id><gtr:name>University of Dresden</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82"><gtr:id>9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82</gtr:id><gtr:name>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F8ECC47E-FF10-432B-A5B1-38D2BD36EEF4"><gtr:id>F8ECC47E-FF10-432B-A5B1-38D2BD36EEF4</gtr:id><gtr:name>Great North Children's Hospital (GNCH)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BF056F42-5CA1-4C02-A8D3-AF6A9AA1A2FD"><gtr:id>BF056F42-5CA1-4C02-A8D3-AF6A9AA1A2FD</gtr:id><gtr:name>Salford Royal NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Cleveland House
Salford</gtr:line1><gtr:city>Greater Manchester</gtr:city><gtr:postCode>M6 8AL</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3BB202F-E9D1-4FB6-B29C-A98ED2C9AECF"><gtr:id>E3BB202F-E9D1-4FB6-B29C-A98ED2C9AECF</gtr:id><gtr:name>University of Seville</gtr:name><gtr:address><gtr:line1>Avda</gtr:line1><gtr:line2>Reina Mercedes, S/n</gtr:line2><gtr:line4>E-41012 Seville</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B"><gtr:id>46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B</gtr:id><gtr:name>Bristol-Myers Squibb</gtr:name><gtr:address><gtr:line1>Bristol-Myers Squibb</gtr:line1><gtr:line2>311 Pennington Rocky Hill Road</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD21B8FC-26A6-4A3A-9A23-207B6667CB41"><gtr:id>DD21B8FC-26A6-4A3A-9A23-207B6667CB41</gtr:id><gtr:name>University of Pittsburgh</gtr:name><gtr:address><gtr:line1>University of Pittsburgh</gtr:line1><gtr:line4>Pittsburgh</gtr:line4><gtr:line5>Pennsylvania</gtr:line5><gtr:postCode>PA 15260</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8FEA6C69-4633-4CAE-B920-88F6F7F57AA7"><gtr:id>8FEA6C69-4633-4CAE-B920-88F6F7F57AA7</gtr:id><gtr:name>Chelsea Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DAFB4671-B85C-4383-B20F-8699CB229939"><gtr:id>DAFB4671-B85C-4383-B20F-8699CB229939</gtr:id><gtr:name>Catalan Health Institute (ICS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/53DD51C1-ACB9-4626-9BD6-81674D63471B"><gtr:id>53DD51C1-ACB9-4626-9BD6-81674D63471B</gtr:id><gtr:name>TcLand Expression</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37D03EDF-A585-4D7B-8E46-7A48F11DA5DC"><gtr:id>37D03EDF-A585-4D7B-8E46-7A48F11DA5DC</gtr:id><gtr:name>University Hospital Regensburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6ED98605-E2D0-401D-A73F-A9923F6C5D9D"><gtr:id>6ED98605-E2D0-401D-A73F-A9923F6C5D9D</gtr:id><gtr:name>East Kent Hospitals University NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/303E9ED2-5A13-4CC2-90BD-034FF298566D"><gtr:id>303E9ED2-5A13-4CC2-90BD-034FF298566D</gtr:id><gtr:firstName>Irene</gtr:firstName><gtr:surname>Rebollo Mesa</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/893D66CD-2721-4DA1-BC08-7050127B4B3A"><gtr:id>893D66CD-2721-4DA1-BC08-7050127B4B3A</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:otherNames>H</gtr:otherNames><gtr:surname>Sacks</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6CF032F8-E4EE-4558-A11F-90C805A52817"><gtr:id>6CF032F8-E4EE-4558-A11F-90C805A52817</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ006742%2F1"><gtr:id>5C9020B5-5161-48B8-BD61-E87E2A3C904C</gtr:id><gtr:title>MRC Centre for Transplantation</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J006742/1</gtr:grantReference><gtr:abstractText>Organ transplantation has saved the lives of many thousands of people, but transplants still don't last as long as they should. In addition, to prevent rejection, high doses of toxic drugs are used to dampen the immune response. These can not only harm the transplant, but can have lethal side effects on the recipient. 

Since it started in October 2007, the Centre has made significant progress towards improving the health of people who need transplants. We have devised ways to make their transplanted organ survive longer. This includes the development of engineered proteins which, when planted in donor kidneys, reduce inflammation and blood clot formation after transplantation. In addition, we have pioneered less harmful, more natural methods to coax the immune system into accepting the transplant, using cells taken from the patient. Remarkably, as a result of monitoring the immune system, we are close to being able to judge which patients can stop taking conventional therapy without rejecting the graft. At the same time, we are developing advanced scanning techniques that will enable physicians to diagnose whether a transplant is inflamed and to offer appropriate treatment. 

As we approach the next five years of development, we shall conduct clinical trials to establish whether these innovations can benefit healthcare as the basic research has promised. Potential benefits include extending the life of the transplant and offering transplantation to more of those in need. We are also supporting new branches of science that make success more likely. 

Advances of this complexity are made possible by bringing together a large workforce of scientists, clinicians and technologists under the same roof. The MRC Centre for Transplantation has created this capability within the UK. It collaborates with the Centre for Medical Law and Ethics at King's College to ensure a high standard of communication and public engagement regarding the regulation and ethics of transplant research. A programme of special events and media coverage will help keep the public and patients informed during innovation. Health economists are also to be part of the Centre to provide the opportunity to make more accurate forecasts about the costs and potential benefits of our research. 

Future success will depend on recruiting and training the brightest minds to deliver this work through the next 5-10 years of development and ensure the research is translated into social and economic benefit.</gtr:abstractText><gtr:technicalSummary>In 2007, the Centre set out to convert its extensive knowledge of inflammation, immunity and tolerance into new treatment, diagnostic and prognostic technologies for the benefit of patients. Our priorities were to overcome the initial barriers to transplantation presented by the immune system and to induce tolerance in patients with guidance from immune prediction and monitoring, so reducing some of the major limitations of modern transplantation.

To do this, we created links with protein and cell therapeutics, imaging sciences and genetics, and between clinical specialities responsible for the treatment of patients with diabetes, liver, kidney, bone marrow and dental diseases. As a result, the first membrane-targeted therapeutic regulators are about to enter a multicentre efficacy trial; the cell therapy strategy has progressed to become part of several investigational protocols designed to induce tolerance; markers of tolerance are undergoing extensive evaluation in man; and new imaging ligands that detect activated complement fragments and migratory T cells have emerged. A teaching framework built around these goals is equipping trainees to engage in multidisciplinary research. A programme of patient and public involvement promotes awareness of the importance of science in transplant medicine and ensures we are responsive to their expectations.

Our plan is to regroup the expanded number of basic and clinical research programmes into fewer themes which reflect areas of strategic value. This includes islet and hepatocyte transplantation, where inadequate long-term outcomes are likely to benefit from the specific expertise of the Centre. In support, an expanded training scheme will develop leadership skills in the distinct areas defined by the new themes, i.e. protein and cell engineering, immune monitoring, imaging and informatics. A parallel theme to improve methods of health economic assessment for early research is designed to support these goals.</gtr:technicalSummary><gtr:potentialImpactText>Benefit to patients
 Improved quality of life, graft and patient survival rates, fewer interventions including less use of drug and dialysis treatment:
 - Painting the donor organ with protective treatment that reduces inflammation and increases the lifespan of the transplant
 - Having to take fewer drugs with unpleasant or dangerous side effects achieved with regimens using cell therapies in place of conventional treatment with broad-acting drugs
 - Better patient stratification with new biomarkers and immune monitoring, allowing reduced drug usage where immune tolerance has developed
 - Shorter wait for a kidney transplant through more donor organs being available with the application of organ-painting
 - Evidence should be visible within 5-10 years

Benefits to the NHS
 Cost/resource/efficiency benefits gained through costs of treatment (drug and dialysis costs) and patient and graft outcomes:
 - Lower dialysis costs by enabling more transplants to be carried out with the use of organ painting and by fewer patients having to return to dialysis after transplantation
 - Lower cost of dialysis in the early post transplant period due to more rapid recovery of painted donor organs
 - Lower maintenance drug costs by keeping patients on fewer drugs where immune tolerance can be detected and/or can be induced by cell therapy
 - Increased patient and graft survival rates with wider application of these treatment and diagnostic technologies, within 10 years

Benefits to the Economy
Exploitation of IP to form new products which contribute to UK economy and allow return on public investment in the work of the MRC Centre/KCL, by:
 - New intellectual property based around these therapeutic and biomarker technologies (interest already showing in new cytotopic products and biomarkers of tolerance)
 - Healthcare savings since maintenance on a transplant is more cost-effective than dialysis.

Benefits to Wider Society
Engagement/participation, leading to:
 - Public confidence in organ donation, building on our ability to engage the public and influence policy on matters that include research in transplantation
 - Influence willingness to participate in organ donations schemes by appreciating the scientific commitment though research</gtr:potentialImpactText><gtr:fund><gtr:end>2018-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2042049</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>Tablet guided surgery</gtr:description><gtr:id>EA6AD735-B977-45F5-9FED-97AB51D65B15</gtr:id><gtr:impact>Developed a tablet based tool and performed the first in man for surgical navigation in UK and Italy. Demonstrated at the World Robotic Surgery Event with KCL being the only selected University from UK amongst 12 globally</gtr:impact><gtr:outcomeId>56e0512e916b54.37555495</gtr:outcomeId><gtr:title>Translucent</gtr:title><gtr:type>Image</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput><gtr:artisticAndCreativeProductOutput><gtr:description>3D printed prostates</gtr:description><gtr:id>E3C058AE-6BAF-4CFA-BFA3-4D21703BAA54</gtr:id><gtr:impact>Developed in collaboration with Nuada Medical for patient counselling and surgical planning during robotic procedures</gtr:impact><gtr:outcomeId>56e05113e14055.40568261</gtr:outcomeId><gtr:title>3D prostates</gtr:title><gtr:type>Image</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Academic Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>FP7 Consortium</gtr:description><gtr:id>3190079E-0AF7-4C55-88F3-93D5D44611A4</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-10</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>E35931F4-DBDE-407A-8FBF-CDB04E9A9DBC</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-11</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Beth Israel Deaconess Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Role of CD39 in T-reg and Th17 plasticity</gtr:description><gtr:id>D7D9B269-41B7-4FCA-A512-ECCC017BF162</gtr:id><gtr:impact>Nine peer-review papers (PMID: 22387392, 23787765, 23292173, 25042541, 25034284, 24681654, 22965858, 25172498 and 24505337) and six abstracts that have been accepted as oral presentations or posters at the Annual Meeting of the American Association of Immunologists (Boston, 4-8 May 2012), the European Congress of Immunology (Glasgow, 5-8 September 2012), the Digestive Disease Week (Orlando, 18-21 May 2013 and Chicago, 3-6 May 2014), the American Association for the Study of Liver Diseases (Boston, 9-13 November 2013). The poster presented at DDW in 2013 was awarded 'poster of distinction'.</gtr:impact><gtr:outcomeId>54578eaf9f4a04.23679297-1</gtr:outcomeId><gtr:partnerContribution>Provided equipment, consumables and animals</gtr:partnerContribution><gtr:piContribution>Investigating the role of CD39 in shaping the balance between T-regs and Th17 cells in health, IBD and animal models of colitis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Xi'an Jiaotong University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>School of Medicine Xi'an Jiaotong</gtr:department><gtr:description>Lecture tour of China</gtr:description><gtr:id>4BFC50DD-CEC6-4060-819E-123CB75F283A</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>imAsyQ3D5eA-1</gtr:outcomeId><gtr:partnerContribution>will be mutual cooperation on various projects</gtr:partnerContribution><gtr:piContribution>Lecturing to establish collaborations in research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chelsea Therapeutics</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Chelsea Therapeutics</gtr:description><gtr:id>99C036FF-E975-485C-9CAA-AE15BE2EAB0E</gtr:id><gtr:impact>We have published a paper, Pubmed ID: 18343249</gtr:impact><gtr:outcomeId>C85CD54F983-1</gtr:outcomeId><gtr:partnerContribution>The company provided a drug compound (an anti-folate)</gtr:partnerContribution><gtr:piContribution>We have developed a biomarker for clinical trials.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Washington University in St Louis</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Prof John Atkinson (Washington University in Saint Louis, USA)</gtr:description><gtr:id>3E172632-4AFA-4605-AB03-4051B8208C50</gtr:id><gtr:impact>Publication currently in press ('Evidence for intracellular C3 activation and its dysregulaion in autoimmune arthritis') was performed in close collaboration with the Atkinson laboratory - this is reflected in the author contributions. The data from this collaboration were presented at the 14th European meeting on Complement in Human Disease and chosen for an oral presentation and outstanding oral presentation award.</gtr:impact><gtr:outcomeId>tEy3Z5jeAVS-1</gtr:outcomeId><gtr:partnerContribution>Collaborative experiments on the role of T cell-derived C3 in human Th1 biology, exchange of data and reagents</gtr:partnerContribution><gtr:piContribution>Collaborative experiments on the role of T cell-derived C3 in human Th1 biology, exchange of data and reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Xi'an Jiaotong University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>Xi'an Jiaotong University, China</gtr:description><gtr:id>585E4BF1-7C0C-48E1-8B33-5D5EA39C1550</gtr:id><gtr:impact>Awarded a King's Worldwide Partnership Fund Award to assist with the collaboration</gtr:impact><gtr:outcomeId>56dd4b22c61703.72771440-1</gtr:outcomeId><gtr:partnerContribution>They will provide the animals and team to assist in performance of experiments</gtr:partnerContribution><gtr:piContribution>Cooperation on a research project which has involved a senior post-doctoral scientist visiting China for 8 weeks</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manchester University NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>C0F20900-1C2A-4B3C-9638-55A4127800B9</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-13</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Uppsala University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>172D4428-4D2C-4FC2-B32D-E3901638F0CA</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-18</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Nantes</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>FP7 Consortium</gtr:description><gtr:id>FA82DF71-74A5-40D7-B68A-932D92E25CB4</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-2</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free London NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>3D0F02E9-7C95-4F94-8D44-DC1250A38AF5</gtr:id><gtr:impact>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:impact><gtr:outcomeId>nXSmrQtFDMZ-12</gtr:outcomeId><gtr:partnerContribution>Enabled the 3rd validation of biomarkers of Tolerance
Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance</gtr:partnerContribution><gtr:piContribution>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Emory University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Emory</gtr:description><gtr:id>92C16A3E-485F-46B4-8A45-F88D646616C4</gtr:id><gtr:impact>Dr Stuart Hurst, a medical trainee from Emory, started the collaborative programme by joining the MRC Centre for Transplantation for 2 years in July 2013, under Professors Anthony Dorling and Steven Sacks' supervision.
Dr Blayne Sayed from Emory has joined the MRC Centre in July 2014 under the supervision of Professor Alberto Sanchez Fueyo. 
The MRC Centre for Transplantation awarded MRC Centre two Emory Bridging Fellowships and appointed two female surgical trainees to carry out research projects at Emory in the USA. Their sabbaticals are due to start in 2015.</gtr:impact><gtr:outcomeId>c67fPV6EPRp-1</gtr:outcomeId><gtr:partnerContribution>What the link embraces
1. Distinctive areas of strength that complement the academic plans at both Centres
2. Added value to the training of future clinical-academic leaders A cross-centre training programme based on a critical set of scientific questions and skills
3. Enhanced metrics for training in health services research
4. Benefits of cross-centre evaluation of clinical-academic programmes 
5. Leveraging funding to support the proposed activities and goals</gtr:partnerContribution><gtr:piContribution>Clinical fellows exchange programme adding value to joint research projects between Emory and KCL.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Zhejiang University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>The KCL-Belgium-China herbal toxicity axis</gtr:description><gtr:id>F85566A4-A78C-4B77-ABF0-2A0F6D65CD10</gtr:id><gtr:impact>This a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&amp;amp;flag=1&amp;amp;journal_id=sjzyyw&amp;amp;year_id=2015
(2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, St&amp;eacute;vigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075
http://www.sciencemag.org/content/347/6219/337.3.summary
(3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075
http://www.sciencemag.org/content/346/6216/1569.4.summary</gtr:impact><gtr:outcomeId>56deb714d837a5.87833543-3</gtr:outcomeId><gtr:partnerContribution>Qu is a visiting fellow in my lab, who brought in knowledge and resources on Chinese herbal medicine and drafted the part of information published in Chinese; Bunel was a PhD studewnt of Duez, who led the first draft, esp. focused on those information published in English; Duez is a long-term collaborator of my FP7 GP-TCM poroject. He brought in expertise and knowledge from a pharmacology/toxicology point of view. Duez and Qu are Co-Chairs of the Pharmacology &amp;amp; Toxicology Interest Group of the GP-TCM Research Association that I led to establish in 2012.</gtr:partnerContribution><gtr:piContribution>I led the conception, research design and oversaw the whole project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Milenia Biotec GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Indices of Tolerance</gtr:description><gtr:id>E3E4009A-708E-4906-B99D-EB1CF0BC5AA0</gtr:id><gtr:impact>JOURNAL ARTICLES:
PMID: 20501946 
PMID: 20501943
PMID: 20383145
PMID: 18633344
TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51
PMID: 17700166
PMID: 16082338 
PMID: 17004249
Transplant Proc. 2007 Oct;39(8):2665-7


COMMUNICATIONS: 
 Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005.
 A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007.

POSTERS
 The Renal Association Annual Conference, May 2007, Brighton UK. &amp;quot;Indices of tolerance in kidney transplants&amp;quot; P103-PG05
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients&amp;quot;.
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Biomarkers of tolerance in kidney transplants&amp;quot;.
 World Transplant Congress July 2006, Boston USA. &amp;quot;Advances in Immune Monitoring in Renal Transplantation&amp;quot;.
 British Transplantation Society, March 2006, Edinburgh UK. &amp;quot;Indices of immunological tolerance&amp;quot;.
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription&amp;quot;.
 British Society of Immunology February 2007, Glasgow UK. &amp;quot;Tregs in peripheral blood of Clinically defined groups of renal transplant recipients&amp;quot;

ORAL COMMUNICATIONS
 XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. &amp;quot;Indices of tolerance in kidney transplants.&amp;quot;
 World Transplant Congress July 2006, Boston USA. &amp;quot;Indices of tolerance: Interim Report&amp;quot;.
 7th Trends in immunosuppression, February 2006 Berlin, Germany. &amp;quot;Fingerprinting tolerance in Renal Transplantation&amp;quot;. Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21
 American Transplant Congress May 2007. &amp;quot;Is it possible to tissue type a kidney donor who is no longer available?&amp;quot;.
 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. &amp;quot;T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection.&amp;quot; Oral presentation by Patrick Miqueu.</gtr:impact><gtr:outcomeId>hCNshj7SE9U-6</gtr:outcomeId><gtr:partnerContribution>Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did &amp;quot;the trans-vivo&amp;quot; DTH assay, etc ....</gtr:partnerContribution><gtr:piContribution>King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator.
We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Universitari Vall d'Hebron</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>79189B1C-8EE6-447C-A232-9B955E1AD6C6</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-19</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Great Ormond Street Hospital (GOSH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Renal Department GOSH</gtr:department><gtr:description>GAMBIT consortium</gtr:description><gtr:id>B80C063A-2120-4A6A-9D22-F2EEFACB5508</gtr:id><gtr:impact>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:impact><gtr:outcomeId>nXSmrQtFDMZ-14</gtr:outcomeId><gtr:partnerContribution>Enabled the 3rd validation of biomarkers of Tolerance
Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance</gtr:partnerContribution><gtr:piContribution>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Interdisciplinary Transplant Research Group</gtr:description><gtr:id>7AE003D5-194D-4D39-ACC7-73F7A420C4F5</gtr:id><gtr:impact>Multidisciplinary: Law, Bioethics, Social Science, Clinical Science, Health Economics, Psychology.</gtr:impact><gtr:outcomeId>Ca9NeC8dpqz-2</gtr:outcomeId><gtr:partnerContribution>Contribution to group by workshop presentations, draft papers. The group is recently formed but outputs in the form of publications and policy document proposals are anticipated. Collaborators from the Universities of Cambridge, Oxford, and Bristol.</gtr:partnerContribution><gtr:piContribution>PI of group and grant holder for programme of research Increasing understanding on the quality and allocation of human organs for transplantation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Lombardi-Nestle</gtr:description><gtr:id>9DF675F7-48F7-4F62-8C27-CB10AA97EF8C</gtr:id><gtr:impact>See publications - PubMed ID 22937164 &amp;amp; J.Exp.Med.209(5) 935-945; Ali et al. Plos ONE (In Press)</gtr:impact><gtr:outcomeId>ZEixCsJSFoj-1</gtr:outcomeId><gtr:partnerContribution>establishing in vivo model of human skin transplantation</gtr:partnerContribution><gtr:piContribution>regulatory T cell expertise and knowledge in the mechanisms of tolerance</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Chemistry</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>BC0F4DFF-14C7-444C-B8FA-C4FB4F6714DD</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-14</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>British Transplantation Society (BTS)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Clinical Trials Network</gtr:department><gtr:description>EMPIRIKAL Consortium</gtr:description><gtr:id>B34171D3-4564-4ADB-9297-3797F4DB27D7</gtr:id><gtr:impact>First investigator meeting held October 2012. Protocol modifications.</gtr:impact><gtr:outcomeId>dvHNwbVBuxo-2</gtr:outcomeId><gtr:partnerContribution>Planning of the protocol. Potential patient involvement.</gtr:partnerContribution><gtr:piContribution>We have provided the underpinning science to the clinical trial (EMPIRIKAL) of a novel membrane associated complement regulator, have formulated the clinical protocol and have secured funding with the MRC DCS to enable the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Colorado Denver</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collectin 11 and lung inflammation with the University of Denver</gtr:description><gtr:id>C2B316BB-70CD-4579-961D-BEBB129B3714</gtr:id><gtr:impact>None so far</gtr:impact><gtr:outcomeId>56d9acf424b086.64954176-1</gtr:outcomeId><gtr:partnerContribution>Expertise on the animal model of lung disease</gtr:partnerContribution><gtr:piContribution>Sent the breeding pairs of mice with deficiency of collectin 11 and telephone conference call set up.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charit? - University of Medicine Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Indices of Tolerance</gtr:description><gtr:id>4A19D218-F450-4B3F-99F9-1CAF0E3D3F06</gtr:id><gtr:impact>JOURNAL ARTICLES:
PMID: 20501946 
PMID: 20501943
PMID: 20383145
PMID: 18633344
TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51
PMID: 17700166
PMID: 16082338 
PMID: 17004249
Transplant Proc. 2007 Oct;39(8):2665-7


COMMUNICATIONS: 
 Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005.
 A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007.

POSTERS
 The Renal Association Annual Conference, May 2007, Brighton UK. &amp;quot;Indices of tolerance in kidney transplants&amp;quot; P103-PG05
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients&amp;quot;.
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Biomarkers of tolerance in kidney transplants&amp;quot;.
 World Transplant Congress July 2006, Boston USA. &amp;quot;Advances in Immune Monitoring in Renal Transplantation&amp;quot;.
 British Transplantation Society, March 2006, Edinburgh UK. &amp;quot;Indices of immunological tolerance&amp;quot;.
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription&amp;quot;.
 British Society of Immunology February 2007, Glasgow UK. &amp;quot;Tregs in peripheral blood of Clinically defined groups of renal transplant recipients&amp;quot;

ORAL COMMUNICATIONS
 XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. &amp;quot;Indices of tolerance in kidney transplants.&amp;quot;
 World Transplant Congress July 2006, Boston USA. &amp;quot;Indices of tolerance: Interim Report&amp;quot;.
 7th Trends in immunosuppression, February 2006 Berlin, Germany. &amp;quot;Fingerprinting tolerance in Renal Transplantation&amp;quot;. Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21
 American Transplant Congress May 2007. &amp;quot;Is it possible to tissue type a kidney donor who is no longer available?&amp;quot;.
 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. &amp;quot;T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection.&amp;quot; Oral presentation by Patrick Miqueu.</gtr:impact><gtr:outcomeId>hCNshj7SE9U-4</gtr:outcomeId><gtr:partnerContribution>Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did &amp;quot;the trans-vivo&amp;quot; DTH assay, etc ....</gtr:partnerContribution><gtr:piContribution>King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator.
We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Belfast Health and Social Care Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>91561FAD-FE46-43F9-9BD9-2D5443E1AE7A</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-9</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Clinical Biochemistry</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>4A154CCE-F64E-4963-AE8E-C9C4831EDA10</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-22</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute for Clinical and Experimental Medicine (IKEM)</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>19AEEF26-280E-4C52-B0CF-3360C8B9C7DC</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-16</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Requirement of complement C3 for transplant tolerance induction</gtr:description><gtr:id>E16B1049-06F5-4950-BE2D-402FA588DCAD</gtr:id><gtr:impact>The initial results showing the requirement for C3 in tolerance to skin grafts was presented at an international meeting.</gtr:impact><gtr:outcomeId>E5078E54AA2-1</gtr:outcomeId><gtr:partnerContribution>Provided a Clinical Fellow with an interest in complement and transplantation. This has enabled a new scientific question to be addressed.</gtr:partnerContribution><gtr:piContribution>Led to the initial observation that C3 deficient mice were resistant to tolerance induction.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>63F5E96D-1C72-475C-B2B9-42AD9D661E74</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-2</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Portsmouth Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>A1FFAB80-761B-4CC5-AE31-EEC58FA3A218</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-6</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>28C7F02F-BE9F-4BAE-B453-D3E0FE5E06F8</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-7</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Libre Bruxelles (Universit? Libre de Bruxelles ULB)</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>The KCL-Belgium-China herbal toxicity axis</gtr:description><gtr:id>D8E1E341-9B3E-412C-AB28-24B06552FEEC</gtr:id><gtr:impact>This a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&amp;amp;flag=1&amp;amp;journal_id=sjzyyw&amp;amp;year_id=2015
(2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, St&amp;eacute;vigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075
http://www.sciencemag.org/content/347/6219/337.3.summary
(3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075
http://www.sciencemag.org/content/346/6216/1569.4.summary</gtr:impact><gtr:outcomeId>56deb714d837a5.87833543-1</gtr:outcomeId><gtr:partnerContribution>Qu is a visiting fellow in my lab, who brought in knowledge and resources on Chinese herbal medicine and drafted the part of information published in Chinese; Bunel was a PhD studewnt of Duez, who led the first draft, esp. focused on those information published in English; Duez is a long-term collaborator of my FP7 GP-TCM poroject. He brought in expertise and knowledge from a pharmacology/toxicology point of view. Duez and Qu are Co-Chairs of the Pharmacology &amp;amp; Toxicology Interest Group of the GP-TCM Research Association that I led to establish in 2012.</gtr:partnerContribution><gtr:piContribution>I led the conception, research design and oversaw the whole project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cellogic GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>FP7 Consortium</gtr:description><gtr:id>25C2F6D4-F5BE-45BB-AFEC-BE5AE69BCD3F</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-13</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Opsona Therapeutics</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>Therapeutic strategy for toll like receptor blockade in ischaemia reperfusion injury of kidney transplant</gtr:description><gtr:id>D86E10D3-1D80-4A7B-AAE6-73CF48249D44</gtr:id><gtr:impact>Publication in FASEBJ concerning the pre-clinical results</gtr:impact><gtr:outcomeId>iYn4Tuff6Qu-2</gtr:outcomeId><gtr:partnerContribution>by providing therapeutic tools their contribution has enhanced our understanding of the role of the innate immune response in transplantation and the interaction between toll like receptors and complementby providing therapeutic tools their contribution has enhanced our understanding of the role of the innate immune response in transplantation and the interaction between toll like receptors and complement</gtr:partnerContribution><gtr:piContribution>Senior PI at the Centre is the chief clinical investigator and leads work packages on biomarker identification and pre-clinical models using therapeutic antibody.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>East Kent Hospitals University NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>B0368ABE-4CDF-459A-9782-F9E6D9945236</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-9</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bern</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>23A4BCE0-38A3-4921-A64C-8AEA637492AF</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-17</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charit? - University of Medicine Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>F5A92B8E-7874-44E8-B0FE-6496B9C3B563</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:outcomeId>Di6eNnTLGsc-1</gtr:outcomeId><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation.

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Wellcome Trust Case Control Consortium 3</gtr:description><gtr:id>22837C94-3F64-4849-8986-CB2D1647A210</gtr:id><gtr:impact>A pilot genome study involving around 600 donor-recipient pairs at Guy's Hospital has been completed. Publication on Complement genes submitted.</gtr:impact><gtr:outcomeId>1488911461E-1</gtr:outcomeId><gtr:partnerContribution>funding and SNP analysis</gtr:partnerContribution><gtr:piContribution>Graham Lord and co-applicants in the MRC Centre put together a transplant GWAS proposal, which led to a network of 22 transplant centres in the UK and Ireland who will contribute donor and recipient DNA.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leicester General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Renal Unit</gtr:department><gtr:description>GAMBIT consortium</gtr:description><gtr:id>1E06AAD2-BDE5-4AD6-9A65-7BA4F3D9F770</gtr:id><gtr:impact>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:impact><gtr:outcomeId>nXSmrQtFDMZ-4</gtr:outcomeId><gtr:partnerContribution>Enabled the 3rd validation of biomarkers of Tolerance
Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance</gtr:partnerContribution><gtr:piContribution>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leeds Teaching Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>BADC4383-1A9B-4698-9E19-5252ACD07870</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-20</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ALTA</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Research and Development in Biotechnology</gtr:department><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>2E808F40-68F1-4A7A-BF8B-F7A629A7994F</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:outcomeId>Di6eNnTLGsc-9</gtr:outcomeId><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation.

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Health Scotland</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>825EA8B0-CEFE-4529-963E-9968A021E748</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-6</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with UCB</gtr:description><gtr:id>80D07C03-520F-4A76-A030-47B605E90EA8</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>5874b8b7c9bc10.59193190-1</gtr:outcomeId><gtr:partnerContribution>UCB will provide a novel drug for this investigator-led study</gtr:partnerContribution><gtr:piContribution>Formal consultancy arrangement with UCB concerning planning and delivery of a phase 2 clinical trial in renal transplant patients</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>592E7488-FBB0-40B9-9148-97DE5096F802</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-27</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Salford Royal NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>1171B37A-9126-4A5B-AA74-CF0C28D203AE</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-5</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals of Leicester NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>8A03867B-38A0-41F2-9071-C7BCF1EE2C9C</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-4</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute for Clinical and Experimental Medicine (IKEM)</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>FP7 Consortium</gtr:description><gtr:id>A1DBC7BF-E166-415D-9A10-7265B299D777</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-6</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of East Anglia</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine UEA</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>686B239F-A95B-4702-B2D2-19F23044D9F6</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-12</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Great Ormond Street Hospital (GOSH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>7CEA9F7D-3D17-44ED-9313-73E44E2C3E10</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-14</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>B1B14989-8140-4E7A-BC82-8BA732A7C57E</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-7</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff and Vale University Health Board</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>0750A0D9-37C1-459A-A8BE-BF35FCA984A8</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-18</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Genome Identification Diagnostics GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>FP7 Consortium</gtr:description><gtr:id>9E48466D-C0D0-4542-A512-344DF9E7B204</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-16</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Transplantation</gtr:department><gtr:description>MRC Centre for Transplantation</gtr:description><gtr:id>D795E93E-69E5-442C-852A-9C7C019922F2</gtr:id><gtr:impact>Being within the MRC Centre, within King's College London, within Guy's Hospital has significantly contributed to success in applications to British Heart Foundation, Kidney Research UK and commercial organisations for research funding.</gtr:impact><gtr:outcomeId>FHAJMkACJEM-1</gtr:outcomeId><gtr:partnerContribution>Increased collaboration with Richard Smith, Steve Sacks, Gio Lombardi and Maria Hernandez-Fuentes. All have had significant intellectual input into the work</gtr:partnerContribution><gtr:piContribution>Team has become emerged within the centre</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cellogic GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>F91064F5-D585-40C4-94B3-69AA3734B74E</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:outcomeId>Di6eNnTLGsc-13</gtr:outcomeId><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation.

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Universitario La Paz</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Cost action in preparation. &amp;quot;Immuno modulation strategies to improve outcomes in transplanted children&amp;quot;</gtr:description><gtr:id>2FAD2637-F98A-4F10-9013-EED24CF9C3BC</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>56d81ecb652ad2.77866236-1</gtr:outcomeId><gtr:partnerContribution>n/a</gtr:partnerContribution><gtr:piContribution>Establishing objectives and partnership</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Infection, Immunity and Inflammation</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>61436912-E6D5-42ED-85C0-CBE6130FB4C2</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-17</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Milenia Biotec GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>FP7 Consortium</gtr:description><gtr:id>7E7C8566-172C-4D23-AE8C-1FD2BEC0EE62</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-17</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Renal Department</gtr:department><gtr:description>OuTSMART investigators</gtr:description><gtr:id>196A2FF5-4855-46F4-A356-92AFF888309B</gtr:id><gtr:impact>None yet, except OuTSMART trial initiated and recruitment started.</gtr:impact><gtr:outcomeId>TmFwQRxxCfC-3</gtr:outcomeId><gtr:partnerContribution>Co-PIs at recruitment site</gtr:partnerContribution><gtr:piContribution>All are co-applicants on OuTSMART grant</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Ophthalmology UCL</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>8F5A36E8-9860-4F72-B448-07A307BEA6C4</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-7</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Cooperation in Science and Technology (COST)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>Cost action BM1305. &amp;quot;Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies (A FACTT)&amp;quot;</gtr:description><gtr:id>6469A30E-9187-461C-9F3F-BC1B1EB64CF1</gtr:id><gtr:impact>1. Science Translational Medicine 09 Sep 2015: Vol. 7, Issue 304, pp. 304ps18 DOI: 10.1126/scitranslmed.aaa7721 2. 3 x Joint Management Committee (MC) and Working Groups (WG) Meetings have taken place in Newcastle (2014), Lisbon (2015) and Gdansk (2015)</gtr:impact><gtr:outcomeId>56d81e14cfe675.26145914-1</gtr:outcomeId><gtr:partnerContribution>Provide talks, information, SOPs and collaborating in writing a manuscript</gtr:partnerContribution><gtr:piContribution>ME and my team participate in 2 working subgroups &amp;quot;Flow Cytometry&amp;quot;, &amp;quot;mRNA-QPCR analysis&amp;quot; and &amp;quot;Functional Analysis&amp;quot;. Mainly in method harmonisation process</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Libre Bruxelles (Universit? Libre de Bruxelles ULB)</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>Indices of Tolerance</gtr:description><gtr:id>699A3934-7CC5-4574-BF9F-1682F1ED6DC1</gtr:id><gtr:impact>JOURNAL ARTICLES:
PMID: 20501946 
PMID: 20501943
PMID: 20383145
PMID: 18633344
TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51
PMID: 17700166
PMID: 16082338 
PMID: 17004249
Transplant Proc. 2007 Oct;39(8):2665-7


COMMUNICATIONS: 
 Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005.
 A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007.

POSTERS
 The Renal Association Annual Conference, May 2007, Brighton UK. &amp;quot;Indices of tolerance in kidney transplants&amp;quot; P103-PG05
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients&amp;quot;.
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Biomarkers of tolerance in kidney transplants&amp;quot;.
 World Transplant Congress July 2006, Boston USA. &amp;quot;Advances in Immune Monitoring in Renal Transplantation&amp;quot;.
 British Transplantation Society, March 2006, Edinburgh UK. &amp;quot;Indices of immunological tolerance&amp;quot;.
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription&amp;quot;.
 British Society of Immunology February 2007, Glasgow UK. &amp;quot;Tregs in peripheral blood of Clinically defined groups of renal transplant recipients&amp;quot;

ORAL COMMUNICATIONS
 XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. &amp;quot;Indices of tolerance in kidney transplants.&amp;quot;
 World Transplant Congress July 2006, Boston USA. &amp;quot;Indices of tolerance: Interim Report&amp;quot;.
 7th Trends in immunosuppression, February 2006 Berlin, Germany. &amp;quot;Fingerprinting tolerance in Renal Transplantation&amp;quot;. Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21
 American Transplant Congress May 2007. &amp;quot;Is it possible to tissue type a kidney donor who is no longer available?&amp;quot;.
 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. &amp;quot;T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection.&amp;quot; Oral presentation by Patrick Miqueu.</gtr:impact><gtr:outcomeId>hCNshj7SE9U-5</gtr:outcomeId><gtr:partnerContribution>Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did &amp;quot;the trans-vivo&amp;quot; DTH assay, etc ....</gtr:partnerContribution><gtr:piContribution>King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator.
We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St James's University Hospital (Jimmy's)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Renal Unit</gtr:department><gtr:description>OuTSMART investigators</gtr:description><gtr:id>BD10CF6C-4987-4A1C-A5F0-9A7F207AD50C</gtr:id><gtr:impact>None yet, except OuTSMART trial initiated and recruitment started.</gtr:impact><gtr:outcomeId>TmFwQRxxCfC-1</gtr:outcomeId><gtr:partnerContribution>Co-PIs at recruitment site</gtr:partnerContribution><gtr:piContribution>All are co-applicants on OuTSMART grant</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>East Kent Hospitals University NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Renal Services East Kent Hospitals University</gtr:department><gtr:description>GAMBIT consortium</gtr:description><gtr:id>149A3D59-8FF1-44A0-BD7D-58BF3DA98D56</gtr:id><gtr:impact>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:impact><gtr:outcomeId>nXSmrQtFDMZ-9</gtr:outcomeId><gtr:partnerContribution>Enabled the 3rd validation of biomarkers of Tolerance
Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance</gtr:partnerContribution><gtr:piContribution>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nottingham University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>F1F8306C-2033-418C-B258-0DD4150BA015</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-3</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hull and East Yorkshire Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>48232001-107C-4076-ADC9-92226D5F01CA</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-3</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manchester University NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>BFEEDA4E-B771-4C98-AFDA-C4A18611B713</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-10</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charit? - University of Medicine Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>BIO-DRIM FP7 EU Consortium</gtr:description><gtr:id>866F7A6C-AA46-4BAC-8FEF-A040BEB3E10F</gtr:id><gtr:impact>No outputs yet.</gtr:impact><gtr:outcomeId>545216a0ed9296.75344185-1</gtr:outcomeId><gtr:partnerContribution>Support on quality of life and health-economic analyses.
Support on biomarker commercialisation strategy.</gtr:partnerContribution><gtr:piContribution>We are the lead investigators in a multi-national clinical trial of immunosuppression discontinuation in liver transplantation. The trial involves clinical sites in UK, Germany, Belgium and Spain, and is funded in part by the EU FP7 BIO-DRIM Consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Human Genetics</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>7282A400-2F89-4C58-A040-9BF168F0B74A</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-4</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Infection, Immunity and Inflammation</gtr:department><gtr:description>Studies on collectin 11 in renal ischaemia-reperfusion injury</gtr:description><gtr:id>4F16D22F-DFED-4E02-A42A-497A93BFC2DB</gtr:id><gtr:impact>Journal of Clinical Investigation publication in press.</gtr:impact><gtr:outcomeId>56d9ae212170f3.10300067-1</gtr:outcomeId><gtr:partnerContribution>Expertise on the lectin pathway.</gtr:partnerContribution><gtr:piContribution>We are the principle investigators on a grant that funds this research. This includes animal models for native and transplanted kidneys and cell culture studies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Astellas Pharma</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>7A3A7169-245D-470C-B5B7-0FB79413B045</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:outcomeId>Di6eNnTLGsc-8</gtr:outcomeId><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation.

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Plymouth Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>AFCD433E-1F3E-450F-BAF4-7648B8073820</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-13</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Research Department of Epidemiology and Public Health</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>AF28E64F-20B8-400A-B07D-A0DA10414390</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-9</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Transplantation</gtr:department><gtr:description>The role of retinioic acid in regulatory t cell function</gtr:description><gtr:id>375779D8-CB57-4C6C-9CD9-930795F399F1</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>LHckfe3Y3UL-1</gtr:outcomeId><gtr:partnerContribution>Defined the role in human regulatory T cells</gtr:partnerContribution><gtr:piContribution>Defined that regulatory T cells need retinoic acid to function</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Catalan Health Institute (ICS)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:department>University Hospital of Bellvitge (HUB)</gtr:department><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>6F40A991-782B-4128-BF45-02018F7A0C30</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:outcomeId>Di6eNnTLGsc-5</gtr:outcomeId><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation.

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Zhejiang University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:department>Institute of Respiratory Medicine</gtr:department><gtr:description>Lecture tour of China 2</gtr:description><gtr:id>FBDB6B00-2BBE-4308-BB9D-59DD0691A6A0</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>tDuUhynGkue-1</gtr:outcomeId><gtr:partnerContribution>Mutual cooperation in research projects</gtr:partnerContribution><gtr:piContribution>Hoping to gain collaborative partners in research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College Hospital NHS Foundation Trust (NCH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>92416B4B-B939-43DC-B758-453F05BC58AC</gtr:id><gtr:impact>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:impact><gtr:outcomeId>nXSmrQtFDMZ-8</gtr:outcomeId><gtr:partnerContribution>Enabled the 3rd validation of biomarkers of Tolerance
Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance</gtr:partnerContribution><gtr:piContribution>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Renal NHSGGC</gtr:department><gtr:description>GAMBIT consortium</gtr:description><gtr:id>1EC51BCA-5D53-45DC-99C2-F9C099944B92</gtr:id><gtr:impact>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:impact><gtr:outcomeId>nXSmrQtFDMZ-2</gtr:outcomeId><gtr:partnerContribution>Enabled the 3rd validation of biomarkers of Tolerance
Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance</gtr:partnerContribution><gtr:piContribution>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Transplantation</gtr:department><gtr:description>Complement and Coagulation interaction in hyperacute rejection</gtr:description><gtr:id>7F549FCC-E900-4217-A726-3023B35EF7EE</gtr:id><gtr:impact>Presentation of findings at international complement and transplant meetings.

Potential new treatment strategy relevant to sentised transplant recipients.

New IP registered for the membrane targeted antithrombin (PTL004 and PTL006).</gtr:impact><gtr:outcomeId>GoXHW4wcbZQ-1</gtr:outcomeId><gtr:partnerContribution>It has exposed new interactions between thrombin and complement regulators induced by antibody bidning and has identified a new therapeutic strategy for prevention of rejection</gtr:partnerContribution><gtr:piContribution>Rat model of hyperacute rejection. Model for therapeutic intervention by treatement of the donor organ with membrane associated thrombin and complement regulators</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ALTA</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>FP7 Consortium</gtr:description><gtr:id>5062E9E6-7410-4199-BB7B-62EF0D6B47BD</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-9</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Hamburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>E0F38E63-D3DC-48D7-AB24-9E38D61A00FD</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:outcomeId>Di6eNnTLGsc-12</gtr:outcomeId><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation.

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Liver Department</gtr:department><gtr:description>Mark Thursz</gtr:description><gtr:id>1ED9D7EA-D589-4565-92F5-5A86FFECF0EC</gtr:id><gtr:impact>Abstract at international meeting 2012</gtr:impact><gtr:outcomeId>fsrz5iz3dmq-1</gtr:outcomeId><gtr:partnerContribution>began a new line of enquiry in a model of liver fibrosis, looking at the contribution of coagulation proteins</gtr:partnerContribution><gtr:piContribution>supply of mice. delivery of a seminar, plus intellectual input into the</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal London Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Royal London Renal Unit</gtr:department><gtr:description>OuTSMART investigators</gtr:description><gtr:id>A7DD6DE8-259D-4B83-AC61-BFE44A5E236B</gtr:id><gtr:impact>None yet, except OuTSMART trial initiated and recruitment started.</gtr:impact><gtr:outcomeId>TmFwQRxxCfC-4</gtr:outcomeId><gtr:partnerContribution>Co-PIs at recruitment site</gtr:partnerContribution><gtr:piContribution>All are co-applicants on OuTSMART grant</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nagoya University</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>Prof Masahide Takahashi (Nagoya University, Japan)</gtr:description><gtr:id>ED47E04B-E6EF-453A-8FDC-9EE91F9F40C7</gtr:id><gtr:impact>Data generation is progressing well, we expect a first collaborative paper in 2014.</gtr:impact><gtr:outcomeId>oHK9fh3Nb4r-1</gtr:outcomeId><gtr:partnerContribution>Dr. Takahashi's group provided the CD109 KO mouse strain to us and is performing at the same time experiments to asses the role of CD109n in vivo in infection models.</gtr:partnerContribution><gtr:piContribution>Collaborative experiments on the role of CD109 in human T cell responses. We are assesing the novel function of CD109 mostly on human T cells.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine Southampton</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>C2389D0F-2712-485F-81B9-80FF0A377458</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-20</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Portsmouth Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>E5FE37A1-D92D-4F3E-A780-32A1386FAA6E</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-22</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ChemoCentryx</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Use of C5a-receptor humanised mice to evolve a treatment strategy in renal infections</gtr:description><gtr:id>230FF392-F4F7-4C74-B17E-5051026F230F</gtr:id><gtr:impact>Obtained a MRC grant</gtr:impact><gtr:outcomeId>54524a2e8039c8.32138663-1</gtr:outcomeId><gtr:partnerContribution>By providing C5aR antagonist andhuman C5aR transgenic mice</gtr:partnerContribution><gtr:piContribution>The company is one of my collaborators on the recently awarded MRC project grant</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>D43DA575-277B-4201-8023-F7DBDC29D17D</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-21</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Mons</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>The KCL-Belgium-HKU herbal fibrosis axis</gtr:description><gtr:id>29918FD6-DF12-472E-B845-1629E2D3A356</gtr:id><gtr:impact>This a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&amp;amp;flag=1&amp;amp;journal_id=sjzyyw&amp;amp;year_id=2015
(2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, St&amp;eacute;vigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075
http://www.sciencemag.org/content/347/6219/337.3.summary
(3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075
http://www.sciencemag.org/content/346/6216/1569.4.summary</gtr:impact><gtr:outcomeId>56deb78711ca29.21702070-2</gtr:outcomeId><gtr:partnerContribution>Feng brought in knowledge and resources on Chinese herbal medicine; Duez is a long-term collaborator of my FP7 GP-TCM poroject. He brought in expertise and knowledge from a pharmacology/toxicology point of view. Duez, as well as King's academic co-authors Hendry and Hylands are members of the GP-TCM Research Association that I led to establish in 2012.</gtr:partnerContribution><gtr:piContribution>I led the conception, research design and oversaw the whole project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>5EB3B03B-9A31-4673-A688-64F77BFF8CB1</gtr:id><gtr:impact>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:impact><gtr:outcomeId>nXSmrQtFDMZ-7</gtr:outcomeId><gtr:partnerContribution>Enabled the 3rd validation of biomarkers of Tolerance
Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance</gtr:partnerContribution><gtr:piContribution>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pennsylvania</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Prof John Lambris (University of Pennsylvania, USA)</gtr:description><gtr:id>9047580F-D69F-4690-9AF4-A627C5DEC1E1</gtr:id><gtr:impact>A manuscript is in preparation. The data from this collaboration were presented at the 14th European meeting on Complement in Human Disease and chosen for an oral presentation and outstanding oral presentation award.</gtr:impact><gtr:outcomeId>cMsxFmYG392-1</gtr:outcomeId><gtr:partnerContribution>Delivery of specific, commercially non-available reagents, performance of experiments</gtr:partnerContribution><gtr:piContribution>Exchange of data on new functions of the C5aR and C5L2 in human T cell biology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Molecular and Cell Biology</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>9D38EA35-7F15-44E8-86AF-09C3DA33CF9D</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-18</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Coventry and Warwickshire NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>70FB32C5-BFAC-4FF8-87DE-0208BAB2B35D</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-23</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC National Institute for Medical Research (NIMR)</gtr:department><gtr:description>Total chemical synthesis of Cytectin</gtr:description><gtr:id>6164BAD4-4376-4DDB-A638-6260AD81FBF6</gtr:id><gtr:impact>draft patent under discussion</gtr:impact><gtr:outcomeId>ou9caHVW1gz-1</gtr:outcomeId><gtr:partnerContribution>Peptide synthesis to the above design</gtr:partnerContribution><gtr:piContribution>chemical design of Cytectin</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Complement UK</gtr:description><gtr:id>9F544D03-15D9-491A-8FBD-11A7B803D17A</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-11</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital Regensburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>EU Consortium</gtr:description><gtr:id>725393E6-C205-4A17-A848-2CBE00D4AAE6</gtr:id><gtr:impact>Few manuscripts submitted.</gtr:impact><gtr:outcomeId>pUHf5L5eKRf-2</gtr:outcomeId><gtr:partnerContribution>Use of different cell type with the aim to induce tolerance in renal transplant patients</gtr:partnerContribution><gtr:piContribution>Use of regulatory Tregs for the induction of tolerance in renal transplant patients</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>36114D51-9BB3-4FCE-96BF-40C23E78F840</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:outcomeId>Di6eNnTLGsc-4</gtr:outcomeId><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation.

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Hong Kong</gtr:collaboratingOrganisation><gtr:country>Hong Kong, Special Administrative Region of China</gtr:country><gtr:description>The KCL-Belgium-HKU herbal fibrosis axis</gtr:description><gtr:id>CD354356-3127-4B4E-8DB2-E44DBDA1E41D</gtr:id><gtr:impact>This a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&amp;amp;flag=1&amp;amp;journal_id=sjzyyw&amp;amp;year_id=2015
(2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, St&amp;eacute;vigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075
http://www.sciencemag.org/content/347/6219/337.3.summary
(3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075
http://www.sciencemag.org/content/346/6216/1569.4.summary</gtr:impact><gtr:outcomeId>56deb78711ca29.21702070-1</gtr:outcomeId><gtr:partnerContribution>Feng brought in knowledge and resources on Chinese herbal medicine; Duez is a long-term collaborator of my FP7 GP-TCM poroject. He brought in expertise and knowledge from a pharmacology/toxicology point of view. Duez, as well as King's academic co-authors Hendry and Hylands are members of the GP-TCM Research Association that I led to establish in 2012.</gtr:partnerContribution><gtr:piContribution>I led the conception, research design and oversaw the whole project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>BDE51620-495A-4C52-9EA9-75FA426DB87B</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-11</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of San Francisco (USF)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Cell therapy in liver transplant patients</gtr:description><gtr:id>450E97A9-063A-494B-9DCD-39C9A02E9943</gtr:id><gtr:impact>1 publication so far.</gtr:impact><gtr:outcomeId>ZLpgfNjv71Z-1</gtr:outcomeId><gtr:partnerContribution>Generation of antigen-specific Tregs using B cells as antigen presenting cells.</gtr:partnerContribution><gtr:piContribution>Comparison of cell therapy using two preparations of regulatory T cells in liver transplant patients with the same clinical therapy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's and St Thomas' NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>F746B9BD-4DB1-467D-9455-C9D5DE33D039</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-15</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biological Sciences</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>4F178981-6719-48BB-B346-C74BF055148A</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-15</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>FP7 Consortium</gtr:description><gtr:id>F09CADAB-F598-4F09-81F4-082B8B308640</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-4</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Mons</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>GP-TCM</gtr:description><gtr:id>8E3F2BD5-9E56-439B-80E1-576BC318742F</gtr:id><gtr:impact>his a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&amp;amp;flag=1&amp;amp;journal_id=sjzyyw&amp;amp;year_id=2015
(2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, St&amp;eacute;vigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075
http://www.sciencemag.org/content/347/6219/337.3.summary
(3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075
http://www.sciencemag.org/content/346/6216/1569.4.summary</gtr:impact><gtr:outcomeId>56deb7f6014c11.88796100-1</gtr:outcomeId><gtr:partnerContribution>Everyone brings in their perspectives and literature study outcomes in terms of integrated toxicological approaches to herbal medicines. I provided my perspectives as the PI of the GP-TCM project and as a nephrologist.</gtr:partnerContribution><gtr:piContribution>I advised the research design and drafted part of the project and provided critical review and revision.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Prof Andrew Cope (King's College London, UK)</gtr:description><gtr:id>D38518E6-D97A-49FB-8937-D6754F28428F</gtr:id><gtr:impact>Several high impact publications over the last 3 years, the last 'Evidence for intracellular C3 activation and its dysregulaion in autoimmune arthritis' which is currently in press. The data from this collaboration were presented at the 14th European meeting on Complement in Human Disease and chosen for an oral presentation and outstanding oral presentation award.</gtr:impact><gtr:outcomeId>oFZiAcfdgdi-1</gtr:outcomeId><gtr:partnerContribution>Delivery of RA patient samples, collaborative experiments (the Cope and Kemper laboratory share a NovoNordisk-funded postdoctoral fellow, Dr. Esperanza perucha) and exchange od data and ideas</gtr:partnerContribution><gtr:piContribution>Assessment of the complement in aberrant T cell resposnes from rheumatoid arthritis (RA) patients</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Liverpool and Broadgreen University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>D340A652-CD4D-4BCB-B1E3-286556E26D28</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-2</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Prof David Abraham (UCL, UK)</gtr:description><gtr:id>6EE6D7BA-E03B-4FB6-8FB8-55A9CD5C83F3</gtr:id><gtr:impact>We expect outputs and outcomes by the middle/end of 2014</gtr:impact><gtr:outcomeId>oSUioLoPXYe-1</gtr:outcomeId><gtr:partnerContribution>Delivery of Scleroderma patients samples, collaborative experiments, exchange of data, reagents and ideas.</gtr:partnerContribution><gtr:piContribution>Collaborative experiments, training of a postdoctoral fellow from Dr. Abraham's laboratory (Dr. Sandra Guerra) in T cell-related techniques with emphasis on the roles of CD46, C5L2 and CD109 in Scleroderma.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Yale University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Yale University</gtr:description><gtr:id>BDFA85D3-E56B-418B-9555-96C2C8064721</gtr:id><gtr:impact>Publication available in e Print. Author Prof Adrian Hayday. Journal of Investigative Dermatology 2009. Study of T cells that promote tissue growth and wound repair.</gtr:impact><gtr:outcomeId>7216E5BB161-1</gtr:outcomeId><gtr:partnerContribution>Development of collaborative programme</gtr:partnerContribution><gtr:piContribution>Development of collaborative research programme</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Interdisciplinary Transplant Research Group</gtr:description><gtr:id>8F1657D0-F1A2-4D73-89A8-23C1CC854F14</gtr:id><gtr:impact>Multidisciplinary: Law, Bioethics, Social Science, Clinical Science, Health Economics, Psychology.</gtr:impact><gtr:outcomeId>Ca9NeC8dpqz-1</gtr:outcomeId><gtr:partnerContribution>Contribution to group by workshop presentations, draft papers. The group is recently formed but outputs in the form of publications and policy document proposals are anticipated. Collaborators from the Universities of Cambridge, Oxford, and Bristol.</gtr:partnerContribution><gtr:piContribution>PI of group and grant holder for programme of research Increasing understanding on the quality and allocation of human organs for transplantation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Mons</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>The KCL-Belgium-China herbal toxicity axis</gtr:description><gtr:id>90C4CE76-AA10-4823-87DB-01616C0E0EBC</gtr:id><gtr:impact>This a multidisciplinary collaboration among nephrologist (Xu), pharmacologist/toxicologist (Duez and Bunel) and expert in traditional Chinese medicine. Outputs include: (1) Bunel V, Qu F, Duez P, Xu Q. Herbal medicines for acute kidney injury: Evidence, gaps and frontiers. World Journal of Traditional Chinese Medicine. 2015;1(3):47-66. ISSN: 2311-8571 http://www.wjtcm.org:8080/ch/reader/create_pdf.aspx?file_no=20150019&amp;amp;flag=1&amp;amp;journal_id=sjzyyw&amp;amp;year_id=2015
(2) Williamson EM, Chan K, Xu Q, Nachtergael A, Bunel V, Zhang L, Ouedraogo M, Nortier J, Qu F, Shaw D, Liu X, St&amp;eacute;vigny C, Kahumba J, Pelkonen O, Duez P. Evaluating the safety of herbal medicines: Integrated toxicological approaches. Science 2015, 347(6219 Suppl), S47-S49. ISSN: 0036-8075
http://www.sciencemag.org/content/347/6219/337.3.summary
(3) Xu Q, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. Science 2014; 346 (6216 Suppl), S19-S20. ISSN: 0036-8075
http://www.sciencemag.org/content/346/6216/1569.4.summary</gtr:impact><gtr:outcomeId>56deb714d837a5.87833543-2</gtr:outcomeId><gtr:partnerContribution>Qu is a visiting fellow in my lab, who brought in knowledge and resources on Chinese herbal medicine and drafted the part of information published in Chinese; Bunel was a PhD studewnt of Duez, who led the first draft, esp. focused on those information published in English; Duez is a long-term collaborator of my FP7 GP-TCM poroject. He brought in expertise and knowledge from a pharmacology/toxicology point of view. Duez and Qu are Co-Chairs of the Pharmacology &amp;amp; Toxicology Interest Group of the GP-TCM Research Association that I led to establish in 2012.</gtr:partnerContribution><gtr:piContribution>I led the conception, research design and oversaw the whole project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Lubeck</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Prof Joerg Koehl (University of Luebeck, Germany)</gtr:description><gtr:id>2199DBCF-DDF0-42CC-B996-8D4E90672A7B</gtr:id><gtr:impact>A manuscript is in preparation. The data from this collaboration were presented at the 14th European meeting on Complement in Human Disease and chosen for an oral presentation and outstanding oral presentation award.</gtr:impact><gtr:outcomeId>k3RUq1bDGZu-1</gtr:outcomeId><gtr:partnerContribution>Collaborative experiments, exchange of data and reagents. Delivery of commercially non-available key reagents.</gtr:partnerContribution><gtr:piContribution>Collaborative experiments on new functions of C5aR and C5L2 in human T cell biology, exchange of ideas and data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Trinity College Dublin</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>Therapeutic strategy for toll like receptor blockade in ischaemia reperfusion injury of kidney transplant</gtr:description><gtr:id>6D3C866B-DECB-4FE9-A2F7-5772365EA4A1</gtr:id><gtr:impact>Publication in FASEBJ concerning the pre-clinical results</gtr:impact><gtr:outcomeId>iYn4Tuff6Qu-1</gtr:outcomeId><gtr:partnerContribution>by providing therapeutic tools their contribution has enhanced our understanding of the role of the innate immune response in transplantation and the interaction between toll like receptors and complementby providing therapeutic tools their contribution has enhanced our understanding of the role of the innate immune response in transplantation and the interaction between toll like receptors and complement</gtr:partnerContribution><gtr:piContribution>Senior PI at the Centre is the chief clinical investigator and leads work packages on biomarker identification and pre-clinical models using therapeutic antibody.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>EMPIRIKAL Consortium</gtr:description><gtr:id>0866CDAA-0A04-4A3B-BB48-F97F0E395954</gtr:id><gtr:impact>First investigator meeting held October 2012. Protocol modifications.</gtr:impact><gtr:outcomeId>dvHNwbVBuxo-1</gtr:outcomeId><gtr:partnerContribution>Planning of the protocol. Potential patient involvement.</gtr:partnerContribution><gtr:piContribution>We have provided the underpinning science to the clinical trial (EMPIRIKAL) of a novel membrane associated complement regulator, have formulated the clinical protocol and have secured funding with the MRC DCS to enable the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bath</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Biology and Biochemistry</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>EF609E37-DEE8-486E-A0AD-D50A9B31268D</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-13</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Transplantation</gtr:department><gtr:description>Retinoic acid in B cell function in the gut</gtr:description><gtr:id>9E5C5A3B-B170-481C-A81F-FA7F811632FC</gtr:id><gtr:impact>none</gtr:impact><gtr:outcomeId>PDBQpcFfEKi-1</gtr:outcomeId><gtr:partnerContribution>Provided systems and technical expertise in analysis of B cell fatee</gtr:partnerContribution><gtr:piContribution>Developed models to study the role of retinoic acid in controlling B cell function</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Indices of Tolerance</gtr:description><gtr:id>6045B082-4709-49E9-91D9-CC92E7862B1F</gtr:id><gtr:impact>JOURNAL ARTICLES:
PMID: 20501946 
PMID: 20501943
PMID: 20383145
PMID: 18633344
TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51
PMID: 17700166
PMID: 16082338 
PMID: 17004249
Transplant Proc. 2007 Oct;39(8):2665-7


COMMUNICATIONS: 
 Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005.
 A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007.

POSTERS
 The Renal Association Annual Conference, May 2007, Brighton UK. &amp;quot;Indices of tolerance in kidney transplants&amp;quot; P103-PG05
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients&amp;quot;.
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Biomarkers of tolerance in kidney transplants&amp;quot;.
 World Transplant Congress July 2006, Boston USA. &amp;quot;Advances in Immune Monitoring in Renal Transplantation&amp;quot;.
 British Transplantation Society, March 2006, Edinburgh UK. &amp;quot;Indices of immunological tolerance&amp;quot;.
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription&amp;quot;.
 British Society of Immunology February 2007, Glasgow UK. &amp;quot;Tregs in peripheral blood of Clinically defined groups of renal transplant recipients&amp;quot;

ORAL COMMUNICATIONS
 XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. &amp;quot;Indices of tolerance in kidney transplants.&amp;quot;
 World Transplant Congress July 2006, Boston USA. &amp;quot;Indices of tolerance: Interim Report&amp;quot;.
 7th Trends in immunosuppression, February 2006 Berlin, Germany. &amp;quot;Fingerprinting tolerance in Renal Transplantation&amp;quot;. Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21
 American Transplant Congress May 2007. &amp;quot;Is it possible to tissue type a kidney donor who is no longer available?&amp;quot;.
 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. &amp;quot;T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection.&amp;quot; Oral presentation by Patrick Miqueu.</gtr:impact><gtr:outcomeId>hCNshj7SE9U-2</gtr:outcomeId><gtr:partnerContribution>Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did &amp;quot;the trans-vivo&amp;quot; DTH assay, etc ....</gtr:partnerContribution><gtr:piContribution>King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator.
We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxford University Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>8F994A49-136E-4624-BBC1-91E5AFE787B1</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-8</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Amsterdam</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>E1EC8EE8-E0EE-482F-B387-747C4AB91BF3</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:outcomeId>Di6eNnTLGsc-10</gtr:outcomeId><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation.

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Immune Tolerance Network</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Immune Tolerance Network</gtr:description><gtr:id>2AE34C52-C267-42B7-BBC1-0447B3810A7E</gtr:id><gtr:impact>No outputs yet.</gtr:impact><gtr:outcomeId>5452183a7229b7.04910512-1</gtr:outcomeId><gtr:partnerContribution>Will provide funds and biological specimens to conduct the outlined experiments.</gtr:partnerContribution><gtr:piContribution>King's will act as the central laboratory for gene expression analysis of the I-WITH trial, a US multi-centre clinical trial of immunosuppression withdrawal in paediatric liver transplant recipients. We will be responsible for conducting PCR and microarray experiments as well as data analysis.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pure Protein LLC</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Pure Protein</gtr:description><gtr:id>ED1C893C-BA8E-4A21-9090-F9681DA739C5</gtr:id><gtr:impact>None yet - we are hoping to identify HLA-specific B cells</gtr:impact><gtr:outcomeId>HSnQ8QBbqvb-1</gtr:outcomeId><gtr:partnerContribution>Biochemical expertise and availability of purified HLA proteins</gtr:partnerContribution><gtr:piContribution>Providing the samples and patient outcome data</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff and Vale University Health Board</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>362714CC-F926-441C-A516-24F1A61B7424</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-1</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oslo</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>Prof Tom Mollnes (Stockholm, Norway)</gtr:description><gtr:id>304C59F8-F5B7-4074-91F3-5D73410AB16D</gtr:id><gtr:impact>A manuscript is in preparation. The data from this collaboration were presented at the 14th European meeting on Complement in Human Disease and chosen for an oral presentation and outstanding oral presentation award.</gtr:impact><gtr:outcomeId>bVdf8VEFyzw-1</gtr:outcomeId><gtr:partnerContribution>Delivery of rare C5-deficient patient samples, collaborative experiments, exchange of reagents</gtr:partnerContribution><gtr:piContribution>Collaborative experiments on new functions of C5aR and C5L2 in human T cell biology, exchange of ideas and data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals of Leicester NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>660B74AE-59BE-4702-BFA1-7790EACC9B39</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-5</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>6EFD691B-DC06-42A3-9DA2-4502CDFA09A4</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-1</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Sir William Dunn School of Pathology</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>02ACC178-C7B6-42BB-A02E-2FBE57AB3D4C</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-19</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Portsmouth Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Queen Alexandra Hospital</gtr:department><gtr:description>GAMBIT consortium</gtr:description><gtr:id>89405368-CA7E-41FF-B4CD-CA828D8932C1</gtr:id><gtr:impact>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:impact><gtr:outcomeId>nXSmrQtFDMZ-6</gtr:outcomeId><gtr:partnerContribution>Enabled the 3rd validation of biomarkers of Tolerance
Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance</gtr:partnerContribution><gtr:piContribution>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Hamburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>FP7 Consortium</gtr:description><gtr:id>8B2954C1-A053-4B78-B525-1AAC14A874D3</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-12</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>9FB070B2-A74C-4A0C-8817-5783DB016F83</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-16</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Milenia Biotec GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>528AFA56-3046-44FE-8AF3-196AA84B3EEF</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:outcomeId>Di6eNnTLGsc-16</gtr:outcomeId><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation.

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Regensburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>EDFEABD3-74F7-4395-ABFE-405D50587334</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:outcomeId>Di6eNnTLGsc-11</gtr:outcomeId><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation.

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>530916C3-B812-4159-BE45-2941393E8EB0</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-26</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>TcLand Expression</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>FP7 Consortium</gtr:description><gtr:id>A9AACBC8-920B-4882-8359-B84ACF44B7AC</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-15</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Sanger Centre</gtr:description><gtr:id>D2C2407E-AA60-4CD8-AB42-EF32B42D5D24</gtr:id><gtr:impact>Publications from Prof Adrian Hayday. Journal of Investigative Dermatology 2009 (eprint ahead of publication). European Journal of Immunology 39: 1794-1806. Study of human gamma delta T-cell subsets and functions.</gtr:impact><gtr:outcomeId>6028D140CAD-1</gtr:outcomeId><gtr:partnerContribution>Development of collaborative programme</gtr:partnerContribution><gtr:piContribution>Development of collaborative programme</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Infection and Immunity</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>82F16CED-0FF2-4932-B0FD-DEA9EACDD07F</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-1</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bristol-Myers Squibb</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>FP7 Consortium</gtr:description><gtr:id>4D537D01-BB11-491A-A3D8-B685D60BD0A0</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-7</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Human Genetics Unit</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>5F76BCF6-1B7D-4FA7-BC54-B93DB8469470</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-16</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Infection, Immunity and Inflammation</gtr:department><gtr:description>The role of the lactin pathway (MASP2) in ischemia reperfusion injury</gtr:description><gtr:id>3CB9A40A-94C8-4E4D-8B5F-79CF6AB6535A</gtr:id><gtr:impact>Presentation at International complement and transplant meetings

Publication in PNAS; second publication submitted

Collaboration with industry (OMEROS) on a new theraputic monoclonal antibody</gtr:impact><gtr:outcomeId>FH8wJG2veKP-1</gtr:outcomeId><gtr:partnerContribution>Revised my thinking on the complement pathway responsible for triggering complement activation during and after transplantation</gtr:partnerContribution><gtr:piContribution>Models for ischemia reperfusion injury in native and transplant organs using knockout mice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ChemoCentryx</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Chemocentryx</gtr:description><gtr:id>7371ACAD-ABBD-4F07-BC69-47D20F2C3F50</gtr:id><gtr:impact>Grant submitted to the MRC using pilot data generated by this partnership.</gtr:impact><gtr:outcomeId>j4h3jvDEwaN-1</gtr:outcomeId><gtr:partnerContribution>Donated the complement inhibitor and transgenic mice expressing the human target.</gtr:partnerContribution><gtr:piContribution>Testing a human complement inhibitor (C5a receptor anatgonist) in animal models.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's and St Thomas' NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Antibody Incompatible Transplantation</gtr:description><gtr:id>94D23F20-4573-4179-9E89-29E2B17DA16D</gtr:id><gtr:impact>The Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK.</gtr:impact><gtr:outcomeId>YLuiYMq4bMV-1</gtr:outcomeId><gtr:partnerContribution>The Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK.</gtr:partnerContribution><gtr:piContribution>Nizam Mamode set up and is Clinical Lead for the Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK. 
As well as reporting outcome data, I am interested in the effect of B cell depletion on T cell responses in blood group incompatible transplant patients. This project was carried out at Guys but has involved collaboration with a national study of blood group incompatible patients (the ABOUT-K study run by Dr Simon Ball in Birmingham).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Sir William Dunn School of Pathology</gtr:department><gtr:description>Cytectin structural studies</gtr:description><gtr:id>DE810A8B-B2ED-45DE-98A7-D12310E20D09</gtr:id><gtr:impact>Publication May 2013 Cell Reports
Cell Rep. 2013 May 30;3(5):1369-77. doi: 10.1016/j.celrep.2013.04.029. Epub 2013 May 9.
Structural basis for recognition of the pore-forming toxin intermedilysin by human complement receptor CD59.
Johnson S, Brooks NJ, Smith RA, Lea SM, Bubeck D.
PMID: 23665225 [PubMed - in process] PMCID: PMC3675674</gtr:impact><gtr:outcomeId>KMCnMHZ3NY5-1</gtr:outcomeId><gtr:partnerContribution>Oxford University provided data on its structural interaction with membranes.</gtr:partnerContribution><gtr:piContribution>Provided Cytectin</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leeds Teaching Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>CAEDDB5E-772A-49E9-AE12-12BF7D2607F5</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-10</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK Autoimmune Hepatitis Consortium</gtr:description><gtr:id>8CDF4D25-C01E-4B38-B423-CA490D002C8B</gtr:id><gtr:impact>Started determination of gene expression profile on liver biopsy samples</gtr:impact><gtr:outcomeId>54578f119ec081.51506325-1</gtr:outcomeId><gtr:partnerContribution>Creating a blood and tissue bank where samples (and data generated from their analysis) can be accessed and used</gtr:partnerContribution><gtr:piContribution>Participation in prospective follow-up cohort studies, GWAS, eQTL and Epigenetics</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Libre Bruxelles (Universit? Libre de Bruxelles ULB)</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>RISET - FP6 Consortium</gtr:description><gtr:id>5D49B8FC-21AB-4B25-9D4E-FA4F6DA68A0B</gtr:id><gtr:impact>Multiple journal articles</gtr:impact><gtr:outcomeId>ATXPotMZoMm-1</gtr:outcomeId><gtr:partnerContribution>There were 15 partners that contributed to 7 workpackages in an integrated study.</gtr:partnerContribution><gtr:piContribution>Reprogramming the Immune System for Establishment of Tolerance. Validated the signature discovered in the Indices of Tolerance study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Antibody Incompatible Transplantation</gtr:description><gtr:id>52E6333B-350C-4331-84F6-0225E974BA9D</gtr:id><gtr:impact>The Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK.</gtr:impact><gtr:outcomeId>YLuiYMq4bMV-2</gtr:outcomeId><gtr:partnerContribution>The Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK.</gtr:partnerContribution><gtr:piContribution>Nizam Mamode set up and is Clinical Lead for the Guys Antibody Incompatible Transplant Programme, the largest in the UK. We now have the first paediatric blood group incompatible transplantation programme in the UK. 
As well as reporting outcome data, I am interested in the effect of B cell depletion on T cell responses in blood group incompatible transplant patients. This project was carried out at Guys but has involved collaboration with a national study of blood group incompatible patients (the ABOUT-K study run by Dr Simon Ball in Birmingham).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Barts Health NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>0B7DC7E4-299B-4474-88C7-4271658658D3</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-15</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pittsburgh</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Pharmaceutical Sciences</gtr:department><gtr:description>University of Pittsburgh - Immunology Department</gtr:description><gtr:id>EB359229-2A4C-4712-98B9-45DC0F305740</gtr:id><gtr:impact>1. Imperial College PhD award for Chih Che Li 2. Publications: a. Pubmed ID: 19000927 b. Pubmed ID: 18791452</gtr:impact><gtr:outcomeId>84AF4D023C4-1</gtr:outcomeId><gtr:partnerContribution>Contributed one year of work in our laboratory for a self funded PhD student.</gtr:partnerContribution><gtr:piContribution>We provided the expertise, laboratory equipment and facilities and intellectual input into this project. The work was partly funded by NIH grant.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Studies on the antagonism of CD59 as an anti-tumour strategy</gtr:description><gtr:id>83DE52FB-CAEE-45E4-BEE9-129764D073DE</gtr:id><gtr:impact>Part of the structural work has been published in 2013</gtr:impact><gtr:outcomeId>5458c7e0ab0d00.33980113-1</gtr:outcomeId><gtr:partnerContribution>Our partners have undertaken structural studies on CD59 and modified CD59 binding to liposomes as a model for cellular interaction.</gtr:partnerContribution><gtr:piContribution>This project concerns the cytotopic modification of a peptide antagonist of CD59. My group has provided recombinant human CD59 in both cytotopic and unmodified forms. We have also provided a cytotopic reagent to permit the modification of the antagonist.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Stanford University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>Tolerance in Renal Transplantation</gtr:description><gtr:id>D4A7569D-2830-4D00-B082-8B362B469888</gtr:id><gtr:impact>This procedure has not yet been performed in Europe and we hope to perform our first case in 2014.</gtr:impact><gtr:outcomeId>aMLHUcmcdVw-2</gtr:outcomeId><gtr:partnerContribution>I have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved collaboration with Prof Spitzer at Harvard University and Prof Strober at Stanford. I lead a large group which is developing this including haematologists and immunologists from Guys and St Thomas Hospital, Kings College Hospital and Kings College. This procedure has not yet been performed in Europe and we hope to perform our first case inI have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved collaboration with Prof Spitzer at Harvard University and Prof Strober at Stanford. I lead a large group which is developing this including haematologists and immunologists from Guys and St Thomas Hospital, Kings College Hospital and Kings College. This procedure has not yet been performed in Europe and we hope to perform our first case in 2014.</gtr:partnerContribution><gtr:piContribution>I have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved collaboration with Prof Spitzer at Harvard University and Prof Strober at Stanford. I lead a large group which is developing this including haematologists and immunologists from Guys and St Thomas Hospital, Kings College Hospital and Kings College. This procedure has not yet been performed in Europe and we hope to perform our first case inI have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved collaboration with Prof Spitzer at Harvard University and Prof Strober at Stanford. I lead a large group which is developing this including haematologists and immunologists from Guys and St Thomas Hospital, Kings College Hospital and Kings College. This procedure has not yet been performed in Europe and we hope to perform our first case in 2014.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff and Vale University Health Board</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>6AFBA6E8-8032-4874-BF37-293CF734A823</gtr:id><gtr:impact>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:impact><gtr:outcomeId>nXSmrQtFDMZ-1</gtr:outcomeId><gtr:partnerContribution>Enabled the 3rd validation of biomarkers of Tolerance
Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance</gtr:partnerContribution><gtr:piContribution>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manchester University NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nephrology and Transplantation</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>E3E9624F-F99F-4631-8D4C-845CE7CFAAD1</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-24</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albert Einstein College of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Structural Studies on VISTA in the mouse</gtr:description><gtr:id>10DA5289-195B-4C19-929F-E89555A07B02</gtr:id><gtr:impact>NIH grant R01 from 2011-2016</gtr:impact><gtr:outcomeId>fHPrT88sQUw-1</gtr:outcomeId><gtr:partnerContribution>Expert structural biologist to study structure function relationships</gtr:partnerContribution><gtr:piContribution>Provision of construcrts of VISTA to study VISTA structure</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>269B385B-0E47-435F-8571-338D693BFCA1</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-5</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Immunotech S.A.S.</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>86801B50-F803-4C97-BE5C-47245C30ECD2</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:outcomeId>Di6eNnTLGsc-14</gtr:outcomeId><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation.

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Brian Sutton- Crystal structure of VISTA</gtr:description><gtr:id>FE30140D-4821-44D5-AA80-AB7BF3E8B89A</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>HCXeLr26WYs-1</gtr:outcomeId><gtr:partnerContribution>They evaluate crystal structure of VISTA</gtr:partnerContribution><gtr:piContribution>We provide recombinant VISTA proteins for structural studies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Alexion Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Alexion Pharmaceuticals</gtr:description><gtr:id>01522F70-B0E2-4290-A91E-6A878D7E029E</gtr:id><gtr:impact>The therapeutic antibody failed to penetrate into transplanted kidney and therefore helped to define types of injury that would not amenable to this particular therapeutic strategy.</gtr:impact><gtr:outcomeId>C3B90176623-1</gtr:outcomeId><gtr:partnerContribution>Alexion Pharmaveuticals provided Chemicals, Consumables and animals to this study</gtr:partnerContribution><gtr:piContribution>We collaborated on an investigator led pre clinical study to determine the impact of complement inhibitor (anti-C5) on reperfusion injury in native and transplant kidneys.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Cellular and Molecular Medicine</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>7A3522F7-0C04-4160-B674-5A7CCFC0B4C6</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-2</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manchester University NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Renal Care</gtr:department><gtr:description>GAMBIT consortium</gtr:description><gtr:id>3C1356BD-0D1E-4D32-91A6-3AE28C0471D5</gtr:id><gtr:impact>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:impact><gtr:outcomeId>nXSmrQtFDMZ-13</gtr:outcomeId><gtr:partnerContribution>Enabled the 3rd validation of biomarkers of Tolerance
Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance</gtr:partnerContribution><gtr:piContribution>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Manchester University NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Renal Care</gtr:department><gtr:description>OuTSMART investigators</gtr:description><gtr:id>7DC0BB15-DAD0-49BC-814F-74F10FFDACFB</gtr:id><gtr:impact>None yet, except OuTSMART trial initiated and recruitment started.</gtr:impact><gtr:outcomeId>TmFwQRxxCfC-2</gtr:outcomeId><gtr:partnerContribution>Co-PIs at recruitment site</gtr:partnerContribution><gtr:piContribution>All are co-applicants on OuTSMART grant</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>STIFF FLOP</gtr:description><gtr:id>AF21036F-F059-47CD-A4BA-008B7F8314E9</gtr:id><gtr:impact>200 publications, over 30 presnetations in international meetings, IEEE workshops, press coverageby the BBC, MULTIDICIPLINARY COLLABORATION between engineers,computer scientists,simulation experts and surgeons</gtr:impact><gtr:outcomeId>56e04b803a3200.72232633-1</gtr:outcomeId><gtr:partnerContribution>?</gtr:partnerContribution><gtr:piContribution>Design, development and validation of an octopus inspired soft robot</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Immunotech S.A.S.</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>FP7 Consortium</gtr:description><gtr:id>A26311F2-C28B-4A47-AEE0-9B48A45C4F7A</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-14</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Indices of Tolerance</gtr:description><gtr:id>653FC918-80B1-40B0-9E0F-E6964AC948A5</gtr:id><gtr:impact>JOURNAL ARTICLES:
PMID: 20501946 
PMID: 20501943
PMID: 20383145
PMID: 18633344
TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51
PMID: 17700166
PMID: 16082338 
PMID: 17004249
Transplant Proc. 2007 Oct;39(8):2665-7


COMMUNICATIONS: 
 Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005.
 A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007.

POSTERS
 The Renal Association Annual Conference, May 2007, Brighton UK. &amp;quot;Indices of tolerance in kidney transplants&amp;quot; P103-PG05
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients&amp;quot;.
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Biomarkers of tolerance in kidney transplants&amp;quot;.
 World Transplant Congress July 2006, Boston USA. &amp;quot;Advances in Immune Monitoring in Renal Transplantation&amp;quot;.
 British Transplantation Society, March 2006, Edinburgh UK. &amp;quot;Indices of immunological tolerance&amp;quot;.
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription&amp;quot;.
 British Society of Immunology February 2007, Glasgow UK. &amp;quot;Tregs in peripheral blood of Clinically defined groups of renal transplant recipients&amp;quot;

ORAL COMMUNICATIONS
 XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. &amp;quot;Indices of tolerance in kidney transplants.&amp;quot;
 World Transplant Congress July 2006, Boston USA. &amp;quot;Indices of tolerance: Interim Report&amp;quot;.
 7th Trends in immunosuppression, February 2006 Berlin, Germany. &amp;quot;Fingerprinting tolerance in Renal Transplantation&amp;quot;. Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21
 American Transplant Congress May 2007. &amp;quot;Is it possible to tissue type a kidney donor who is no longer available?&amp;quot;.
 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. &amp;quot;T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection.&amp;quot; Oral presentation by Patrick Miqueu.</gtr:impact><gtr:outcomeId>hCNshj7SE9U-1</gtr:outcomeId><gtr:partnerContribution>Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did &amp;quot;the trans-vivo&amp;quot; DTH assay, etc ....</gtr:partnerContribution><gtr:piContribution>King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator.
We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Veterinary School</gtr:department><gtr:description>Mirococept collaboration with Cambridge University</gtr:description><gtr:id>470B1371-3F37-425C-A4B9-A233EEE036BA</gtr:id><gtr:impact>Supportive data for clinical use of Mirococept in novel indications.</gtr:impact><gtr:outcomeId>F66QxKTQ74L-1</gtr:outcomeId><gtr:partnerContribution>Providing laboratory facilities and Factor I</gtr:partnerContribution><gtr:piContribution>Supplied Mirococept and other reagents and collaborated in experiments.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Renal Unit Sheffield Teaching Hospitals</gtr:department><gtr:description>GAMBIT consortium</gtr:description><gtr:id>641DD1B9-0BCA-4DE7-A660-FCC690409F78</gtr:id><gtr:impact>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:impact><gtr:outcomeId>nXSmrQtFDMZ-11</gtr:outcomeId><gtr:partnerContribution>Enabled the 3rd validation of biomarkers of Tolerance
Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance</gtr:partnerContribution><gtr:piContribution>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dresden</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Islet research group Dresden</gtr:description><gtr:id>3D1C30CE-48EE-40E3-8708-991A25AE2360</gtr:id><gtr:impact>1st successful grant application</gtr:impact><gtr:outcomeId>5460bc22a146f9.84042221-1</gtr:outcomeId><gtr:partnerContribution>Our team provide human islets for research and we are about to start a King's based Diabetes UK funded study of implanting minimal islet mass in an immune isolating device in adults with type 1 diabetes as a pilot trial. &amp;pound; 79020 has been awarded from Diabetes UK.</gtr:partnerContribution><gtr:piContribution>Sharing of human islet resources; collaborative grant application for trial of implantable device</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free London NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>66095934-DB74-47D3-A04F-7169BFDC6033</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-12</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>BMI The Beaumont Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>8192B4DE-1214-4DC2-AFCA-F4089C0EA283</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-19</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Opsona Therapeutics</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>MABSOT Trial</gtr:description><gtr:id>47B8E588-CDF1-4E85-B38A-56502FDC5AF2</gtr:id><gtr:impact>Drug manufacture. Completion of Phase 1 study in healthy volunteers. Identification of several potential biomarkers for ischaemia reperfusion injury of transplanted kidney. Clinical Trial recruitment started.</gtr:impact><gtr:outcomeId>q6pWVqvtzVm-1</gtr:outcomeId><gtr:partnerContribution>Provided the therapeutic agent, anti-TLR2 antibody. They also provided the contract work for analysis of biomarkers (with Almac).</gtr:partnerContribution><gtr:piContribution>Co-Chief investigator for the clinical trial. PI on work packages in animal, biomarker and Serum Amyloid A studies to support the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Catalan Health Institute (ICS)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:department>University Hospital of Bellvitge (HUB)</gtr:department><gtr:description>FP7 Consortium</gtr:description><gtr:id>27411FFF-6F2F-4E8A-AF70-9127C62ACDF9</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-5</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Transplantation</gtr:department><gtr:description>Suppression of kidney disease by VISTA-Ig</gtr:description><gtr:id>CBFA4E44-0CA9-4AB3-B461-D9AAAB07395A</gtr:id><gtr:impact>none</gtr:impact><gtr:outcomeId>Q9Vjp2bdPPz-1</gtr:outcomeId><gtr:partnerContribution>Developed murine models of kidney disease to test VISTA-Ig</gtr:partnerContribution><gtr:piContribution>Developed VISTA-Ig as an immunosuppressive drug</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>FDFF2391-843E-4CF5-A32C-9E33411FB0BE</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-17</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's and St Thomas' NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>EFD0EFCA-B4EC-4350-BD7E-30ABA9D38F7C</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-25</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Transplantation</gtr:department><gtr:description>The role of VISTA in inflammatory bowel disease</gtr:description><gtr:id>7AD4FB2E-4529-4468-A795-FA7207D5087E</gtr:id><gtr:impact>AICR grant from 2012-2015</gtr:impact><gtr:outcomeId>B59vQvEDSWP-1</gtr:outcomeId><gtr:partnerContribution>Developed systems to test the role of VISTA in murine models of IBD</gtr:partnerContribution><gtr:piContribution>Showed that VISTA was expressed in the gut</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute for Clinical and Experimental Medicine (IKEM)</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>F5B05CC4-041B-4934-9BB9-BBE5C0D62AAA</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:outcomeId>Di6eNnTLGsc-6</gtr:outcomeId><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation.

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's and St Thomas' NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Assessing the role of complement-mediated regulation of Th1 responses in health and disease</gtr:description><gtr:id>F57D9124-FFE2-45C2-9D48-6837048F636F</gtr:id><gtr:impact>&amp;quot;Grant money: 2011-2018. IMI (Innovative Medicine Initiative - FP7/2009) by the European Union. Understanding aberrant adaptive immunity mechanisms in human chronic immune-mediated diseases: rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease. Application package jointly submitted by 14 European Research Institutions and 11 Biotechnology companies. Coordinating Director: Prof. Dr. T.W.J. Huizinga, Leiden University, Netherlands. &amp;Acirc;?6.5 Mio. King&amp;Acirc;' College portion: &amp;Acirc;&amp;pound;680.000 Role: Leading Scientist (King&amp;Acirc;'s College Stream; Lead-PI: Andy Cope) 2011-2014 MRC Project Grant. The molecular and cellular basis of complement-mediated T helper 1 (Th1) differentiation and regulation. Kemper C, Cope A, Rebello-Mesa I and Lavender P. &amp;Acirc;&amp;pound;860.000 Role: 

PI Peer reviewed publications:

 1.Cardone, J, Le Friec, G, Vantourout, P, Roberts, A, Fuchs, A, Jackson, I, Suddason, T, Lord, G, Atkinson, JP, Cope, A, Hayday, A and Kemper, C. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol 2010. 11(9):862-871. 
 2. Cope, A, Le Friec, G, Cardone, C and Kemper, C. The lifecycle of Th1 cells: molecular control of IFN-&amp;Icirc;&amp;sup3; to IL-10 switching. TRENDS Immunol 2011. 32:278-286.
 3. Cardone, C, Le Friec, G, and Kemper, C. CD46 in innate and adaptive immunity: An update. Clin Exp Immunol 2011. 164:301-311. 
4. Heeger, P, and Kemper, C. Novel roles of complement in T effector cell regulation. Immunobiology. 2011. doi:10.1016/j.imbio.2011.06.004

 Conference presentations/invited lectures: 
Immunology Seminar Series, Oxford University, Dunn School of Pathology; Complement and T cell homeostasis. 2010 &amp;Acirc;'John Humphrey Seminar Series&amp;Acirc;' at Imperial College, London, UK; Complement: Tipping the balance between successful host defense and autoimmunity. 2010 Regional BSI group seminar series Cardiff University, UK; Complement during T cell activation: Timing (and the microenvironment) is key. 2010 BSI Annual Conference, Liverpool, UK; Complement, T cells and autoimmunity. 2011 Immunology Seminar Series, Cambridge University; Innate signals regulating Th1 immunity. 2011 Wright-Fleming Institute Seminar Series, Imperial College London; Towards a molecular Th1 life cycle signature. 2011 UCB, Slough, UK. Therapeutic interventions in Th1-mediated autoimmune disease states. 2011 8th International Conference on Innate Immunity, Chania, Greece: Innate immune signals in the regulation of Th1 responses. 2011 Annual BSI &amp;Acirc;'Showcase of Immunology&amp;Acirc;', London, UK; CD46: Just a Notch up your common complement regulator.&amp;quot;</gtr:impact><gtr:outcomeId>YhSkCCpS9qs-1</gtr:outcomeId><gtr:partnerContribution>We have partnered with several clinicians working on rheumatoid arthritis (RA) at Guy's hospital. In addition, we are now included in an ongoing clinical trial at Guy's Hospital assessing factors that help predicting if and when RA patients can be 'weaned off' anti-TNF therapy.</gtr:partnerContribution><gtr:piContribution>We have discovered one of the molecular pathways controlling IFN-gamma ; 'shut down' in Th1 cells and the corresponding defect in RA patients T cells. We are now assessing this pathway in detail - as the 'basic science team' - and keep collaborating with the clinical team to asses if identified deregulation points can be predicted or corrected therapeutically in RA patients.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Rigel Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Rigel Pharmaceuticals</gtr:description><gtr:id>157D8F22-5CAD-4ABC-8F88-3092FA75E5A6</gtr:id><gtr:impact>We have published a paper, Pubmed ID: 16946104</gtr:impact><gtr:outcomeId>E022DA382DD-1</gtr:outcomeId><gtr:partnerContribution>Rigel has provided a new drug compound (syk kinase inhibitor)</gtr:partnerContribution><gtr:piContribution>We have developed a biomarker for clinical trial of the syk kinase inhibitor.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nantes</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Indices of Tolerance</gtr:description><gtr:id>29B12A75-D1AC-4DAF-A9A7-46C0D7CB562B</gtr:id><gtr:impact>JOURNAL ARTICLES:
PMID: 20501946 
PMID: 20501943
PMID: 20383145
PMID: 18633344
TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51
PMID: 17700166
PMID: 16082338 
PMID: 17004249
Transplant Proc. 2007 Oct;39(8):2665-7


COMMUNICATIONS: 
 Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005.
 A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007.

POSTERS
 The Renal Association Annual Conference, May 2007, Brighton UK. &amp;quot;Indices of tolerance in kidney transplants&amp;quot; P103-PG05
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients&amp;quot;.
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Biomarkers of tolerance in kidney transplants&amp;quot;.
 World Transplant Congress July 2006, Boston USA. &amp;quot;Advances in Immune Monitoring in Renal Transplantation&amp;quot;.
 British Transplantation Society, March 2006, Edinburgh UK. &amp;quot;Indices of immunological tolerance&amp;quot;.
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription&amp;quot;.
 British Society of Immunology February 2007, Glasgow UK. &amp;quot;Tregs in peripheral blood of Clinically defined groups of renal transplant recipients&amp;quot;

ORAL COMMUNICATIONS
 XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. &amp;quot;Indices of tolerance in kidney transplants.&amp;quot;
 World Transplant Congress July 2006, Boston USA. &amp;quot;Indices of tolerance: Interim Report&amp;quot;.
 7th Trends in immunosuppression, February 2006 Berlin, Germany. &amp;quot;Fingerprinting tolerance in Renal Transplantation&amp;quot;. Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21
 American Transplant Congress May 2007. &amp;quot;Is it possible to tissue type a kidney donor who is no longer available?&amp;quot;.
 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. &amp;quot;T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection.&amp;quot; Oral presentation by Patrick Miqueu.</gtr:impact><gtr:outcomeId>hCNshj7SE9U-3</gtr:outcomeId><gtr:partnerContribution>Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did &amp;quot;the trans-vivo&amp;quot; DTH assay, etc ....</gtr:partnerContribution><gtr:piContribution>King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator.
We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Alexion Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collectin 11 at the front line of tissue response stress - Complement UK research studentship</gtr:description><gtr:id>F5CFD552-6C73-497B-93FA-FAAC4C627A7A</gtr:id><gtr:impact>Obtained a full PhD studentship (4 years)</gtr:impact><gtr:outcomeId>54524ab6192d66.91162313-1</gtr:outcomeId><gtr:partnerContribution>Full PhD scholarship (4 years)</gtr:partnerContribution><gtr:piContribution>Prepared PhD project proposal and being the primary supervisor of the PhD student</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard Medical School</gtr:department><gtr:description>Tolerance in Renal Transplantation</gtr:description><gtr:id>F3E08C27-C3D7-4223-8CFE-88014F664AC3</gtr:id><gtr:impact>This procedure has not yet been performed in Europe and we hope to perform our first case in 2014.</gtr:impact><gtr:outcomeId>aMLHUcmcdVw-1</gtr:outcomeId><gtr:partnerContribution>I have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved collaboration with Prof Spitzer at Harvard University and Prof Strober at Stanford. I lead a large group which is developing this including haematologists and immunologists from Guys and St Thomas Hospital, Kings College Hospital and Kings College. This procedure has not yet been performed in Europe and we hope to perform our first case inI have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved collaboration with Prof Spitzer at Harvard University and Prof Strober at Stanford. I lead a large group which is developing this including haematologists and immunologists from Guys and St Thomas Hospital, Kings College Hospital and Kings College. This procedure has not yet been performed in Europe and we hope to perform our first case in 2014.</gtr:partnerContribution><gtr:piContribution>I have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved collaboration with Prof Spitzer at Harvard University and Prof Strober at Stanford. I lead a large group which is developing this including haematologists and immunologists from Guys and St Thomas Hospital, Kings College Hospital and Kings College. This procedure has not yet been performed in Europe and we hope to perform our first case inI have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved collaboration with Prof Spitzer at Harvard University and Prof Strober at Stanford. I lead a large group which is developing this including haematologists and immunologists from Guys and St Thomas Hospital, Kings College Hospital and Kings College. This procedure has not yet been performed in Europe and we hope to perform our first case in 2014.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leeds Teaching Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>840D85B3-0704-4BBD-87C9-2DE10A7E8B41</gtr:id><gtr:impact>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:impact><gtr:outcomeId>nXSmrQtFDMZ-10</gtr:outcomeId><gtr:partnerContribution>Enabled the 3rd validation of biomarkers of Tolerance
Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance</gtr:partnerContribution><gtr:piContribution>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Immune Tolerance Network</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Indices of Tolerance</gtr:description><gtr:id>EA319145-B4C4-4C50-B067-15F331E251DB</gtr:id><gtr:impact>JOURNAL ARTICLES:
PMID: 20501946 
PMID: 20501943
PMID: 20383145
PMID: 18633344
TRANSPLANT PROC. 2008 Jul-Aug;40(6):1847-51
PMID: 17700166
PMID: 16082338 
PMID: 17004249
Transplant Proc. 2007 Oct;39(8):2665-7


COMMUNICATIONS: 
 Induction of tolerance to living donor liver transplantion using myeloconditionning and donor stem cells infusion: A pilot study. American Transplant Congress 2005, Seattle, USA, May 2005.
 A rapid test of alloreactivity based on IL2 mRNA expression might identify liver transplant recipients developing donor-specific hyporesponsiveness. European Society for Organ Transplantation, Prague, October 2007.

POSTERS
 The Renal Association Annual Conference, May 2007, Brighton UK. &amp;quot;Indices of tolerance in kidney transplants&amp;quot; P103-PG05
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Monitoring peripheral blood regulatory T cells on clinically defined groups of kidney transplant recipients&amp;quot;.
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Biomarkers of tolerance in kidney transplants&amp;quot;.
 World Transplant Congress July 2006, Boston USA. &amp;quot;Advances in Immune Monitoring in Renal Transplantation&amp;quot;.
 British Transplantation Society, March 2006, Edinburgh UK. &amp;quot;Indices of immunological tolerance&amp;quot;.
 American Transplant Congress May 2007, San Francisco USA. &amp;quot;Identification of tolerant patients based on a combinatorial analysis of Foxp3 and aMannosidase transcription&amp;quot;.
 British Society of Immunology February 2007, Glasgow UK. &amp;quot;Tregs in peripheral blood of Clinically defined groups of renal transplant recipients&amp;quot;

ORAL COMMUNICATIONS
 XXXI CONGRESSO della Societa Italiana Trapianti d'Organo, November 2007, Modena Italy. &amp;quot;Indices of tolerance in kidney transplants.&amp;quot;
 World Transplant Congress July 2006, Boston USA. &amp;quot;Indices of tolerance: Interim Report&amp;quot;.
 7th Trends in immunosuppression, February 2006 Berlin, Germany. &amp;quot;Fingerprinting tolerance in Renal Transplantation&amp;quot;. Sagoo P, Hernandez-Fuentes M, Jimenez-Vera E, Rovis F, Hilton R, Warrens A, Lechler RI. Abstract book p A21
 American Transplant Congress May 2007. &amp;quot;Is it possible to tissue type a kidney donor who is no longer available?&amp;quot;.
 8th International Conference on New Trends in Immunosuppression and Immunotherapy, Berlin, Germany from February 14 - 17, 2008. &amp;quot;T cell repertoire anaysis of stable kidney graft recipients for detection of low and high risk of chronic rejection.&amp;quot; Oral presentation by Patrick Miqueu.</gtr:impact><gtr:outcomeId>hCNshj7SE9U-7</gtr:outcomeId><gtr:partnerContribution>Each centre contributed with results with the assays they were experts in. As an example, Miltenyi did microarrays, University of Oxford did &amp;quot;the trans-vivo&amp;quot; DTH assay, etc ....</gtr:partnerContribution><gtr:piContribution>King's College London, led the consortium. We were the coordination centre and Prof Robert Lechler was the Chief Invstigator. Maria Hernandez-Fuentes was the study coordinator.
We obtained blood samples from 75 patients and 19 healthy controls to discover a set of biomarkers that would identify tolerant kidney transplant recipients</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College Hospital NHS Foundation Trust (NCH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>79FDDC5D-09E8-4CFA-A61B-DE45F08AC99A</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-8</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>FP7 Consortium</gtr:description><gtr:id>6CAE45FE-D4FF-453D-9084-2B99660A9180</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-3</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bristol-Myers Squibb</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>iPerian</gtr:department><gtr:description>Ipierian</gtr:description><gtr:id>9D33DBA8-8198-4C2E-89CA-676DB70BAF34</gtr:id><gtr:impact>showed the antibody (against human complement) was non functional in a rat model system.</gtr:impact><gtr:outcomeId>rv8YANf7oiV-1</gtr:outcomeId><gtr:partnerContribution>Provided the antibody and funding.</gtr:partnerContribution><gtr:piContribution>Tested the biological activity of antibody against the classical pathway of complement in an animal model.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Society of Edinburgh (RSE)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Royal Society of Edinburgh</gtr:description><gtr:id>1C5E33DE-674D-497E-8893-5431189EA9C0</gtr:id><gtr:impact>Multidisciplinary - Applied Philosophy, Health Law, Bioethics, Medicine</gtr:impact><gtr:outcomeId>Z6QarFox4zZ-1</gtr:outcomeId><gtr:partnerContribution>Application and submission and award of RS Edin grant</gtr:partnerContribution><gtr:piContribution>Oral presentation and contribution to expert working group on organ donation</gtr:piContribution><gtr:sector>Learned Society</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Structural Molecular Biology</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>590FFBF5-BCBD-4863-A023-A34B65BCA30C</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-10</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Seville</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Transplant Asia</gtr:description><gtr:id>D7459F74-A409-4058-81F2-8B3ABFBFA9F8</gtr:id><gtr:impact>Funding application was unsuccessful but the partnerships and collaborations are still active to pursue further funding opportunities</gtr:impact><gtr:outcomeId>pCvN2H2CP6Q-1</gtr:outcomeId><gtr:partnerContribution>Design the teaching materials</gtr:partnerContribution><gtr:piContribution>Designed a master course to develop a national transplantation strategy and health service in Kazakhstan, Kyrgyzstan and Tajikistan.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>50EBCEC1-49D9-4F6A-A112-9F58850A8EB4</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:outcomeId>Di6eNnTLGsc-3</gtr:outcomeId><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation.

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hull and East Yorkshire Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Renal Hull and East Yorkshire</gtr:department><gtr:description>GAMBIT consortium</gtr:description><gtr:id>D355CF75-ABEF-4711-A664-1F7C2205479F</gtr:id><gtr:impact>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:impact><gtr:outcomeId>nXSmrQtFDMZ-3</gtr:outcomeId><gtr:partnerContribution>Enabled the 3rd validation of biomarkers of Tolerance
Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance</gtr:partnerContribution><gtr:piContribution>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free London NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT Consortium</gtr:description><gtr:id>DF27E616-0EBF-41BE-ADC3-4D69A59B5222</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:outcomeId>jky4LgVRMgs-12</gtr:outcomeId><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CL-11 Ligand characterization</gtr:description><gtr:id>FDBA5391-996C-40A9-A3FB-4A022247184D</gtr:id><gtr:impact>preliminary carbohydrate array work carried out and being further developed.</gtr:impact><gtr:outcomeId>545cd340e09c16.42637094-1</gtr:outcomeId><gtr:partnerContribution>Specialist knowledge concerning carbohydrate arrays enabling exploration of the Collectin-11 ligand on renal tissue.</gtr:partnerContribution><gtr:piContribution>We established the relationship on the basis of preliminary data on Collectin-11. We provided the research question in support of the successful grant application awarded by the MRC.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Transplantation</gtr:department><gtr:description>VISTA in regualtory t cell function</gtr:description><gtr:id>133C2BFF-DC12-4093-B432-6F9A39DA3C63</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>V1AVYLTkSm1-1</gtr:outcomeId><gtr:partnerContribution>Defining the function of VISTA on human reguatory T cells</gtr:partnerContribution><gtr:piContribution>Defined the function of VISTA on murine regulatory t cells</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>720E316F-3B93-4366-9E48-8AB0C1593921</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-8</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Anti inflammatory and anti thrombin - Duke University</gtr:description><gtr:id>91814D58-B8D3-4908-8E78-78971FD3DD18</gtr:id><gtr:impact>Abstract at the American Society for Transplantation</gtr:impact><gtr:outcomeId>56d9b039cbb619.28759086-1</gtr:outcomeId><gtr:partnerContribution>Research training and consumables including non human primates.</gtr:partnerContribution><gtr:piContribution>What the link embraces
1. Distinctive areas of strength that complement the academic plans at both Centres
2. Added value to the training of future clinical-academic leaders A cross-centre training programme based on a critical set of scientific questions and skills
3. Enhanced metrics for training in health services research
4. Benefits of cross-centre evaluation of clinical-academic programmes 
5. Leveraging funding to support the proposed activities and goals</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Interdisciplinary Transplant Research Group</gtr:description><gtr:id>ECB0E7BF-8C04-442A-AEBE-45396AC699F1</gtr:id><gtr:impact>Multidisciplinary: Law, Bioethics, Social Science, Clinical Science, Health Economics, Psychology.</gtr:impact><gtr:outcomeId>Ca9NeC8dpqz-3</gtr:outcomeId><gtr:partnerContribution>Contribution to group by workshop presentations, draft papers. The group is recently formed but outputs in the form of publications and policy document proposals are anticipated. Collaborators from the Universities of Cambridge, Oxford, and Bristol.</gtr:partnerContribution><gtr:piContribution>PI of group and grant holder for programme of research Increasing understanding on the quality and allocation of human organs for transplantation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Genome Identification Diagnostics GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>F55E6AE6-9E28-4E0F-9CAC-A37EBB7FA53B</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:outcomeId>Di6eNnTLGsc-15</gtr:outcomeId><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation.

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Minnesota</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Role of RA in GVHD</gtr:description><gtr:id>4AD62A6F-ADE6-47BE-A292-B02F18146AE2</gtr:id><gtr:impact>NIH Grant R01 from 2012-2015</gtr:impact><gtr:outcomeId>amvT7FTqCzU-1</gtr:outcomeId><gtr:partnerContribution>Expertise in GVHD models</gtr:partnerContribution><gtr:piContribution>Systems to stydy RA synthesis and signaling in the immune system</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cambridge University Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>7415FC2A-EB13-462E-8777-40A11683539F</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-4</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leeds Teaching Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Clinical Haematology</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>135C867B-2982-4611-9F9D-426A8E225952</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-23</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard Medical School</gtr:department><gtr:description>Harvard University</gtr:description><gtr:id>FD055DB6-A08A-422D-97FF-6C3DB4431620</gtr:id><gtr:impact>1. Organising GMEC Genetics Symposium (2009) 2. Organising workshops 3. Putting in two grant applications 4. Partnership with Quest (negotiation stage)</gtr:impact><gtr:outcomeId>CE9D59F4830-1</gtr:outcomeId><gtr:partnerContribution>We have access to confidential information and primer sequences that define potential biomarkers currently under investigation in our Centre as a result. It has facilitated recruitment of a new Professor to the MRC Centre from the USA.</gtr:partnerContribution><gtr:piContribution>We have built a research collaboration on biomarkers in transplantation with Professor Terry Strom, by giving him access to patients and testing his samples in the kidney transplant unit. We have jointly written grant awards (L. Barber and S. Longi) and we have jointly funded a joint postdoctoral researcher to look at tissue stress factors in transplantation. In addition, we have set up teaching sessions to introduce research opportunities from Harvard University and we have set up a major international symposium (GMEC Genetics Symposium, November 2009) which featured his work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Salford Royal NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>B5B824E7-CD18-4FE6-AC44-5ABA50FAB829</gtr:id><gtr:impact>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:impact><gtr:outcomeId>nXSmrQtFDMZ-5</gtr:outcomeId><gtr:partnerContribution>Enabled the 3rd validation of biomarkers of Tolerance
Enabled the plan for a clinical trial where Biomarkers will be testedEnabled the 3rd Validation of Biomarkers toleranceEnabled the 3rd validation of Biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biomarkers of toleranceEnabled the 3rd validation of biomarkers of toleranceenabled the 3rd validation of biormakers of tolerance</gtr:partnerContribution><gtr:piContribution>Enabled the 3rd validation of biomarkers of tolerance

Enabled the plan for a clinical Trial where Biomarkers will be tested</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's and St Thomas' NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Tolerance in Renal Transplantation</gtr:description><gtr:id>1C523C21-2830-406D-AB04-D08023BD34EA</gtr:id><gtr:impact>This procedure has not yet been performed in Europe and we hope to perform our first case in 2014.</gtr:impact><gtr:outcomeId>aMLHUcmcdVw-3</gtr:outcomeId><gtr:partnerContribution>I have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved collaboration with Prof Spitzer at Harvard University and Prof Strober at Stanford. I lead a large group which is developing this including haematologists and immunologists from Guys and St Thomas Hospital, Kings College Hospital and Kings College. This procedure has not yet been performed in Europe and we hope to perform our first case inI have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved collaboration with Prof Spitzer at Harvard University and Prof Strober at Stanford. I lead a large group which is developing this including haematologists and immunologists from Guys and St Thomas Hospital, Kings College Hospital and Kings College. This procedure has not yet been performed in Europe and we hope to perform our first case in 2014.</gtr:partnerContribution><gtr:piContribution>I have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved collaboration with Prof Spitzer at Harvard University and Prof Strober at Stanford. I lead a large group which is developing this including haematologists and immunologists from Guys and St Thomas Hospital, Kings College Hospital and Kings College. This procedure has not yet been performed in Europe and we hope to perform our first case inI have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved collaboration with Prof Spitzer at Harvard University and Prof Strober at Stanford. I lead a large group which is developing this including haematologists and immunologists from Guys and St Thomas Hospital, Kings College Hospital and Kings College. This procedure has not yet been performed in Europe and we hope to perform our first case in 2014.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Prof Susan Lea (Oxford University, UK)</gtr:description><gtr:id>5DB8A2C9-CB72-47E5-A0F0-A2EAD0A80500</gtr:id><gtr:impact>High Impact publication in 2010. Next collaborative publication is expected in 2014.</gtr:impact><gtr:outcomeId>K7jdsiD9ZWa-1</gtr:outcomeId><gtr:partnerContribution>Collaborative experiments on the role of the CD46/IL-2R crosstalk directing Th1 contraction, exchange of reagents, data and ideas.</gtr:partnerContribution><gtr:piContribution>Collaborative experiments on the role of the CD46/IL-2R crosstalk directing Th1 contraction, exchange of reagents, data and ideas.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charit? - University of Medicine Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>FP7 Consortium</gtr:description><gtr:id>A127F273-6C2E-4933-A796-61F07E74D3E1</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-1</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Epsom and St Helier University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>59501CC3-318E-4B9A-9A61-C598E67CBE47</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-24</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>DC7E2768-5C11-431A-AB06-86769D4EB031</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-3</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Astellas Pharma</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>FP7 Consortium</gtr:description><gtr:id>44B0F550-3BB2-4CD4-B17B-088C14AB1555</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-8</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Catholic University of Louvain</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>Jean-Paul Decuypere ERA-EDTA fellowship</gtr:description><gtr:id>551C9D89-689C-4F50-AC16-EED3C9E12021</gtr:id><gtr:impact>ERA-EDTA fellowship</gtr:impact><gtr:outcomeId>545cf751792e51.43660275-1</gtr:outcomeId><gtr:partnerContribution>Bring expertise in autophagy tot he Centre and the ongoing research programme on Complement research.</gtr:partnerContribution><gtr:piContribution>ongoing scientific collaboration, support by offering space ad facilities available for the research to be carried out and shared authorship of any publications that may arise form this collaboration; enabled fellow to obtain an ERA-EDTA fellowship.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Great North Children's Hospital (GNCH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Pediatric Nephrology</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>2AC31CD5-F717-4C33-BCD2-F7B45880A1F8</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-6</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pittsburgh</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Thomas E Starzl Transplantation Institute</gtr:department><gtr:description>NIH Xenotransplantation at Pittsburgh</gtr:description><gtr:id>C398A93D-36F5-44C9-A925-375CF4F2939D</gtr:id><gtr:impact>Multiple papers, reported elsewhere - 1st author Lin CC</gtr:impact><gtr:outcomeId>Mzym3QyWdVB-1</gtr:outcomeId><gtr:partnerContribution>PhD student to work/train in my lab. Collaboration to supply membrane tethered hirulog (thrombalexin) 2013</gtr:partnerContribution><gtr:piContribution>Collaborator on NIH-funded Xenotransplantation programme. Latterly, advisor to renewed prgramme</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College Hospital NHS Foundation Trust (NCH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Tolerance in Renal Transplantation</gtr:description><gtr:id>207CABCB-8E36-4133-A633-16D98145D840</gtr:id><gtr:impact>This procedure has not yet been performed in Europe and we hope to perform our first case in 2014.</gtr:impact><gtr:outcomeId>aMLHUcmcdVw-4</gtr:outcomeId><gtr:partnerContribution>I have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved collaboration with Prof Spitzer at Harvard University and Prof Strober at Stanford. I lead a large group which is developing this including haematologists and immunologists from Guys and St Thomas Hospital, Kings College Hospital and Kings College. This procedure has not yet been performed in Europe and we hope to perform our first case inI have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved collaboration with Prof Spitzer at Harvard University and Prof Strober at Stanford. I lead a large group which is developing this including haematologists and immunologists from Guys and St Thomas Hospital, Kings College Hospital and Kings College. This procedure has not yet been performed in Europe and we hope to perform our first case in 2014.</gtr:partnerContribution><gtr:piContribution>I have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved collaboration with Prof Spitzer at Harvard University and Prof Strober at Stanford. I lead a large group which is developing this including haematologists and immunologists from Guys and St Thomas Hospital, Kings College Hospital and Kings College. This procedure has not yet been performed in Europe and we hope to perform our first case inI have set up a programme to introduce combined bone marrow and renal transplantation, to induce tolerance; this has involved collaboration with Prof Spitzer at Harvard University and Prof Strober at Stanford. I lead a large group which is developing this including haematologists and immunologists from Guys and St Thomas Hospital, Kings College Hospital and Kings College. This procedure has not yet been performed in Europe and we hope to perform our first case in 2014.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>Complement and Coagulation interaction in hyperacute rejection</gtr:description><gtr:id>5BB783FA-FDCD-4AD7-B973-1FFE134CBB07</gtr:id><gtr:impact>Presentation of findings at international complement and transplant meetings.

Potential new treatment strategy relevant to sentised transplant recipients.

New IP registered for the membrane targeted antithrombin (PTL004 and PTL006).</gtr:impact><gtr:outcomeId>GoXHW4wcbZQ-2</gtr:outcomeId><gtr:partnerContribution>It has exposed new interactions between thrombin and complement regulators induced by antibody bidning and has identified a new therapeutic strategy for prevention of rejection</gtr:partnerContribution><gtr:piContribution>Rat model of hyperacute rejection. Model for therapeutic intervention by treatement of the donor organ with membrane associated thrombin and complement regulators</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Warwick</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Warwick Medical School</gtr:department><gtr:description>Complement UK</gtr:description><gtr:id>56AD5DCA-7CD0-4FEA-92E0-4AC5044F0727</gtr:id><gtr:impact>Alexion funded four year PhD Studentships x 4
First annual conference 2011; repeated 2012, 2013.
Special Editions of the Journal of Immunobiology (November 2012); (2013 in prep)</gtr:impact><gtr:outcomeId>dfjK8MFHQz8-21</gtr:outcomeId><gtr:partnerContribution>The partners consist of over 30 PIs at over 20 Centres in the UK. They have contributed through an Executive Committee to the strategy development and implementation. In particular they have helped run annual events and studentship funding.</gtr:partnerContribution><gtr:piContribution>Initiated formation of Complement UK in conjunction with Prof Paul Morgan (Cardiff University). Developed a research and training strategy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bristol-Myers Squibb</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>DA3175E0-9A42-4C2A-B550-EF83E4491286</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:outcomeId>Di6eNnTLGsc-7</gtr:outcomeId><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation.

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Regensburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>FP7 Consortium</gtr:description><gtr:id>D2586C37-C19B-4256-A7F2-73BA2172C172</gtr:id><gtr:impact>FP7 project submitted in September 2011 for an EU wide consortium on Biomarkers tolerance</gtr:impact><gtr:outcomeId>tQ1PUa6TFPQ-11</gtr:outcomeId><gtr:piContribution>KCL will be leading WP1 of this call; that will involve management and trial recruitment coordinator, work as a core biomarker studies. Also, KCL will be leading WP4B that involves data management / biostatistics</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>A966E305-FBDC-4AB9-BC9D-F26A001AF573</gtr:id><gtr:impact>Transplantomics III: conference where we had 3 invited speakers from the consortium
http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140

Publications:
1. Okada Y, et al; Nat Genet. 2012. PMID 22797727
2. Wain LV, et al; Nat Genet. 2011. PMID 21909110
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011. PMID 21909115

Conference communication in British Transplantation Society, March 2013. Bournemouth, UK.</gtr:impact><gtr:outcomeId>JxySEhCDjXL-14</gtr:outcomeId><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Lombardi-Mullen</gtr:description><gtr:id>E7889024-E940-479E-8E0E-8A5CF4BC0380</gtr:id><gtr:impact>2 publications already in pub med and 3 more in preparation</gtr:impact><gtr:outcomeId>p4FrZKkH8CZ-1</gtr:outcomeId><gtr:partnerContribution>expertise in full body imaging</gtr:partnerContribution><gtr:piContribution>regulatory T cell expertise and models of skin transplantation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Apellis Pharmaceutical</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Apellis (Louisville, USA)</gtr:description><gtr:id>6D4CF067-4ACB-4330-8670-B2E4A0A5B0F2</gtr:id><gtr:impact>Patent application pending</gtr:impact><gtr:outcomeId>Crq2V6xUfnQ-1</gtr:outcomeId><gtr:partnerContribution>Generation and provision of human C5L2 targeted reagents (agonists and antagonists).</gtr:partnerContribution><gtr:piContribution>Experiments on the role of C5L2 in T cell responses in in vivo disease models.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Transplantation &amp; Immunology</gtr:department><gtr:description>Novartis</gtr:description><gtr:id>10A16F82-F237-443D-A2AF-710E83CB058D</gtr:id><gtr:impact>Paper in preparation.</gtr:impact><gtr:outcomeId>c4M1W6NeLzi-1</gtr:outcomeId><gtr:partnerContribution>Financial assistance, technical help</gtr:partnerContribution><gtr:piContribution>Two way sharing of data and techniques - including a trip to Basel in August 2011 to visit Novartis Global Research and to give a talk</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Nantes</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>3C18A90C-2402-416F-B7FF-88D048584FB0</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:outcomeId>Di6eNnTLGsc-2</gtr:outcomeId><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation.

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MRC Centenary- Science Museum London Centres Cluster</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0F11C1BC-51E9-4AB7-AD77-1016E7B41E9E</gtr:id><gtr:impact>On the 15th and 16th June, volunteers from the Centre took part in the MRC Science Festival at London's Science Museum. Nine London MRC Centres came together to create 'Life: A healthy game of chance and choice', showcasing the latest MRC research. Our volunteers teamed up with Morgan, the organ delivery driver from performance group Non Zero One, to create our stand 'replacement parts', where visitors discovered what happens after a transplant and the research taking place in the Centre, which aims to help patients return to a healthy life.

1,332 visitors attended the festival over the weekend, with 97% reporting the event as &amp;quot;good&amp;quot; or &amp;quot;very good&amp;quot;</gtr:impact><gtr:outcomeId>cYc8hw2YTb4</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.centenary.mrc.ac.uk/events/science-festival/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Key note speaker to conference- Club de la Transplantation- Lille, France</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9F8C1C1A-1FCC-4B4B-93F5-7E5E79CBFB84</gtr:id><gtr:impact>Gave a talk entitled: &amp;quot;Immunotherapy after TH, ThRIL Trial</gtr:impact><gtr:outcomeId>58b59195e52e09.44254586</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Liver cell therapy workshop, warwickshire UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1FEF8ED6-90C8-483F-98BD-A41740827FC9</gtr:id><gtr:impact>Session Chair at the 4th Liver Cell Therapy Workshop, Warwickshire, UK provoking discussion and debate</gtr:impact><gtr:outcomeId>58c910dcde5644.69074324</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Steve Sacks - Royal Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>24470CFE-13DE-4EE2-BCDD-365126A74FF1</gtr:id><gtr:impact>Invited speaker, Royal Society Meeting on Complement: driver of inflammation and therapeutic target in diverse disease, Buckinghamshire, UK</gtr:impact><gtr:outcomeId>56d815e68eab89.13903213</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Steve Sacks - 8th International Conference on Complement Therapeutics, Crete, Greece</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>90370264-8C16-4AEB-81A3-E6690FF699C2</gtr:id><gtr:impact>Invited speaker</gtr:impact><gtr:outcomeId>56d8175fc9a761.29910487</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Committee Member- ONE Study, Regensberg</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A8C8D268-F504-4E67-85CB-61A89D64DEEF</gtr:id><gtr:impact>Participant to discussions as a member of the committee and working group</gtr:impact><gtr:outcomeId>58b5911d7d37e6.80632122</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Key note speaker at a conference- 3rd International Molecular and Immunology &amp; Immunogenetics Congress</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B517D446-B69F-48E1-83BC-FC91C39B34A7</gtr:id><gtr:impact>Talk entitled: &amp;quot;Clinical grade manufacture of Regulatory T cells to promote Transplantation Tolerance: Challenges and Achievements.&amp;quot;</gtr:impact><gtr:outcomeId>58b58e40ac7075.22974876</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Committee Chair Member- Cost, Galway</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>19E77523-0CE8-4583-AE59-EF131E247DDC</gtr:id><gtr:impact>Chair person and participant to discussions at COST, Galway meeting</gtr:impact><gtr:outcomeId>58b5907d4da571.91069489</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Steve Sacks - American Society of Nephrology, San Diego, USA</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7400824F-03EE-4C7F-BC40-AC7C45F263AA</gtr:id><gtr:impact>Invited speaker</gtr:impact><gtr:outcomeId>56d817d24d4f97.95177549</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Social Mobility Foundation Inernship programme</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>15F0423E-80DC-497E-B648-71592D1494A1</gtr:id><gtr:impact>The Social Mobility Foundation is organising Internship Programmes every year and the MRC Centre offered to be involved,

quote from one of our interns &amp;quot;I just wanted to say a quick thank you as the internship was very useful as it has undoubtedly heightened my understanding of the career path that I am considering. Not only has it allowed me to expand my knowledge beyond the curriculum but it has also boosted my confidence and interpersonal skills.

Thank you very much for such a great opportunity.&amp;quot;
This student is about to start her final year and pass her A levels and move on to a science higher degree.</gtr:impact><gtr:outcomeId>3349360660D</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.socialmobility.org.uk/</gtr:url><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Steve Sacks - Joint British Transplantation Society and Nederlandse Tranplantatie Vereniging Congress, Bournemouth, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4B6AA0AE-3016-4835-AE51-AD8548729FD0</gtr:id><gtr:impact>Invited speaker. 
Talk title: ' A new signal for cell death in post-ischaemic injury'</gtr:impact><gtr:outcomeId>56d8167e586763.03326367</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ericsson-KCL event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9D930396-C6D7-4B6D-B78E-514A7C0A48E4</gtr:id><gtr:impact>Unique collaboration on 5G technology. Packaging advances in surgical science to a lay audience</gtr:impact><gtr:outcomeId>56e04f3a12a063.83771564</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Steve Sacks - BANFF-CST</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CD1CA2FE-31D3-4B1C-9D6A-ED973538E46D</gtr:id><gtr:impact>Invited speaker for the BANFF-CST Joint Scientific Meeting, Vancouver, Canada</gtr:impact><gtr:outcomeId>56d8179b540a18.88129981</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Association of Urology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0A53143C-3BDA-4DEB-9D1F-12B9AF758E22</gtr:id><gtr:impact>-</gtr:impact><gtr:outcomeId>56e04deb02bef9.39496421</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Urological Society of India</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F4EBDC2B-B614-4FAA-9F8B-8B9A0A509284</gtr:id><gtr:impact>2000 attendees came to my session on systematic reviews and critical appraisal</gtr:impact><gtr:outcomeId>56e04d7d222394.68143184</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>clinical trials day 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CF0DC967-E0D0-4A8C-B7F1-4F87435B0600</gtr:id><gtr:impact>Leaflet and attendance at clinical trials day organised by the GSTT NHS trust in hospital foyer - describing trials based within the centre - stall open to general public.</gtr:impact><gtr:outcomeId>58c6c291dd0e95.58614322</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ERUS</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5EB82DB7-6FD6-4FDF-A28E-567149FDC5A4</gtr:id><gtr:impact>Live surgery. Best poster award</gtr:impact><gtr:outcomeId>56e04e3c8afe03.99803695</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British GQ Special Report: A delicate operation</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AAA7968D-6907-4D4C-B0E0-17D5AEB23ABE</gtr:id><gtr:impact>The Centre's Professor Prokar Dasgupta stars in this autumn's British GQ Special Report: A delicate operation, which tells the story of when one of the world's leading prostate surgeons, Professor Roger Kirby, himself underwent a radical prostatectomy following a diagnosis of prostate cancer in September last year. Professor Dasgupta, who learned robotics alongside Kirby in the US and has helped pioneer robotic urological surgical techniques, led the team who performed the 90 minute operation with the hi-tech da Vinci robot, one of 30 such instruments in Britain and the gold-standard treatment for a number of cancers. The article, as well as covering Kirby's diagnosis and treatment, explores the highly controversial PSA (prostate-specific antigen) screening and the arguments for and against surgical intervention, &amp;quot;a debate peppered with issues of priorities, medical expertise, money and robotic science&amp;quot;. The full article can be found in the September 2013 issue of British Gentlemen's Quarterly, also available on iPad.

The article, as well as covering Kirby's diagnosis and treatment, explores the highly controversial PSA (prostate-specific antigen) screening and the arguments for and against surgical intervention, &amp;quot;a debate peppered with issues of priorities, medical expertise, money and robotic science&amp;quot;.</gtr:impact><gtr:outcomeId>CCL7F81T5Tc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://transplantation.kcl.ac.uk/sections/site/news</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Key note speaker- Inaugural UK Regenerative Medicine Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>73E1A5BE-936E-44B9-8E2B-FE663906554F</gtr:id><gtr:impact>Gave a talk entitled: &amp;quot; Immunological characterisation of IPS-derived cells.&amp;quot;</gtr:impact><gtr:outcomeId>58b58ff4727bb4.37533680</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Away Day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>698FAC4B-E54D-443F-BEC6-180233BE69D0</gtr:id><gtr:impact>We formulated a workshop programme for the renewal phase of the Centre.

Holding a series of interdisciplinary workshops with specific academic and translational goals.</gtr:impact><gtr:outcomeId>F4RreGbZMCe</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National Institutes of Health Immunology Interest Group Seminar Series</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>769C68A4-D002-41F7-94FA-92007E62B978</gtr:id><gtr:impact>Data presentation increased awareness of our research among the scientific and clinical community which then lead to increased requests for scientific future collaborations.</gtr:impact><gtr:outcomeId>56c2eefbaa28a1.63301976</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary- The Future of Transplantation with Jonathan Dimbleby</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>96592D0C-B0C4-4BAC-84FB-AFA89FEA03FF</gtr:id><gtr:impact>In the evening, approximately 180 attendees were treated to a debate on The Future of Transplantation, hosted by Jonathan Dimbleby. Following a welcome from the Principal, a distinguished panel from the worlds of science, literature and philosophy engaged in a lively and entertaining discussion exploring topics such as the use of stem cells and its public and political acceptability, and the role of genetic research in transplant science. Panellists were:

? Stuart Forbes, Professor of Transplantation and Regenerative Medicine, University of Edinburgh
? Sir Robert Lechler, Vice-Principal (Health) and Executive Director of King's Health Partners Academic Health Sciences Centre at King's College, London
? Rutger Ploeg, Professor of Transplant Biology and Transplant Surgeon, University of Oxford
? Janet Radcliffe Richards, Professor of Practical Philosophy, University of Oxford
? Sue Townsend, novelist and kidney transplant recipient
? Eleanor Updale, writer, historian and lay member of the UK Donation Ethics Committee



Statistics from the Eventbrite registration website show that although a total of 39% of those who attended were employed in the medical or scientific professions, 23% were from other professions and the individual group with the highest representation was students, making up 30% of the audience. This included a class of 30 A-Level students. Of those who attended, approximately half have received a transplant or know someone who has.</gtr:impact><gtr:outcomeId>ngiedF19sz4</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://transplantation.kcl.ac.uk/sections/site/education-information</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The 2016 Immunosuppression Summit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>898BA5AF-3AB4-4FA0-A5FC-F2F06B00BB2F</gtr:id><gtr:impact>Talk title: Targeting donor rather than recipient cells to prevent rejection of transplanted organs.</gtr:impact><gtr:outcomeId>56deade1662af6.98808056</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Personally asked as a key note speaker to a conference- AFACRR Management Committee and working group- Belgrade</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0698B0EB-4428-4F95-93DE-DC64F1049E04</gtr:id><gtr:impact>Gave a talk entitled: &amp;quot;Clinical grade manufacture of Regulatory T Cells to promote Transplantation Tolerance: Challenges and Achievements.&amp;quot;</gtr:impact><gtr:outcomeId>58b58ef5d4e468.67590100</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LMB Alumni Symposium</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>94032BD7-132C-4899-82E8-187A794A494C</gtr:id><gtr:impact>Saw new state of the art facilities in the new LMB and made contact with several key principal investigators; linked up with colleagues from the past who have made subsequent contributions to science

Drawn attention to new programme of work in field of complement at the LMB</gtr:impact><gtr:outcomeId>545b8999158d03.60557220</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Athena Swan Away Day 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>60A2D920-29A0-4133-890E-D8C0FB819921</gtr:id><gtr:impact>We hosted a Divisional away afternoon; half of the meeting was dedicated to Athena Swan and the other half was dedicated to increasing our teaching activities. We had talks followed by team working sessions; each team was given a specific question to focus on and answer. All the answers were fedback and discussed at the end of the session. The afternoon concluded with a networking &amp;amp; social reception.

This informed our strategy and action plan for Athena Swan. We are no w preparing to submit an application for Silver Award and have a local self-assessment team that meets regularly and that is chaired by a Female Senior Clinical Lecturer. We have changed some of our practices and have put actions in place that support the Athena Swan Charter and our peers. Some of those actions include monthly lunch time seminars dedicated to our postdoctoral researchers; decision making meetings rotate day and time and always occur during core hours; our division has a dedicated Athena Swan &amp;quot;our women in science&amp;quot; section- the MRC Centre website links to this.</gtr:impact><gtr:outcomeId>545cfddeb78266.20227848</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.kcl.ac.uk/lsm/research/divisions/timb/athena/casestudiestimb.aspx</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Steve Sacks - Complement UK Symposium and Training Course, Cambridge, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DA11A1E3-2ABC-4252-9040-3B9DB083349F</gtr:id><gtr:impact>Co-organiser and speaker</gtr:impact><gtr:outcomeId>56d816d04fcd73.91382365</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American Urological Association</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7A9AFF9D-5A71-4ABE-A237-E9BE02F74E95</gtr:id><gtr:impact>?</gtr:impact><gtr:outcomeId>56e04dbc52b1a4.01849704</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit of MEP and MP</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>65DD0701-00F3-4016-ACEB-49D13A4AB78E</gtr:id><gtr:impact>One MEP and one MP attended to receive information about the involvement of King's in EU funding scheme.

They will report the success of Kings in gaining EU funding at parliamentary and european levels.</gtr:impact><gtr:outcomeId>X4t8fasojWJ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Claire Sharpe gender equality in labs - huffington post</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>28B0CB17-9D25-468F-A7FD-1A896EC8B788</gtr:id><gtr:impact>Blog post about the current and future of gender equality in research labs</gtr:impact><gtr:outcomeId>58ca6d1f1edaa7.76024359</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Organ Lottery: why access to more and better transplants matters</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A3BEB8F3-D26C-42B4-BEBF-DADB8917BC6C</gtr:id><gtr:impact>Questions and answers in the world of organ donation are far from black and white. Yet for those not immersed in this world daily who are thrust into situations they are unprepared for when a loved one falls ill, it's almost impossible to see medical decisions from every angle and understand the possible benefits of transplant research. In this interactive debate, we will explore multiple points of view, considerations and medical opinions that come together at this crucial point to make a life or death decision. Jonathan Dimbleby and a panel of experts will discuss what lies behind a transplant decision at an exciting debate organised by the Centre's Dr Antonia Cronin and King's Policy Institute. The event takes place on 10th December at 6pm at Wellcome Collection, 183 Euston Road, NW1 2BE. It is free to attend but entry is ticketed with limited availability

Event not yet taken place</gtr:impact><gtr:outcomeId>5458ee10c63293.77670364</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.eventbrite.co.uk/e/the-organ-lottery-why-access-to-more-and-better-transplants-matters-registration-12851564375</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>First ERUS International Robotic Curriculum</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6B77716F-79B2-41EA-A7B0-75B1524B577F</gtr:id><gtr:impact>Professor Prokar Dasgupta has helped to develop the first ERUS (European Association of Urology Robotic Urology Section) international robotic curriculum. Designed for surgeons specialising in robotic urology, the ERUS Fellowship lasts for 6-12 months and provides a structured training pathway to enable surgeons to perform a robot-assisted prostatectomy independently

http://erus2013.com/
 Guy's and St Thomas' NHS Foundation Trust is one of 10 participating institutions and the only host-institute in the UK. Professor Dasgupta has mentored one of the first graduating fellows through the initial 3 month pilot study, the first time that a formal curriculum has been tried and tested by participants; the results were presented at this year's ERUS Congress in Stockholm.</gtr:impact><gtr:outcomeId>hsTFE6mbDAy</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.uroweb.org/index.php?id=462%20</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American Association of Immunologists, Annual meeting in New Orleans, LA, USA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A72A1810-F16C-45A8-83E1-3CDA9D1BF9AB</gtr:id><gtr:impact>Data presentation increased awareness of our research among the scientific and clinical community which then lead to increased requests for scientific future collaborations.</gtr:impact><gtr:outcomeId>56c2eeb1596319.21080585</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International conferenc on complement therapeutics Rhodes 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8C7A4E77-B072-484F-9751-3D007E352696</gtr:id><gtr:impact>Invited speaker at the 9th International conference on complement therapeutics, Rhodes 2016. Talk give on the Role of Collectin 11 in injury of the newly transplanted kidney providing opportunity for feedback and discussion</gtr:impact><gtr:outcomeId>58c90ef181cf92.70179679</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>key note speaker to conference- Instituo de Medicina Molecular- Lisbon</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>22B7BF76-6BE0-436B-92ED-542C5C6C3652</gtr:id><gtr:impact>Gave a talk entitled: &amp;quot;Approaching clinical Transplantation tolerance.&amp;quot;</gtr:impact><gtr:outcomeId>58b5926037a424.83087103</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cold Spring Harbor Laboratory Conference 'Fundamental Immunology &amp; Its Therapeutic Potential', Cold Spring Harbor, NY, USA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E31C0693-DC74-41DF-8777-05E297FEC74B</gtr:id><gtr:impact>Data presentation increased awareness of our research among the scientific and clinical community which then lead to increased requests for scientific future collaborations as well as 3 invitations to write reviews for (high impact) journals.</gtr:impact><gtr:outcomeId>56c2edc41514b8.91635323</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ELRIG Research and Innovation conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B1BB2A83-DCEC-48F6-B3E5-5027831AFD98</gtr:id><gtr:impact>Regulatory T cell therapy in organ transplantation</gtr:impact><gtr:outcomeId>58c2d0979198d2.69395638</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>USANZ, Australia</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E8226CB4-9690-440A-8492-89B7CCCE261F</gtr:id><gtr:impact>Global prize</gtr:impact><gtr:outcomeId>56e04e6dc5bb39.27820432</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Steve Sacks - CEOT Symposium, Phoenix, USA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>90069F40-6E82-48A2-B4E4-4459C6968F6C</gtr:id><gtr:impact>Invited speaker</gtr:impact><gtr:outcomeId>56d8184e324847.78787772</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Co-organiser and chair person at Humanised Mouse Symposium</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FD988E11-2841-4694-BCC7-D7A4FC9F5710</gtr:id><gtr:impact>Co-organised and chaired a workshop humanised mouse symposium</gtr:impact><gtr:outcomeId>58c2d027776281.41210299</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Member of committee- TWO Study meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F4DAC00C-8E99-49A6-A47F-AAC09BF70742</gtr:id><gtr:impact>participant of committee and to discussions at this meeting</gtr:impact><gtr:outcomeId>58b591e5823725.38678282</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Martin Drage in BBC2's Keeping Britain Alive</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B2681A3E-DD92-40B5-AA71-0B9BEEE26CFF</gtr:id><gtr:impact>Martin Drage in BBC2's Keeping Britain Alive
Mr Martin Drage, Consultant Transplant Surgeon, MRC Centre for Transplantation, starred in episode 2 of BBC series, 'Keeping Britain Alive: The NHS in a day', broadcast on Tuesday 2nd April 21.00 - 22.00 on BBC Two.
Filmed on Thursday 18 October 2012 by 100 camera crews across the country, this ground-breaking series explores the breadth of demands that are placed on the NHS in one single day. This episode features a transplant operation in which Alan is donating a kidney to his wife of 27 years Ann. The programme features Mr Drage preparing the patients and performing the possibly life-threatening surgery. The programme will be available to view on BBC iPlayer until 21st May.


better understanding of the health care system and organ transplantation; highlights the importance of the work carried out at the MRC Centre for Transplantation.</gtr:impact><gtr:outcomeId>pYxfkY6e5Sj</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/b01rsvxd</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Association of Physicians of G B &amp; Ireland Annual meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5FEF12DF-0B2C-4DC1-A99A-C802E67865F1</gtr:id><gtr:impact>Networking with academic colleagues

Progressed discussions with Head of Biochemistry at Cambridge</gtr:impact><gtr:outcomeId>545ca495a41884.17273686</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ISN Nexus 2016 Berlin</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1D606322-0901-42EA-8528-1042305F620B</gtr:id><gtr:impact>Invited speaker and session chair ISN Nexus Symposium Berlin to share results and provoke discussion.</gtr:impact><gtr:outcomeId>58c90df46fcd61.24299383</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Seminar - Sir William Dunn School of Pathology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>85E45417-C24C-4990-8B8E-092A8DD561C7</gtr:id><gtr:impact>Interest and further discussions followed

Strengthened links in support of application for UKRMP Immunology Stem Cell Hub</gtr:impact><gtr:outcomeId>545b88d8231e42.40563279</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>1 lecture in Science week Instituto Canada Blanch</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>44FA7E5D-8F4F-4272-8D1C-4CD31EA68B73</gtr:id><gtr:impact>http://www.sruk.org.uk/documents/press-releases/130430-SRUKScienceWeek-Eng.pdf</gtr:impact><gtr:outcomeId>Km7HpNNZok8</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://monix.a.tripod.com/spanish_school_london/welcome.html</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary Max Perutz Science Writing Award ceremony</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FCB5FCCB-8A92-42B0-A694-3C6CDA928636</gtr:id><gtr:impact>re-used some of our MRC open day event exhibits: A life without medication; multi-player video game :

? &amp;quot;Excellent exhibition. Great use of multimedia and very worthwhile exhibit. A very good way to commemorate the MRC!&amp;quot; ? &amp;quot;Really enjoyed layout and presentation of projected images. Great interactive game!&amp;quot;</gtr:impact><gtr:outcomeId>rL15Ppx5Dg3</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.mrc.ac.uk/Newspublications/News/MRC009446</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Session Organiser for BSI 2013</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>590DB2E8-4343-4AB8-8B7C-DC1BE720CF09</gtr:id><gtr:impact>None as yet - Meeting occurring 2-5 December 2013</gtr:impact><gtr:outcomeId>Bi5LqS5quVC</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.bsicongress.com/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Key note speaker at conference- CST-CNTRP-SQT Joint scientific Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7237B96A-F91C-423A-A291-637AECAB1774</gtr:id><gtr:impact>Gave a talk entitled: &amp;quot;The use of Tregs in Kidney Transplantation.&amp;quot;</gtr:impact><gtr:outcomeId>58b590d2c75879.07597781</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NIHR in BTRU in ODT</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>13CDC9D5-306E-418A-9F07-39BBBBB7B1C8</gtr:id><gtr:impact>interactive workshop involving academics creating a forum to present and share ideas</gtr:impact><gtr:outcomeId>58c2d13768af86.00605240</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Transplantation morning 19 May 2015</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>92ABB155-E8E2-49E9-911F-D8C88E95D1E0</gtr:id><gtr:impact>The biomarker team had an informal talk about biomarker research mostly with local patients and staff.</gtr:impact><gtr:outcomeId>56d81f82a92035.50283029</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Response to SKY TV media enquiry on the Human Tissue (Wales) Act 2013</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C7A2F24F-0A96-47AB-8D6B-75F5EB38C5AD</gtr:id><gtr:impact>Response to SKY TV media enquiry on the Human Tissue (Wales) Act 2013 - which received Royal Assent in September 2013. 
An Act of the National Assembly for Wales to make provision concerning the consent required for 
the removal, storage and use of human organs and tissue for the purpose of transplantation; and 
for connected purposes.

Passed by the National Assembly for Wales and received the assent of Her Majesty in September 2013. The law will come fully into effect on 1st December 2015.</gtr:impact><gtr:outcomeId>BLPmMpMb4oW</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Transcampus Transplantation programme with Dresden</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>180B53C6-2F0B-4C8C-84A2-4BE4B0E1A942</gtr:id><gtr:impact>Transcampus meeting between the MRC Centre for Transplantation and the DFG Centre for Xenotransplantation based in Munich. Involved research presentations, planning and follow up visits.</gtr:impact><gtr:outcomeId>56d9b43ceecd92.87356184</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary- The Science and Art of Transplantation</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F76AB410-BD71-4FF2-9FD0-18EEB7DC44AD</gtr:id><gtr:impact>The exhibition, attended by 189 visitors throughout the day, consisted of five multimedia galleries, with volunteers from the Centre on hand throughout the day to speak to visitors about their research. ? Pioneers Gallery - interviews from pioneers of science and transplantation, connecting MRC discoveries with the treatment of transplant patients today
? Extending the life of the transplant; &amp;quot;Pepper's Ghost&amp;quot; holographic model with kidney perfusion video footage 
? A life without medication; multi-player video game 
? Cell Transplantation; plasma information screen focusing on the hepatocyte programme, islet, and bone marrow work 
? Patient journey; patient wall with stories from 28 transplant recipients and their families. Patients Richard Lane and Lesley Beadle also attended giving visitors the opportunity to hear first-hand about life as a transplant donor or recipient

84 % of those who returned a feedback form reported that the exhibition had improved their understanding of the Medical Research Council and of the work that it has achieved. Further, 81% claimed a better understanding of organ transplantation following the event.
? &amp;quot;Excellent exhibition. Great use of multimedia and very worthwhile exhibit. A very good way to commemorate the MRC!&amp;quot;
? &amp;quot;It was great! And no jargon so easily understandable&amp;quot;
? &amp;quot;Really enjoyed the exhibition and speaking with the researchers especially. The work they are doing is so interesting!&amp;quot;
? &amp;quot;Keep up the good work!&amp;quot;
? &amp;quot;I appreciated how well the professor explained the research and how encouraging they were&amp;quot;
? &amp;quot;Really enjoyed layout and presentation of projected images. Great interactive game!&amp;quot;

See text above for statistics and feedback. We have been asked to re-use some of our exhibits (the digital multiplayer interactive game showing transplant tolerance versus rejection) for the Science Museum late series for the MRC Max Perutz Science Writing Award ceremony.</gtr:impact><gtr:outcomeId>E4MtCpaDzmU</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://transplantation.kcl.ac.uk/sections/site/education-information</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pankaj chandak - MRC insight</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>21E87DCE-8054-459F-A1C2-668946291D44</gtr:id><gtr:impact>MRC insight post about &amp;quot;transforming transplantation&amp;quot; Dr Pankaj Chandak's work with 3D printing to facilitate cmioplex transplantation surgery.</gtr:impact><gtr:outcomeId>58ca72170cebc2.99267776</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GAMBIT/Decisions open evening</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0EFB643D-F06A-45AA-8350-41EC835D6769</gtr:id><gtr:impact>Event organised to provide members of the public that had participated the DECISIONS and GAMBIT transplant studies with a chance to learn more about the findings from the research and how the work will help our patients.
The event, included a tour of the Medical Research Council Centre for Transplantation at Guy's Hospital, an overview of the key findings from both studies and a research poster presentation and reception.


This enabled findings to be shared with patients and investigators felt that being able to meet the patients and explain the processes behind the scenes reaffirmed the importance of our research, and was a fantastic way to round off the work we have achieved together.&amp;quot;
The feedback received following the event was overwhelmingly positive, one patient commented:
&amp;quot;It was interesting to see how the equipment and technology has changed over the years. The evening was an excellent presentation of results. It's so good to have all of this information</gtr:impact><gtr:outcomeId>58ca6b86d2dea4.86915392</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Transplantomics Conference Organiser &amp; Chair</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CBF2E224-5D87-492D-B360-2F621DC985CA</gtr:id><gtr:impact>100 attendees; location: Cambridge UK; May 2013; 4th International Conference onTransplantomics and Biomarkers.

excellent feedback; Transplantation journal issue pending.</gtr:impact><gtr:outcomeId>T9eVsY4ksu5</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>workexperience students</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5CA8D06D-FE64-4B0F-AFC4-FBFA9FE55587</gtr:id><gtr:impact>student spent 1 week in the immunoregulation laboratory doing cell culture and watching other experiments.

improved understanding of science- student wants to learn science after her A levels.</gtr:impact><gtr:outcomeId>F9gmpYtRwm6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC R4 - Recorded broadcast with Dame Joan Bakewell 'Inside the Ethics Committee'</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>28A46D74-CB3E-4C78-B394-558380E4AE2A</gtr:id><gtr:impact>BBC R4 - Recorded broadcast with Dame Joan Bakewell on Transplantation for the BBC R4 series 'Inside the Ethics Committee'


In Inside the Ethics Committee, Joan Bakewell presents real life medical cases to a panel of experts, each of whom sits on clinical ethics committees around the UK. By examining testimonies from patients, relatives and clinicians, the panel will weigh up the ethical dilemmas involved and make their recommendations about the case at the end of the programme.</gtr:impact><gtr:outcomeId>mtqcwQVj3kf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/podcasts/series/iec; http://www.bbc.co.uk/programmes/b007xbtd</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BTS Harrogate 2017</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>79790F22-75C9-4894-B439-D4EF15FF2A40</gtr:id><gtr:impact>Invited speaker and Medawar Medal Interlocuter, British transplant Society Congress 2017, Harrogate UK
Talk deliverd on Fucose: a promising new therapeutic target in kidney transplants? providing opportunity for discussion and feedback</gtr:impact><gtr:outcomeId>58c91015dd7925.27345423</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American Association of Asthma, Allergy and Immunology Annual Conference, Houston, Texas</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E1081980-F1A4-4A6D-965D-0A240802D906</gtr:id><gtr:impact>Data presentation increased awareness of our research among the scientific and clinical community which then lead to increased requests for scientiiucfuture collaborations</gtr:impact><gtr:outcomeId>56c2ecf618f340.53227501</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1677143</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>National Institute of Health Research Efficacy and Mechanism Evaluation (EME) Programme</gtr:description><gtr:end>2020-11-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>13/94/55</gtr:fundingRef><gtr:id>A04A87E2-6E0C-4A57-8A53-1166488F5B49</gtr:id><gtr:outcomeId>54521aaeb44fb2.55942167</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>73882</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KHP Challenge Fund</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>King?s Health Partners</gtr:fundingOrg><gtr:fundingRef>R140807</gtr:fundingRef><gtr:id>B9E61059-C98E-48E0-A54B-C82BC029AA93</gtr:id><gtr:outcomeId>5452337e888e02.11915641</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>295551</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UK Regenerative Medicine Platform (UKRMP) - Research Hub (Prof Steve Sacks)</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L022699/1</gtr:fundingRef><gtr:id>8E48516A-04D9-49EA-8E8D-BB9FC2829EFE</gtr:id><gtr:outcomeId>5458b480389a36.55228777</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>324500</gtr:amountPounds><gtr:country>Spain, Kingdom of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Marato TV3 Foundation</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>La Marat? de TV3 Foundation</gtr:fundingOrg><gtr:id>E75C229D-1FC4-442A-A2DC-AB440F4EFDEB</gtr:id><gtr:outcomeId>545242b44d0f95.64403362</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>876000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR HS&amp;amp;DR (Health Services and Delivery Research)</gtr:description><gtr:end>2020-01-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>DC76051B-F22F-426D-99B8-864319DF6FCE</gtr:id><gtr:outcomeId>5458de7a854e47.20703834</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Roche Organ Transplantation Research Foundation</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Roche Organ Transplantation Research Foundation (ROTRF)</gtr:fundingOrg><gtr:fundingRef>560883191 ROTRF</gtr:fundingRef><gtr:id>C4FE924D-85AC-4134-A741-B0CAA52FE5E6</gtr:id><gtr:outcomeId>5452329937a6b8.72150118</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1241563</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR EME</gtr:description><gtr:end>2019-05-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>13/94/10</gtr:fundingRef><gtr:id>CE1CBDB1-DF48-4810-968E-99A51552736B</gtr:id><gtr:outcomeId>56deabc258f311.27486889</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M012263/1</gtr:fundingRef><gtr:id>271D33D7-B450-4314-9077-1F653E346C4C</gtr:id><gtr:outcomeId>545cf9f65ae611.82852522</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>244237</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Training Fellowship for Dr Hannah Burton</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M01813X/1</gtr:fundingRef><gtr:id>AEC6D4C2-7EB3-48CD-9A31-87CF94FADC2C</gtr:id><gtr:outcomeId>5649b9914e99b2.48396724</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1241563</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Efficacy and Mechanism Evaluation (EME) Programme</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>13/94/10</gtr:fundingRef><gtr:id>CC979108-2038-49EB-B055-90D726DC6605</gtr:id><gtr:outcomeId>5458e4b82e78c9.19307843</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Prostate Cancer Research Centre King's College London</gtr:description><gtr:fundingOrg>Prostate Cancer Research Charity</gtr:fundingOrg><gtr:id>B39A787D-ED42-46A3-9D24-81B842A715A6</gtr:id><gtr:outcomeId>545b9655ecef94.42186671</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1168806</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EME programme award (Co-applicant with M Robson)</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>13/94/10</gtr:fundingRef><gtr:id>60A67904-5FDD-4CD7-BB59-B5334483E6F8</gtr:id><gtr:outcomeId>544fda194ad2e6.11944468</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>37317</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Guy?s and St Thomas? Kidney Patients' Association (GSTT KPA)</gtr:department><gtr:description>Establishing the optimising Transplant Survival Clinic</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Guy's and St Thomas' NHS Foundation Trust</gtr:fundingOrg><gtr:id>4A9BE72F-EE05-4E2D-859A-B5659342D4C5</gtr:id><gtr:outcomeId>SfVm7VJfn7X</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>China Scholarship Council</gtr:department><gtr:description>Fan Qu visit - CSC fellowship</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>University of Leeds</gtr:fundingOrg><gtr:id>AB105B71-2187-45EB-87EF-57A2ED7F327D</gtr:id><gtr:outcomeId>56deb8be4613e2.28410445</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1690000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Capital Bid</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>35979B03-A6CF-45BA-BCA1-D3E1C4CA23E7</gtr:id><gtr:outcomeId>X155vhCAuzV</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Efficacy and Mechanism Evaluation (EME)</gtr:description><gtr:end>2019-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>13/94/55</gtr:fundingRef><gtr:id>32F28090-E03A-4CE6-B58C-FFC2C26FC823</gtr:id><gtr:outcomeId>545a3b2bc6cc45.83113060</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100157</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Immune Tolerance Network</gtr:description><gtr:fundingOrg>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:fundingOrg><gtr:id>8B888379-4C88-44B9-A522-16F16E9A3A28</gtr:id><gtr:outcomeId>58ca6d8974d9a3.08359031</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>91000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>King's Health Partners Research and Development Challenge Fund</gtr:department><gtr:description>KHP Research Grant</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>King?s Health Partners</gtr:fundingOrg><gtr:id>644E8A47-E002-47FD-A72C-FA32DA80EE15</gtr:id><gtr:outcomeId>544b8ea38de6b7.13537750</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>223234</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Training Fellowship for Dr Harriot Doiuthwaite</gtr:description><gtr:end>2019-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>75B80A14-65AE-4299-A593-DFA73A63660B</gtr:id><gtr:outcomeId>56dd470fe0e867.10477844</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>310822</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UK Regenerative Medicine Platform (UKRMP) - Research Hub (Prof Lombardi)</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L022699/1</gtr:fundingRef><gtr:id>CDD3F312-D935-44BE-81D6-147085A2D4DD</gtr:id><gtr:outcomeId>5458b0bc5b7302.10308165</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1519891</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust New Investigator Award (Dr Claudia Kemper)</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>102932/Z/13/Z</gtr:fundingRef><gtr:id>46795C07-D416-4FC0-B59E-58F099D71498</gtr:id><gtr:outcomeId>545794a4830168.38544040</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pilot funding for retinoid dietary intervention in ADPKD mice</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>PKD Charity</gtr:fundingOrg><gtr:fundingRef>N/A</gtr:fundingRef><gtr:id>2067CC14-631B-48B4-8380-C8FE51BC560E</gtr:id><gtr:outcomeId>ScmoeeY6NAa</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>UK-AIH</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>3BBE2999-CE6E-466B-89C9-4C9EEBFBAE23</gtr:id><gtr:outcomeId>58ca713d4930e9.04703954</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25920</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Allergy, Immunology, and Transplantation Research</gtr:description><gtr:fundingOrg>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:fundingOrg><gtr:id>33C04F10-BAE3-4091-B4C5-21B793BB9AB5</gtr:id><gtr:outcomeId>58ca6f734f5950.01244310</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>130213</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>King's Commercialisation Institute</gtr:department><gtr:description>King's Health Accelerator Award</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:id>6D4711BD-8C4B-4E04-901F-851F67054B14</gtr:id><gtr:outcomeId>58a407b82ee9b2.44044756</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>464744</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant Application - Targeting C5aR in chronic inflammation, renal fibrosis and late graft dysfunction</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L020254/1</gtr:fundingRef><gtr:id>A081263E-78BE-4682-A8E3-FA98342F2CC6</gtr:id><gtr:outcomeId>5458dc92c6d659.68662909</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>203000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Centre Directors Capital Bid 2013: CEL (Cell Engineering Laboratory)</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J006742/1</gtr:fundingRef><gtr:id>FDC85B7C-B709-4B35-9648-BDE49F4FBF37</gtr:id><gtr:outcomeId>JncEXnysHQZ</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>76000</gtr:amountPounds><gtr:country>Japan</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Investigator Driven Clinical Study Astellas</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Astellas Pharma</gtr:fundingOrg><gtr:id>8F313BE5-FE6D-4E1A-9BBB-3DA1091496C4</gtr:id><gtr:outcomeId>545236eca39f80.72390737</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1007574</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DPFS</gtr:description><gtr:end>2021-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N019334/1</gtr:fundingRef><gtr:id>C1A84C5D-5753-439A-BC63-35607001874E</gtr:id><gtr:outcomeId>58c9bf6f2f8107.50506797</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Centenary Award 2013</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>PO Number 4050246766</gtr:fundingRef><gtr:id>810A91FA-A1C6-43A4-8885-FF2657B87335</gtr:id><gtr:outcomeId>BPHFtdHSUQp</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>210000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Complement UK PhD studentships 2016</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Alexion Pharmaceuticals</gtr:fundingOrg><gtr:id>5780D82D-46EA-4847-8E3E-829ECCB64225</gtr:id><gtr:outcomeId>56f28e9c314908.33635839</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>308873</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>NIH research award</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>5U01AI100807-03</gtr:fundingRef><gtr:id>9545CEAE-7650-4289-8024-BF23DECDD2C2</gtr:id><gtr:outcomeId>545b52bc749191.80303654</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>44155</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Allergy, Immunology and Transplantation Research</gtr:description><gtr:fundingOrg>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:fundingOrg><gtr:id>F182AB09-61C9-439C-B95F-D1F666B1E23E</gtr:id><gtr:outcomeId>58ca6c8aae03f1.21951026</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>483000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC project Grant (Co-applicant with G. Lombardi)</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>F94EDB53-2C25-4BD9-BD11-8FC4B824C0BF</gtr:id><gtr:outcomeId>W8a4qDdpMFk</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60608</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Quality in Organ Donation (QUOD)</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>NHS Blood and Transplant (NHSBT)</gtr:fundingOrg><gtr:fundingRef>QUOD Centre</gtr:fundingRef><gtr:id>31FFB53B-4C87-483B-B402-56D01466FA9C</gtr:id><gtr:outcomeId>5458e63e3cea13.24904921</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>School of Medicine KCL</gtr:department><gtr:description>Funding for 4-year PhD studentships (x2) from KCL</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:fundingRef>MJKRAAR</gtr:fundingRef><gtr:id>43CC752F-485F-4A01-B8F6-2F1AA98C8358</gtr:id><gtr:outcomeId>guMzjdVocYj</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Impact Grant King's Policy Institute</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:fundingRef>MJK9408</gtr:fundingRef><gtr:id>210FB63B-6886-4EB7-9EA7-BC4378C7EF91</gtr:id><gtr:outcomeId>545a3e2631b9b0.57094200</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Immune Tolerance Network</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>National Institute of Allergy and Infectious Diseases (NIAID)</gtr:fundingOrg><gtr:id>A29CA4E2-020B-42E2-9AC1-3AB667EF72E0</gtr:id><gtr:outcomeId>58ca6e179547f5.25378465</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>876303</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Intermediate Clinical Fellowship - Dr Nicholas Powell</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>101159/Z/13/Z</gtr:fundingRef><gtr:id>2AE8DF07-458D-4E25-B929-6F8EFF31B4FC</gtr:id><gtr:outcomeId>5458b8dbe15995.06356430</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>202047</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ROTRF</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Roche Organ Transplantation Research Foundation (ROTRF)</gtr:fundingOrg><gtr:id>79CD834C-9798-4727-96DB-E815AD06286A</gtr:id><gtr:outcomeId>56debdbf6bfd54.72862468</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>258741</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Kidney Research UK Research Training Fellowship - Dr Philippa Dodd</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:fundingRef>TF1/2014</gtr:fundingRef><gtr:id>87E90D0A-6C18-4F19-9169-5E4AF6153EC0</gtr:id><gtr:outcomeId>5458ba2fe58277.28658561</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1984</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>King's Worldwide Partnership Fund</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>King's College London</gtr:fundingOrg><gtr:id>BCD82AE3-31BA-4BB3-BC7F-0DA0146FEF68</gtr:id><gtr:outcomeId>56dd4a0f023ac0.06199715</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>258741</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KRUK Clinical Training Fellowship to Dr Philippa Dodd</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>C9A8A772-455F-41F9-A803-1E6444DFED6F</gtr:id><gtr:outcomeId>542aa652217c10.79630856</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Centenary Award for early career researchers</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J006742/1</gtr:fundingRef><gtr:id>02966665-B09A-4C3B-9268-E2B01F0C8F92</gtr:id><gtr:outcomeId>SqTjzTGoYdb</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>560440</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Collectin-11 as a trigger of the innate immune response in renal transplantation</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M01226311</gtr:fundingRef><gtr:id>6AEEDFE9-2052-4077-B0B8-925BEC027711</gtr:id><gtr:outcomeId>56f290115414b0.28533383</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>66989</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR BRC Bridging Fellowship - Dr Niloufar Safinia</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>A14CD55B-63BD-4A37-9C62-15EDEA9C4DAE</gtr:id><gtr:outcomeId>5458b80288dc46.44550516</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>96708</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KHP R&amp;amp;D Challenge Fund</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Guy?s &amp; St Thomas? Charity</gtr:fundingOrg><gtr:fundingRef>R1405170</gtr:fundingRef><gtr:id>21CAABCC-D7A1-4AB7-9FC5-9A50F4569864</gtr:id><gtr:outcomeId>5458dd4d681b30.75663268</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>199867</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Kidney Research UK - M Robson</gtr:description><gtr:end>2018-11-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:fundingRef>RP1/2015</gtr:fundingRef><gtr:id>86070EA0-BAB0-4D55-AFE6-5736F63DD972</gtr:id><gtr:outcomeId>56deac0fb0a9b5.05892672</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Translation Award (Co-applicant with Richard Smith)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>4BEBAA2E-C8B6-4CF0-A5D9-423F16E064F9</gtr:id><gtr:outcomeId>Xbi1GNjJjZ9</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>947966</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Fellowship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0902288</gtr:fundingRef><gtr:id>14546B28-C6FA-40B4-85FD-AD280ED2E2C5</gtr:id><gtr:outcomeId>544b90c1833c98.43935993</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2386712</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Single Cell-Level Functional Proteomics and Genomics exemplified in Cancer and Immunology</gtr:description><gtr:end>2018-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>80732760-A683-4BF9-B933-0A542B6DE297</gtr:id><gtr:outcomeId>56f2a096573d86.52657165</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MiR-acles in collecting ducts underlie albuminuria-induced renal fibrosis</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>04B44603-1B9B-401D-B8C7-39A1C510627D</gtr:id><gtr:outcomeId>54ae65ccdb56d3.93777162</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A method of determining an individual's transplantation tolerance by determining the level of a number of biomarkers. The patent application PCT/GB2011/050874, priority date 4 May 2010, entitled &amp;quot;Method of Determining Tolerance&amp;quot; will enter National Phase prosecution on 4 November 2012.
Assignees: King's College London, Charit&amp;eacute; - Universit&amp;auml;tsmedizin Berlin, Miltenyi Biotech GmbH
Inventors: Maria Hernandez-Fuentes, Irene Rebollo Mesa, Birgit Sawitski, Hans-Dieter Volk, Uwe Janssen, Stefan Tomiuk</gtr:description><gtr:grantRef>MR/J006742/1</gtr:grantRef><gtr:id>C83E9423-68A6-4E2F-992B-0ECE7F265D10</gtr:id><gtr:impact>A method of determining an individual's transplantation tolerance by determining the level of a number of biomarkers</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>rsFAUiREYeJ</gtr:outcomeId><gtr:patentId>WO2011138609</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Method of determining tolerance</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>http://inventions.dartmouth.edu/technologies/j269/regulatory-t-cell-mediator-proteins 
Dartmouth researchers have now found a novel member of the PD-L1 family expressed by Treg cells. This novel protein has been designated PD-L3. Like other members of the PD-L1 family, PD-L3 co-stimulates aCD3 proliferation of T cells in vitro. In addition, the expression of PD-L3 is increased in aCD3-activated Treg and reduced in the presence of aGITR. A second, TNF-like, protein has also been identified as being upregulated upon aCD3/aGITR stimulation. This protein has been designated Treg-sTNF. These proteins may be involved in contact-dependent and paracrine suppression of immunity and can therefore be used to modulate immune responses and treat diseases and conditions involving Treg signaling.

Defined a new negtive checkpoint regulator that will be valuabl in treating human</gtr:description><gtr:grantRef>MR/J006742/1</gtr:grantRef><gtr:id>738EA834-236A-4593-8E50-3B807601334D</gtr:id><gtr:impact>Yes. To JNJ. A licensing agreemnt &amp;gt;$150 million dollars. Therapeutic antibodies are being developed.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>ScAXKzKPRYr</gtr:outcomeId><gtr:patentId>US8236304</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Noelle patent 11/912,397</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Defined a new class of therappeutics to treat autoimmune diseases. 
The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates aCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon aCD3/aGITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed 
http://www.patentbuddy.com/Patent/20120195894</gtr:description><gtr:grantRef>MR/J006742/1</gtr:grantRef><gtr:id>B1BA4768-63D2-4BED-B81D-475095E85727</gtr:id><gtr:impact>Currenlty evaluating multiple term sheets from Pharma and will likely close an agreement in the next 6 months.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>c7g4ekuuNos</gtr:outcomeId><gtr:patentId>US8465740</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Noelle patent 13/326,792</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Policy Document to guide clinical practice</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AF3EFB77-7BF2-43DC-B980-CD0D8E9C920B</gtr:id><gtr:impact>.</gtr:impact><gtr:outcomeId>iZNx3yQW4wV</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>House of Lords Regenerative Medicine Report (3 Centre PIs gave independent evidence)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E473A941-7F51-4736-90CC-4BFA4DEF082A</gtr:id><gtr:outcomeId>KjPQ6hiMuYA</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Appointed expert member of clinical and ethics/legal sub-group, and author of report. Presentation of findings at the Royal College of Paedicatric Child Health and Department of Health</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>31AC1B3E-E83B-4731-B6EC-A8625C984186</gtr:id><gtr:impact>If the Department of Health adopts the recommended changes this will impact on efficiency of healthcare delivery, it will facilitate research and it is anticipted it will improve survival and quality of life ofDCD transplantrecipients.</gtr:impact><gtr:outcomeId>PJnk7xvUbdk</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>The first international robotics training curriculum</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>19DB2C24-41BC-4F11-A155-B1F6C46E9E54</gtr:id><gtr:impact>-</gtr:impact><gtr:outcomeId>56e050197ca525.51370262</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influence on TTS policy on China</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>B8216D55-7958-4B2D-9BF6-B2A066F9FACA</gtr:id><gtr:outcomeId>ttFhApHwEys</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Invited to small working group at the Human Tissue Authority- in view of publications writtenon the subject and published in high impact factor ethics/law journals</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0AA82330-EB4B-4E9A-94BD-495FFE2A63FB</gtr:id><gtr:outcomeId>gPUP6ub8tEG</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Expert reviewer and collaborator</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9FD6114F-3193-4396-8E06-AB6239CB4496</gtr:id><gtr:outcomeId>Fqed4AY5iRR</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in subsequent frameowrk document</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7DA22ABC-2D43-4467-B950-75D7C8089546</gtr:id><gtr:impact>Changed the arrangements for distribution for research purposes of organs retrieved but not transplanted</gtr:impact><gtr:outcomeId>oqX6HsWv4Vn</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Scientific Advisory Board, DIREKT EC Framework Programme</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>00FA9500-570D-4CCA-B087-B8FC66E73D8E</gtr:id><gtr:outcomeId>54637b22ee19d3.12687920</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Technology Strategy Board Assessor Briefing for Healthcare</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>42B9548B-1767-4192-82D4-682FDE4C0210</gtr:id><gtr:outcomeId>545ca1618df9e3.81311432</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CORAL and subsequent Cochrane review on robotic cystectomy</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F37AC31C-20FB-4476-974D-558DB0CD375B</gtr:id><gtr:impact>-</gtr:impact><gtr:outcomeId>56e04fe4546fa4.76432819</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Membrane - interactive complement inhibitor used by ex vivo perfusion into isolated organ. About to enter definitive Phase II study. Drug manufacture completed to accepted standard. MHRA approved. Patient recruitment imminent. Souce of funding: MRC DCS grant. Recruitment began in July 2015 and 19 patients are now undergoing treatment.</gtr:description><gtr:id>A1393FB5-4E91-43E8-8006-C82248DA7461</gtr:id><gtr:impact>Validation of the membrane-binding (cytotopic) approach used in Mirococept and the consequent development of this technology as a platform. Large scale manufacture and quality assessment for clinical trial completed. Completed investigators brochure. Ethics approved. MHRA approved. Patient recruitment open.</gtr:impact><gtr:outcomeId>tFCqbjC6TeG</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Empirikal-Mirococept</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.mykidney.org/Research/ResearchAtGuys.aspx</gtr:url><gtr:yearDevCompleted>2006</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Aim to develop a novel method by which the risk associated with biomarker-led care can be adjusted to individual patient's circumstances.
? Objectives: a) to identify the level of risk that patients may be willing to take, and investigate whether this is related to their symptom burden and quality-of-life, and b) to elicit attitudes to risk and uncertainty and the range of influences affecting patients' choice and decision making.
? Mixed method study. a) Quantitative: Modified Standard Gamble to measure patient's willingness to take biomarker-led care depending on different levels of risk (sensitivity and specificity). Quality-of-life and symptom burden questionnaires will also be completed. b) Qualitative study comprises in-depth semi-structured interviews to investigate influences on choices and decision-making. 
? Hypothesis: high symptom burden and low quality of life is positively associated with a willingness to take risks associated with less accurate biomarker tests. Qualitative interviews will inform whether risk perception is related to particular factors other than symptom burden.
We anticipate this study will develop the methodology to incorporate patient's preference into the translation of biomarker tests into clinical practice.</gtr:description><gtr:id>4E006D79-DAFB-4696-B5BF-7B2F173FD5BC</gtr:id><gtr:impact>NOT YET CURRENTLY DATA COLLECTING</gtr:impact><gtr:outcomeId>gbhLp4thWU3</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>DECISIONS</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Preventing immunological rejection of transplanted organs without the need for long-term use of pharmacological immunosuppression is a primary objective in transplantation medicine. For this reason new transplant research should concentrate on early strategies that support long-term immunological acceptance of transplants, allowing for at least a reduction in the use of general immunosuppression. Conditioning the immune response of solid organ transplant recipients towards allograft acceptance using cell-based therapies is now becoming technically
feasible and clinically promising. The central focus of the ONE Study cooperative work programme is to: produce and manufacture distinct populations of haematopoietic immunoregulatory cells comparatively study the immunosuppressive characteristics of these regulatory cell types
test these cell therapy products side-by-side in a clinical trial in living donor renal transplant recipient
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-004301-24 
2014 Recruitment update: 12 patients need to be recruited (between KCL and Oxford). Oxford has recruited 5 (4 have already received the cells and for 1 the cell preparation failed) and KCL have recruited 3 (for 1 the cells are expanding in the GMP and they will be injected in January). 4 more patients need to be recruited between KCL (3) and Oxford (2)</gtr:description><gtr:id>081EDAA1-EE58-4D85-B0FE-34AE669A1977</gtr:id><gtr:impact>recruiting</gtr:impact><gtr:outcomeId>ZGiqEi6VupN</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>The ONE Study: A unified approach to evaluating cellular immunotherapy in solid organ transplantation</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:url>http://www.onestudy.org/documents/ONE_STUDY_BROCHURE_2013.pdf</gtr:url><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Cell therapy in liver transplant patients. Cell product in development in the GMP facility. Financed by the MRC.
7 patients have been recruited and for 1 the cells are expanding in the GMP facility and the cells will be injected in 3 months. We plan to open three more sites to increase the number of patients recruited.</gtr:description><gtr:id>ECAC8A67-0525-4749-B054-F11185B262AA</gtr:id><gtr:impact>Immunosuppressive withdraw in liver transplant patients and indefinite survival of the transplant.</gtr:impact><gtr:outcomeId>PDLKmQ2voJf</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>ThRIL-liver transplant patients</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=16775</gtr:url><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>An international multicentre randomised controlled trial of an experimental drug in kidney transplant patients to prevent infection from a virus called cytomegalovirus (CMV). CMV can cause fever and fatigue, and can damage important organs, including the transplant. In this 
study, patients will get either placebo (a non-active substance) or the active study drug. The trial hopes to show that this new drug is safe and effective. The trial is funded and sponsored by Genentech pharmaceuticals. Recruitment has now closed but trial participants remain under 
active follow-up</gtr:description><gtr:id>74F1765E-0FF4-4E35-9F7E-0317FE250A4B</gtr:id><gtr:impact>x</gtr:impact><gtr:outcomeId>5457d75a0e8ce9.93430703</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>Clinical study of MCMV5322A/MCMV3068A  in kidney transplant recipients at high  risk for CMV disease</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:url>http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012-002245-37-NO</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Everybody has antibodies. In kidney transplantation, the important antibodies are blood group (ABO) and tissue type (HLA). We would like to measure the antibody strength (titre) of ABO-blood group antibodies for renal failure patients on the deceased donor waiting list. These ABO-blood group antibodies vary between people which is why we want to measure them in a large number of patients. We would also like to know if these antibody levels and other cells associated with the antibody response change with time which is why we plan to test them at 0, 6 &amp;amp; 12 months. At the moment, we measure antibody levels to different tissue types (HLA) for patients on the deceased donor list every 3 months, and we would time these tests to coincide as we would like to know if the strength of blood group (ABO) antibodies is in any way related to the strength of tissue type (HLA) antibodies. We don't routinely test ABO-blood group antibody strength unless a patient is having a live donor blood group incompatible transplant. This kind of transplant requires antibody removal before the transplant can go ahead safely. For some patients with weak (titre) blood group antibodies it is possible to have a transplant without antibody removal. ABO blood group incompatible transplantation from a deceased donor is not normally performed. We hope that by doing this study, we will identify how many patients have weak enough blood group antibodies to allow a blood group incompatible transplant without needing antibody removal. This might mean that they could be listed to accept more kidneys, which might make a deceased donor transplant more likely.</gtr:description><gtr:id>800BDBB0-321C-444B-86AE-97F14A5CD6A4</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>aEK1xKiNWWJ</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>ABO Antibody Titres in Adult Patients Waiting for a Transplant</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=14694</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>large multicentre, investigator led randomised controlled trial of rituximab for induction in renal transplantation. This study will assess the safety and efficacy of using B cell depletion to permit minimisation of immunosuppression. In addition, the effects of B cell depletion on T cell responses and B cell reconstitution will be studied. Professor Giovanna Lombardi from the MRC Centre for Transplantation is collaborating on this aspect of the study, preliminary work has been carried out using samples from patients undergoing blood group incompatible transplantation. The study has been funded, is on the NIHR CLRN portfolio and has ethical and MHRA approval. Recruitment has now started, with 7 centres across the UK participating.</gtr:description><gtr:id>AC2007C8-D609-4BFA-A9CC-5CE11BDD2E4F</gtr:id><gtr:impact>The study has been funded, is on the NIHR CLRN portfolio and has ethical and MHRA approval. Recruitment has now started, with 7 centres across the UK participating.</gtr:impact><gtr:outcomeId>aSupUQZv5vE</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>ReMIND Rituximab in Renal Transplantation</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=9154</gtr:url><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>I am principal investigator for two new multicentre studies of eculizumab in highly sensitized patients; these examine the effects of complement inhibition as prophylaxis against early antibody mediated rejection, and both are ground-breaking studies of a new therapy. We are also carrying out a sub-study using samples from participants across the world to examine the effects of the drug on complement activation pathways.
Recruitment is now closed.</gtr:description><gtr:id>ABA8E023-A321-4CF1-B0DA-06FE044BB0CD</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>pA4Tf4FFs2E</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Safety &amp; Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.controlled-trials.com/ISRCTN45444578/</gtr:url><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A placebo-controlled double-blind randomised trial to investigate the efficacy of Rifaximin versus placebo in improving systemic inflammation and neutrophil malfunction in patients with cirrhosis and chronic hepatic encephalopathy. Patients with liver cirrhosis are particularly at risk of getting bacterial infections, and these can lead to complications such as hepatic encephalopathy (HE). This affects brain function and can cause symptoms that range from changes in personality to altered memory, concentration, or even loss of consciousness, affecting quality of life in a major way and often leading to hospital admission, and sometimes even the need for liver transplantation. This study aims to assess an antibiotic called Rifaximin to measure how it affects those processes that are thought to be important in the development of HE. These include the immune function and changes in gut bacteria and overall gut 'leakiness'. The trial is funded by Norgine UK Ltd and will be recruiting from mid-2014 for 12 months</gtr:description><gtr:id>4FAE4659-2F47-4308-8C8F-5A077EFCC922</gtr:id><gtr:impact>58% relative reduction in the risk of breakthrough episodes of overt hepatic encephalopathy over 6 months (Hazard ratio 0.42; p&amp;lt;0.001). Thus the numbers needed to treat 
? A 50% relative reduction in the risk of hospitalisations caused by HE over 6 months (Hazard ratio 0.50; p=0.01). Thus the numbers needed to treat</gtr:impact><gtr:outcomeId>5457da0db6bdf3.05527622</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Rifaximin</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.norgine.com/get-file/files/press%20releases/2013/UK%20TARGAXAN%20Press%20Release_1.pdf</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>It has been found that linkage of anticoagulant peptides to membrane-localising (&amp;quot;cytotopic&amp;quot;) reagents generates conjugates which are capable of inhibiting thrombin when attached to cell surfaces. This enables organs to be anticoagulated by perfusion ex-vivo prior to transplantation into the recipient. For the first time, it appears to be possible to separate local antithrombotic effects from systemic pharmacological ones using a readily translatable therapeutic agent. It may be possible to control thrombosis in transplantation (for example, in pancreatic and islet cell transplantation and in the prevention of antibody-mediated acute rejection) using this approach.</gtr:description><gtr:id>DCD95E4C-527D-4224-B172-03486B3DD291</gtr:id><gtr:impact>First product of its kind enabling prevention of Thrombosis in an organ transplant without having to anti-coagulate the recipient. Potential use in organs transplanted into pre-sensitised recipients.</gtr:impact><gtr:outcomeId>6B2382568B7</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>Antithrombotic agent (PTL004)</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Modified human cytokine designed to generate regioselective immune stimulation within human tumours. Principle source of funding: Prostate Cancer UK/Heathside Fund</gtr:description><gtr:id>4B3FDE30-F9BA-49E5-A07F-A1DE95BF1CE8</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>S7cHYsZUG8t</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Cytotopic human interleukin 15</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>two new multicentre studies of eculizumab in highly sensitized patients; these examine the effects of complement inhibition as prophylaxis against early antibody mediated rejection, and both are ground-breaking studies of a new therapy. We are also carrying out a sub-study using samples from participants across the world to examine the effects of the drug on complement activation pathways.</gtr:description><gtr:id>DE58846C-39B1-41AC-BC33-969651E6D9C7</gtr:id><gtr:impact>I am principal investigator for two new multicentre studies of eculizumab in highly sensitized patients; these examine the effects of complement inhibition as prophylaxis against early antibody mediated rejection, and both are ground-breaking studies of a new therapy. We are also carrying out a sub-study using samples from participants across the world to examine the effects of the drug on complement activation pathways.</gtr:impact><gtr:outcomeId>Z8JiU6UkjKZ</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>Safety &amp; Efficacy of Eculizumab to Prevent AMR in Deceased Donor Kidney Transplant Recipients Requiring Desensitization</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://clinicaltrials.gov/show/NCT01399593</gtr:url><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>pan-London study which is funded by the NIHR and is on the CLRN portfolio. The study will examine the role of antibiotics in these patients as well as studying wound healing and factors affecting this, and is the first such study worldwide. The trial includes a novel sub-study to assess the use of ultrasound in measuring wound healing. The project has ethical approval and recruitment is about to start.</gtr:description><gtr:id>682E218A-AA8B-495B-B340-1D3CF57C472F</gtr:id><gtr:impact>The project has ethical approval and recruitment is about to start.</gtr:impact><gtr:outcomeId>EEPPAwudGKK</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>PoWAR Randomised controlled trial of antibiotics in laparoscopic donor nephrectomy</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=13238</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>active recruitment of patients since 2013. We are measuring immune function in 3 cohorts: patients with acute kidney injury (AKI), patients with systemic inflammatory response syndrome (SIRS) and patients without AKI and without SIRS. The aim is to deterimine whether AKI per se affects immune function.</gtr:description><gtr:id>491A7130-DA73-4680-9EEE-07CFA2AA5134</gtr:id><gtr:impact>results will serve to improve the knowledge of the impact of AKI and may help to explain the serious short- and long-term comorbidities of AKI.</gtr:impact><gtr:outcomeId>546365b195bee6.07643422</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Evaluation of immune function in patients with acute kidney injury; Immune function in AKI</gtr:title><gtr:type>Support Tool - For Fundamental Research</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A multicentre randomised controlled trial to compare the efficacy of ex-vivo normothermic machine perfusion with static cold storage in human liver transplantation. The standard method of storing and transporting a liver for transplantation is to perfuse with a cold perfusion solution and store the liver in an ice box. To optimise the condition of such higher risk organs there is increased interest in continuous perfusion of 
the organ with blood at normal body temperature (normothermic perfusion). Livers will be randomly allocated to static cold storage (control group) or normothermic machine perfusion using the OrganOx metra device (study group). Recipients will then undergo transplantation and be managed according to standard local protocols. The two groups will be compared to investigate the potential benefit of normothermic machine perfusion. The trial is funded by the European Union Seventh Framework Programme (FP7): the COPE study (Work Package WP2).</gtr:description><gtr:id>40497F7E-97CE-434F-9BBE-26493BB934F7</gtr:id><gtr:impact>Several studies demonstrate that the quality of preservation can be improved substantially by warm perfusion, by combining the avoidance of cooling with the maintenance of a supply of oxygen and nutrition</gtr:impact><gtr:outcomeId>5457dbdccc7700.01643955</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>ORGANOX</gtr:title><gtr:type>Products with applications outside of medicine</gtr:type><gtr:url>http://www.organox.com/products/organ-asessment/</gtr:url><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Diagnostic test to identify tolerance in kidney transplant recipients. We are developing the application strategy for patients. Needs a biomarker-led clinical trial that has not been funded yet.</gtr:description><gtr:id>9557520C-EE58-4124-8B01-C143D2F64B0C</gtr:id><gtr:impact>If the clinical trial shows clinical benefit for the patients who are in the biomarker-led group, we will have a tool to personalise the post-transplant management of a set of patients (5-15%) that will mean less immunosuppression, with the lower rate of secondary events this has and better quality of life.</gtr:impact><gtr:outcomeId>CGCLtParrSW</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>A method for evaluating transplantation tolerance</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Up to now it has been impossible to determine if a patient has developed tolerance to their graft as there have been no validated biomarkers that can be used to define immunological tolerance in kidney transplant recipients. Even if complete elimination of the immunosuppressants was not possible, lowering the doses of each drug might be expected to benefit patients by potentially reducing the above mentioned risks. However the benefits of minimizing immunosuppression must be weighed against the risks of precipitating acute rejection or propagating chronic transplant dysfunction. 

GAMBIT study 

In the present study we propose to capitalise on these established collaborations and validate a common biomarker set of tolerance, using newly recruited kidney transplant recipients, to get closer to fully translating these results to a clinically applicable diagnostic test of tolerance.</gtr:description><gtr:id>5855BCC5-7964-4FE9-B526-B64D14CB3419</gtr:id><gtr:impact>currently recruiting</gtr:impact><gtr:outcomeId>X9iKLQNn2aJ</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>GAMBIT Genetic Analysis and Monitoring of Biomarkers of Immunological Tolerance</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=7521</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Immuno isolating device for implantation of islet cells, with associated oxygen chamber. Due to start clinical trial.</gtr:description><gtr:id>38A02820-4A14-41BF-B3AB-39DEDB1D0CC8</gtr:id><gtr:impact>Increased collaboration with islet team at Dresden through the process of developing this study</gtr:impact><gtr:outcomeId>545784a0c1ebc6.60616718</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Beta Air</gtr:title><gtr:type>Therapeutic Intervention - Medical Devices</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Together with JNJ we are developing anti-VISTA therapy for clinical trials in oncology</gtr:description><gtr:id>3EE2D87E-A10B-4F60-91C9-00902F03FD29</gtr:id><gtr:impact>none</gtr:impact><gtr:outcomeId>rDEK6jF9pyw</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>anti-VISTA therapy for clinical trials  in oncology</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The present &amp;quot;gold standard&amp;quot; test for diagnosis of Acute Rejection (AR) remains histological examination of a biopsy, and a key diagnostic feature is infiltration of the graft with cells of the immune system, especially lymphocytes. Gene products involved in lymphocyte migration, activation, effector pathways and regulation might provide early targets in the diagnosis of AR. In this study we aim to provide a reliable set of genes that could predict acute rejection obtaining serial measurements of gene expression in each patient. 
measurements:
PBMC stored in liquid nitrogen
mRNA from blood
plasma
fresh urine - frozen - 
mRNA extracted from urine</gtr:description><gtr:id>A904BB16-C456-428B-9817-6EF67E32D68B</gtr:id><gtr:impact>non yet sample collection</gtr:impact><gtr:outcomeId>aySUDC9rRdm</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Kalibre Kidney Allograft Immunological Biomarkers of Rejection Episodes</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Treatment of kidney disease accounts for a significant proportion of NHS spending. Although transplantation is the best treatment for kidney failure, most transplants do not survive for the recipient's natural lifespan, but instead fail after 10-12 years. Damage by the immune system, called 'chronic rejection' accounts for 50% of failing transplants and it is now possible to identify patients at risk by screening for 'HLA antibodies' in the blood. This application is to test a screening and treatment protocol for antibodies in a randomised controlled trial. Those with antibodies will be randomised into biomarker-led (BLC) or standard care (SC) groups. In the former, test results are revealed and recruits will have their anti-rejection drugs changed to a regime of prednisone, tacrolimus and MMF, each already licensed for use in transplant recipients. We have evidence that this regime is effective at preventing graft dysfunction and expect this to feed through to improvements in survival. In the SC group, screening results are double blinded and recruits will remain on their current therapies. In those without antibodies, recruits will be randomised to either blinded or unblinded screening and remain on standard treatment. Testing will continue every 8 months; recruits in the unblinded screening group will move into the BLC group if they become antibody positive. The primary outcome is kidney failure rates within 3 years of randomisation in HLA antibody+ recruits, predicted to be approximately 20% in the SC but &amp;lt;10% in the BLC groups. Secondary outcomes include rates of deterioration, the incidence of infections, cancers and diabetes, an analysis of the role of non-adherence with medication, and a scientific study to identify new biomarkers associated with outcomes. A cost analysis will confirm whether the screening programme and treatment protocol can save money by keeping kidney transplants functioning for longer. 
? From Sept 2013 to Nov 2014 we set up and began recruiting from the 5 original research sites including Guy's Hospital, Manchester Royal Infirmary, Royal London Hospital, St James's University Hospital Leeds, University Hospital Birmingham. 
? To increase recruitment rates we are now also recruiting from King's College Hospital and University Hospitals Coventry and Warwickshire NHS Trust. 
? York Hospital will also be joining the study as the 8th research site in December 2014.
? To date we have consented 861 participants.
? Our recruitment target is 2800 by December 2015</gtr:description><gtr:id>A8C07F11-88F7-4F6C-B9F5-4AF58F4538AF</gtr:id><gtr:impact>currently recruiting</gtr:impact><gtr:outcomeId>hH1b1bMVQ8v</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>OuTSMART</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:url>http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=13990</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Purpose of clinical trial; Evaluate the effectiveness of rituximab in C4d+ CAN
 
Primary objective; To determine whether anti-CD20 therapy can stabilize or improve renal function and/or proteinuria in patients with C4d+, chronic (humoral) rejection in whom standard therapeutic approaches have failed.
 
Secondary objective (s);
 ?To compare patient and graft survival between control and rituximab-treated groups
 ?To evaluate the adverse effect profile of rituximab in this group
 ?To correlate changes in circulating B cell numbers, anti-HLA and non-HLA Ab profiles and titre with responses to standard therapy and / or rituximab
 ?To correlate changes in T cell responsiveness to alloantigens with responses to standard therapy and / or rituximab</gtr:description><gtr:id>F93E4A60-3BAA-435A-BA46-00A437431C20</gtr:id><gtr:impact>currently recruiting</gtr:impact><gtr:outcomeId>K3PP62RrLL5</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>RituxiCAN-C4 trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://clinicaltrials.gov/show/NCT00476164</gtr:url><gtr:yearDevCompleted>2007</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>study, which aims to develop mechanisms to predict poor psychosocial outcomes after living donation, and to assess the extent of psychosocial benefit after donation. The study has been developed in collaboration with Professor John Weinmann from the Department of Psychology at Guys Hospital. The project includes the first study in the UK of those undertaking non-directed (altruistic) donation, which is being carried out in collaboration with NHS Blood and Transplant.
Recruitment is underway.</gtr:description><gtr:id>7A76A300-AEF0-4C36-A711-EA9F4B7398A2</gtr:id><gtr:impact>Recruitment is underway.</gtr:impact><gtr:outcomeId>JEvdgwVv2xU</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Pyschosocial aspects of living donation</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>active recruitment of patients commenced in March 2014. We are actively recruiting patients who have biochemical or histological evidence of acute kidney injury following administration of one of 40 drugs. The genetic profile wil be determined using blood and urine samples. The objective is to investigate if a genetic predisposition exists for the development of drug induced renal injury.</gtr:description><gtr:id>CC22F8A7-23B4-41B0-8C8A-061A2EAD5B88</gtr:id><gtr:impact>provides the opportunity of personalised medicine</gtr:impact><gtr:outcomeId>54636529ce82e2.78426516</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Genomics of drug induced renal injury (DIRECT)</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:url>http://www.saeconsortium.org/</gtr:url><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Prostate Cancer Research Centre &amp;pound;2.1 million</gtr:description><gtr:id>EEA1FC32-FD7F-4F8A-B0F3-29564182C9AA</gtr:id><gtr:impact>Our cytotopically modified agents can kill prostate cancer in a murine model in 73 days without any obvious side effects or collateral damage</gtr:impact><gtr:outcomeId>56e050d07cf975.75969998</gtr:outcomeId><gtr:status>Under active development/distribution</gtr:status><gtr:title>immunotherapy for prostate cancer</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>A membrane targeted anti-coagulant for intented use in donor kidneys transplanted into high risk (highly sensitised) recipients. Currently at proof-of-principle stage in rat model. Current funding - MRC Centre Grant Directors Initiative.</gtr:description><gtr:id>E34F84FD-4AD6-4A52-B42C-0DC5D47D64C1</gtr:id><gtr:impact>Patent application registered.</gtr:impact><gtr:outcomeId>Ly2vea15K3U</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Membrane targeted anti-thrombin PTL006</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Database containing sequential liver histology from liver transplant recipients enrolled in immunosuppression withdrawal trials.</gtr:description><gtr:id>8A09BD99-3256-4BEB-B84E-2D927EB5DAB0</gtr:id><gtr:impact>- Identification of transient inflammatory changes in the liver allografts of patients undergoing successful immunosuppression withdrawal.

- Has allowed us define the acceptable inclusion/exclusion criteria for future immunosuppression withdrawal trials.</gtr:impact><gtr:outcomeId>5452382e014fd2.71831926</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Liver Tolerance Database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>National Publicly available database</gtr:description><gtr:id>E32BD43C-B855-4715-94B2-C677BD3E1E11</gtr:id><gtr:impact>First such national data on cancer patients</gtr:impact><gtr:outcomeId>56e0506563ef38.24712689</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>British Association of Urological Surgeons,</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.baus.org.uk/</gtr:url></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Integration of anonymised clinical data and &amp;quot;omics&amp;quot; for research and clinical purposes</gtr:description><gtr:id>AF94D0C7-43F9-464B-BFF2-E256D548E967</gtr:id><gtr:impact>No impact yet.
4 collaborating groups: Cambridge, Oxford, Imperial and KCL. It will be expanded UK-wide within 3 - 5 years
It will facilitate research and clinical practice in a large scale</gtr:impact><gtr:outcomeId>56d821940862c8.29847227</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>NHR-HIC</gtr:title><gtr:type>Data handling &amp; control</gtr:type><gtr:url>http://www.nihr.ac.uk/about/hic.htm</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>antibodies specific to human and mouse VISTA</gtr:description><gtr:id>485D5B11-EE1A-4C68-AF51-D6647F401088</gtr:id><gtr:impact>new target for immnotherapy</gtr:impact><gtr:outcomeId>DvQuoGmsVvb</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>anti-human and mouse VISTA monoclonal antibidies</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>PBMC stored in liquid nitrogen
mRNA from blood
plasma
fresh urine - frozen - 
mRNA extracted from urine</gtr:description><gtr:id>832F75FB-A415-4869-915E-8BEFB949C779</gtr:id><gtr:impact>Not yet</gtr:impact><gtr:outcomeId>LQkhpLPhx29</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>KALIBRE mRNA and cell collection</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Immunodeficient mice reconstituted with human blood to study human immune responses in vivo and develop strategies to interfere with them.</gtr:description><gtr:id>B83C9188-E095-412B-862B-50897456EBAB</gtr:id><gtr:impact>Publications and future collaborations.</gtr:impact><gtr:outcomeId>hkC3uwry5qj</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Humanised mouse model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>an animal model for laparoscopic renal transplantation, a novel clinical technique, which has involved collaboration with Prof Campistol in Barcelona, and with the surgical department at St Georges hospital. The model is being refined with a view to translation to human subjects later this year.</gtr:description><gtr:id>036B3783-412D-4F51-B721-1E046E07A0DA</gtr:id><gtr:impact>The model is being refined with a view to translation to human subjects later this year.</gtr:impact><gtr:outcomeId>XRrHCzAgeHs</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>laparoscopic renal transplantation</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Data on mRNA array</gtr:description><gtr:id>1179258B-DF6E-4A17-9743-FC8D2EFAC9BB</gtr:id><gtr:impact>Access by other researchers
PMID: 21827613</gtr:impact><gtr:outcomeId>KThYjfoqdTF</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Indices of Tolerance Array</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:url>http://GSO.htm</gtr:url><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Mouse engineered to express fluorescein-labelled complement protein (C3) that can be tracked in vivo.</gtr:description><gtr:id>6A0E0B79-E46D-44C4-A770-A78FB1C03308</gtr:id><gtr:impact>The mouse has only just been generated.</gtr:impact><gtr:outcomeId>W9Fgc4XKhLg</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>GFP-C3 mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A new less traumatic method to perform heart transplant in mice</gtr:description><gtr:id>51301F99-47C7-438D-A765-E86E8DBE52BF</gtr:id><gtr:impact>It is now published, others using the technique can easily learn it with the help of an on line video</gtr:impact><gtr:outcomeId>56debbb95e84d4.90288221</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Refinement of heart transplant technique</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The PCEIA is a generic system for the assay of cytotopic agents (CTAs). CTAs are modified protein or peptides which possess the ability to bind to phosphatidyl serine (PS) and related acidic phospholipids in cell membranes. The assay uses PS deposited on the wells of microtitre plates as the capture step. The protein or peptide component of the CTA is then detected with a specific antibody followed by a secondary antibody linked to an enzyme component such as horseradish peroxidase. The signal is detected colorimetrically with an appropriate enzyme substrate.</gtr:description><gtr:id>1AD4B0CF-3474-4395-A40F-96F54B2047B9</gtr:id><gtr:impact>A PCEIA for the complement inhibitor Mirococept was initially developed in response to a regulatory requirement (from the UK MHRA) for an additional potency assay for this agent. It was reasoned that an assay which was dependent not only on the ability to bind PS but also on the antigenic identity of the CTA would be complementary to the existing biological assay for complement inhibitors which is cell-based. This proved to be the case and the new assay was incorporated into a revised MIrococept Investigational Medicinal Product Dossier (IMPD) filed in late 2013. We realized that the same capture step could be applied to all CTAs regardless of the modified &amp;quot;cargo&amp;quot;. During 2014 we have validated this approach for the anticoagulant Thrombolexin and the complement terminal pathway inhibitor Cytectin. This work has been written up for publication and we expect it to contribute not only to the development of a range of CTAs but also to ultimate commercialization</gtr:impact><gtr:outcomeId>5452b74de92123.54997292</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Phospholipid Capture Enzyme Immunoassay (PCEIA)</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>An immunotoxin that kills donor passenger leukocytes can induce indefinite survial of donor allografts</gtr:description><gtr:id>DE6A02FF-CB6F-4F28-9708-14A588605337</gtr:id><gtr:impact>This can be adopted in the clinic to prolong graft survival in humans.</gtr:impact><gtr:outcomeId>56debbff7f3e50.15291320</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Immunotoxin to prolong graft survival</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Measures number of cytokine-producing cells after stimulation in vitro</gtr:description><gtr:id>1D89089B-33E0-48E4-9E71-B6B99EC32896</gtr:id><gtr:impact>Standarization of method that will be used to stratify kidney transplant recipients if the trial is positive</gtr:impact><gtr:outcomeId>56d82016ad6be9.44135195</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Elispot Standardisation</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.biodrim.eu/description.html</gtr:url></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>cells
mRNA from blood
serum
urine mRNA
fresh urine</gtr:description><gtr:id>BFEC0F9F-2377-4906-9A92-BE0451C7BBE5</gtr:id><gtr:impact>Future biomarkers of tolerance to be developed</gtr:impact><gtr:outcomeId>dACUySJ61cp</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>GAMBIT cell and mRNA collection</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>Web version of BJUI</gtr:description><gtr:id>99F0FC42-8102-4097-AD27-A39B707E01DD</gtr:id><gtr:impact>Most read surgical journal on the web, Altmetric top 100 in 2015</gtr:impact><gtr:outcomeId>56e051745d4944.61999754</gtr:outcomeId><gtr:title>Almetric</gtr:title><gtr:type>Webtool/Application</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>ImmuNext</gtr:companyName><gtr:description>Discovery of immunoregulatory moecuels for therapy.
ImmuNext is dedicated to developing novel therapeutics that modulate the immune system to treat cancer and autoimmune diseases. Dr. Randolph Noelle, our founder, from the Geisel School of Medicine at Dartmouth, has identified a number of immuno-modulatory targets and related drug candidates. The lead program is based on VISTA, a novel checkpoint regulator in the B7 family.
We are located in Lebanon, NH, with a great combination of intellectual stimulation from Dartmouth College and the beauty of rural New England.</gtr:description><gtr:id>CCD37B24-FBC5-47D7-A661-E3943A149871</gtr:id><gtr:impact>Licensed VISTA to JNJ (Janseen Biothech) for cancer immunotherapy</gtr:impact><gtr:outcomeId>ratyAV431ue</gtr:outcomeId><gtr:url>http://immunext.com</gtr:url><gtr:yearCompanyFormed>2009</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>D2DCFE7B-2B86-480F-9637-497BBE48D5EE</gtr:id><gtr:title>R-spondins/Lgrs expression in tooth development.</gtr:title><gtr:parentPublicationTitle>Developmental dynamics : an official publication of the American Association of Anatomists</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd18a892575e404c08ea9af51928ea3b"><gtr:id>fd18a892575e404c08ea9af51928ea3b</gtr:id><gtr:otherNames>Kawasaki M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-8388</gtr:issn><gtr:outcomeId>5457a95eda94f8.51863292</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0045C50A-254C-405E-8444-A5207716D111</gtr:id><gtr:title>Incidence and Outcome of C4d Staining With Tubulointerstitial Inflammation in Blood Group-incompatible Kidney Transplantation.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/039435ec9c62b952072970cc24f17401"><gtr:id>039435ec9c62b952072970cc24f17401</gtr:id><gtr:otherNames>Couzi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>561354872325b3.57357128</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4391AFC0-21B9-4E49-9644-93F2511D22B7</gtr:id><gtr:title>Tracking single cells in live animals using a photoconvertible near-infrared cell membrane label.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2515d789f9d2785c28646378ba4a1ee"><gtr:id>f2515d789f9d2785c28646378ba4a1ee</gtr:id><gtr:otherNames>Carlson AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_13110_ne_0069257</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E12547EE-1CF6-48E6-BB0F-872287CEE317</gtr:id><gtr:title>Vitamin D supplementation with monthly bolus oral cholecalciferol is both safe and effective in Vitamin D deficient renal transplant patients</gtr:title><gtr:parentPublicationTitle>Joint Renal Association and British Transplantation Society Congress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25c7d3461a35be5521a4b0abe9e9ef09"><gtr:id>25c7d3461a35be5521a4b0abe9e9ef09</gtr:id><gtr:otherNames>Potowki-O'Rourke A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>jPHqDGc3PXD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90F76BA2-058D-4792-8CF6-FDDD8A1230AE</gtr:id><gtr:title>The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data.</gtr:title><gtr:parentPublicationTitle>Brain imaging and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/545bcb850f5bee6c4b4bb77b4df4cf03"><gtr:id>545bcb850f5bee6c4b4bb77b4df4cf03</gtr:id><gtr:otherNames>Thompson PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1931-7557</gtr:issn><gtr:outcomeId>5457ac9eb9b139.57089830</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C2E2B9A-1DD0-4C98-9172-4E477C56FEC2</gtr:id><gtr:title>NON-STANDARD KIDNEYS FOR TRANSPLANTS: CLINICAL MARGINS, MEDICAL MORALITY AND THE LAW</gtr:title><gtr:parentPublicationTitle>TRANSPLANT INTERNATIONAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa0c5048075e339b70558634a0f1de1a"><gtr:id>fa0c5048075e339b70558634a0f1de1a</gtr:id><gtr:otherNames>Cronin Antonia</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>iZhVBtYyivS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F550DDA-CD5C-4C61-A9BB-DF0E3F69E595</gtr:id><gtr:title>Conformational plasticity at the IgE-binding site of the B-cell receptor CD23.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1cd44326634381f2c4a83a751b43ea0"><gtr:id>a1cd44326634381f2c4a83a751b43ea0</gtr:id><gtr:otherNames>Dhaliwal B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>doi_13110_013_07_005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF44B70B-721C-499F-AF57-1E3F56B04E65</gtr:id><gtr:title>Reversal of acquired hepatocerebral degeneration with living donor liver transplantation.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0196293c270f04bb27922a9457b746f1"><gtr:id>0196293c270f04bb27922a9457b746f1</gtr:id><gtr:otherNames>Salehi SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>56dda49dbc6de1.33893390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79CA705C-7838-403E-96F0-E99CD22D14B1</gtr:id><gtr:title>Tolerance profiles and immunosuppression.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc6207574d1c0261d152ca4d9177b63b"><gtr:id>dc6207574d1c0261d152ca4d9177b63b</gtr:id><gtr:otherNames>Sanchez-Fueyo A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>5452131ba871c1.86894448</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58394B2D-9874-43D2-850D-F41D742FAC68</gtr:id><gtr:title>Complement-Mediated Regulation of Metabolism and Basic Cellular Processes.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11d5ac8821c4ca962f397f3e6f77157e"><gtr:id>11d5ac8821c4ca962f397f3e6f77157e</gtr:id><gtr:otherNames>Hess C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>585d6e0fab3cd1.02911816</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A1C404A-3FC1-44CE-9E73-BB1D08EEFFA0</gtr:id><gtr:title>The relationship between diabetic retinopathy and cognitive impairment.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6af4f03e47c5c28fa6b56d74f42dbc7"><gtr:id>c6af4f03e47c5c28fa6b56d74f42dbc7</gtr:id><gtr:otherNames>Crosby-Nwaobi RR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>doi_13110__dc12_2141</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87083A47-EC69-4739-B82D-62CA5CD432E4</gtr:id><gtr:title>Noninvasive assessment of LV contraction patterns using CMR to identify responders to CRT.</gtr:title><gtr:parentPublicationTitle>JACC. Cardiovascular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b35ea001a7fce2c2b01c48f419dfe3e"><gtr:id>8b35ea001a7fce2c2b01c48f419dfe3e</gtr:id><gtr:otherNames>Sohal M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1876-7591</gtr:issn><gtr:outcomeId>doi_13110_012_11_019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>326DD7AC-A0B6-4084-9D12-412A749897C1</gtr:id><gtr:title>Improving the evidence for robot-assisted radical prostatectomy.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>56e046a81608f0.45324677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33CF5DC0-B90C-4479-A4F8-636FF5ACABA9</gtr:id><gtr:title>Full immersion simulation: validation of a distributed simulation environment for technical and non-technical skills training in Urology.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37f7707194fa120d13e01c91cde34b6b"><gtr:id>37f7707194fa120d13e01c91cde34b6b</gtr:id><gtr:otherNames>Brewin J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>54579d2c55b4f2.60256778</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B290EB4E-7A5E-45AF-B377-63EE4E963E96</gtr:id><gtr:title>Genome-wide sequencing of cellular microRNAs identifies a combinatorial expression signature diagnostic of sepsis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/417d43a7089aa342f399b24e0f14fc1c"><gtr:id>417d43a7089aa342f399b24e0f14fc1c</gtr:id><gtr:otherNames>Ma Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545251d6a3b2d8.79457422</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A75CD6C-B537-49A8-9BF7-37FA800E74D4</gtr:id><gtr:title>Allogeneic stem cell transplantation in MDS: how? When?</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/703b8eba3010fbc8d3cd8a386e16a6af"><gtr:id>703b8eba3010fbc8d3cd8a386e16a6af</gtr:id><gtr:otherNames>Platzbecker U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1521-6926</gtr:issn><gtr:outcomeId>5457aab4046488.64548817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3694FD90-62A2-486A-9A37-B2B43E011C50</gtr:id><gtr:title>Hepatocellular adenoma in glycogen storage disorder type I: a clinicopathological and molecular study.</gtr:title><gtr:parentPublicationTitle>Histopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36aca209e43f16d51b347e51d9e101ff"><gtr:id>36aca209e43f16d51b347e51d9e101ff</gtr:id><gtr:otherNames>Sakellariou S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0309-0167</gtr:issn><gtr:outcomeId>doi_13110_11_04153_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD942636-E1C5-43CF-8DB6-624073B625F5</gtr:id><gtr:title>UK Renal Registry 16th annual report: chapter 4 demography of patients waitlisted for renal transplantation in the UK: national and centre-specific analyses.</gtr:title><gtr:parentPublicationTitle>Nephron. Clinical practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d00d37635115274162c59df06e5c9cb3"><gtr:id>d00d37635115274162c59df06e5c9cb3</gtr:id><gtr:otherNames>Pruthi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1660-2110</gtr:issn><gtr:outcomeId>544a6594212c26.24049759</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A79545F-A594-413D-ADAF-03712CBF13E6</gtr:id><gtr:title>Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a501a6a9751751d9907ecb97f8214a5f"><gtr:id>a501a6a9751751d9907ecb97f8214a5f</gtr:id><gtr:otherNames>Scott? C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>56dee59cb16140.03186462</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DE5CD18-84C9-4AD5-86D0-DE043D6D4D3C</gtr:id><gtr:title>Liver transplantation in human immunodeficiency virus-infected patients: procoagulant, but is antithrombotic prophylaxis required?</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d1e4211e465d846348b2621ae736e7c"><gtr:id>6d1e4211e465d846348b2621ae736e7c</gtr:id><gtr:otherNames>Cherian PT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>doi_13110_2_lt_22449</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D54EF80-6F79-43C5-871D-80F70C37FE31</gtr:id><gtr:title>Investigation of intracellular signalling cascades mediating stimulatory effect of a Gymnema sylvestre extract on insulin secretion from isolated mouse and human islets of Langerhans.</gtr:title><gtr:parentPublicationTitle>Diabetes, obesity &amp; metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e695d1623c14bc029f2bad220bfc2ca"><gtr:id>1e695d1623c14bc029f2bad220bfc2ca</gtr:id><gtr:otherNames>Al-Romaiyan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1462-8902</gtr:issn><gtr:outcomeId>doi_13110_12_01660_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD1ECB4B-1574-459F-BCCC-5CE9EF457D3B</gtr:id><gtr:title>The NF-?B1 is a key regulator of acute but not chronic renal injury.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/294be60e190fb1d59439f4a4192c3af6"><gtr:id>294be60e190fb1d59439f4a4192c3af6</gtr:id><gtr:otherNames>Fearn A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aaa692fa3e143.49258345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2C49EC9-A225-4B0D-86DA-09FA4F9D8018</gtr:id><gtr:title>In-vitro regulation of odontogenic gene expression in human embryonic tooth cells and SHED cells.</gtr:title><gtr:parentPublicationTitle>Cell and tissue research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5bf02a0cf4f3e8ac2592ab4ec1a79e5"><gtr:id>b5bf02a0cf4f3e8ac2592ab4ec1a79e5</gtr:id><gtr:otherNames>Leone A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0302-766X</gtr:issn><gtr:outcomeId>doi_13110_012_1379_7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9588B8ED-24D3-49AA-88BC-C4FCB96205B4</gtr:id><gtr:title>Acute pulmonary vein isolation is achieved by a combination of reversible and irreversible atrial injury after catheter ablation: evidence from magnetic resonance imaging.</gtr:title><gtr:parentPublicationTitle>Circulation. Arrhythmia and electrophysiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be83d0a02fdc36d7b8dcee04a473e4e7"><gtr:id>be83d0a02fdc36d7b8dcee04a473e4e7</gtr:id><gtr:otherNames>Arujuna A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1941-3084</gtr:issn><gtr:outcomeId>doi_13110_111_966523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73A00B59-CA36-4BBA-A918-403DCA65CA1B</gtr:id><gtr:title>Long- and short-term outcomes in renal allografts with deceased donors: A large recipient and donor genome-wide association study.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27d136cb0b10a6c9ffc7a02a0d6f2ffb"><gtr:id>27d136cb0b10a6c9ffc7a02a0d6f2ffb</gtr:id><gtr:otherNames>Hernandez-Fuentes MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>5a995ecad2ff70.89275474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5414FF25-0CB6-4C71-8F51-AEC8822FA85E</gtr:id><gtr:title>Experiences, views, and support needs of family members of people with hypoglycemia unawareness: interview study.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebfbde9c26bb395d80c1cef6ce2e1ba0"><gtr:id>ebfbde9c26bb395d80c1cef6ce2e1ba0</gtr:id><gtr:otherNames>Lawton J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>doi_13110__dc13_1154</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB74273B-F60B-434D-B4D8-784029977F5E</gtr:id><gtr:title>Thrombalexins: Cell-Localized Inhibition of Thrombin and Its Effects in a Model of High-Risk Renal Transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f37d17d516a262388eb2f6b8c9a954b"><gtr:id>2f37d17d516a262388eb2f6b8c9a954b</gtr:id><gtr:otherNames>Karegli J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>57c8203157a040.44535310</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>821DB2DE-51E8-4D17-BA52-962D8BD05A76</gtr:id><gtr:title>An organ allocation system for liver transplantation based on ordinal regression</gtr:title><gtr:parentPublicationTitle>APPLIED SOFT COMPUTING</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d8620c1d457ade0c74a6ebe28d12e17"><gtr:id>1d8620c1d457ade0c74a6ebe28d12e17</gtr:id><gtr:otherNames>Perez-Ortiz M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1568-4946</gtr:issn><gtr:outcomeId>5457af093faaf1.04882706</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>949AED37-6791-41C6-AC19-AEEE987A9388</gtr:id><gtr:title>Mesenchymal stromal cells as a means of controlling pathological T-cell responses in allogeneic islet transplantation.</gtr:title><gtr:parentPublicationTitle>Current opinion in organ transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7757760750e306c256b60d0266f85451"><gtr:id>7757760750e306c256b60d0266f85451</gtr:id><gtr:otherNames>Reading JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1087-2418</gtr:issn><gtr:outcomeId>doi_13110_32835c2adf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA3F58A0-A140-4D68-822A-09AB8F08DAB6</gtr:id><gtr:title>Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af432166ccb48fa8cb9a2f2939eccc19"><gtr:id>af432166ccb48fa8cb9a2f2939eccc19</gtr:id><gtr:otherNames>Garg G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>doi_13110_ol_1100272</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CFC4AA8-592B-4AA1-8A39-CE4894836F34</gtr:id><gtr:title>Patient-specific modeling of atrial fibrosis increases the accuracy of sinus rhythm simulations and may explain maintenance of atrial fibrillation.</gtr:title><gtr:parentPublicationTitle>Journal of electrocardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aeb4b381e8c48b594ed49f966f319e70"><gtr:id>aeb4b381e8c48b594ed49f966f319e70</gtr:id><gtr:otherNames>Krueger MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-0736</gtr:issn><gtr:outcomeId>5457b0538a4677.93333383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>524AFB9D-F441-4C0F-B85C-CE043021557D</gtr:id><gtr:title>Development and content validation of a surgical safety checklist for operating theatres that use robotic technology.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e0b4786411cafcf44ac496e87ec7b61"><gtr:id>6e0b4786411cafcf44ac496e87ec7b61</gtr:id><gtr:otherNames>Ahmed K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_13110_20_23601155</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>225AE268-B9D0-41D0-9C8E-987E1B49C586</gtr:id><gtr:title>Autoimmune hepatitis.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3a37063525ad4ecaac899b68014b3eb"><gtr:id>e3a37063525ad4ecaac899b68014b3eb</gtr:id><gtr:otherNames>Heneghan MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>54578b54885708.37574522</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E964D774-540E-4C46-84C5-85565B436A6B</gtr:id><gtr:title>Real-time continuous glucose monitoring significantly reduces severe hypoglycemia in hypoglycemia-unaware patients with type 1 diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf1705bc4f64641034438d1c29e3e3dd"><gtr:id>bf1705bc4f64641034438d1c29e3e3dd</gtr:id><gtr:otherNames>Choudhary P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>doi_13110__dc13_0939</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F12A354-DED1-4063-AFFF-9B15F6EEFE70</gtr:id><gtr:title>Human liver regeneration is characterized by the coordinated expression of distinct microRNA governing cell cycle fate.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2f3c0cc5e96bb6370c90806cc3168a1"><gtr:id>d2f3c0cc5e96bb6370c90806cc3168a1</gtr:id><gtr:otherNames>Salehi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>doi_13110__ajt_12183</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>353DC855-E757-49B5-AD42-45047F096C87</gtr:id><gtr:title>The IL23R A/Gln381 Allele Promotes IL-23 Unresponsiveness in Human Memory T-Helper 17 Cells and Impairs Th17 Responses in Psoriasis Patients</gtr:title><gtr:parentPublicationTitle>Journal of Investigative Dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e88821cf25005216ad94d24a572ef57"><gtr:id>0e88821cf25005216ad94d24a572ef57</gtr:id><gtr:otherNames>Di Meglio P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>doi_13110_d_2013_324</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6210AAAC-EF55-4B58-B85D-3092E01DA973</gtr:id><gtr:title>Systematic review of the relationship between artificial sweetener consumption and cancer in humans: analysis of 599,741 participants.</gtr:title><gtr:parentPublicationTitle>International journal of clinical practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e850a25a22dc916a88e64c1254f72ea6"><gtr:id>e850a25a22dc916a88e64c1254f72ea6</gtr:id><gtr:otherNames>Mishra A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1368-5031</gtr:issn><gtr:outcomeId>56e046a37b9781.84000134</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EF739BD-BB1B-426A-AB6D-A59FA4A03045</gtr:id><gtr:title>Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2469eb9871682cdbb02c64f8194ee83d"><gtr:id>2469eb9871682cdbb02c64f8194ee83d</gtr:id><gtr:otherNames>Haas M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>5452131bcaed01.75949063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDE89EB8-1609-43F9-833A-4924A83E5BE3</gtr:id><gtr:title>Complement nomenclature 2014.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97f2649fc7b89e5df4f4848bcd6d3cea"><gtr:id>97f2649fc7b89e5df4f4848bcd6d3cea</gtr:id><gtr:otherNames>Kemper C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>544653aeac5339.14410910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA8A9AF1-9CF9-4840-90F0-7F5058D197DD</gtr:id><gtr:title>STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9303b6eec1da862b838633fd0230674e"><gtr:id>9303b6eec1da862b838633fd0230674e</gtr:id><gtr:otherNames>Jerez A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5457aab354b802.00705220</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>313CA377-07FC-43B5-AC65-ABC7D78587F8</gtr:id><gtr:title>Maximising living donation with paediatric blood-group-incompatible renal transplantation.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9413f2084c871a74507fc204ce76f415"><gtr:id>9413f2084c871a74507fc204ce76f415</gtr:id><gtr:otherNames>Mamode N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>544a65944de801.18223364</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E91AF705-F68B-4A86-988C-0A21E7C9D616</gtr:id><gtr:title>Image guided robotic surgery: current evidence for effectiveness in urology.</gtr:title><gtr:parentPublicationTitle>Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39e9e887f01ede81d569de817ae01518"><gtr:id>39e9e887f01ede81d569de817ae01518</gtr:id><gtr:otherNames>Pervez A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1124-3562</gtr:issn><gtr:outcomeId>56e0047172cf59.40757221</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A4E1B50-2FB7-4858-BBEA-7B232206C707</gtr:id><gtr:title>Development of a standardised training curriculum for robotic surgery: a consensus statement from an international multidisciplinary group of experts.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e0b4786411cafcf44ac496e87ec7b61"><gtr:id>6e0b4786411cafcf44ac496e87ec7b61</gtr:id><gtr:otherNames>Ahmed K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56deff0f9375f6.72618809</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DCD43D4-9487-463F-9F20-2D973B48CB3C</gtr:id><gtr:title>Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6682b85c220c8c8bd534e7066c4856a9"><gtr:id>6682b85c220c8c8bd534e7066c4856a9</gtr:id><gtr:otherNames>Williams R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56e006b403e3c4.01747386</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>394305F3-E010-42AE-9675-DF47AC5B782A</gtr:id><gtr:title>Ethical, Legal and Psychosocial Aspects of Organ Transplantation: Global Issues, Local Solutions</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71cf298212a487b0841c9cb4f0b3b483"><gtr:id>71cf298212a487b0841c9cb4f0b3b483</gtr:id><gtr:otherNames>Cronin, Antonia J</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>jRXxVZhc4De</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>473AF10E-B279-4D80-8BBC-AA820B4326B3</gtr:id><gtr:title>Galectin-1 is required for the regulatory function of B cells.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58ff17d77279e3959684be392b8509a3"><gtr:id>58ff17d77279e3959684be392b8509a3</gtr:id><gtr:otherNames>Alhabbab R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a90090830ceb6.68948624</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DCF5B8A-7039-48E9-80CC-13C2D281EDA4</gtr:id><gtr:title>Genetic variants alter T-bet binding and gene expression in mucosal inflammatory disease.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ccf9faaa1f42b507e4b9de00b98315c"><gtr:id>0ccf9faaa1f42b507e4b9de00b98315c</gtr:id><gtr:otherNames>Soderquest K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>5aaa728c02c219.43185439</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>510DBD81-DB98-49C1-A3B0-0FA1963C97CE</gtr:id><gtr:title>Robot-assisted partial nephrectomy in cystic tumours: analysis of the Vattikuti Global Quality Initiative in Robotic Urologic Surgery (GQI-RUS) database.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/963b4362ca39c106da013a98da5f39f6"><gtr:id>963b4362ca39c106da013a98da5f39f6</gtr:id><gtr:otherNames>Novara G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56dffd4a2f9140.02158486</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53E6EA8B-4D13-4276-BF7A-52C6F44D7C65</gtr:id><gtr:title>The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c527f88ccb091966ae1ccaa57f48d497"><gtr:id>c527f88ccb091966ae1ccaa57f48d497</gtr:id><gtr:otherNames>Powell N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>doi_13110_012_09_008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E6A9707-4F92-4842-8168-D8CB15E4BF24</gtr:id><gtr:title>The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.</gtr:title><gtr:parentPublicationTitle>Platelets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035f6ac39e1e0dc2b6df50798858cfc1"><gtr:id>035f6ac39e1e0dc2b6df50798858cfc1</gtr:id><gtr:otherNames>Jakubowski JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0953-7104</gtr:issn><gtr:outcomeId>5458d805488e59.93027597</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>817B6B4D-53F3-4213-B1FD-0915CE6C15B3</gtr:id><gtr:title>&amp;quot;The most read surgical journal on the web&amp;quot;</gtr:title><gtr:parentPublicationTitle>BJU International</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_13110_12_11705_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2936B9D-1F95-46A2-B3D1-3084428A79F1</gtr:id><gtr:title>The European Association of Urology Robotic Urology Section (ERUS) survey of robot-assisted radical prostatectomy (RARP).</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27d8f8189a89239872f7de9b094df754"><gtr:id>27d8f8189a89239872f7de9b094df754</gtr:id><gtr:otherNames>Ficarra V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_13110_20_23551442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C01CC561-4AC5-4566-AE16-3D959836CB29</gtr:id><gtr:title>T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4? T cells.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5da642625a311858b22adc626593801"><gtr:id>e5da642625a311858b22adc626593801</gtr:id><gtr:otherNames>Arbore G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>585d4ffcdc2a07.26763928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17EF516D-1FF4-44E9-A0A3-20BA115125E5</gtr:id><gtr:title>Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.</gtr:title><gtr:parentPublicationTitle>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a02ccdc78234d7aa21cb2fcd8f7dca0"><gtr:id>3a02ccdc78234d7aa21cb2fcd8f7dca0</gtr:id><gtr:otherNames>Nagler A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1083-8791</gtr:issn><gtr:outcomeId>doi_13110_012_02_013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26731FDE-43D0-4B2E-8C5D-629E32E3A164</gtr:id><gtr:title>Thrombalexin: Use of a Cytotopic Anticoagulant to Reduce Thrombotic Microangiopathy in a Highly Sensitized Model of Kidney Transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/722c4ac63ded662dc422a0a61495e934"><gtr:id>722c4ac63ded662dc422a0a61495e934</gtr:id><gtr:otherNames>Manook M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>58ae98a89ee3c1.38127672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E934F5C-CE4F-4D2A-9AFF-4ED77C310D2E</gtr:id><gtr:title>PKA regulatory subunit expression in tooth development.</gtr:title><gtr:parentPublicationTitle>Gene expression patterns : GEP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/047df6ccdf48b87a65172c079783073c"><gtr:id>047df6ccdf48b87a65172c079783073c</gtr:id><gtr:otherNames>de Sousa SF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1567-133X</gtr:issn><gtr:outcomeId>5457a95eb83b98.10147465</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4DEAB1B-0C9D-4778-AABE-C59FA115F02C</gtr:id><gtr:title>Enhanced effect of inhibition of thrombin on endothelium in murine endotoxaemia: specific inhibition of thrombocytopenia.</gtr:title><gtr:parentPublicationTitle>Thrombosis research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ef91a6d242b3418b3065118aa4f2f60"><gtr:id>2ef91a6d242b3418b3065118aa4f2f60</gtr:id><gtr:otherNames>Chen D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0049-3848</gtr:issn><gtr:outcomeId>pm_13110_20_24161661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C8A4AFC-2218-489A-8AC6-B198FE462D09</gtr:id><gtr:title>Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/624d1d622d3da595ca0a04611094bf74"><gtr:id>624d1d622d3da595ca0a04611094bf74</gtr:id><gtr:otherNames>Manodoro F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5457abfec08aa7.18446034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A73E885-DF66-4A43-9959-CC6033AC9EAE</gtr:id><gtr:title>Is single-port laparoscopy feasible after liver transplant?</gtr:title><gtr:parentPublicationTitle>Pediatric transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a19fbdc4a6058721590d6bd1d16f98db"><gtr:id>a19fbdc4a6058721590d6bd1d16f98db</gtr:id><gtr:otherNames>Zani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1397-3142</gtr:issn><gtr:outcomeId>54579b7250d3c8.28241211</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3295A63B-A6EC-4224-99B5-11D1E20CDB15</gtr:id><gtr:title>The impact of the BJUI and what influences it today: does impact factor matter?</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27d8f8189a89239872f7de9b094df754"><gtr:id>27d8f8189a89239872f7de9b094df754</gtr:id><gtr:otherNames>Ficarra V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>54579d2b534106.06174077</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61A6AEC9-3A19-4609-99F3-210AC8F684AA</gtr:id><gtr:title>Anonymity and Live-Donor Transplantation</gtr:title><gtr:parentPublicationTitle>Transplantation Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/212fdf632f93bda6e33a3dcc7067a91b"><gtr:id>212fdf632f93bda6e33a3dcc7067a91b</gtr:id><gtr:otherNames>&amp;NA;</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_13110_31828ce474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F16372B5-733B-4A98-81D3-0B8FF699023A</gtr:id><gtr:title>Anaphylatoxins in organ transplantation.</gtr:title><gtr:parentPublicationTitle>Seminars in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ef586f0ee752b9a48fb0607626bbadf"><gtr:id>8ef586f0ee752b9a48fb0607626bbadf</gtr:id><gtr:otherNames>Li K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1044-5323</gtr:issn><gtr:outcomeId>doi_13110_013_04_013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1CBED78-9685-41DE-AF94-58E2187C4A2F</gtr:id><gtr:title>Adult human gingival epithelial cells as a source for whole-tooth bioengineering.</gtr:title><gtr:parentPublicationTitle>Journal of dental research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/587afa02e57bdc1139ff00725170292d"><gtr:id>587afa02e57bdc1139ff00725170292d</gtr:id><gtr:otherNames>Angelova Volponi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-0345</gtr:issn><gtr:outcomeId>doi_13110_4513481041</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34AD2175-43B6-4C01-AD53-2F87F6BDE966</gtr:id><gtr:title>Genetically engineered human islets protected from CD8-mediated autoimmune destruction in vivo.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48275e5f74516854a34dbf8f4f4807fc"><gtr:id>48275e5f74516854a34dbf8f4f4807fc</gtr:id><gtr:otherNames>Zaldumbide A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>doi_13110_t_2013_105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEB768E6-AA5E-4C95-9F25-0DE851912DDD</gtr:id><gtr:title>Design and evaluation of an image-guidance system for robot-assisted radical prostatectomy.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c0254f5b7f14f6e240f08790ae6c527"><gtr:id>4c0254f5b7f14f6e240f08790ae6c527</gtr:id><gtr:otherNames>Thompson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>doi_13110_12_11692_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>283E0555-0D95-4389-8110-C1ED4064A662</gtr:id><gtr:title>Introducing the productive operating theatre programme in urology theatre suites.</gtr:title><gtr:parentPublicationTitle>Urologia internationalis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e0b4786411cafcf44ac496e87ec7b61"><gtr:id>6e0b4786411cafcf44ac496e87ec7b61</gtr:id><gtr:otherNames>Ahmed K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0042-1138</gtr:issn><gtr:outcomeId>pm_13110_20_23548373</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>947C50B3-2E7C-42E4-A6CD-FC69164E9E3D</gtr:id><gtr:title>Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a ?3-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/875417b93bd9ca5b906e89e9855e1aae"><gtr:id>875417b93bd9ca5b906e89e9855e1aae</gtr:id><gtr:otherNames>Rossanese M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>54579d2cde9186.77073150</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF701160-B001-45BD-BD84-130F1EF6761C</gtr:id><gtr:title>Re: Willem M. Brinkman, Irene M. Tjiam, Barbara M.A. Schout, et al. Results of the European Basic Laparoscopic Urological Skills examination. Eur Urol 2014;65:490-6.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd0938c60157f1301ed3eb8e647339c7"><gtr:id>fd0938c60157f1301ed3eb8e647339c7</gtr:id><gtr:otherNames>Abboudi H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>56e047e8cfe767.47328592</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>134E196A-2E85-46B4-B0C7-C7D24E93FDDD</gtr:id><gtr:title>Human stem cell-derived retinal epithelial cells activate complement via collectin 11 in response to stress.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3de384593a446e5775a4a0b661e6b8dc"><gtr:id>3de384593a446e5775a4a0b661e6b8dc</gtr:id><gtr:otherNames>Fanelli G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa931c7f2ef09.94915200</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A574E64-FFC5-4000-A97C-8F92706F409D</gtr:id><gtr:title>Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e0b4786411cafcf44ac496e87ec7b61"><gtr:id>6e0b4786411cafcf44ac496e87ec7b61</gtr:id><gtr:otherNames>Ahmed K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>54579d2d382303.40422031</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4287DE4E-53D4-41DD-9537-75561947DAF4</gtr:id><gtr:title>Diagnostic criteria of autoimmune hepatitis.</gtr:title><gtr:parentPublicationTitle>Autoimmunity reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88ce4a32e863de105770d1d6c3b2aab"><gtr:id>f88ce4a32e863de105770d1d6c3b2aab</gtr:id><gtr:otherNames>Liberal R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1568-9972</gtr:issn><gtr:outcomeId>54578b53e58918.01674887</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E2A79C8-3C23-4420-8E12-98DB7601AD45</gtr:id><gtr:title>Role of the lectin complement pathway in kidney transplantation.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f41571013db636d13570fa10eaf335ba"><gtr:id>f41571013db636d13570fa10eaf335ba</gtr:id><gtr:otherNames>Farrar CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn><gtr:outcomeId>585d34585d0342.44088323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25623D8C-B80D-4471-B14D-3577A9736E9A</gtr:id><gtr:title>Complotype affects the extent of down-regulation by Factor I of the C3b feedback cycle in vitro.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44451b5381a73f924cb847c4db2f0420"><gtr:id>44451b5381a73f924cb847c4db2f0420</gtr:id><gtr:otherNames>Lay E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>54539f0a3ef835.02641748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A5F2773-25B9-4A59-86F0-97D0A595404A</gtr:id><gtr:title>Boosting translational research in the U.K.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c16c5f479e3899cefda351da6e95ef87"><gtr:id>c16c5f479e3899cefda351da6e95ef87</gtr:id><gtr:otherNames>Anandagoda N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>58c6b17aaded97.17343099</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C63B1034-EAA0-4395-B39A-D9F8EFC8A964</gtr:id><gtr:title>Clinical applications of image fusion for electrophysiology procedures</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d45cbf70b22d187841755d6a01d09b9"><gtr:id>9d45cbf70b22d187841755d6a01d09b9</gtr:id><gtr:otherNames>Rhode K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>978-1-4577-1857-1</gtr:isbn><gtr:outcomeId>doi_13110_12_6235840</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB69657C-FC57-4B4F-A3C1-3E14D899BCF8</gtr:id><gtr:title>Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdd6234818e384ba39a1a4d1aa05c098"><gtr:id>cdd6234818e384ba39a1a4d1aa05c098</gtr:id><gtr:otherNames>Burnett AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>doi_13110_u_2012_360</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC44BED1-5F60-41A8-B5AF-3921AC414208</gtr:id><gtr:title>Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC).</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf0a46d4c3e1d8e2dc84257bfb60af5b"><gtr:id>cf0a46d4c3e1d8e2dc84257bfb60af5b</gtr:id><gtr:otherNames>Marshall SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>doi_13110_12_11583_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>933CC74A-8BD8-4099-8BBC-3B2139CFA6A6</gtr:id><gtr:title>The epigenetic regulator PLZF represses L1 retrotransposition in germ and progenitor cells.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/489918b469a8775c60719eb67756d60b"><gtr:id>489918b469a8775c60719eb67756d60b</gtr:id><gtr:otherNames>Puszyk W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>doi_13110_j_2013_118</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BEC7DCB9-18BE-4B82-A286-27BD2A7D67DE</gtr:id><gtr:title>Successful outcome of renal transplantation in a child with HIV-associated nephropathy.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42950074035240bf79a7333ba3dadc2f"><gtr:id>42950074035240bf79a7333ba3dadc2f</gtr:id><gtr:otherNames>Shroff RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>544a6591baee81.17201763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B8595F0-F68F-4BF4-93EE-E5AF62319770</gtr:id><gtr:title>Dysregulated CD46 shedding interferes with Th1-contraction in systemic lupus erythematosus.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0de952c695f1b495a2aedcf1fab293fa"><gtr:id>0de952c695f1b495a2aedcf1fab293fa</gtr:id><gtr:otherNames>Ellinghaus U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>5a2fd786dbeeb4.54668606</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57BE05B3-7342-40F1-A99C-65685CA2FA19</gtr:id><gtr:title>Validation of the bladder control self-assessment questionnaire (B-SAQ) in men.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e9f2004e7d87500a4279587b7743a69"><gtr:id>6e9f2004e7d87500a4279587b7743a69</gtr:id><gtr:otherNames>Sahai A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_540e192e192f862fc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1392FA59-538A-499A-8EC6-37E667276A1E</gtr:id><gtr:title>Should peritoneal dialysis catheters be removed at the time of kidney transplantation?</gtr:title><gtr:parentPublicationTitle>Canadian Urological Association journal = Journal de l'Association des urologues du Canada</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/054f3bba9caed9d94eeada32f9cb44f8"><gtr:id>054f3bba9caed9d94eeada32f9cb44f8</gtr:id><gtr:otherNames>Warren J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1911-6470</gtr:issn><gtr:outcomeId>doi_13110_cuaj_12112</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1639353B-50D1-4AEE-A38C-9131F519554B</gtr:id><gtr:title>Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cf2e8ed3d7468c8796e10ceaddea37f"><gtr:id>4cf2e8ed3d7468c8796e10ceaddea37f</gtr:id><gtr:otherNames>Menon KV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>doi_13110__apt_12185</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58936915-722A-44B8-9FD7-140488B97D77</gtr:id><gtr:title>P1294 : Proof-of-principle evaluation of immunomodulatory drugs in promoting phagocytosis capacity in patients with liver failure</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0342018420be2cbe7f9f5ab7010f8eb6"><gtr:id>0342018420be2cbe7f9f5ab7010f8eb6</gtr:id><gtr:otherNames>Bernsmeier C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56e00040208179.40151856</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2404D11A-D910-4A92-A3D6-FBE87C1A496D</gtr:id><gtr:title>Long-term survival in infantile malignant autosomal recessive osteopetrosis secondary to homozygous p.Arg526Gln mutation in CLCN7.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89c865e85352461568bd1cafa6173cf4"><gtr:id>89c865e85352461568bd1cafa6173cf4</gtr:id><gtr:otherNames>Kantaputra PN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1552-4825</gtr:issn><gtr:outcomeId>doi_13110_mg_a_35264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D302E397-EF43-4453-9BFC-9527E0993362</gtr:id><gtr:title>Increasing importance of truly informed consent: the role of written patient information.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2986f38093912d086d7fe8ec16e20d7e"><gtr:id>2986f38093912d086d7fe8ec16e20d7e</gtr:id><gtr:otherNames>Kirby R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_13110_20_23419205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97CFA6B3-AEDB-4BA7-94CE-B00D8BD1831A</gtr:id><gtr:title>Effects of an agonist interleukin-2/Fc fusion protein, a mutant antagonist interleukin-15/Fc fusion protein, and sirolimus on cardiac allograft survival in non-human primates.</gtr:title><gtr:parentPublicationTitle>The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ab5a0b8a22a4e509f579b6729740eb2"><gtr:id>9ab5a0b8a22a4e509f579b6729740eb2</gtr:id><gtr:otherNames>Millington T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1053-2498</gtr:issn><gtr:outcomeId>doi_13110_012_01_864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7F8DD5A-3902-4FE2-89EE-741F05D3FEF1</gtr:id><gtr:title>A whole-body dual-modality radionuclide optical strategy for preclinical imaging of metastasis and heterogeneous treatment response in different microenvironments.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0a6ebfb3613d0ae467bfe5669016829"><gtr:id>a0a6ebfb3613d0ae467bfe5669016829</gtr:id><gtr:otherNames>Fruhwirth GO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>5458d75752a331.88732993</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84ABABA1-B388-46CC-8A8A-3699801A2CA5</gtr:id><gtr:title>Corticosteroid withdrawal normalises the proportion of transitional B cells but does not significantly change gene expression in renal transplant recipients</gtr:title><gtr:parentPublicationTitle>British Society for Immunology Congress 2013</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a7dbb6ad6c534ce7d878d1fd2d97148"><gtr:id>2a7dbb6ad6c534ce7d878d1fd2d97148</gtr:id><gtr:otherNames>Smallcombe N</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>5452574c33a8c7.98387215</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>332567C0-FFDD-4BBE-9C70-8D21EBF91B1B</gtr:id><gtr:title>A Workflow to Improve the Alignment of Prostate Imaging with Whole-mount Histopathology.</gtr:title><gtr:parentPublicationTitle>Academic radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43405bdee47846dd21c53267cfab3fd4"><gtr:id>43405bdee47846dd21c53267cfab3fd4</gtr:id><gtr:otherNames>Yamamoto H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1076-6332</gtr:issn><gtr:outcomeId>54579d2e911576.94427132</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F01F169-AC91-4626-ABEE-581819E91CFE</gtr:id><gtr:title>Cytoreductive nephrectomy in the era of targeted therapies: a review.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/977c0c1d68a3ebd357a91d86ae123e54"><gtr:id>977c0c1d68a3ebd357a91d86ae123e54</gtr:id><gtr:otherNames>Pindoria N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>5aa7f057e989e5.38411410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B39E0BB-8D6B-43B9-8C45-78107BF67C89</gtr:id><gtr:title>Robotic surgery in trauma and orthopaedics: a systematic review.</gtr:title><gtr:parentPublicationTitle>The bone &amp; joint journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2fb0d8aafc2000bf126a8f548cfa275"><gtr:id>d2fb0d8aafc2000bf126a8f548cfa275</gtr:id><gtr:otherNames>Karthik K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2049-4394</gtr:issn><gtr:outcomeId>56e046a60e4cc2.20616858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFF7B1AE-0792-4C57-A50C-79326E341413</gtr:id><gtr:title>Clinical science workshop: targeting the gut-liver-brain axis.</gtr:title><gtr:parentPublicationTitle>Metabolic brain disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88dec011ba6ff341da2ff046e3579948"><gtr:id>88dec011ba6ff341da2ff046e3579948</gtr:id><gtr:otherNames>Patel VC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0885-7490</gtr:issn><gtr:outcomeId>56dee6b6791728.78364327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B92AB0BB-DAE8-4651-8A09-707764EF3180</gtr:id><gtr:title>Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model.</gtr:title><gtr:parentPublicationTitle>Leukemia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/add156abaf191551d4afc4dd2ebc17d3"><gtr:id>add156abaf191551d4afc4dd2ebc17d3</gtr:id><gtr:otherNames>Fenaux P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0145-2126</gtr:issn><gtr:outcomeId>5457aab53f13d2.68269226</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6534736-4DC6-4EB9-9D53-AFE4261FE323</gtr:id><gtr:title>Complement and glomerular diseases.</gtr:title><gtr:parentPublicationTitle>Nephron. Clinical practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1ab6bc223ade8f25eba4d3a76df65cf"><gtr:id>d1ab6bc223ade8f25eba4d3a76df65cf</gtr:id><gtr:otherNames>Popat RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1660-2110</gtr:issn><gtr:outcomeId>56deaaee043a89.91908398</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E99C5DA1-FC68-4FC8-924B-3E822C72E988</gtr:id><gtr:title>Complement-here, there and everywhere, but what about the transplanted organ?</gtr:title><gtr:parentPublicationTitle>Seminars in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08e7acccc697d335a9c9faa7f6a259c1"><gtr:id>08e7acccc697d335a9c9faa7f6a259c1</gtr:id><gtr:otherNames>Montero RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1044-5323</gtr:issn><gtr:outcomeId>58c6b5f9b562e3.90532659</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF5A3013-C773-4B1C-8FFD-1FE40F371A52</gtr:id><gtr:title>Granulocyte colony stimulating factor exacerbates antineutrophil cytoplasmic antibody vasculitis.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ff09c7595c7f1b1582e2a909a1edfa8"><gtr:id>7ff09c7595c7f1b1582e2a909a1edfa8</gtr:id><gtr:otherNames>Freeley SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_13110_20_23087180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AD38ECC-E97B-4F52-8A6C-38175C530BC5</gtr:id><gtr:title>Tablet based simulation provides a new solution to accessing laparoscopic skills training.</gtr:title><gtr:parentPublicationTitle>Journal of surgical education</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0aae6b835cd1217dd0d751adc9312359"><gtr:id>0aae6b835cd1217dd0d751adc9312359</gtr:id><gtr:otherNames>Bahsoun AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1878-7452</gtr:issn><gtr:outcomeId>doi_13110_012_08_008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A7B1D7E-368D-4278-B65A-D749DB791E7C</gtr:id><gtr:title>Autoantibody and human leukocyte antigen profiles in children with autoimmune liver disease and their first-degree relatives.</gtr:title><gtr:parentPublicationTitle>Journal of pediatric gastroenterology and nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d744b37eab5d54815ab8dca6c36aae5"><gtr:id>5d744b37eab5d54815ab8dca6c36aae5</gtr:id><gtr:otherNames>Wang P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-2116</gtr:issn><gtr:outcomeId>54578b5418f116.49173132</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82D18FA4-3F23-4368-A05B-B972C0493F96</gtr:id><gtr:title>Bmp signalling in filiform tongue papillae development.</gtr:title><gtr:parentPublicationTitle>Archives of oral biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cbdc06b13d8462c6fc642914100ca07"><gtr:id>4cbdc06b13d8462c6fc642914100ca07</gtr:id><gtr:otherNames>Kawasaki K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-9969</gtr:issn><gtr:outcomeId>doi_13110_011_11_014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAC871F0-F561-41B9-9677-41B09103090D</gtr:id><gtr:title>Holmium Laser Enucleation of the Prostate: Simulation-Based Training Curriculum and Validation.</gtr:title><gtr:parentPublicationTitle>Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc32f1a27511368503c1643fca28655e"><gtr:id>cc32f1a27511368503c1643fca28655e</gtr:id><gtr:otherNames>Kuronen-Stewart C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0090-4295</gtr:issn><gtr:outcomeId>56e046a434e766.89011306</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55CA6B9A-966A-4134-B148-AF2CF6E2877A</gtr:id><gtr:title>Exploring a Role for IL-7-Induced Homeostatic Reconstitution of Regulatory T Cells Postbasiliximab Therapy: Implications for Transplantation Tolerance.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be4eba9249e5210879c5ba825b58c879"><gtr:id>be4eba9249e5210879c5ba825b58c879</gtr:id><gtr:otherNames>Mason GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>58c6b17c192406.87981529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4AD27ED9-CEF1-4C52-9941-6BC613B295C5</gtr:id><gtr:title>A Patient-Centred Approach to Biomarkers of Tolerance</gtr:title><gtr:parentPublicationTitle>World Transplant Congress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e426fdbd821c397196746d5832db40"><gtr:id>63e426fdbd821c397196746d5832db40</gtr:id><gtr:otherNames>Harrington, J</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>545269573a6113.94513204</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D19B8964-BDF8-47C5-BAFD-EBA4EEB1D068</gtr:id><gtr:title>Attainment of metabolic goals in the integrated UK islet transplant program with locally isolated and transported preparations.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa233d531e7c8fbf7bcf1d610d18e49e"><gtr:id>fa233d531e7c8fbf7bcf1d610d18e49e</gtr:id><gtr:otherNames>Brooks AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>54579ae10c3719.75179990</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D3B357F-0CA3-4FED-B35B-87A0353054C4</gtr:id><gtr:title>Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0f1a793db16a455db9d28894e0e9cd9"><gtr:id>c0f1a793db16a455db9d28894e0e9cd9</gtr:id><gtr:otherNames>Freeman SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>5457abfe708240.89387796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1B3703F-E7C5-489E-87C6-E753A03CB8EE</gtr:id><gtr:title>A need for biomarkers of operational tolerance in liver and kidney transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/022cf0357038acd640d421c8ccf7409f"><gtr:id>022cf0357038acd640d421c8ccf7409f</gtr:id><gtr:otherNames>Londo?o MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>doi_13110_12_04035_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CCCF4AD-8E11-4BE0-B939-969272472BFC</gtr:id><gtr:title>Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.</gtr:title><gtr:parentPublicationTitle>Critical reviews in oncology/hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ee45aea156761e55db9e0e3a59d9172"><gtr:id>1ee45aea156761e55db9e0e3a59d9172</gtr:id><gtr:otherNames>Santini V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1040-8428</gtr:issn><gtr:outcomeId>5457aab3cd2ab4.80404394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3074B655-0EDD-4F32-A9A2-092EE5D24088</gtr:id><gtr:title>The roles of thrombin and protease-activated receptors in inflammation.</gtr:title><gtr:parentPublicationTitle>Seminars in immunopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e22ea8b9a5712de0fb5c6c45e86833"><gtr:id>54e22ea8b9a5712de0fb5c6c45e86833</gtr:id><gtr:otherNames>Ma L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1863-2297</gtr:issn><gtr:outcomeId>544f5918840277.84554298</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7998ACCE-FB90-4A6E-9728-DCCF6E63FA2B</gtr:id><gtr:title>The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT.</gtr:title><gtr:parentPublicationTitle>Bone marrow transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d954d7ef0b3a67c8d3f0b6de4f0d8006"><gtr:id>d954d7ef0b3a67c8d3f0b6de4f0d8006</gtr:id><gtr:otherNames>Giebel S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>doi_13110_t_2012_131</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEE0CD20-94D2-4774-8F5C-9076942C694C</gtr:id><gtr:title>Efficacy of robot-assisted radical cystectomy (RARC) in advanced bladder cancer: results from the International Radical Cystectomy Consortium (IRCC).</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8037a4d157ec732757aa4235b1fabb18"><gtr:id>8037a4d157ec732757aa4235b1fabb18</gtr:id><gtr:otherNames>Al-Daghmin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>54579d2e6c03c1.02970159</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23EA160F-8D07-4CFB-BA78-7AC38E31FC31</gtr:id><gtr:title>UK DONATION ETHICS COMMITTEE (UKDEC) DRAFT GUIDANCE ON PRE-MORTEM INTERVENTIONS TO OPTIMISE DONOR ORGAN QUALITY AND IMPROVE TRANSPLANT OUTCOMES IN DCD</gtr:title><gtr:parentPublicationTitle>TRANSPLANT INTERNATIONAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67120fa11448156b024966f69f6e1986"><gtr:id>67120fa11448156b024966f69f6e1986</gtr:id><gtr:otherNames>Lewis Penney</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>K4mB1zqrZU3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C526B62F-0ED6-4CCC-8AA2-2E218245AF5F</gtr:id><gtr:title>Registration of 3D trans-esophageal echocardiography to X-ray fluoroscopy using image-based probe tracking.</gtr:title><gtr:parentPublicationTitle>Medical image analysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98d952a0c0e869717a5832b68363285e"><gtr:id>98d952a0c0e869717a5832b68363285e</gtr:id><gtr:otherNames>Gao G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1361-8415</gtr:issn><gtr:outcomeId>doi_13110_011_05_003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5476935-8890-414B-B83A-B36B13F3BF51</gtr:id><gtr:title>Non-Invasive whole-body detection of complement activation using radionuclide imaging in a mouse model of myocardial ischaemia-reperfusion injury.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fb958eb3535e59307e26530390bd12c"><gtr:id>2fb958eb3535e59307e26530390bd12c</gtr:id><gtr:otherNames>Sharif-Paghaleh E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa9322e690e82.70117432</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43C99602-29D0-4207-B533-1D423CE31DF7</gtr:id><gtr:title>Collectin-11 Is an Important Modulator of Retinal Pigment Epithelial Cell Phagocytosis and Cytokine Production.</gtr:title><gtr:parentPublicationTitle>Journal of innate immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8529b95f762c00cf1e0a6a341a5c28aa"><gtr:id>8529b95f762c00cf1e0a6a341a5c28aa</gtr:id><gtr:otherNames>Dong X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1662-811X</gtr:issn><gtr:outcomeId>5aa6587e424828.59034428</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE611214-A5FA-4B3D-979F-712240A540E6</gtr:id><gtr:title>Magnetic resonance imaging catheter stress haemodynamics post-Fontan in hypoplastic left heart syndrome.</gtr:title><gtr:parentPublicationTitle>European heart journal cardiovascular Imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2615b37135016fba5b4536fd6f67b05b"><gtr:id>2615b37135016fba5b4536fd6f67b05b</gtr:id><gtr:otherNames>Pushparajah K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2047-2404</gtr:issn><gtr:outcomeId>585d6e14f18ba6.91208659</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09DF669C-FAD7-4778-BB06-260DA736A7B5</gtr:id><gtr:title>Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study.</gtr:title><gtr:parentPublicationTitle>The lancet. Diabetes &amp; endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f6477458bd5d6ee9008dfdb15621825"><gtr:id>2f6477458bd5d6ee9008dfdb15621825</gtr:id><gtr:otherNames>Thabit H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2213-8587</gtr:issn><gtr:outcomeId>54579ae2e09318.71583469</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A9C6F39-A69A-4261-91FC-5E228B9C56F3</gtr:id><gtr:title>T-bet as a key regulator of mucosal immunity.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47f35f946f30921891c7358065bf53e2"><gtr:id>47f35f946f30921891c7358065bf53e2</gtr:id><gtr:otherNames>Mohamed R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>58c6b17db11812.12993708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FC752AA-E5B6-43AF-86E0-5D4FA8EFF063</gtr:id><gtr:title>National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16ef3f06f7ed7678dc7e6e97daa474d2"><gtr:id>16ef3f06f7ed7678dc7e6e97daa474d2</gtr:id><gtr:otherNames>Sujenthiran A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>5aa7ef2cbeb2b0.55879974</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26368BEA-E7E8-44EF-AA8F-F805C8C03710</gtr:id><gtr:title>Using ancestry-informative markers to identify fine structure across 15 populations of European origin.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcf05d319a117307d29b184d0a50813b"><gtr:id>fcf05d319a117307d29b184d0a50813b</gtr:id><gtr:otherNames>Huckins LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>5457ab63344f71.91926523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75D982C8-DBFD-460B-A497-B81A48571D0A</gtr:id><gtr:title>The use of botulinum toxin for the treatment of urologic pain.</gtr:title><gtr:parentPublicationTitle>Current opinion in urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb15b6f1eb2a9719928597c0b2ad1805"><gtr:id>fb15b6f1eb2a9719928597c0b2ad1805</gtr:id><gtr:otherNames>Russell A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0963-0643</gtr:issn><gtr:outcomeId>54579d2b28adc7.67674615</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96737200-8923-4280-8DE5-456ABBC669BD</gtr:id><gtr:title>The IL-23/IL-17 axis in psoriatic arthritis.</gtr:title><gtr:parentPublicationTitle>Autoimmunity reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73a419f8623f75c4e445e2042e368b84"><gtr:id>73a419f8623f75c4e445e2042e368b84</gtr:id><gtr:otherNames>Suzuki E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1568-9972</gtr:issn><gtr:outcomeId>5457a86dba6f73.13049698</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B236F252-1C71-4A49-8E4E-4868D38224C9</gtr:id><gtr:title>Personalization of atrial anatomy and electrophysiology as a basis for clinical modeling of radio-frequency ablation of atrial fibrillation.</gtr:title><gtr:parentPublicationTitle>IEEE transactions on medical imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aeb4b381e8c48b594ed49f966f319e70"><gtr:id>aeb4b381e8c48b594ed49f966f319e70</gtr:id><gtr:otherNames>Krueger MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0278-0062</gtr:issn><gtr:outcomeId>doi_13110_12_2201948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4219547-76DA-4FD6-9D20-495FD045FCA9</gtr:id><gtr:title>Analysis of aortopulmonary window using cardiac magnetic resonance imaging.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/740dde37cd7b401af6860b9f00241df7"><gtr:id>740dde37cd7b401af6860b9f00241df7</gtr:id><gtr:otherNames>Wong J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>doi_13110_112_108183</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D53DD632-C47D-4020-B59D-64C30962D5F1</gtr:id><gtr:title>Transplant accommodation--are the lessons learned from xenotransplantation pertinent for clinical allotransplantation?</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7c701d8e064a4012140c494c65b7417"><gtr:id>a7c701d8e064a4012140c494c65b7417</gtr:id><gtr:otherNames>Dorling A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>544f5918e29f05.20064685</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5A7F0DC-14A5-4BB9-932B-3CD81961384D</gtr:id><gtr:title>Depression and kidney transplantation.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f5b52700b2af65acd20d20d4f58fc38"><gtr:id>9f5b52700b2af65acd20d20d4f58fc38</gtr:id><gtr:otherNames>Chilcot J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>544a6592b621f0.63240177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED27967E-7377-49E5-979C-FE6FD0C11BAC</gtr:id><gtr:title>Non-invasive biomarkers to guide management following renal transplantation: the need for a multiplatform approach.</gtr:title><gtr:parentPublicationTitle>Current opinion in organ transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce71fe9aea464999cf689aa64bf424e9"><gtr:id>ce71fe9aea464999cf689aa64bf424e9</gtr:id><gtr:otherNames>Chowdhury P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1087-2418</gtr:issn><gtr:outcomeId>pm_13110_20_23283248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94813FE8-0D28-4DF8-923C-EEB4813D6900</gtr:id><gtr:title>Synthesis and characterisation of zirconium complexes for cell tracking with Zr-89 by positron emission tomography.</gtr:title><gtr:parentPublicationTitle>Dalton transactions (Cambridge, England : 2003)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef11f018c0170773362a5e66ba46f688"><gtr:id>ef11f018c0170773362a5e66ba46f688</gtr:id><gtr:otherNames>Ferris TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1477-9226</gtr:issn><gtr:outcomeId>5458d757a07da5.88479736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A33208D1-416F-40F7-9640-7927F387D1B1</gtr:id><gtr:title>NICE guidance and the BJUI.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>5aa7ee94eeea25.05781657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>907AABAF-4630-49BA-99F3-097134D39A24</gtr:id><gtr:title>Immunologic human renal allograft injury associates with an altered IL-10/TNF-a expression ratio in regulatory B cells.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5f44bb44b03638a9aaf1c176153f1c0"><gtr:id>c5f44bb44b03638a9aaf1c176153f1c0</gtr:id><gtr:otherNames>Cherukuri A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>545251d7237f03.89273840</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CBF454D-2272-4A1C-931E-03CF0BF4E022</gtr:id><gtr:title>Unraveling the autoimmune translational research process layer by layer.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6eacd85cd95c31e69b2a37ae2009d0d4"><gtr:id>6eacd85cd95c31e69b2a37ae2009d0d4</gtr:id><gtr:otherNames>Blumberg RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>doi_13110_38_nm_2632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8016D178-B3F4-4B6A-B433-6D6EEECF0741</gtr:id><gtr:title>Haematopoietic stem cell transplantation for acquired aplastic anaemia.</gtr:title><gtr:parentPublicationTitle>Current opinion in hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c75b9d21c1422cf7db65339fa32d0065"><gtr:id>c75b9d21c1422cf7db65339fa32d0065</gtr:id><gtr:otherNames>Young ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1065-6251</gtr:issn><gtr:outcomeId>5457aab3a49de4.04725033</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5B9A156-28F2-44D8-8857-9953B408BAD6</gtr:id><gtr:title>Development and validation of the pediatric liver transplantation quality of life: a disease-specific quality of life measure for pediatric liver transplant recipients.</gtr:title><gtr:parentPublicationTitle>The Journal of pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6879ed0ffa451c5b9d13d4a394e474aa"><gtr:id>6879ed0ffa451c5b9d13d4a394e474aa</gtr:id><gtr:otherNames>Ng V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3476</gtr:issn><gtr:outcomeId>54579b7298e946.02640373</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BAD7F0E-B3D6-4102-B8A9-2F21AC10ADB3</gtr:id><gtr:title>Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: initiation via direct platelet signaling.</gtr:title><gtr:parentPublicationTitle>Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3c3adc3d12b62d518d051fcb7cd2183"><gtr:id>f3c3adc3d12b62d518d051fcb7cd2183</gtr:id><gtr:otherNames>Durazzo TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1473-0502</gtr:issn><gtr:outcomeId>5457983f5e46f5.75251936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82F45425-DFE1-495C-8A02-F1CDCC1A6E93</gtr:id><gtr:title>Pancreatectomy with synchronous vascular resection--an argument in favour.</gtr:title><gtr:parentPublicationTitle>The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f675baafb2965ea8a85dc20c2e28e561"><gtr:id>f675baafb2965ea8a85dc20c2e28e561</gtr:id><gtr:otherNames>Marangoni G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1479-666X</gtr:issn><gtr:outcomeId>doi_13110_011_12_001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56F8B23C-A0B5-446A-8208-6347DCF27FF9</gtr:id><gtr:title>An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc70510ec78fb6c1db3b387b7122ce72"><gtr:id>dc70510ec78fb6c1db3b387b7122ce72</gtr:id><gtr:otherNames>Mangera A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>54579d2d821597.48968662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F931FD9-6D6F-4591-97C7-DF4414684EF5</gtr:id><gtr:title>Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci.</gtr:title><gtr:parentPublicationTitle>Annals of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e46d4ee199e251c31c3a7a4780236cd5"><gtr:id>e46d4ee199e251c31c3a7a4780236cd5</gtr:id><gtr:otherNames>Holton P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-4800</gtr:issn><gtr:outcomeId>doi_13110__ahg_12000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D7EC389-324B-43CE-BE7A-A785181A031F</gtr:id><gtr:title>A role for gut-associated lymphoid tissue in shaping the human B cell repertoire.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13a5c401c9f6a3fab61e33f17b4c450d"><gtr:id>13a5c401c9f6a3fab61e33f17b4c450d</gtr:id><gtr:otherNames>Vossenk?mper A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>pm_13110_20_23940259</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD04343E-39AD-4925-A0D3-F06879C22D92</gtr:id><gtr:title>Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4(+)CD25(+)FOXP3(+) T regulatory cell subpopulations.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a501a6a9751751d9907ecb97f8214a5f"><gtr:id>a501a6a9751751d9907ecb97f8214a5f</gtr:id><gtr:otherNames>Scott? C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>pm_13110_20_23242600</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DE23BFD-716E-4FBE-87B3-9312D0F14D1F</gtr:id><gtr:title>Learning the lessons from 1000 robot-assisted radical prostatectomy procedures.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2986f38093912d086d7fe8ec16e20d7e"><gtr:id>2986f38093912d086d7fe8ec16e20d7e</gtr:id><gtr:otherNames>Kirby R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_13110_20_23107391</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E469B75-F68A-4E34-B097-8EC29AF6ED46</gtr:id><gtr:title>SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/620c32debfab8521e02f0f04add64937"><gtr:id>620c32debfab8521e02f0f04add64937</gtr:id><gtr:otherNames>Mian SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56ddb1ca7bbce0.22287447</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74342BDB-E257-444A-8C42-90BE21B06B78</gtr:id><gtr:title>Correction: the buccohypophyseal canal is an ancestral vertebrate trait maintained by modulation in sonic hedgehog signaling</gtr:title><gtr:parentPublicationTitle>BMC Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6eeaf89451f8cf9ae3ab95a8d8dc5d6"><gtr:id>c6eeaf89451f8cf9ae3ab95a8d8dc5d6</gtr:id><gtr:otherNames>Khonsari R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_13110_7007_11_70</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B971491F-A78D-4646-9CAF-E4EEF8883377</gtr:id><gtr:title>Steroid Withdrawal Kidney transplant recipients normalise their proportion of Transitional B Cells in periphery, contrary to the absence of change in gene expression</gtr:title><gtr:parentPublicationTitle>World Transplant Congress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc95925114361aa21b01c2540942e28f"><gtr:id>fc95925114361aa21b01c2540942e28f</gtr:id><gtr:otherNames>Mobillo, P</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>54526ab6b4dd40.61112672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FC0F56A-6FE1-42AD-BEDF-3EC8D26E2551</gtr:id><gtr:title>Coinheritance of COL4A5 and MYO1E mutations accentuate the severity of kidney disease.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54ab7e3bb69e1fb68a55a57b0178c654"><gtr:id>54ab7e3bb69e1fb68a55a57b0178c654</gtr:id><gtr:otherNames>Lennon R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>56dffad40bbe71.80203426</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E16CA78-5DA1-4520-8003-54B3AFC44C69</gtr:id><gtr:title>From immunosuppression to tolerance.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/856c31f0b7d46b833b854dca3afb28a6"><gtr:id>856c31f0b7d46b833b854dca3afb28a6</gtr:id><gtr:otherNames>Adams DH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56df03561e8da6.83193794</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB92DD8C-86C5-4888-A4E7-0FF481168397</gtr:id><gtr:title>Tubulin ?-III: a novel immunohistochemical marker for intrahepatic peripheral cholangiocarcinoma.</gtr:title><gtr:parentPublicationTitle>Histopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a35f8880f3a4aee14365b9a3bd7e1bc"><gtr:id>4a35f8880f3a4aee14365b9a3bd7e1bc</gtr:id><gtr:otherNames>Zen Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0309-0167</gtr:issn><gtr:outcomeId>56e00471ebd8f0.36503397</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>047C6690-08E2-4715-8209-CC16AE208811</gtr:id><gtr:title>CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a24f02668e536a6d0df0cd985e178d88"><gtr:id>a24f02668e536a6d0df0cd985e178d88</gtr:id><gtr:otherNames>Afzali B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_13110_20_23677517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC7EB02B-D605-4CC5-8443-36521047B5F5</gtr:id><gtr:title>B7 family checkpoint regulators in immune regulation and disease.</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eec8150503ee523e784a00bba8222bc5"><gtr:id>eec8150503ee523e784a00bba8222bc5</gtr:id><gtr:otherNames>Ceeraz S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn><gtr:outcomeId>doi_13110_013_07_003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>549E252F-8BD1-48CF-B6A3-BFAD815A8240</gtr:id><gtr:title>Emergent Transcriptomic Technologies and Their Role in the Discovery of Biomarkers of Liver Transplant Tolerance.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc197d71ebab96406580aa5d525e391a"><gtr:id>bc197d71ebab96406580aa5d525e391a</gtr:id><gtr:otherNames>Mastoridis S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>56debcfc6551c0.64227763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CED23F28-1F94-472E-86ED-BE7867C8157E</gtr:id><gtr:title>Postthymic expansion in human CD4 naive T cells defined by expression of functional high-affinity IL-2 receptors.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d827f4cf163bdfedc6b6e833f08e27f"><gtr:id>5d827f4cf163bdfedc6b6e833f08e27f</gtr:id><gtr:otherNames>Pekalski ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>doi_13110_ol_1202914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65FA58F1-7E11-4374-86B1-8C0A80879E7C</gtr:id><gtr:title>Progress in immune-based therapies for type 1 diabetes.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c92a36a38ce1501a293fe436965d8f20"><gtr:id>c92a36a38ce1501a293fe436965d8f20</gtr:id><gtr:otherNames>von Herrath M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>doi_13110__cei_12085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39FE2144-622C-4E54-960F-0426C35375D5</gtr:id><gtr:title>Understanding the mechanisms amenable to CRT response: from pre-operative multimodal image data to patient-specific computational models.</gtr:title><gtr:parentPublicationTitle>Medical &amp; biological engineering &amp; computing</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdb5cc6e51b68fcca43c68015df18bc3"><gtr:id>cdb5cc6e51b68fcca43c68015df18bc3</gtr:id><gtr:otherNames>Tobon-Gomez C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-0118</gtr:issn><gtr:outcomeId>5457b051b6df22.29636870</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7DD46CD-1F67-4E91-BE5F-A4E4328A90E2</gtr:id><gtr:title>The diaphragms of fenestrated endothelia: gatekeepers of vascular permeability and blood composition.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4ac4ae1006ba152d55ab78a525f0eb0"><gtr:id>d4ac4ae1006ba152d55ab78a525f0eb0</gtr:id><gtr:otherNames>Stan RV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn><gtr:outcomeId>doi_13110_012_11_003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F25B99B3-6D27-4911-BA7C-7481245C48A7</gtr:id><gtr:title>Hyperdiploidy with 49-65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95dcf47bd58ce7a47216c4d1785232ce"><gtr:id>95dcf47bd58ce7a47216c4d1785232ce</gtr:id><gtr:otherNames>Chilton L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>doi_13110_u_2013_198</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2319928-3576-4EBB-A90F-53871D7A2D5A</gtr:id><gtr:title>The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90509523adb96ea1aa3696ac87c9450d"><gtr:id>90509523adb96ea1aa3696ac87c9450d</gtr:id><gtr:otherNames>Smith BN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>doi_13110_hg_2012_98</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6799C11-E22D-401C-B507-C465CC8F346D</gtr:id><gtr:title>Complement Recognition Pathways in Renal Transplantation.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8c0c8e4bc3c81039bafb922af1e3d42"><gtr:id>a8c0c8e4bc3c81039bafb922af1e3d42</gtr:id><gtr:otherNames>Nauser CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>5a35e2be03cc79.48665408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39C45DA2-518B-403B-BA8D-E4EB2E74A880</gtr:id><gtr:title>Analyses of the redistribution of work following cardiac resynchronisation therapy in a patient specific model.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e00a205df4c1593666658b6e9822b134"><gtr:id>e00a205df4c1593666658b6e9822b134</gtr:id><gtr:otherNames>Niederer SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_13110_ne_0043504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>083F170E-624E-419E-BF07-586B8776EAE1</gtr:id><gtr:title>Improved insulin sensitivity despite increased visceral adiposity in mice deficient for the immune cell transcription factor T-bet.</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e476949dc4c4ee8bd7d9c756e635262"><gtr:id>1e476949dc4c4ee8bd7d9c756e635262</gtr:id><gtr:otherNames>Stolarczyk E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn><gtr:outcomeId>doi_13110_013_02_019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D53BB10-3D82-40D1-BF87-F193AE9E82FE</gtr:id><gtr:title>Renal allograft recipients fail to increase interferon-? during invasive fungal diseases.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1bcaf5967d9e114942c20e54388995f"><gtr:id>f1bcaf5967d9e114942c20e54388995f</gtr:id><gtr:otherNames>Armstrong-James D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>pm_13110_20_22974244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>200B944F-1CFB-4213-853A-F329FA3346C9</gtr:id><gtr:title>Ethical, Legal and Psychosocial Aspects of Organ Transplantation: Global Issues, Local Solutions</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71cf298212a487b0841c9cb4f0b3b483"><gtr:id>71cf298212a487b0841c9cb4f0b3b483</gtr:id><gtr:otherNames>Cronin, Antonia J</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>cbjkueggq1J</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92302FBE-83E3-4997-809A-DA32C2836FB9</gtr:id><gtr:title>Granular jamming transitions for a robotic mechanism</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0028dc86b8d9b2b4aea1230ffbfc307"><gtr:id>d0028dc86b8d9b2b4aea1230ffbfc307</gtr:id><gtr:otherNames>Jiang A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_13110__1_4811948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E8109D8-2315-4748-8037-63BEF8C6DE9C</gtr:id><gtr:title>Immune modulation by apoptotic dental pulp stem cells in vivo.</gtr:title><gtr:parentPublicationTitle>Immunotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80f402ed5a658810e9f8ef86605e10f1"><gtr:id>80f402ed5a658810e9f8ef86605e10f1</gtr:id><gtr:otherNames>Laing AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1750-743X</gtr:issn><gtr:outcomeId>5a900908620382.32034888</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E0E773B-9FE0-4FEB-B615-7E416B90CF60</gtr:id><gtr:title>Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA).</gtr:title><gtr:parentPublicationTitle>EJNMMI research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f69ceeaa5152079e6ce4e4bd392bf496"><gtr:id>f69ceeaa5152079e6ce4e4bd392bf496</gtr:id><gtr:otherNames>Kampmeier F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5458d7572ba960.41346366</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1490FC71-8BB3-42A6-90E0-C2102D3BF7CF</gtr:id><gtr:title>PREVALENCE AND TREATMENT OF PROTEINURIA IN LONG-TERM KIDNEY TRANSPLANT PATIENTS</gtr:title><gtr:parentPublicationTitle>TRANSPLANT INTERNATIONAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24f7f58f1b6588b97d5c3e37ae1a8e5a"><gtr:id>24f7f58f1b6588b97d5c3e37ae1a8e5a</gtr:id><gtr:otherNames>Belete Martha</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>AULHvxgEbCW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C09D13A-F20C-4096-BAE7-CFBCD307BBB4</gtr:id><gtr:title>Promotion of natural tooth repair by small molecule GSK3 antagonists.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2eb43522bc9b39ee7a6e433cd49fc552"><gtr:id>2eb43522bc9b39ee7a6e433cd49fc552</gtr:id><gtr:otherNames>Neves VC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>589466560eaa49.19130506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19F3C1E9-309F-4DEE-98FA-C3B1CB7D2B00</gtr:id><gtr:title>Structured and Modular Training Pathway for Robot-assisted Radical Prostatectomy (RARP): Validation of the RARP Assessment Score and Learning Curve Assessment.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2b5f7aa740f0d16cda4430fc97f3207"><gtr:id>b2b5f7aa740f0d16cda4430fc97f3207</gtr:id><gtr:otherNames>Lovegrove C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>56e0450b2081f5.50928644</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>504101CD-9D33-4609-B029-8E7F852296A7</gtr:id><gtr:title>Validation of the GreenLight? Simulator and development of a training curriculum for photoselective vaporisation of the prostate.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d56aff527715c429c6f28b0fc7d2c3e1"><gtr:id>d56aff527715c429c6f28b0fc7d2c3e1</gtr:id><gtr:otherNames>Aydin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>54579d2b9edb24.60099351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE6A6DB2-EB1C-4BA2-BAF2-0283B35239D1</gtr:id><gtr:title>Ring1a/b polycomb proteins regulate the mesenchymal stem cell niche in continuously growing incisors.</gtr:title><gtr:parentPublicationTitle>Developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a6c2e800dcf800f18d5e31700e70918"><gtr:id>3a6c2e800dcf800f18d5e31700e70918</gtr:id><gtr:otherNames>Lapthanasupkul P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0012-1606</gtr:issn><gtr:outcomeId>doi_13110_012_04_029</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B38E1EE-6CFB-4BAF-9551-A4F452DB3081</gtr:id><gtr:title>Periodic stripe formation by a Turing mechanism operating at growth zones in the mammalian palate.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0aaee62a29b68f21a72b4d9a2a3de35"><gtr:id>a0aaee62a29b68f21a72b4d9a2a3de35</gtr:id><gtr:otherNames>Economou AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>doi_13110_38_ng_1090</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB4124CC-37B3-41E9-88E4-A9E5F2194254</gtr:id><gtr:title>Suppression of IL-7-dependent Effector T-cell Expansion by Multipotent Adult Progenitor Cells and PGE2.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7757760750e306c256b60d0266f85451"><gtr:id>7757760750e306c256b60d0266f85451</gtr:id><gtr:otherNames>Reading JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>56deff437bab61.13111281</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6C1A4AF-C51E-4FC5-A68A-4B015072EC97</gtr:id><gtr:title>Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6edbf63ed60ec50dcf00c4121c43bfc"><gtr:id>b6edbf63ed60ec50dcf00c4121c43bfc</gtr:id><gtr:otherNames>Uttenthal B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5457abfe989503.66889584</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A3B633C-4925-45D5-B6F7-4C8D43FD27ED</gtr:id><gtr:title>Effective non-technical skills are imperative to robot-assisted surgery.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebc4da9c11d432d58cf3f380b3c63dc5"><gtr:id>ebc4da9c11d432d58cf3f380b3c63dc5</gtr:id><gtr:otherNames>Brunckhorst O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>54579d2c7eb5a4.77601108</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6571333A-9581-407F-8CAC-F46811025881</gtr:id><gtr:title>Utility of drain fluid amylase measurement on the first postoperative day after pancreaticoduodenectomy.</gtr:title><gtr:parentPublicationTitle>World journal of surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e1448251affe854438eb751134b7d0e"><gtr:id>5e1448251affe854438eb751134b7d0e</gtr:id><gtr:otherNames>Sutcliffe RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0364-2313</gtr:issn><gtr:outcomeId>doi_13110_012_1460_0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDDD05B8-33E7-45C2-9818-D164A19E0F6A</gtr:id><gtr:title>Evaluation of current algorithms for segmentation of scar tissue from late gadolinium enhancement cardiovascular magnetic resonance of the left atrium: an open-access grand challenge.</gtr:title><gtr:parentPublicationTitle>Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec7e887e5a9d035c7a0a0939b3da640f"><gtr:id>ec7e887e5a9d035c7a0a0939b3da640f</gtr:id><gtr:otherNames>Karim R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1097-6647</gtr:issn><gtr:outcomeId>5457b0523917e1.93501094</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68A5E8B3-6372-4EF4-B36D-F717BDF5D6F1</gtr:id><gtr:title>Widespread sex differences in gene expression and splicing in the adult human brain.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fc9b26a4f240104f4f5378597d75aff"><gtr:id>0fc9b26a4f240104f4f5378597d75aff</gtr:id><gtr:otherNames>Trabzuni D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5457ac9e919f24.44698817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8231138-ABAB-4EA2-80B4-7AF4405647F5</gtr:id><gtr:title>Inflow typology and ventricular geometry determine efficiency of filling in the hypoplastic left heart.</gtr:title><gtr:parentPublicationTitle>The Annals of thoracic surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e8d97a4106a90b455502c0c757d2610"><gtr:id>4e8d97a4106a90b455502c0c757d2610</gtr:id><gtr:otherNames>de Vecchi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-4975</gtr:issn><gtr:outcomeId>doi_13110_012_05_122</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5EAE20F-FC62-47F1-A650-CC44FDF09B99</gtr:id><gtr:title>Crystal structure of the human IgG4 C(H)3 dimer reveals the role of Arg409 in the mechanism of Fab-arm exchange.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d113a1d20fe106ce208a0bf8036d73c"><gtr:id>4d113a1d20fe106ce208a0bf8036d73c</gtr:id><gtr:otherNames>Davies AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>doi_13110_012_10_029</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE433E8B-7336-4840-95F7-C840D72854DE</gtr:id><gtr:title>Long-term outcomes of robot-assisted radical cystectomy for bladder cancer.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/449d0fd41b23ccaad0d1ba2a66472152"><gtr:id>449d0fd41b23ccaad0d1ba2a66472152</gtr:id><gtr:otherNames>Khan MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>doi_13110_013_01_006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98737AF6-7C5C-4C76-B0AD-07D60716FA0B</gtr:id><gtr:title>A complement a day keeps the Fox(p3) away.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8675b34ec9571215a904cc99c2130cdf"><gtr:id>8675b34ec9571215a904cc99c2130cdf</gtr:id><gtr:otherNames>Le Friec G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>doi_13110_38_ni_2515</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74352181-2AEB-41E8-9CB8-D8BD137ECBED</gtr:id><gtr:title>The severity of circulating neutrophil dysfunction in patients with cirrhosis is associated with 90-day and 1-year mortality.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e73ce910c6ef21eb6bc897b9da38fef9"><gtr:id>e73ce910c6ef21eb6bc897b9da38fef9</gtr:id><gtr:otherNames>Taylor NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>5460a1abdc7fd8.55263964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F52DAD0B-431C-4B1E-8DF7-6E1DB8D5CCAF</gtr:id><gtr:title>A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/449d0fd41b23ccaad0d1ba2a66472152"><gtr:id>449d0fd41b23ccaad0d1ba2a66472152</gtr:id><gtr:otherNames>Khan MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>56e046a34b28a7.38533983</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D181FF1-7FB8-49A4-A3FE-2E48C2BCBFFC</gtr:id><gtr:title>Berberine Inhibition of Fibrogenesis in a Rat Model of Liver Fibrosis and in Hepatic Stellate Cells.</gtr:title><gtr:parentPublicationTitle>Evidence-based complementary and alternative medicine : eCAM</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3870c7fa98c17916b4bda38eb582e070"><gtr:id>3870c7fa98c17916b4bda38eb582e070</gtr:id><gtr:otherNames>Wang N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-427X</gtr:issn><gtr:outcomeId>58ca77ea0d8003.27661336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B5CB0A5-57F9-4902-AA7E-8836592DFA6E</gtr:id><gtr:title>Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0342018420be2cbe7f9f5ab7010f8eb6"><gtr:id>0342018420be2cbe7f9f5ab7010f8eb6</gtr:id><gtr:otherNames>Bernsmeier C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>56dff81834dcb7.75104364</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED3B1C4E-FBCE-4712-AA09-B602C2A2C338</gtr:id><gtr:title>A tale of tails: A novel approach to immunotherapy of prostate cancer</gtr:title><gtr:parentPublicationTitle>European Urology Supplements</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c16e043f78ae84a85d84c938e59af5c"><gtr:id>7c16e043f78ae84a85d84c938e59af5c</gtr:id><gtr:otherNames>Galustian C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa7ed83c0f092.51715363</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>282F832B-58D8-4CEC-A3F4-BA65F73E1A1E</gtr:id><gtr:title>Creative and innovative good practice in traditional Chinese medicine clinical studies: strategies for sustainable development.</gtr:title><gtr:parentPublicationTitle>Journal of ethnopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04a9a6b2932d03b2dcd5077983eaaf72"><gtr:id>04a9a6b2932d03b2dcd5077983eaaf72</gtr:id><gtr:otherNames>Lu A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0378-8741</gtr:issn><gtr:outcomeId>54ae5535f19d05.32777660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>945BC70E-F866-402F-B797-9B112BA6982D</gtr:id><gtr:title>HES1 in immunity and cancer.</gtr:title><gtr:parentPublicationTitle>Cytokine &amp; growth factor reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4bd41f5e795706d066b9db464defb69"><gtr:id>d4bd41f5e795706d066b9db464defb69</gtr:id><gtr:otherNames>Rani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-6101</gtr:issn><gtr:outcomeId>58c6b17de16331.77008552</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90210BE5-608D-42BD-AF6B-071E08243145</gtr:id><gtr:title>Steroid Withdrawal Normalises The Proportion Of Transitional B Cells But Does Not Significantly Change Gene Expression In Renal Transplant Recipients</gtr:title><gtr:parentPublicationTitle>British Transplantation Society Annual Congress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc95925114361aa21b01c2540942e28f"><gtr:id>fc95925114361aa21b01c2540942e28f</gtr:id><gtr:otherNames>Mobillo, P</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>545262751ac243.27068245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0476F97E-C449-4BE1-ACEA-E082683C62AD</gtr:id><gtr:title>Systematic review of prostate cancer risk and association with consumption of fish and fish-oils: analysis of 495,321 participants.</gtr:title><gtr:parentPublicationTitle>International journal of clinical practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2b5f7aa740f0d16cda4430fc97f3207"><gtr:id>b2b5f7aa740f0d16cda4430fc97f3207</gtr:id><gtr:otherNames>Lovegrove C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1368-5031</gtr:issn><gtr:outcomeId>56e046a765ca38.90390771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FD1A6F8-4445-4594-97E0-C808AE8C0CA1</gtr:id><gtr:title>Conversion of Robot-assisted Partial Nephrectomy to Radical Nephrectomy: A Prospective Multi-institutional Study.</gtr:title><gtr:parentPublicationTitle>Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/101748da8606bc3b0b1af494aacecc75"><gtr:id>101748da8606bc3b0b1af494aacecc75</gtr:id><gtr:otherNames>Arora S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0090-4295</gtr:issn><gtr:outcomeId>5aa7ee50da2035.27177596</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60661AF2-975E-408D-B266-2A66CE12FE70</gtr:id><gtr:title>Expression and regulation of complement receptors by human natural killer cells.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a8b5035d757670da98f2299a8c7d9ef"><gtr:id>2a8b5035d757670da98f2299a8c7d9ef</gtr:id><gtr:otherNames>Min X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn><gtr:outcomeId>54524737da57c7.01808622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20FAB880-B2AF-4650-BFA2-66A717EEA83D</gtr:id><gtr:title>Character and temporal evolution of apoptosis in acetaminophen-induced acute liver failure*.</gtr:title><gtr:parentPublicationTitle>Critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eee8b47b413a4ed31c63b33f6107a7c2"><gtr:id>eee8b47b413a4ed31c63b33f6107a7c2</gtr:id><gtr:otherNames>Possamai LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0090-3493</gtr:issn><gtr:outcomeId>doi_13110_31829791a2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42AA8F14-6453-4744-B789-AA03E2BDD23F</gtr:id><gtr:title>Science AAS</gtr:title><gtr:parentPublicationTitle>The hunt for antifibrotic and profibrotic botanicals</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/425f54aac0981bb29160f2062b0a9a9b"><gtr:id>425f54aac0981bb29160f2062b0a9a9b</gtr:id><gtr:otherNames>Xu, Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56deb569d052e7.32490655</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD1CEE20-FD31-4E20-A72D-EC7A54DB517F</gtr:id><gtr:title>Toward Prediction of Immune Mechanisms and Design of Immunotherapies in Melanoma</gtr:title><gtr:parentPublicationTitle>Critical Reviews? in Biomedical Engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cbbd22b96b2dc222d62c6279db79e80"><gtr:id>8cbbd22b96b2dc222d62c6279db79e80</gtr:id><gtr:otherNames>Tsoka S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_13110__v40_i4_40</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A7B9D61-E167-453C-B964-977A1AA55A29</gtr:id><gtr:title>An overview of the use and implementation of checklists in surgical specialities - a systematic review.</gtr:title><gtr:parentPublicationTitle>International journal of surgery (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bbcb6a79c342894a240292e71ae43f6"><gtr:id>7bbcb6a79c342894a240292e71ae43f6</gtr:id><gtr:otherNames>Patel J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1743-9159</gtr:issn><gtr:outcomeId>56e004714c6649.87150653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0F536C6-D107-424D-B851-1BBFFE878250</gtr:id><gtr:title>Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4fb28c7b7f759ed5da54d4f587d639a"><gtr:id>c4fb28c7b7f759ed5da54d4f587d639a</gtr:id><gtr:otherNames>Wang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5458d9602f75f4.85483013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C2EB2D6-843D-4054-9117-7F975C1777F5</gtr:id><gtr:title>Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f3f271c872e6312ac7a7971d88879a3"><gtr:id>8f3f271c872e6312ac7a7971d88879a3</gtr:id><gtr:otherNames>Pollak TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>5457ad08e09b56.64470350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>875F5D3A-1BCD-4276-8484-41BA231114AE</gtr:id><gtr:title>Iron Deficiency Impairs Intra-Hepatic Lymphocyte Mediated Immune Response.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/772dc66fc06b3d44d0b267a21aaccf93"><gtr:id>772dc66fc06b3d44d0b267a21aaccf93</gtr:id><gtr:otherNames>Bonaccorsi-Riani E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5675ea75458a0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2A422A6-EA26-4A67-8B6E-828978D6A3E4</gtr:id><gtr:title>Novel roles for complement receptors in T cell regulation and beyond.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97f2649fc7b89e5df4f4848bcd6d3cea"><gtr:id>97f2649fc7b89e5df4f4848bcd6d3cea</gtr:id><gtr:otherNames>Kemper C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>doi_13110_013_05_223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB80E615-8878-49A7-BFF3-4D400A6640CF</gtr:id><gtr:title>Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72ed78c054ebfae69f6741adc38164f9"><gtr:id>72ed78c054ebfae69f6741adc38164f9</gtr:id><gtr:otherNames>Orban T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>5457ad0849b034.87902174</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E4D4CF1-ED91-45AD-B437-9E2490DA940F</gtr:id><gtr:title>The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-a.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e616040fa72f24472deec98001b5e4f"><gtr:id>6e616040fa72f24472deec98001b5e4f</gtr:id><gtr:otherNames>Orr JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>58c6b17e3a0ad2.65795280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC8D73AA-3FD3-450C-8943-3E56EECF92EB</gtr:id><gtr:title>Promoting transplantation tolerance; adoptive regulatory T cell therapy.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>pm_13110_20_23574313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1999D84A-D21C-4520-BCFB-8EE4573233B8</gtr:id><gtr:title>The role of complement in CD4? T cell homeostasis and effector functions.</gtr:title><gtr:parentPublicationTitle>Seminars in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a788c06853e465636748c7f0ce3e416"><gtr:id>2a788c06853e465636748c7f0ce3e416</gtr:id><gtr:otherNames>Kolev M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1044-5323</gtr:issn><gtr:outcomeId>doi_13110_013_04_012</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA357823-54CE-480A-AF10-B9E605612C48</gtr:id><gtr:title>Risk of clinical deterioration in patients with lupus nephritis receiving rituximab.</gtr:title><gtr:parentPublicationTitle>Lupus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/947c5a43354c3716d642bc86d18145f6"><gtr:id>947c5a43354c3716d642bc86d18145f6</gtr:id><gtr:otherNames>Manou-Stathopoulou S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0961-2033</gtr:issn><gtr:outcomeId>5aaa69301e2d97.12770466</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>037BECEB-32DC-4E30-B057-E22645214B8E</gtr:id><gtr:title>Animal models of anti-neutrophil cytoplasmic antibody-associated vasculitis.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/225398404f1cd0c804bbb1623de3f6f6"><gtr:id>225398404f1cd0c804bbb1623de3f6f6</gtr:id><gtr:otherNames>Coughlan AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>doi_13110_12_04616_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12BAFAB6-AC0B-411C-B64D-D8B785769644</gtr:id><gtr:title>The &amp;quot;ins and outs&amp;quot; of complement-driven immune responses.</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df53cca10e10256cacd72f567b44d0cb"><gtr:id>df53cca10e10256cacd72f567b44d0cb</gtr:id><gtr:otherNames>Freeley S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn><gtr:outcomeId>58c6b17a53a253.85055480</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53E4600D-72C1-4493-948F-76B2708030C9</gtr:id><gtr:title>Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4df843270706e7e5613529762e74a529"><gtr:id>4df843270706e7e5613529762e74a529</gtr:id><gtr:otherNames>Vergis N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>56dda49e215049.19667627</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C6DFDDD-A8CD-4A99-89DC-AD868D09B372</gtr:id><gtr:title>Orphan nuclear receptor Nur77 promotes acute kidney injury and renal epithelial apoptosis.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34724aff9820f0363e347bd5beb5ea12"><gtr:id>34724aff9820f0363e347bd5beb5ea12</gtr:id><gtr:otherNames>Balasubramanian S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>doi_13110_2011070646</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BE6A075-2D81-4C38-831F-E29F5EEB87B3</gtr:id><gtr:title>Retinoic acid is essential for Th1 cell lineage stability and prevents transition to a Th17 cell program.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0101f59a2e529784546a74fddb5e47d4"><gtr:id>0101f59a2e529784546a74fddb5e47d4</gtr:id><gtr:otherNames>Brown CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>doi_55f98698636c2896</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBBBD9AD-3C73-499A-BE36-25F856DF90CD</gtr:id><gtr:title>Effect of Continuous Renal Replacement Therapy on Outcome in Pediatric Acute Liver Failure.</gtr:title><gtr:parentPublicationTitle>Critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/719c91f41b54a294bef4209f2f4dc8da"><gtr:id>719c91f41b54a294bef4209f2f4dc8da</gtr:id><gtr:otherNames>Deep A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0090-3493</gtr:issn><gtr:outcomeId>58c6b17d0206d3.40699773</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EAC34A3-2AC0-4DE8-933A-F8DEAF97CC9B</gtr:id><gtr:title>The unusual suspects--innate lymphoid cells as novel therapeutic targets in IBD.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81e25d677f4c39f2d3e25cf56613ee7f"><gtr:id>81e25d677f4c39f2d3e25cf56613ee7f</gtr:id><gtr:otherNames>Goldberg R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1759-5045</gtr:issn><gtr:outcomeId>56def95d46ddd7.88665933</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B14E8F9B-6F3D-4C36-9D9A-8F63EC7B88F3</gtr:id><gtr:title>Mental capacity in the shadow of suicide: What can the law do?</gtr:title><gtr:parentPublicationTitle>International Journal of Law in Context</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94f75f94ab49ebfc27653c4c955d8795"><gtr:id>94f75f94ab49ebfc27653c4c955d8795</gtr:id><gtr:otherNames>Richardson G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_13110_231200050X</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>351E07C7-A96D-468B-83BE-7B8E51435260</gtr:id><gtr:title>Early Oncologic Failure after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e471552c010934f5ba492f2fe94d9202"><gtr:id>e471552c010934f5ba492f2fe94d9202</gtr:id><gtr:otherNames>Hussein AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>5aa7f03a347996.07544638</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A1053BC-3EBE-435D-A1C8-EE185E7E746F</gtr:id><gtr:title>Biomarkers of tolerance.</gtr:title><gtr:parentPublicationTitle>Current opinion in organ transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29dcf1b4d5dd496e0c0d7f8aefbe6b29"><gtr:id>29dcf1b4d5dd496e0c0d7f8aefbe6b29</gtr:id><gtr:otherNames>G?kmen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1087-2418</gtr:issn><gtr:outcomeId>doi_13110_3283636fd5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2236161-D596-4DB8-8550-21F230ADC8A3</gtr:id><gtr:title>IL-10-produced by human transitional B-cells down-regulates CD86 expression on B-cells leading to inhibition of CD4+T-cell responses.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a852e087195ad0146102a9de3e4ab8b"><gtr:id>4a852e087195ad0146102a9de3e4ab8b</gtr:id><gtr:otherNames>Nova-Lamperti E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56d58522d89947.81795689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9AD8A5B-A284-433C-8C21-02F55E28A099</gtr:id><gtr:title>Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c1a043f3590ec4bea165c237e148c0a"><gtr:id>3c1a043f3590ec4bea165c237e148c0a</gtr:id><gtr:otherNames>Malcovati L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5457aab37cc687.43070468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5ED66B91-3022-4674-A115-C3FECBAC2F09</gtr:id><gtr:title>VITAMIN D STATUS AND REPLETION IN KIDNEY TRANSPLANTATION - THE TIME FOR ACTION IS NOW</gtr:title><gtr:parentPublicationTitle>TRANSPLANT INTERNATIONAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0dfed47db420035078ffe407648b9f4a"><gtr:id>0dfed47db420035078ffe407648b9f4a</gtr:id><gtr:otherNames>Gauge Nathan</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>MUgp8i8BtXH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A0D4195-4F66-44B5-A4F1-CDC46AB31177</gtr:id><gtr:title>New developments in the delivery of cardiac resynchronization therapy: targeted lead placement, multi-site and endocardial pacing.</gtr:title><gtr:parentPublicationTitle>Expert review of medical devices</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b35ea001a7fce2c2b01c48f419dfe3e"><gtr:id>8b35ea001a7fce2c2b01c48f419dfe3e</gtr:id><gtr:otherNames>Sohal M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1743-4440</gtr:issn><gtr:outcomeId>5457b053b21b85.27381611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A06A503-E711-4137-A8F2-AFDDD2AF309B</gtr:id><gtr:title>Science journal</gtr:title><gtr:parentPublicationTitle>Evaluating the safety of herbal medicines: Integrated toxicological approaches</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b86a2f2229578792bb02dce55d5f9ce5"><gtr:id>b86a2f2229578792bb02dce55d5f9ce5</gtr:id><gtr:otherNames>Williamson, E M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56deb6230da4e4.48600335</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>479771E8-AF0D-43CC-9C6B-3BC281917F26</gtr:id><gtr:title>An Extraperitoneal Technique for Murine Heterotopic Cardiac Transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f35a08fa619df0eb0095b0a2649d5a0"><gtr:id>3f35a08fa619df0eb0095b0a2649d5a0</gtr:id><gtr:otherNames>Nowocin AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>5675e4f29aeb2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>039CBE66-A61E-481A-BB5D-3516E5CF3292</gtr:id><gtr:title>Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/106c16d6f9893f7a7d87dd13518ba4f7"><gtr:id>106c16d6f9893f7a7d87dd13518ba4f7</gtr:id><gtr:otherNames>Canavan JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>56d5847e476a66.34718307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B13078AB-EB7C-4DFB-8BB0-448428C18ED5</gtr:id><gtr:title>Reduced dosage of ERF causes complex craniosynostosis in humans and mice and links ERK1/2 signaling to regulation of osteogenesis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d72dd3d808c0e61e97ae41b202875ea9"><gtr:id>d72dd3d808c0e61e97ae41b202875ea9</gtr:id><gtr:otherNames>Twigg SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>doi_13110_38_ng_2539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90060227-3E69-40C4-88FB-99AB4BECBA81</gtr:id><gtr:title>Treg therapy in transplantation: a general overview.</gtr:title><gtr:parentPublicationTitle>Transplant international : official journal of the European Society for Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32ae8244d7b23002c2b8fee8ecc0bf07"><gtr:id>32ae8244d7b23002c2b8fee8ecc0bf07</gtr:id><gtr:otherNames>Romano M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>58c6b179d869f1.85014512</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF03D1C9-4A9A-4FDF-83E8-C78C52FDC386</gtr:id><gtr:title>Noninvasive Imaging of Activated Complement in Ischemia-Reperfusion Injury Post-Cardiac Transplant.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fb958eb3535e59307e26530390bd12c"><gtr:id>2fb958eb3535e59307e26530390bd12c</gtr:id><gtr:otherNames>Sharif-Paghaleh E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>56dfefb5b0f6c0.16057064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E87C60DE-A4E1-4BDD-B7A0-E601B50ABEAF</gtr:id><gtr:title>Whole-heart coronary MRA with 3D affine motion correction using 3D image-based navigation.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e575ba36b90afcaad6f3da8dbf8d1106"><gtr:id>e575ba36b90afcaad6f3da8dbf8d1106</gtr:id><gtr:otherNames>Henningsson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0740-3194</gtr:issn><gtr:outcomeId>5457b05288af03.40220087</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E875E03-E801-482C-B643-9F4628BE892F</gtr:id><gtr:title>Cytoplasmic plaque formation in hemidesmosome development is dependent on SoxF transcription factor function.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a7bc7e97b2be3a83a1cb88cf0b0216e"><gtr:id>8a7bc7e97b2be3a83a1cb88cf0b0216e</gtr:id><gtr:otherNames>Oommen S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_13110_ne_0043857</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C540AF14-5F76-4877-9AD0-60DDE9A11833</gtr:id><gtr:title>NON-STANDARD KIDNEYS FOR TRANSPLANTS: CLINICAL MARGINS, MEDICAL MORALITY AND THE LAW</gtr:title><gtr:parentPublicationTitle>TRANSPLANT INTERNATIONAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa0c5048075e339b70558634a0f1de1a"><gtr:id>fa0c5048075e339b70558634a0f1de1a</gtr:id><gtr:otherNames>Cronin Antonia</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>F8zaKvfJvoh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7FD31EC-DC31-4618-A441-57B3289E0E75</gtr:id><gtr:title>Biomarkers and immunopathology of tolerance.</gtr:title><gtr:parentPublicationTitle>Current opinion in organ transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc197d71ebab96406580aa5d525e391a"><gtr:id>bc197d71ebab96406580aa5d525e391a</gtr:id><gtr:otherNames>Mastoridis S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1087-2418</gtr:issn><gtr:outcomeId>56ddb103b38be6.67126595</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F168E23-9337-423E-A426-F44DF2D7705A</gtr:id><gtr:title>The IL23R A/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e88821cf25005216ad94d24a572ef57"><gtr:id>0e88821cf25005216ad94d24a572ef57</gtr:id><gtr:otherNames>Di Meglio P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>doi_13110_d_2013_170</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E08BE168-42B7-4DFF-B475-3E957CC31C6B</gtr:id><gtr:title>What on &amp;quot;irf&amp;quot; is this gene 4? Irf4 transcription-factor-dependent dendritic cells are required for T helper 2 cell responses in murine skin.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a5c4d212349e34c72c1ab6f4da7c7ba"><gtr:id>0a5c4d212349e34c72c1ab6f4da7c7ba</gtr:id><gtr:otherNames>Flutter B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>doi_13110_013_09_008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EB9A4F3-5062-4AF2-9710-26B8817B09E9</gtr:id><gtr:title>Balancing effectiveness and equality of opportunity in organ allocation.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a1f7e1848a757ee57b6d95cb6755d7d"><gtr:id>3a1f7e1848a757ee57b6d95cb6755d7d</gtr:id><gtr:otherNames>Cronin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_13110_20_23706800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74249C14-0734-45CB-A795-F792927619F6</gtr:id><gtr:title>Multi-site left ventricular pacing as a potential treatment for patients with postero-lateral scar: insights from cardiac magnetic resonance imaging and invasive haemodynamic assessment.</gtr:title><gtr:parentPublicationTitle>Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0fc60b03eb52ec9a35cc864e1783503"><gtr:id>c0fc60b03eb52ec9a35cc864e1783503</gtr:id><gtr:otherNames>Ginks MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1099-5129</gtr:issn><gtr:outcomeId>doi_13110_ace_eur336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D387A224-0B5F-4CFD-AF20-1C888B2E563C</gtr:id><gtr:title>Development and validation of a tool for non-technical skills evaluation in robotic surgery-the ICARS system.</gtr:title><gtr:parentPublicationTitle>Surgical endoscopy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67b8d9f4806cd1136bf6068efac182fa"><gtr:id>67b8d9f4806cd1136bf6068efac182fa</gtr:id><gtr:otherNames>Raison N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0930-2794</gtr:issn><gtr:outcomeId>5aa7eff9620c23.01085400</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FADEB67-F541-464A-A127-AEB243C10B84</gtr:id><gtr:title>La Crosse viral infection in hospitalized pediatric patients in Western North Carolina.</gtr:title><gtr:parentPublicationTitle>Hospital pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85627c6740fc4161499910b00f7a76e7"><gtr:id>85627c6740fc4161499910b00f7a76e7</gtr:id><gtr:otherNames>Miller A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2154-1671</gtr:issn><gtr:outcomeId>pm_540e193e1930221c1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0518D476-3DF8-45D3-92A0-3F967D3FB269</gtr:id><gtr:title>Substantial reductions in the number of diabetic ketoacidosis and severe hypoglycaemia episodes requiring emergency treatment lead to reduced costs after structured education in adults with Type 1 diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetic medicine : a journal of the British Diabetic Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c0ba31be9b929cad9ae2a08a3a59577"><gtr:id>2c0ba31be9b929cad9ae2a08a3a59577</gtr:id><gtr:otherNames>Elliott J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0742-3071</gtr:issn><gtr:outcomeId>54579ae2663c01.90941902</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD90AE3E-F62C-4C92-9B02-943FFD4A372A</gtr:id><gtr:title>Ca2+-dependent structural changes in the B-cell receptor CD23 increase its affinity for human immunoglobulin E.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ce305de8784b1832b40dbf75ddb4b84"><gtr:id>2ce305de8784b1832b40dbf75ddb4b84</gtr:id><gtr:otherNames>Yuan D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>doi_13110_113_480657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7CD52E1-A138-44A3-811B-FBD8DB657C8D</gtr:id><gtr:title>Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-? production by Th1 cells.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25ee74e60fac27a1dbf2c03b22f0cff8"><gtr:id>25ee74e60fac27a1dbf2c03b22f0cff8</gtr:id><gtr:otherNames>Shiu KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>58c6b17872e2b3.08655520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9599A6D0-6EAB-46E7-9E18-D1884C39C12E</gtr:id><gtr:title>Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy?</gtr:title><gtr:parentPublicationTitle>Expert review of gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/423ae2fd93d62c14fa63d990115ba836"><gtr:id>423ae2fd93d62c14fa63d990115ba836</gtr:id><gtr:otherNames>Shawcross DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1747-4124</gtr:issn><gtr:outcomeId>56def95d6d0847.95051761</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>009C39F8-F19B-4105-B080-C278D996DD5D</gtr:id><gtr:title>Neutrophil Toll-Like Receptor 9 Expression and the Systemic Inflammatory Response in Acetaminophen-Induced Acute Liver Failure.</gtr:title><gtr:parentPublicationTitle>Critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc455dc91dc48632fe78b43ad9534cd4"><gtr:id>bc455dc91dc48632fe78b43ad9534cd4</gtr:id><gtr:otherNames>Manakkat Vijay GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0090-3493</gtr:issn><gtr:outcomeId>56dee59cf3de07.54820537</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>722A5832-FFB2-4BEB-9280-190E1045826F</gtr:id><gtr:title>Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal Inflammation.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c527f88ccb091966ae1ccaa57f48d497"><gtr:id>c527f88ccb091966ae1ccaa57f48d497</gtr:id><gtr:otherNames>Powell N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>56defe749522e9.66126540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>892EBD72-9CBB-4A2F-85A3-0C2C826873F3</gtr:id><gtr:title>Purinergic signaling in liver disease.</gtr:title><gtr:parentPublicationTitle>Digestive diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52440cb3044a4ffe9cd4d054726785a1"><gtr:id>52440cb3044a4ffe9cd4d054726785a1</gtr:id><gtr:otherNames>Vaughn BP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0257-2753</gtr:issn><gtr:outcomeId>54578b5344ae82.95324779</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F02F0AD9-6D89-426F-A002-6B70A39C144F</gtr:id><gtr:title>Genetics of liver disease: From pathophysiology to clinical practice.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f700a304ed44a4098411179f03147e78"><gtr:id>f700a304ed44a4098411179f03147e78</gtr:id><gtr:otherNames>Karlsen TH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56df03564ca613.22501877</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C141FA4C-8843-49CE-8377-EB096CD2ECE8</gtr:id><gtr:title>How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist.</gtr:title><gtr:parentPublicationTitle>European journal of gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/423ae2fd93d62c14fa63d990115ba836"><gtr:id>423ae2fd93d62c14fa63d990115ba836</gtr:id><gtr:otherNames>Shawcross DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0954-691X</gtr:issn><gtr:outcomeId>56dee59c19c2f0.51084080</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D2C578E-C55E-4C88-9D57-75059E65A564</gtr:id><gtr:title>Molecular Characterization of Acute Cellular Rejection Occurring During Intentional Immunosuppression Withdrawal in Liver Transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/772dc66fc06b3d44d0b267a21aaccf93"><gtr:id>772dc66fc06b3d44d0b267a21aaccf93</gtr:id><gtr:otherNames>Bonaccorsi-Riani E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>56ddacce79a871.35284783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EE6CEEC-3FCE-49D8-B493-B1D95A25F49C</gtr:id><gtr:title>Receptor for advanced glycation end products contributes to postnatal pulmonary development and adult lung maintenance program in mice.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory cell and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63f7c9328706ca913ca175cf2dd2f199"><gtr:id>63f7c9328706ca913ca175cf2dd2f199</gtr:id><gtr:otherNames>Fineschi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1044-1549</gtr:issn><gtr:outcomeId>doi_13110_012_0111OC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9CED3E1-E86C-40C6-A22A-E63A71BC2D18</gtr:id><gtr:title>Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0f57543875d4dd743593a0ba909f59e"><gtr:id>f0f57543875d4dd743593a0ba909f59e</gtr:id><gtr:otherNames>Bohne F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>doi_13110_2_JCI59411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83581779-879E-4B4E-B012-40A9F5291EA6</gtr:id><gtr:title>Regenerative Medicine Applications in Organ Transplantation</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f68854484a6adf46e3d9317b8d8b256f"><gtr:id>f68854484a6adf46e3d9317b8d8b256f</gtr:id><gtr:otherNames>Nizam Mamode</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>BtmSi6sEB1i</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42578AF5-0C31-4D98-A844-51B9DA18FA0F</gtr:id><gtr:title>Collectin-11 detects stress-induced L-fucose pattern to trigger renal epithelial injury.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f41571013db636d13570fa10eaf335ba"><gtr:id>f41571013db636d13570fa10eaf335ba</gtr:id><gtr:otherNames>Farrar CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>585d6e1b0dcf39.56778252</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>152DCDF8-C15B-4C8F-A8AC-12783671692F</gtr:id><gtr:title>Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a788c06853e465636748c7f0ce3e416"><gtr:id>2a788c06853e465636748c7f0ce3e416</gtr:id><gtr:otherNames>Kolev M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>5675e6c092469</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56EEE604-7340-4ABA-9C32-4C47CDC3C678</gtr:id><gtr:title>Novel Force Sensing Approach Employing Prismatic-Tip Optical Fiber Inside an Orthoplanar Spring Structure</gtr:title><gtr:parentPublicationTitle>IEEE/ASME Transactions on Mechatronics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c1c3e7116ac37a9c5d8618a242faab9"><gtr:id>0c1c3e7116ac37a9c5d8618a242faab9</gtr:id><gtr:otherNames>Ataollahi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>doi_13110_12_2222906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AEA3250-1CD8-470D-8D79-C17B436AF5D8</gtr:id><gtr:title>Can a combined screening/treatment programme prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies: study protocol for the multicentre randomised controlled OuTSMART trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7c701d8e064a4012140c494c65b7417"><gtr:id>a7c701d8e064a4012140c494c65b7417</gtr:id><gtr:otherNames>Dorling A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>54509db9d2a2c5.88656844</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4E97766-CDD5-43FA-A07F-BB71ECC5B4DA</gtr:id><gtr:title>Ocular photodynamic therapy--standard applications and new indications. Part 2. Review of the literature and personal experience.</gtr:title><gtr:parentPublicationTitle>Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/632855fd151474b713273770227bb2c5"><gtr:id>632855fd151474b713273770227bb2c5</gtr:id><gtr:otherNames>Mennel S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0030-3755</gtr:issn><gtr:outcomeId>doi_13110__000332145</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D0588EF-5A5A-4CB8-8150-6DB3E503AB8F</gtr:id><gtr:title>Severe hypoglycaemia in type 1 diabetes mellitus: underlying drivers and potential strategies for successful prevention.</gtr:title><gtr:parentPublicationTitle>Diabetes/metabolism research and reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40b222d29a555c4bc5f0dd3ba85950a7"><gtr:id>40b222d29a555c4bc5f0dd3ba85950a7</gtr:id><gtr:otherNames>Little SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1520-7552</gtr:issn><gtr:outcomeId>54579ae18cae04.28023378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4736D1EC-7E00-4C3B-8243-304BDF982076</gtr:id><gtr:title>Real-time differential tracking of human neutrophil and eosinophil migration in vivo.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a951437637a8ef3cc332a5aabe90dd7f"><gtr:id>a951437637a8ef3cc332a5aabe90dd7f</gtr:id><gtr:otherNames>Lukawska JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>doi_13110_013_06_031</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D292BB8-9B00-4DFB-9DB1-99F625705503</gtr:id><gtr:title>The future of robotics.</gtr:title><gtr:parentPublicationTitle>Investigative and clinical urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70bb76ba344d3534572d13bbeaffe532"><gtr:id>70bb76ba344d3534572d13bbeaffe532</gtr:id><gtr:otherNames>Warren H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2466-0493</gtr:issn><gtr:outcomeId>5aa7ef61db5fc1.59426299</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1E9C471-32D0-476F-BDC4-5D188A770762</gtr:id><gtr:title>Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56dc92676fb2486aed9c0f0f153df562"><gtr:id>56dc92676fb2486aed9c0f0f153df562</gtr:id><gtr:otherNames>Bulek AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>doi_13110_38_ni_2206</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0757FE7-1AFB-4CB3-BD78-B51DAD3E494A</gtr:id><gtr:title>Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bb453a9737fc82f8737f2fba61ff2cc"><gtr:id>2bb453a9737fc82f8737f2fba61ff2cc</gtr:id><gtr:otherNames>Putnam AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>543b98d787c351.72963403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F356730E-6478-43FF-92AE-052F15086E61</gtr:id><gtr:title>Molecular analysis of precursor lesions in familial pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bea40c8e5561ef7cd6885621829d0a1"><gtr:id>5bea40c8e5561ef7cd6885621829d0a1</gtr:id><gtr:otherNames>Crnogorac-Jurcevic T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_13110_ne_0054830</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE450EDF-441F-4821-ACB4-FFE616F746B0</gtr:id><gtr:title>'Rabone' and four unresolved problems in mental health law</gtr:title><gtr:parentPublicationTitle>The Psychiatrist</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d81eaeca924f11b0df8e31e45fc7efc9"><gtr:id>d81eaeca924f11b0df8e31e45fc7efc9</gtr:id><gtr:otherNames>Szmukler G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>doi_13110_113_043273</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A81C6DE-C10F-4955-A758-A790B5380030</gtr:id><gtr:title>Immunosuppressive drugs affect interferon (IFN)-? and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f73f820f0aa9cc7c43d87294ec7d4ef"><gtr:id>2f73f820f0aa9cc7c43d87294ec7d4ef</gtr:id><gtr:otherNames>Grant CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>5a8ed91533c605.97724199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFB7A75E-1D4A-4C13-A527-D6B40FF6D215</gtr:id><gtr:title>Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/703b8eba3010fbc8d3cd8a386e16a6af"><gtr:id>703b8eba3010fbc8d3cd8a386e16a6af</gtr:id><gtr:otherNames>Platzbecker U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>56e00684a64076.63846323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>610253A5-7082-4FF4-8A5A-54FDD399A6B0</gtr:id><gtr:title>Ureteric injury: a challenging condition to diagnose and manage.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd0938c60157f1301ed3eb8e647339c7"><gtr:id>fd0938c60157f1301ed3eb8e647339c7</gtr:id><gtr:otherNames>Abboudi H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>doi_13110_l_2012_254</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D91E26DE-D77C-4242-9FFE-4C96DFABFD96</gtr:id><gtr:title>VISTA is an immune checkpoint molecule for human T cells.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a63a52c25ec842dc9d87dc1d2307187"><gtr:id>7a63a52c25ec842dc9d87dc1d2307187</gtr:id><gtr:otherNames>Lines JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>5458d960acacf9.56618419</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E0FEC2E-0E06-41A8-98E0-953556EACB3F</gtr:id><gtr:title>Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ff09c7595c7f1b1582e2a909a1edfa8"><gtr:id>7ff09c7595c7f1b1582e2a909a1edfa8</gtr:id><gtr:otherNames>Freeley SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>58c6b17ad1d656.16984805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3774D52-CE84-46DD-B079-4928D9B239EE</gtr:id><gtr:title>VISTA Regulates the Development of Protective Antitumor Immunity.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e917868103bca329240ffdd149cf12f"><gtr:id>2e917868103bca329240ffdd149cf12f</gtr:id><gtr:otherNames>Le Mercier I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>5458d960812b35.63262789</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB7D28CC-1A2E-4DB9-B50A-1351AC4E6E2B</gtr:id><gtr:title>A patient-centred approach to biomarkers of transplant tolerance</gtr:title><gtr:parentPublicationTitle>.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf4f11663e65b16f03b2d6b515db635b"><gtr:id>bf4f11663e65b16f03b2d6b515db635b</gtr:id><gtr:otherNames>Harrington J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>YrgBxVmyo5F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D95965C6-CCB4-44A5-A73A-2E1A02A6E77F</gtr:id><gtr:title>An endogenous nanomineral chaperones luminal antigen and peptidoglycan to intestinal immune cells.</gtr:title><gtr:parentPublicationTitle>Nature nanotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/130a2588ddb118bf1b0e7ca5389a3197"><gtr:id>130a2588ddb118bf1b0e7ca5389a3197</gtr:id><gtr:otherNames>Powell JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1748-3387</gtr:issn><gtr:outcomeId>56dffad3d04a49.97560505</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10154D93-6310-47DA-AD66-CEC96DD7E520</gtr:id><gtr:title>Oral lining mucosa development depends on mesenchymal microRNAs.</gtr:title><gtr:parentPublicationTitle>Journal of dental research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7424f208e03f6fac0c2e9dd3fd959fbb"><gtr:id>7424f208e03f6fac0c2e9dd3fd959fbb</gtr:id><gtr:otherNames>Otsuka-Tanaka Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-0345</gtr:issn><gtr:outcomeId>doi_13110_4512470830</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22A29B46-7E62-44A2-9F5E-B8B0B589AF2F</gtr:id><gtr:title>Possible involvement of CCL1-CCR8 interaction in lymphocytic recruitment in IgG4-related sclerosing cholangitis.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a35f8880f3a4aee14365b9a3bd7e1bc"><gtr:id>4a35f8880f3a4aee14365b9a3bd7e1bc</gtr:id><gtr:otherNames>Zen Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>doi_13110_013_06_016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2F8C685-11E6-4BAC-BF12-89748696616E</gtr:id><gtr:title>The British Association of Urological Surgeons nephrectomy audit for T1 renal tumours.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e0450b049ae8.66552482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>286A34E1-C127-491B-A4BE-CDAB9C48B574</gtr:id><gtr:title>IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f89870d0b8fd725d19cd396e83423e42"><gtr:id>f89870d0b8fd725d19cd396e83423e42</gtr:id><gtr:otherNames>Whitehouse G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5a2fd36fae23b6.31622458</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35F8058D-219E-495F-A22C-7A2EE75129EB</gtr:id><gtr:title>Design of a variable stiffness flexible manipulator with composite granular jamming and membrane coupling</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0028dc86b8d9b2b4aea1230ffbfc307"><gtr:id>d0028dc86b8d9b2b4aea1230ffbfc307</gtr:id><gtr:otherNames>Jiang A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>978-1-4673-1737-5</gtr:isbn><gtr:outcomeId>doi_13110_12_6385696</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B92F9933-52D7-4E35-BF4B-6B0B84FA52ED</gtr:id><gtr:title>How we treat sickle hepatopathy and liver transplantation in adults.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da7de470552fbe19eaeccb55dde6bf0e"><gtr:id>da7de470552fbe19eaeccb55dde6bf0e</gtr:id><gtr:otherNames>Gardner K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5457af0a248236.95334707</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D669991-05EE-4251-A59E-979BDAEC3920</gtr:id><gtr:title>Assessment of regulatory T-cell function in forthcoming clinical trials of cell therapy.</gtr:title><gtr:parentPublicationTitle>Expert review of molecular diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/106c16d6f9893f7a7d87dd13518ba4f7"><gtr:id>106c16d6f9893f7a7d87dd13518ba4f7</gtr:id><gtr:otherNames>Canavan JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1473-7159</gtr:issn><gtr:outcomeId>pm_13110_20_23256698</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC3144A0-E0B5-496A-BC20-077B27076E0D</gtr:id><gtr:title>Keeping It All Going-Complement Meets Metabolism.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a788c06853e465636748c7f0ce3e416"><gtr:id>2a788c06853e465636748c7f0ce3e416</gtr:id><gtr:otherNames>Kolev M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>58c6b17936bbe2.75215249</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B95F43AA-E323-45CD-86E6-A64B88A4B59C</gtr:id><gtr:title>e-Learning in Surgical Education: A Systematic Review.</gtr:title><gtr:parentPublicationTitle>Journal of surgical education</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4d9e5d9203a471c8c41b90bf7d18371"><gtr:id>d4d9e5d9203a471c8c41b90bf7d18371</gtr:id><gtr:otherNames>Jayakumar N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1878-7452</gtr:issn><gtr:outcomeId>56e046a45ca4f8.97131935</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>464A7A84-2927-4F3A-8E92-9437D662A75C</gtr:id><gtr:title>A case report of massive vaginal variceal hemorrhage in a patient with cirrhosis secondary to nonalcoholic steatohepatitis unresolved even after successful liver transplantation.</gtr:title><gtr:parentPublicationTitle>Transplantation proceedings</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14d18085fb6110c442a70e492f4a1e56"><gtr:id>14d18085fb6110c442a70e492f4a1e56</gtr:id><gtr:otherNames>Chan G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0041-1345</gtr:issn><gtr:outcomeId>doi_13110_012_04_033</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D95FDCB-FEA3-41D4-9185-EFF00F27784D</gtr:id><gtr:title>A Novel Modified Standard-Gamble Task to Measure Patients' Preferences for Biomarker-Led Care</gtr:title><gtr:parentPublicationTitle>The 35th Annual Conference of the International Society for Clinical Biostatistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e426fdbd821c397196746d5832db40"><gtr:id>63e426fdbd821c397196746d5832db40</gtr:id><gtr:otherNames>Harrington, J</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>54526b41ee2cf7.72534540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3E4DB36-1724-4A14-AE1F-99713C2AED11</gtr:id><gtr:title>Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4717a33e3de4d26fd08f078530538ac0"><gtr:id>4717a33e3de4d26fd08f078530538ac0</gtr:id><gtr:otherNames>European Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-GEI)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>54609f53dec076.00719912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C146A428-69FA-4B8E-9D20-82E53B1311F4</gtr:id><gtr:title>NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR.</gtr:title><gtr:parentPublicationTitle>Genes, chromosomes &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3a6e2032832c29f48457e799ff56bc9"><gtr:id>a3a6e2032832c29f48457e799ff56bc9</gtr:id><gtr:otherNames>Akiki S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1045-2257</gtr:issn><gtr:outcomeId>doi_13110__gcc_22100</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F55C8063-4049-43E3-863D-08D55AD258CD</gtr:id><gtr:title>IgG4 antibodies and cancer-associated inflammation: Insights into a novel mechanism of immune escape.</gtr:title><gtr:parentPublicationTitle>Oncoimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1ca9da6894e26b6337b69fcd4be667c"><gtr:id>c1ca9da6894e26b6337b69fcd4be667c</gtr:id><gtr:otherNames>Karagiannis P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2162-4011</gtr:issn><gtr:outcomeId>doi_13110_onci_24889</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A09A8F8C-C470-46F9-9943-C075D0218896</gtr:id><gtr:title>Ageing diminishes the modulation of human brain responses to visual food cues by meal ingestion.</gtr:title><gtr:parentPublicationTitle>International journal of obesity (2005)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0164d5032fc9e9d779980c0c1b030e6"><gtr:id>d0164d5032fc9e9d779980c0c1b030e6</gtr:id><gtr:otherNames>Cheah YS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0307-0565</gtr:issn><gtr:outcomeId>54579ae13995e3.65131216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D105AD4-29AC-449A-AD9D-E01BC100BEC4</gtr:id><gtr:title>Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/722c4ac63ded662dc422a0a61495e934"><gtr:id>722c4ac63ded662dc422a0a61495e934</gtr:id><gtr:otherNames>Manook M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5874a8c48cefe4.59676050</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E1528A2-2B36-4E4F-A6BD-BDCE9A0EE89C</gtr:id><gtr:title>Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FceRI.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1cd44326634381f2c4a83a751b43ea0"><gtr:id>a1cd44326634381f2c4a83a751b43ea0</gtr:id><gtr:otherNames>Dhaliwal B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>doi_13110_1207278109</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCC4A817-F737-4F2E-8C2D-34C93B29D6E6</gtr:id><gtr:title>In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88ce4a32e863de105770d1d6c3b2aab"><gtr:id>f88ce4a32e863de105770d1d6c3b2aab</gtr:id><gtr:otherNames>Liberal R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56b4882284a550.93513593</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>235C1350-D8CB-4E18-8698-2435037E4431</gtr:id><gtr:title>Peptide length determines the outcome of TCR/peptide-MHCI engagement.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/992b542acd15f78e277d8de28fa4f4e7"><gtr:id>992b542acd15f78e277d8de28fa4f4e7</gtr:id><gtr:otherNames>Ekeruche-Makinde J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>doi_13110__06_437202</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD3A4997-346D-425B-9E3E-9B42A2F89717</gtr:id><gtr:title>Hepatocellular carcinoma associated with tight-junction protein 2 deficiency.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf718ff7d1450b2d6d791149cba67dcc"><gtr:id>bf718ff7d1450b2d6d791149cba67dcc</gtr:id><gtr:otherNames>Zhou S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56def95d1e9045.79909006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B80FE824-8B60-4C6F-81D2-333B8D0EDC07</gtr:id><gtr:title>Patients with alcohol-related liver disease--beliefs about their illness and factors that influence their self-management.</gtr:title><gtr:parentPublicationTitle>Journal of advanced nursing</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce15566119b24b1f18134f933283a746"><gtr:id>ce15566119b24b1f18134f933283a746</gtr:id><gtr:otherNames>Lau-Walker M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0309-2402</gtr:issn><gtr:outcomeId>56ddb0963dd5c3.06344745</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>292E51B1-68C0-49E0-92A7-7A659F0D62C0</gtr:id><gtr:title>Mannan-binding lectin-associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a316adfc796e81a38c1044af9c04fdd4"><gtr:id>a316adfc796e81a38c1044af9c04fdd4</gtr:id><gtr:otherNames>Asgari E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>545247380edc99.90771742</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5D92A87-EDBE-48AF-83CE-53932ACEB81F</gtr:id><gtr:title>Alpha 1-antitrypsin reduces inflammation and enhances mouse pancreatic islet transplant survival.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e9820dba35d75da368f8ccb50424b81"><gtr:id>7e9820dba35d75da368f8ccb50424b81</gtr:id><gtr:otherNames>Koulmanda M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>doi_13110_1018366109</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69E80779-49D7-4E26-9707-D83696AC3C42</gtr:id><gtr:title>Current status and effectiveness of mentorship programmes in urology: a systematic review.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4372a7f2d5ea1d6313b49e5c539a538"><gtr:id>f4372a7f2d5ea1d6313b49e5c539a538</gtr:id><gtr:otherNames>Hay D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>54579d2ca5c918.88873312</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB554452-3C74-4383-931D-26A617B82A21</gtr:id><gtr:title>Transplant rejection and paradigms lost.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cd9620fe8f88594ef951a6abe23fa00"><gtr:id>5cd9620fe8f88594ef951a6abe23fa00</gtr:id><gtr:otherNames>Strom TB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>doi_13110_2_JCI69385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6FA5691-34C3-48BC-A73C-E66E2A3937B5</gtr:id><gtr:title>Coculture with mesenchymal stem cells results in improved viability and function of human hepatocytes.</gtr:title><gtr:parentPublicationTitle>Cell transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d91f85f16285c0dd1478285cf73f500"><gtr:id>8d91f85f16285c0dd1478285cf73f500</gtr:id><gtr:otherNames>Fitzpatrick E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0963-6897</gtr:issn><gtr:outcomeId>56dffb503614e6.05647509</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE7CF31E-A9D8-4A0F-9948-530B401ED892</gtr:id><gtr:title>C3a modulates IL-1? secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a316adfc796e81a38c1044af9c04fdd4"><gtr:id>a316adfc796e81a38c1044af9c04fdd4</gtr:id><gtr:otherNames>Asgari E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_13110_20_23878142</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>517D7E43-9E24-4C67-9437-22BDC6E045C8</gtr:id><gtr:title>TIM family proteins promote the lysosomal degradation of the nuclear receptor NUR77.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34724aff9820f0363e347bd5beb5ea12"><gtr:id>34724aff9820f0363e347bd5beb5ea12</gtr:id><gtr:otherNames>Balasubramanian S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn><gtr:outcomeId>doi_13110_al_2003200</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>897E9FCD-DFE4-4030-AC05-F5391ED7478B</gtr:id><gtr:title>Cardiac magnetic resonance and electroanatomical mapping of acute and chronic atrial ablation injury: a histological validation study.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b28ffc1e244bfdc104cb447c2c3a2d91"><gtr:id>b28ffc1e244bfdc104cb447c2c3a2d91</gtr:id><gtr:otherNames>Harrison JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>5457b05453ad00.78835692</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>803D9EB4-EC8E-479E-89CF-88A97D47210F</gtr:id><gtr:title>A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma.</gtr:title><gtr:parentPublicationTitle>World journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/260fdd75aa2bcadb988f4e213683bd99"><gtr:id>260fdd75aa2bcadb988f4e213683bd99</gtr:id><gtr:otherNames>Hernandez-Alejandro R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>doi_13110_8_i31_4145</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>294B1035-E39B-4A4A-B57B-887BDF02712B</gtr:id><gtr:title>CXCL10 levels identify individuals with rapid fibrosis at 12 months post-transplant for hepatitis C virus and predict treatment response.</gtr:title><gtr:parentPublicationTitle>Clinical transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2da0d197ccf3f2b68433be172c4e55d"><gtr:id>a2da0d197ccf3f2b68433be172c4e55d</gtr:id><gtr:otherNames>Joshi D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0902-0063</gtr:issn><gtr:outcomeId>5457af0a4c3f74.55367112</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99CD3BAC-01EF-48BD-B888-C5E3C7966B51</gtr:id><gtr:title>Triaxial Catheter-Tip Force Sensor for MRI-Guided Cardiac Procedures</gtr:title><gtr:parentPublicationTitle>IEEE/ASME Transactions on Mechatronics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/201fa3420a9605514409482169b47670"><gtr:id>201fa3420a9605514409482169b47670</gtr:id><gtr:otherNames>Polygerinos P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_13110_11_2181405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F8BCB8C-CE62-4701-8FF9-932A20B2DD15</gtr:id><gtr:title>Flying high as a kite.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e047e8039204.17523878</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48EC359F-E513-4201-AC62-C7ECE53AC4AF</gtr:id><gtr:title>An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5f44bb44b03638a9aaf1c176153f1c0"><gtr:id>c5f44bb44b03638a9aaf1c176153f1c0</gtr:id><gtr:otherNames>Cherukuri A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>doi_13110_11_03891_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3BA70E0-D637-475A-9E58-C69259472827</gtr:id><gtr:title>Salient Feature of Haptic-Based Guidance of People in Low Visibility Environments Using Hard Reins.</gtr:title><gtr:parentPublicationTitle>IEEE transactions on cybernetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7371b334f477ce33a42d02d26e98c820"><gtr:id>7371b334f477ce33a42d02d26e98c820</gtr:id><gtr:otherNames>Ranasinghe A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2168-2267</gtr:issn><gtr:outcomeId>56e046a481b205.19228146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88DF8AEB-D293-49CC-8A90-6A697ECD2D93</gtr:id><gtr:title>A new and clinically relevant murine model of solid-organ transplant aspergillosis.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a72830ea0c2b656d2b69838ea5d4bae7"><gtr:id>a72830ea0c2b656d2b69838ea5d4bae7</gtr:id><gtr:otherNames>Herbst S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn><gtr:outcomeId>pm_13110_20_23264562</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6021160-DD9B-4E03-A465-CAF33953EA3B</gtr:id><gtr:title>The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b704c81cfb9d9e239f47c45f00acd5b4"><gtr:id>b704c81cfb9d9e239f47c45f00acd5b4</gtr:id><gtr:otherNames>Costantini B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>doi_13110_012_074823</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF293E9A-86A4-469B-A63A-EED037DC39D2</gtr:id><gtr:title>Immunosuppression minimization vs. complete drug withdrawal in liver transplantation.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/022cf0357038acd640d421c8ccf7409f"><gtr:id>022cf0357038acd640d421c8ccf7409f</gtr:id><gtr:otherNames>Londo?o MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5452131b4f7e17.42028582</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68AA6E81-FE63-40BD-AB78-17693C163D7B</gtr:id><gtr:title>Characterization of human CD39+ Th17 cells with suppressor activity and modulation in inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e548356ff97da703ae8a04a9207d18f"><gtr:id>3e548356ff97da703ae8a04a9207d18f</gtr:id><gtr:otherNames>Longhi MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54578b53bf8e70.49417428</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D097E0C2-859F-4691-84AC-2B8247FFB18E</gtr:id><gtr:title>Retinoic Acid Signaling in B Cells Is Required for the Generation of an Effective T-Independent Immune Response.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66e95ca3e92f14403a202ab031548843"><gtr:id>66e95ca3e92f14403a202ab031548843</gtr:id><gtr:otherNames>Marks E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a2fd37e671027.42530693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E452058-7B69-468B-A056-140FC09A9D5F</gtr:id><gtr:title>Reply: To PMID 23787765.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f73f820f0aa9cc7c43d87294ec7d4ef"><gtr:id>2f73f820f0aa9cc7c43d87294ec7d4ef</gtr:id><gtr:otherNames>Grant CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>54578b531f5722.30874360</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A414D437-E0B0-412C-829B-A86F65D2CE90</gtr:id><gtr:title>Optimization of current and future therapy for autoimmune diseases.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae0b8b637e169d545e5252ed4f05b8e1"><gtr:id>ae0b8b637e169d545e5252ed4f05b8e1</gtr:id><gtr:otherNames>Steinman L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>doi_13110_38_nm_2625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1927C51E-A8C5-42F7-A611-78AD6A44290A</gtr:id><gtr:title>T-bet: a bridge between innate and adaptive immunity.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9080e0d6fa9107a456ae38ee165626f9"><gtr:id>9080e0d6fa9107a456ae38ee165626f9</gtr:id><gtr:otherNames>Lazarevic V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>doi_13110_38_nri3536</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3818EE77-E0DE-4B65-A3BE-3A0C6D3B31A3</gtr:id><gtr:title>Validation of the Advanced Scope Trainer for Flexible Ureterorenoscopy Training.</gtr:title><gtr:parentPublicationTitle>Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1cdf4af1a8c3e0238bd98ab5d5f41ac"><gtr:id>f1cdf4af1a8c3e0238bd98ab5d5f41ac</gtr:id><gtr:otherNames>Al-Jabir A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0090-4295</gtr:issn><gtr:outcomeId>5aa7efa08bdcf1.95191832</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B1FB634-CF70-4DB0-A17D-EA8DB9B12A77</gtr:id><gtr:title>Mesenchymal Cell Community Effect in Whole Tooth Bioengineering.</gtr:title><gtr:parentPublicationTitle>Journal of dental research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/567a6df44fe9ec1809d4232be794446a"><gtr:id>567a6df44fe9ec1809d4232be794446a</gtr:id><gtr:otherNames>Yang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-0345</gtr:issn><gtr:outcomeId>589466562ef906.97073995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9CF4323-8147-431D-B664-17D89E53201E</gtr:id><gtr:title>Benefits of endocardial and multisite pacing are dependent on the type of left ventricular electric activation pattern and presence of ischemic heart disease: insights from electroanatomic mapping.</gtr:title><gtr:parentPublicationTitle>Circulation. Arrhythmia and electrophysiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0fc60b03eb52ec9a35cc864e1783503"><gtr:id>c0fc60b03eb52ec9a35cc864e1783503</gtr:id><gtr:otherNames>Ginks MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1941-3084</gtr:issn><gtr:outcomeId>doi_13110_111_967505</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18116433-8FF8-4A04-9C4B-71D9D1D470CD</gtr:id><gtr:title>Soluble CD23 controls IgE synthesis and homeostasis in human B cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4726c27867b62772e7873f5ec3ae3e94"><gtr:id>4726c27867b62772e7873f5ec3ae3e94</gtr:id><gtr:otherNames>Cooper AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>doi_13110_ol_1102689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCBC0B39-5E7A-4250-B20C-3CEB3BBA438C</gtr:id><gtr:title>Interventions for impaired bladders in paediatric renal transplant recipients with lower urinary tract dysfunction.</gtr:title><gtr:parentPublicationTitle>Transplant international : official journal of the European Society for Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c60aaec8e38c50823475098ca4ca3e08"><gtr:id>c60aaec8e38c50823475098ca4ca3e08</gtr:id><gtr:otherNames>Al-Khudairi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>544a6593b965a8.80001120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CCA7669-CF26-47C7-8A72-2C2F9ECC8DC9</gtr:id><gtr:title>The role of simulation in urological training - A quantitative study of practice and opinions.</gtr:title><gtr:parentPublicationTitle>The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d56aff527715c429c6f28b0fc7d2c3e1"><gtr:id>d56aff527715c429c6f28b0fc7d2c3e1</gtr:id><gtr:otherNames>Aydin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1479-666X</gtr:issn><gtr:outcomeId>56e046a40f3cb8.00176183</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A2C0CAA-9B06-4815-804D-3FC8880D583F</gtr:id><gtr:title>Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27f75498a252b067b1c34b7667309c44"><gtr:id>27f75498a252b067b1c34b7667309c44</gtr:id><gtr:otherNames>Thompson WS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>5457ad092bbb25.92350904</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDF6CBA0-42D4-499C-91DC-BDE6DE5117D2</gtr:id><gtr:title>The challenges of stratifying patients for trials in inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd3c7bb2e0c18b309a753ad12f80deb4"><gtr:id>fd3c7bb2e0c18b309a753ad12f80deb4</gtr:id><gtr:otherNames>Biancheri P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn><gtr:outcomeId>doi_13110_013_08_002</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4209D64D-CD62-4009-A6BC-3CE9ECFD6D69</gtr:id><gtr:title>Miniature 3-Axis Distal Force Sensor for Minimally Invasive Surgical Palpation</gtr:title><gtr:parentPublicationTitle>IEEE/ASME Transactions on Mechatronics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/170e2bf62eef1cc88a04cd6c69e2b622"><gtr:id>170e2bf62eef1cc88a04cd6c69e2b622</gtr:id><gtr:otherNames>Puangmali P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_13110_11_2116033</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>958FC907-CA8E-4D92-8449-E688EAF122EE</gtr:id><gtr:title>Defects of CRB2 cause steroid-resistant nephrotic syndrome.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/232708da4ffa4f4a2b25b8538b1c8384"><gtr:id>232708da4ffa4f4a2b25b8538b1c8384</gtr:id><gtr:otherNames>Ebarasi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>56dffad387a397.41117503</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17100D8D-4DC7-4AE1-9ED6-166229D30805</gtr:id><gtr:title>At the BJUI the best things in life are free.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e046a7405907.11742674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A095153D-3637-4B5E-92EC-8F55036C3849</gtr:id><gtr:title>Follicular cholangitis and pancreatitis - clinicopathological features and differential diagnosis of an under-recognized entity.</gtr:title><gtr:parentPublicationTitle>Histopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a35f8880f3a4aee14365b9a3bd7e1bc"><gtr:id>4a35f8880f3a4aee14365b9a3bd7e1bc</gtr:id><gtr:otherNames>Zen Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0309-0167</gtr:issn><gtr:outcomeId>doi_13110_11_04078_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>172F9A14-2783-467E-868A-8E0991F9412E</gtr:id><gtr:title>Systematic assessment of the influence of complement gene polymorphisms on kidney transplant outcome.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ad81811cead7fc395938bf1797e0921"><gtr:id>9ad81811cead7fc395938bf1797e0921</gtr:id><gtr:otherNames>Ermini L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn><gtr:outcomeId>56ddb19e7cea15.94177244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62B17B89-46F8-4EED-ADC4-BBFC5BC874E3</gtr:id><gtr:title>CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88ce4a32e863de105770d1d6c3b2aab"><gtr:id>f88ce4a32e863de105770d1d6c3b2aab</gtr:id><gtr:otherNames>Liberal R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>58c6b17d2934d1.43035581</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67117CE9-549E-4273-BC70-FD2B60853884</gtr:id><gtr:title>Ethical and legal issues related to the donation and use of nonstandard organs for transplants.</gtr:title><gtr:parentPublicationTitle>Anesthesiology clinics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d43b0f505fe6b34fb772ce661e3daa0"><gtr:id>4d43b0f505fe6b34fb772ce661e3daa0</gtr:id><gtr:otherNames>Cronin AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-2275</gtr:issn><gtr:outcomeId>sjYdpXjWvCx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51F6B34A-39C8-4E2E-907C-086EEC1B4B6B</gtr:id><gtr:title>Vitamin D levels in adults with Crohn's disease are responsive to disease activity and treatment.</gtr:title><gtr:parentPublicationTitle>Inflammatory bowel diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/663d8014cef8ffb02f4a605f921fa784"><gtr:id>663d8014cef8ffb02f4a605f921fa784</gtr:id><gtr:otherNames>Ham M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1078-0998</gtr:issn><gtr:outcomeId>54578b536d19c3.84746754</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2527DDBE-E643-4038-8E9E-26792FC82ACF</gtr:id><gtr:title>'Trifecta' outcomes of robot-assisted partial nephrectomy in solitary kidney: a Vattikuti Collective Quality Initiative (VCQI) database analysis.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/101748da8606bc3b0b1af494aacecc75"><gtr:id>101748da8606bc3b0b1af494aacecc75</gtr:id><gtr:otherNames>Arora S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>5aa7ee135f7087.56714177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20A4E02A-120D-4203-8B0F-242D30C119F0</gtr:id><gtr:title>Structural and functional diversity of collectins and ficolins and their relationship to disease.</gtr:title><gtr:parentPublicationTitle>Seminars in immunopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8b59c328d0d1a6b8b8404a53c8fddc3"><gtr:id>f8b59c328d0d1a6b8b8404a53c8fddc3</gtr:id><gtr:otherNames>Howard M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1863-2297</gtr:issn><gtr:outcomeId>5aa933b83914b8.34379272</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>612382BE-324F-4C4D-AB32-B9E3834C1D55</gtr:id><gtr:title>Technological innovation in the BJUI.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_13110_20_24028757</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>937DB3B6-2974-4D36-BA2A-4C0C6336F94D</gtr:id><gtr:title>Labeling of cell therapies: How can we get it right?</gtr:title><gtr:parentPublicationTitle>Oncoimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d28dabb099cbcd327d02fdf83f74a111"><gtr:id>d28dabb099cbcd327d02fdf83f74a111</gtr:id><gtr:otherNames>Waiczies S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2162-4011</gtr:issn><gtr:outcomeId>5a900e32dca125.40885535</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1FD1AAC-3D80-401E-9013-83BF2F5F0B5F</gtr:id><gtr:title>PAK5 mediates cell: cell adhesion integrity via interaction with E-cadherin in bladder cancer cells.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/892439fdd68cf271dab80e7be837bdeb"><gtr:id>892439fdd68cf271dab80e7be837bdeb</gtr:id><gtr:otherNames>Ismail AF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>5aa7f0c96e3cb1.43190578</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5D3EDBE-E6CF-46FC-8FC0-2C95C90F544A</gtr:id><gtr:title>Do we need a different organ allocation system for kidney transplants using donors after circulatory death?</gtr:title><gtr:parentPublicationTitle>BMC nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be7fb85a01a69a7aeab3d15e9a8dea20"><gtr:id>be7fb85a01a69a7aeab3d15e9a8dea20</gtr:id><gtr:otherNames>Benaragama SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2369</gtr:issn><gtr:outcomeId>544a6592598928.97088896</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49469F27-9382-4F9E-9D00-EF796A91697D</gtr:id><gtr:title>Genome-scale methods converge on key mitochondrial genes for the survival of human cardiomyocytes in hypoxia.</gtr:title><gtr:parentPublicationTitle>Circulation. Cardiovascular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc422603ad74930c96e228bdb2281407"><gtr:id>dc422603ad74930c96e228bdb2281407</gtr:id><gtr:otherNames>Edwards LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1942-3268</gtr:issn><gtr:outcomeId>5457ac9f9440c4.77096437</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEAE33EA-9AFC-4B33-A16D-F2562FD8FE00</gtr:id><gtr:title>National cohort study comparing severe medium-term urinary complications after robot-assisted vs laparoscopic vs retropubic open radical prostatectomy.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16ef3f06f7ed7678dc7e6e97daa474d2"><gtr:id>16ef3f06f7ed7678dc7e6e97daa474d2</gtr:id><gtr:otherNames>Sujenthiran A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>5aa7eec7c761d3.24189796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D54E4C5-A9C8-4ACC-855B-4E0122FDB83C</gtr:id><gtr:title>Re: Hinata et al.: Novel telementoring system for robot-assisted radical prostatectomy: impact on the learning curve. (Urology 2014;83:1088-92).</gtr:title><gtr:parentPublicationTitle>Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2ef1f8e70adeeebe1bb2a18ef76b1cf"><gtr:id>b2ef1f8e70adeeebe1bb2a18ef76b1cf</gtr:id><gtr:otherNames>Yu AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0090-4295</gtr:issn><gtr:outcomeId>54579d2f270400.92675337</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D8E2A4A-F251-4422-AD00-A8E9DAD46576</gtr:id><gtr:title>Incorporating Patient-Preference in the Translation of Biomarkers of Tolerance</gtr:title><gtr:parentPublicationTitle>British Transplantation Society Annual Congress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e426fdbd821c397196746d5832db40"><gtr:id>63e426fdbd821c397196746d5832db40</gtr:id><gtr:otherNames>Harrington, J</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>54525ef50b30b2.77261379</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF36D265-4722-4A77-A732-2135D6162701</gtr:id><gtr:title>Points mean prizes: priority points, preferential status and directed organ donation in Israel.</gtr:title><gtr:parentPublicationTitle>Israel journal of health policy research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d43b0f505fe6b34fb772ce661e3daa0"><gtr:id>4d43b0f505fe6b34fb772ce661e3daa0</gtr:id><gtr:otherNames>Cronin AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2045-4015</gtr:issn><gtr:outcomeId>5458d8b3488679.88938620</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFC53398-3244-4C8B-8651-61712F0720B9</gtr:id><gtr:title>Dendritic cell modification as a route to inhibiting corneal graft rejection by the indirect pathway of allorecognition.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5283b1274ae083686f0d2ca68b97784a"><gtr:id>5283b1274ae083686f0d2ca68b97784a</gtr:id><gtr:otherNames>Khan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_13110_20_23212959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08D4F966-A07D-496A-8EDB-F1258E2418DC</gtr:id><gtr:title>Surface flattening of the human left atrium and proof-of-concept clinical applications.</gtr:title><gtr:parentPublicationTitle>Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec7e887e5a9d035c7a0a0939b3da640f"><gtr:id>ec7e887e5a9d035c7a0a0939b3da640f</gtr:id><gtr:otherNames>Karim R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0895-6111</gtr:issn><gtr:outcomeId>5457b053d5f079.86659088</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2442C275-EEEA-4260-B537-647ED484F1E9</gtr:id><gtr:title>Using visual cues to enhance haptic feedback for palpation on virtual model of soft tissue.</gtr:title><gtr:parentPublicationTitle>Medical &amp; biological engineering &amp; computing</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00fdefe91ff283a2134de1284108f187"><gtr:id>00fdefe91ff283a2134de1284108f187</gtr:id><gtr:otherNames>Li M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0140-0118</gtr:issn><gtr:outcomeId>56e046a52b03d0.36746741</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FB7D3BD-0792-4EFE-B1DF-79AA2BB079B1</gtr:id><gtr:title>Salivary microbiota-immune profiling in cirrhosis: could this be the noninvasive strategy that will revolutionize prognostication in hepatology?</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88dec011ba6ff341da2ff046e3579948"><gtr:id>88dec011ba6ff341da2ff046e3579948</gtr:id><gtr:otherNames>Patel VC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56dee59d2191c4.75892177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2A4FDB7-7AB6-4326-A386-11AA06073EDC</gtr:id><gtr:title>CD39 and CD161 modulate Th17 responses in Crohn's disease.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a13b521ad50adb257cbf8dd02528735"><gtr:id>3a13b521ad50adb257cbf8dd02528735</gtr:id><gtr:otherNames>Bai A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>54578b52ed3112.17242693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58FDF7B9-365F-4D30-A608-3FA5CD29D857</gtr:id><gtr:title>Nontechnical skill training and the use of scenarios in modern surgical education.</gtr:title><gtr:parentPublicationTitle>Current opinion in urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebc4da9c11d432d58cf3f380b3c63dc5"><gtr:id>ebc4da9c11d432d58cf3f380b3c63dc5</gtr:id><gtr:otherNames>Brunckhorst O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0963-0643</gtr:issn><gtr:outcomeId>5aa7f0b19332c6.73737045</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>480A8BF8-25D1-4EF3-80C3-D5515BF630C4</gtr:id><gtr:title>Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7a487776927702f0e2714d73f629af4"><gtr:id>c7a487776927702f0e2714d73f629af4</gtr:id><gtr:otherNames>Boardman DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>58c6b179ae85e4.04285709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BE0DBB7-5BC3-4868-8717-9CFDCEE29310</gtr:id><gtr:title>Long-term oncologic outcomes following robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/521b44172c08c1736638673c71532035"><gtr:id>521b44172c08c1736638673c71532035</gtr:id><gtr:otherNames>Raza SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>56e046a54f0ab1.43859684</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D842C29A-3B1A-45A8-887F-DED5603B2FC1</gtr:id><gtr:title>The changing face of urinary continence surgery in England: a perspective from the Hospital Episode Statistics database.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a254707982b87b9591e26b0a2f74482e"><gtr:id>a254707982b87b9591e26b0a2f74482e</gtr:id><gtr:otherNames>Withington J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>doi_55f9869863764af4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87A3DD8A-4BEB-4EA4-A118-E7DCB9830B67</gtr:id><gtr:title>Non-invasive molecular imaging of inflammatory macrophages in allograft rejection.</gtr:title><gtr:parentPublicationTitle>EJNMMI research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/243fe4d0f38d033944707f60bc39af22"><gtr:id>243fe4d0f38d033944707f60bc39af22</gtr:id><gtr:otherNames>O'Neill AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56ddb2280b1e76.90138544</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB994660-250E-4DF6-8202-6AFF855E8FA9</gtr:id><gtr:title>Novel System for Real-Time Integration of 3-D Echocardiography and Fluoroscopy for Image-Guided Cardiac Interventions: Preclinical Validation and Clinical Feasibility Evaluation.</gtr:title><gtr:parentPublicationTitle>IEEE journal of translational engineering in health and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8eb220584e33c167c89454d7bf2c282"><gtr:id>e8eb220584e33c167c89454d7bf2c282</gtr:id><gtr:otherNames>Arujuna AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-2372</gtr:issn><gtr:outcomeId>5457b052d67a51.55917472</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>837559BD-35EF-4BA0-A6A5-9AF71AB0D693</gtr:id><gtr:title>Central nervous system malformations and deformations in FGFR2-related craniosynostosis.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53ebda0ef1d5f34531df76cc3306c305"><gtr:id>53ebda0ef1d5f34531df76cc3306c305</gtr:id><gtr:otherNames>Khonsari RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1552-4825</gtr:issn><gtr:outcomeId>doi_13110_mg_a_35598</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F86528A-45CF-47AB-A2E7-2B0C4A29A251</gtr:id><gtr:title>The surgeon as educator: fundamentals of faculty training in surgical specialties.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4565dafaf87d213d5e13e790513349db"><gtr:id>4565dafaf87d213d5e13e790513349db</gtr:id><gtr:otherNames>Khan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_13110_20_22928668</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4228C542-AA87-4B8F-9A84-FE3B534872C6</gtr:id><gtr:title>Air-float palpation probe for tissue abnormality identification during minimally invasive surgery.</gtr:title><gtr:parentPublicationTitle>IEEE transactions on bio-medical engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73056b2fe3f8500fce0d4d30ca25975f"><gtr:id>73056b2fe3f8500fce0d4d30ca25975f</gtr:id><gtr:otherNames>Wanninayake IB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0018-9294</gtr:issn><gtr:outcomeId>pm_13110_20_23708764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBD48BA4-9089-495C-806A-475ED582556D</gtr:id><gtr:title>The novel chemokine receptor, G-protein-coupled receptor 75, is expressed by islets and is coupled to stimulation of insulin secretion and improved glucose homeostasis.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4377ed4861af442d6d8939bfb897ce6"><gtr:id>a4377ed4861af442d6d8939bfb897ce6</gtr:id><gtr:otherNames>Liu B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>54609f53bc49e7.92832013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>543C7CFD-6E6A-4DBB-AC15-1B77480C440A</gtr:id><gtr:title>Multiple postnatal craniofacial anomalies are characterized by conditional loss of polycystic kidney disease 2 (Pkd2).</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53ebda0ef1d5f34531df76cc3306c305"><gtr:id>53ebda0ef1d5f34531df76cc3306c305</gtr:id><gtr:otherNames>Khonsari RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>doi_13110_hmg_ddt041</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA15A204-C3A3-40A3-B629-F252CD7CB552</gtr:id><gtr:title>The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review.</gtr:title><gtr:parentPublicationTitle>Annals of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b056ebd525a3f82e22b1c43010afc913"><gtr:id>b056ebd525a3f82e22b1c43010afc913</gtr:id><gtr:otherNames>G?kmen MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-4819</gtr:issn><gtr:outcomeId>doi_13110_3190_00006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD403233-38B7-4C0F-9D72-50793AB0C0B4</gtr:id><gtr:title>Alcohol dehydrogenase-specific T-cell responses are associated with alcohol consumption in patients with alcohol-related cirrhosis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f18ad6a1ed5da875b8a7e3c3966b8830"><gtr:id>f18ad6a1ed5da875b8a7e3c3966b8830</gtr:id><gtr:otherNames>Lin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>doi_13110__hep_26334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F69B0E86-558C-420B-94D2-49D3F38A8A41</gtr:id><gtr:title>Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&amp;amp;MPNr-EuroNet (COST action BM0902) study.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1521a7b5c376e70f0197d6d7b8d19b2d"><gtr:id>1521a7b5c376e70f0197d6d7b8d19b2d</gtr:id><gtr:otherNames>Jovanovic JV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>doi_13110_u_2013_219</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18A64942-3C16-42B8-B015-9DEABA6EF478</gtr:id><gtr:title>Characterisation of Tumour-Infiltrating Lymphocytes in primary breast cancer</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bea03513679fa191422f7d8b658bbcf"><gtr:id>7bea03513679fa191422f7d8b658bbcf</gtr:id><gtr:otherNames>Kyle, F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>545798e1cfc1e7.92098219</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF10E01E-519D-4497-B385-59C29BF55503</gtr:id><gtr:title>Non-standard kidneys for transplants: clinical margins, medical morality, and the law.</gtr:title><gtr:parentPublicationTitle>Medical law review</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d43b0f505fe6b34fb772ce661e3daa0"><gtr:id>4d43b0f505fe6b34fb772ce661e3daa0</gtr:id><gtr:otherNames>Cronin AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0967-0742</gtr:issn><gtr:outcomeId>pm_13110_20_23570691</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FE12CFD-A562-4799-9347-234D76C3DCCC</gtr:id><gtr:title>Aerobic capacity during cardiopulmonary exercise testing and survival with and without liver transplantation for patients with chronic liver disease.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e58e67c4ba1efbe5887452e360284b6"><gtr:id>2e58e67c4ba1efbe5887452e360284b6</gtr:id><gtr:otherNames>Bernal W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>5457af09633ba8.70522105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBE9D5E4-8908-4082-A798-6C3D97988775</gtr:id><gtr:title>The effect of anterograde persufflation on energy charge and hepatocyte function in donation after cardiac death livers unsuitable for transplant.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d35a1df08772a9b7e323b19cdf0eb58"><gtr:id>8d35a1df08772a9b7e323b19cdf0eb58</gtr:id><gtr:otherNames>Khorsandi SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>54579b7274d774.01768793</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FA3D259-8D26-4D9F-B8E2-736EB50D41D9</gtr:id><gtr:title>Vitamin D in renal transplantation - from biological mechanisms to clinical benefits.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54d33de7162c615825f1c4048312df98"><gtr:id>54d33de7162c615825f1c4048312df98</gtr:id><gtr:otherNames>McGregor R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>543b98d88f3d03.57010236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A287CDA-D0BD-4A81-9503-9EF7E6ADEEFE</gtr:id><gtr:title>The transcriptional regulator Aire coopts the repressive ATF7ip-MBD1 complex for the induction of immunotolerance.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e742f1b1e7e3618b12939d7ef3121433"><gtr:id>e742f1b1e7e3618b12939d7ef3121433</gtr:id><gtr:otherNames>Waterfield M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>56debcfbd62274.05309674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>988B85E7-DA47-4293-86F0-DF9A91456BA2</gtr:id><gtr:title>A prospective evaluation of cardiovascular magnetic resonance measures of dyssynchrony in the prediction of response to cardiac resynchronization therapy.</gtr:title><gtr:parentPublicationTitle>Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b35ea001a7fce2c2b01c48f419dfe3e"><gtr:id>8b35ea001a7fce2c2b01c48f419dfe3e</gtr:id><gtr:otherNames>Sohal M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1097-6647</gtr:issn><gtr:outcomeId>5457b054a1c372.55954937</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>262CE1D3-B244-4689-8031-BB5EFC8726F0</gtr:id><gtr:title>Evidence for intracellular C3 activation and its dysregulaion in autoimmune arthritis</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/977de17ecf85557c0d8a12adcb124e8d"><gtr:id>977de17ecf85557c0d8a12adcb124e8d</gtr:id><gtr:otherNames>Kemper, Claudia</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>bQoebRCUNFx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AD5A262-42B0-4361-83E1-02105C77DB99</gtr:id><gtr:title>Final robotic frontier: the evolution and current state of robot-assisted radical cystectomy.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/978d3b508fdb1c0f6672d27a6eeca916"><gtr:id>978d3b508fdb1c0f6672d27a6eeca916</gtr:id><gtr:otherNames>Tran T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e0450a6c6853.60750113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D4E4E33-CADB-47CD-AC61-161D628EEB4B</gtr:id><gtr:title>PREVALENCE OF PSYCHOLOGICAL ILLNESS IN LONG-TERM RENAL TRANSPLANT PATIENTS</gtr:title><gtr:parentPublicationTitle>TRANSPLANT INTERNATIONAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23e101a2ec2154da86f579951d74bebd"><gtr:id>23e101a2ec2154da86f579951d74bebd</gtr:id><gtr:otherNames>Frame Sharon</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>USmryawwuPt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5343E5ED-2A47-44A8-8D1B-CA84E01E6297</gtr:id><gtr:title>Patient-specific electromechanical models of the heart for the prediction of pacing acute effects in CRT: a preliminary clinical validation.</gtr:title><gtr:parentPublicationTitle>Medical image analysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b20a6af5746c91da8ea9c48f00612a42"><gtr:id>b20a6af5746c91da8ea9c48f00612a42</gtr:id><gtr:otherNames>Sermesant M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1361-8415</gtr:issn><gtr:outcomeId>doi_13110_011_07_003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE01EAB4-A0E5-42D6-B71B-090ACC734491</gtr:id><gtr:title>Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa0c0acf3b2630f69a51c5549f4f1b73"><gtr:id>aa0c0acf3b2630f69a51c5549f4f1b73</gtr:id><gtr:otherNames>Khan SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>doi_13110_011_301748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0866C875-09BF-46A2-AE57-6E5E5ECAF29B</gtr:id><gtr:title>Oncological outcomes of robotic-assisted radical prostatectomy after more than 5 years.</gtr:title><gtr:parentPublicationTitle>World journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7240e4392867944b42ffaa59854b1416"><gtr:id>7240e4392867944b42ffaa59854b1416</gtr:id><gtr:otherNames>Billia M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0724-4983</gtr:issn><gtr:outcomeId>pm_13110_20_23817889</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F93AEEEB-52B9-4EEC-9DDD-84F3D611BCB3</gtr:id><gtr:title>Gene expression changes with age in skin, adipose tissue, blood and brain.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/090dbbc0432bfda4750a3ea381e6a5f5"><gtr:id>090dbbc0432bfda4750a3ea381e6a5f5</gtr:id><gtr:otherNames>Glass D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn><gtr:outcomeId>doi_13110_3_14_7_r75</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>964BE3B1-AEF2-4521-8C66-B47995332812</gtr:id><gtr:title>Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia.</gtr:title><gtr:parentPublicationTitle>International journal of hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fe26393ce1a826c37d2c03b54270978"><gtr:id>7fe26393ce1a826c37d2c03b54270978</gtr:id><gtr:otherNames>Gandhi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0925-5710</gtr:issn><gtr:outcomeId>doi_13110_013_1333_9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0B2BAE0-5E26-4956-A80B-FE0A1D7B0B6E</gtr:id><gtr:title>Kidney transplantation in HIV-positive adults: the UK experience.</gtr:title><gtr:parentPublicationTitle>International journal of STD &amp; AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20baeddabbda138319ec6d67b71fb35b"><gtr:id>20baeddabbda138319ec6d67b71fb35b</gtr:id><gtr:otherNames>Gathogo EN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0956-4624</gtr:issn><gtr:outcomeId>5457996b81b516.95739535</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC5804F0-6240-468D-8733-778D5C300C17</gtr:id><gtr:title>Lessons learned from Asian Urology.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7cd3d26bd96828d46ab736c4644afb"><gtr:id>1e7cd3d26bd96828d46ab736c4644afb</gtr:id><gtr:otherNames>Chu PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e046a8a92bb3.37204599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7509B310-8705-4EF1-8DA9-29064869862E</gtr:id><gtr:title>3D-holoscopic imaging: a new dimension to enhance imaging in minimally invasive therapy in urologic oncology.</gtr:title><gtr:parentPublicationTitle>Journal of endourology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d489475faadf25435b817ab4150082a1"><gtr:id>d489475faadf25435b817ab4150082a1</gtr:id><gtr:otherNames>Makanjuola JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0892-7790</gtr:issn><gtr:outcomeId>doi_13110__2012_0368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7480C7EB-0F69-4CBD-9AE5-A334F6D477CF</gtr:id><gtr:title>Rituximab in renal transplantation.</gtr:title><gtr:parentPublicationTitle>Transplant international : official journal of the European Society for Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4de086c273c0c67e49e3b833cb39f230"><gtr:id>4de086c273c0c67e49e3b833cb39f230</gtr:id><gtr:otherNames>Barnett AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>544a6593863b54.03288952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7603CCF0-B6A6-45D4-BF83-951448A70B43</gtr:id><gtr:title>Can we predict allograft tolerance in experimental animal models of transplantation?</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/022cf0357038acd640d421c8ccf7409f"><gtr:id>022cf0357038acd640d421c8ccf7409f</gtr:id><gtr:otherNames>Londo?o MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>doi_13110_2_lt_23382</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABDEE926-8B11-46A6-8C29-2DD753903CC2</gtr:id><gtr:title>A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation.</gtr:title><gtr:parentPublicationTitle>Thrombosis research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035f6ac39e1e0dc2b6df50798858cfc1"><gtr:id>035f6ac39e1e0dc2b6df50798858cfc1</gtr:id><gtr:otherNames>Jakubowski JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0049-3848</gtr:issn><gtr:outcomeId>5458d805004254.39529920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1994D9F-42F5-4FEE-A982-308A3B2A42CB</gtr:id><gtr:title>The innate immune system and transplantation.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor perspectives in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f41571013db636d13570fa10eaf335ba"><gtr:id>f41571013db636d13570fa10eaf335ba</gtr:id><gtr:otherNames>Farrar CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2157-1422</gtr:issn><gtr:outcomeId>pm_13110_20_24086066</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDC815A6-D3B4-4F8C-ACF0-B7927343127B</gtr:id><gtr:title>Ex vivo expanded human regulatory T cells delay islet allograft rejection via inhibiting islet-derived monocyte chemoattractant protein-1 production in CD34+ stem cells-reconstituted NOD-scid IL2r?null mice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2a65dd598c0cffda8550314e8f13a61"><gtr:id>a2a65dd598c0cffda8550314e8f13a61</gtr:id><gtr:otherNames>Xiao F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>543b98d85db977.28018238</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE7E8DD4-87AD-4485-84C5-62BF235D11DC</gtr:id><gtr:title>Recent advances in the diagnosis and treatment of bladder cancer.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ab883ce8996eea1e80ef7877f13064d"><gtr:id>0ab883ce8996eea1e80ef7877f13064d</gtr:id><gtr:otherNames>Cheung G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>doi_13110_7015_11_13</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEE8C62C-CB69-4748-9160-8C625ED80CFD</gtr:id><gtr:title>Metabolic neuroimaging of the brain in diabetes mellitus and hypoglycaemia.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0164d5032fc9e9d779980c0c1b030e6"><gtr:id>d0164d5032fc9e9d779980c0c1b030e6</gtr:id><gtr:otherNames>Cheah YS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1759-5029</gtr:issn><gtr:outcomeId>doi_13110_do_2012_97</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1DB3BF2-5428-4EBE-A6C0-EB83081404EC</gtr:id><gtr:title>Pathophysiology of cerebral oedema in acute liver failure.</gtr:title><gtr:parentPublicationTitle>World journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d7e3aa9bc41c74d271e16cd7db75cfa"><gtr:id>7d7e3aa9bc41c74d271e16cd7db75cfa</gtr:id><gtr:otherNames>Scott TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>doi_55f986986380d88d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A22A72AE-94D5-4462-8CFD-32B9BDC2C65D</gtr:id><gtr:title>Design and the new BJUI.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40ad2d3be338e61118503281999024b4"><gtr:id>40ad2d3be338e61118503281999024b4</gtr:id><gtr:otherNames>Yap T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_13110_20_23551436</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>603D4652-F04C-4F1E-896A-8CCBEEF1B35F</gtr:id><gtr:title>Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa1191a975cfc7e1e479734387c50f83"><gtr:id>fa1191a975cfc7e1e479734387c50f83</gtr:id><gtr:otherNames>Westbrook RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>doi_13110_2_lt_23443</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE8973BD-076C-48BF-8C21-B31E7F6A9E20</gtr:id><gtr:title>Collectin-11 Promotes the Development of Renal Tubulointerstitial Fibrosis.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e6762650ea24f04eb0c3da85919e9da"><gtr:id>6e6762650ea24f04eb0c3da85919e9da</gtr:id><gtr:otherNames>Wu W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>5aa6587e71d8d6.79299866</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F7A3AB8-05C2-4225-8F8B-BAAC2B735543</gtr:id><gtr:title>High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84c82c5bc0ed0e71e8dd7b3bd4974222"><gtr:id>84c82c5bc0ed0e71e8dd7b3bd4974222</gtr:id><gtr:otherNames>Larsen FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56dee91557d621.79078162</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4301105D-9CA7-47EF-B395-C07DB7083AAA</gtr:id><gtr:title>Protection against RNA-induced liver damage by myeloid cells requires type I interferon and IL-1 receptor antagonist in mice.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e756a7aabd12887e584d998f4373b316"><gtr:id>e756a7aabd12887e584d998f4373b316</gtr:id><gtr:otherNames>Conrad E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5457af09cece13.79902848</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>674B709C-BDBC-4018-B3A9-0406E21760EE</gtr:id><gtr:title>TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff1b4f6148da6bc96ac5c5b83d0ded0f"><gtr:id>ff1b4f6148da6bc96ac5c5b83d0ded0f</gtr:id><gtr:otherNames>Kulasekararaj AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>doi_13110__bjh_12203</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D0676D8-36E0-46E7-A71A-E4237D9093E9</gtr:id><gtr:title>The emerging role of cardiovascular magnetic resonance in the evaluation of Kawasaki disease.</gtr:title><gtr:parentPublicationTitle>The international journal of cardiovascular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f429dba3026012c29bd51c7af063133"><gtr:id>5f429dba3026012c29bd51c7af063133</gtr:id><gtr:otherNames>Mavrogeni S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1569-5794</gtr:issn><gtr:outcomeId>pm_540e192e192ed7c1e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF9FECF8-2EA2-443B-887C-8DC0479B4273</gtr:id><gtr:title>Targeting the Dark Horse of complement: the first generation of functionally selective C5aR2 ligands.</gtr:title><gtr:parentPublicationTitle>Immunology and cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97f2649fc7b89e5df4f4848bcd6d3cea"><gtr:id>97f2649fc7b89e5df4f4848bcd6d3cea</gtr:id><gtr:otherNames>Kemper C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0818-9641</gtr:issn><gtr:outcomeId>58c6b17cca38e8.36315045</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>241EAA9C-86E6-414C-998C-B8C217CC54C9</gtr:id><gtr:title>Mechanism of activation of natural killer and CD8 T cells by interleukin 15 in the prostate cancer microenvironment</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9a927d1f4660e0a7b04c286f43e4ce9"><gtr:id>d9a927d1f4660e0a7b04c286f43e4ce9</gtr:id><gtr:otherNames>Elhage O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56e04990acf634.13162291</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>629607AA-6A0D-47E0-BFBF-DBAE2A3461BB</gtr:id><gtr:title>Changing paradigms in the investigation of an elevated PSA level.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2986f38093912d086d7fe8ec16e20d7e"><gtr:id>2986f38093912d086d7fe8ec16e20d7e</gtr:id><gtr:otherNames>Kirby R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_13110_20_23419175</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4148867-B2C2-40E9-BB9E-040BA7A3B92B</gtr:id><gtr:title>HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0f57543875d4dd743593a0ba909f59e"><gtr:id>f0f57543875d4dd743593a0ba909f59e</gtr:id><gtr:otherNames>Bohne F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>545212120f8e57.52589344</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30F8957C-BD9A-4036-AD35-5A0B0FB10ECF</gtr:id><gtr:title>Patient perception of skin-cancer prevention and risk after liver transplantation.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa43b535cf5bcef3d97a0562978fe13d"><gtr:id>fa43b535cf5bcef3d97a0562978fe13d</gtr:id><gtr:otherNames>Thomas BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0307-6938</gtr:issn><gtr:outcomeId>doi_13110__ced_12159</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4AA96E6-8B20-447E-98A1-DE0ACA17A34D</gtr:id><gtr:title>Then and now</gtr:title><gtr:parentPublicationTitle>BJU International</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_13110__bju_12178</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E3D249E-7D2F-43A2-B29A-FB1FAB84CD7E</gtr:id><gtr:title>Is it unethical for doctors to encourage a healthy adult to donate a kidney to a stranger?</gtr:title><gtr:parentPublicationTitle>International Association of Bioethics, World Congress of Bioethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5994cfe1fcc6cb53757f531cf754127"><gtr:id>e5994cfe1fcc6cb53757f531cf754127</gtr:id><gtr:otherNames>Cronin Antonia J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>o3bgziXyzGb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F39FBA39-CA54-4EED-A0FC-A7714D7ECB1E</gtr:id><gtr:title>Bile salt export pump-reactive antibodies form a polyclonal, multi-inhibitory response in antibody-induced bile salt export pump deficiency.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87efbc9db204fd65fff98ca5aa8d67a0"><gtr:id>87efbc9db204fd65fff98ca5aa8d67a0</gtr:id><gtr:otherNames>Stindt J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56ddb15e67c275.11391475</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2531C464-2F96-4221-BEE4-945BEB198D56</gtr:id><gtr:title>Simulation-based ureteroscopy skills training curriculum with integration of technical and non-technical skills: a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Surgical endoscopy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebc4da9c11d432d58cf3f380b3c63dc5"><gtr:id>ebc4da9c11d432d58cf3f380b3c63dc5</gtr:id><gtr:otherNames>Brunckhorst O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0930-2794</gtr:issn><gtr:outcomeId>5675dd7f7a12e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BB306A7-B5A6-4655-B59D-692EB0BF7A59</gtr:id><gtr:title>Mortality and incidence of renal replacement therapy in people with type 1 diabetes mellitus--a three decade long prospective observational study in the Lainz T1DM cohort.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ae580e99b60dc6e4e99e16daa2bab69"><gtr:id>4ae580e99b60dc6e4e99e16daa2bab69</gtr:id><gtr:otherNames>Stadler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>56e00471938e32.94110534</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7583CD94-859B-44E9-AC8D-148BB50C4772</gtr:id><gtr:title>MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fc9b26a4f240104f4f5378597d75aff"><gtr:id>0fc9b26a4f240104f4f5378597d75aff</gtr:id><gtr:otherNames>Trabzuni D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>doi_13110_hmg_dds238</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D0579ED-FBF6-457D-838F-B8A6A518A55F</gtr:id><gtr:title>The acute hemodynamic response to LV pacing within individual branches of the coronary sinus using a quadripolar lead.</gtr:title><gtr:parentPublicationTitle>Pacing and clinical electrophysiology : PACE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13ee7b0a284b01d86daa7c5f851c45ab"><gtr:id>13ee7b0a284b01d86daa7c5f851c45ab</gtr:id><gtr:otherNames>Shetty AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0147-8389</gtr:issn><gtr:outcomeId>doi_13110_11_03268_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A2E9769-98CA-442A-9837-CE0D35D98192</gtr:id><gtr:title>A life in balance: wandering the pathways of control</gtr:title><gtr:parentPublicationTitle>Diabetic Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/462586ddc6049743165c21a82f0e9961"><gtr:id>462586ddc6049743165c21a82f0e9961</gtr:id><gtr:otherNames>Amiel S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54579ae1dd9612.80453517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BF82B84-548E-46C5-92ED-E5E4933BD866</gtr:id><gtr:title>The calcium-sensing receptor and ?-cell function.</gtr:title><gtr:parentPublicationTitle>Vitamins and hormones</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33f9d68b5b6cbf727929dc0b1e1368ba"><gtr:id>33f9d68b5b6cbf727929dc0b1e1368ba</gtr:id><gtr:otherNames>Squires PE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>9780128001745</gtr:isbn><gtr:issn>0083-6729</gtr:issn><gtr:outcomeId>54609f5395ef95.21472124</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23BA011A-F552-4300-B390-53428C3E9788</gtr:id><gtr:title>Combined coronary lumen and vessel wall magnetic resonance imaging with i-T2prep: influence of nitroglycerin.</gtr:title><gtr:parentPublicationTitle>The international journal of cardiovascular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eff72137fec9d02822310b2e710bc8f1"><gtr:id>eff72137fec9d02822310b2e710bc8f1</gtr:id><gtr:otherNames>Hussain T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1569-5794</gtr:issn><gtr:outcomeId>54609f9ce17185.70373470</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B12A00B-C990-461C-9349-2DEC42F0D599</gtr:id><gtr:title>Tracking Donor-Reactive T Cells: Perspectives for the Development of Tolerance Protocols.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80a387b7c9213a8a1190296046e23764"><gtr:id>80a387b7c9213a8a1190296046e23764</gtr:id><gtr:otherNames>Martinez-Llordella M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>56debcfd277413.55196033</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>234E71AF-F8D2-45BB-A287-78C0A4C0B110</gtr:id><gtr:title>Adverse response to cardiac resynchronisation therapy in patients with septal scar on cardiac MRI preventing a septal right ventricular lead position.</gtr:title><gtr:parentPublicationTitle>Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9a0f6193b11a33fe2a2a92dc20fde96"><gtr:id>b9a0f6193b11a33fe2a2a92dc20fde96</gtr:id><gtr:otherNames>Duckett SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1383-875X</gtr:issn><gtr:outcomeId>doi_13110_011_9630_9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B27FA22B-7502-40DF-A420-5E8BB312FD2D</gtr:id><gtr:title>Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67313328223bd54d86a91a9b8cb23701"><gtr:id>67313328223bd54d86a91a9b8cb23701</gtr:id><gtr:otherNames>Britton D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5457af09a7bbc0.91949170</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>138CFA02-281A-4ADA-B5BC-BB8730993656</gtr:id><gtr:title>Strategies for minimizing immunosuppression: State of the Art.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc6207574d1c0261d152ca4d9177b63b"><gtr:id>dc6207574d1c0261d152ca4d9177b63b</gtr:id><gtr:otherNames>Sanchez-Fueyo A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>58c6b17a2b9a32.56205351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EE752DD-606D-46DA-88D8-9EA0EA8CA577</gtr:id><gtr:title>Regulatory T cells in renal cell carcinoma: additional fuel to the bonfire of debate.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a24f02668e536a6d0df0cd985e178d88"><gtr:id>a24f02668e536a6d0df0cd985e178d88</gtr:id><gtr:otherNames>Afzali B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_14815_25_23924422</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70A5BEAD-DBE6-4CC1-BDCA-99AA4C7F4F86</gtr:id><gtr:title>Lessons from look-back in acute liver failure? A single centre experience of 3300 patients.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e58e67c4ba1efbe5887452e360284b6"><gtr:id>2e58e67c4ba1efbe5887452e360284b6</gtr:id><gtr:otherNames>Bernal W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>doi_13110_013_02_010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D07D474-3170-4D3D-B596-EAB43618234F</gtr:id><gtr:title>An over-view of robot assisted surgery curricula and the status of their validation.</gtr:title><gtr:parentPublicationTitle>International journal of surgery (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67d95c7da689523addd2b23d1b01abcc"><gtr:id>67d95c7da689523addd2b23d1b01abcc</gtr:id><gtr:otherNames>Fisher RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1743-9159</gtr:issn><gtr:outcomeId>56e046a7e86f29.62228071</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA0FA27C-0FDC-48BC-A2F5-174C7560D893</gtr:id><gtr:title>Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/242d38e6f500f0c99817ab8ebb21c441"><gtr:id>242d38e6f500f0c99817ab8ebb21c441</gtr:id><gtr:otherNames>Goodfellow H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>54579d2ebac621.68403746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>861859B5-D2CB-4785-A270-E9D8BC01B345</gtr:id><gtr:title>Clinical and histological outcomes following living-related liver transplantation in children.</gtr:title><gtr:parentPublicationTitle>Clinics and research in hepatology and gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a4bc2519ac24cff553415f47e126d2f"><gtr:id>5a4bc2519ac24cff553415f47e126d2f</gtr:id><gtr:otherNames>Dattani N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2210-7401</gtr:issn><gtr:outcomeId>5457af0a002200.87904581</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>643A9B32-D02A-402E-AA29-DB1C55FEADE1</gtr:id><gtr:title>Scientific community: Tapping into success and collaboration.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/328b544605f784abfe3f65b6558593ba"><gtr:id>328b544605f784abfe3f65b6558593ba</gtr:id><gtr:otherNames>Weale M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>doi_13110_38_498299b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B4013BC-08CB-438F-A878-58257C7272F9</gtr:id><gtr:title>Hepatology</gtr:title><gtr:parentPublicationTitle>Hemostatic profiles in liver disease: novel evidence of mixed phenotype in critically-ill patients with cirrhosis and liver failure and implications for clinical management of hemostatic disturbance.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b016767e0b08657968d837243264ee1"><gtr:id>1b016767e0b08657968d837243264ee1</gtr:id><gtr:otherNames>Patel, V. C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56dffe58476b30.67882080</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD808929-C4A4-44F0-9099-3D647AA8977F</gtr:id><gtr:title>Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation.</gtr:title><gtr:parentPublicationTitle>Bone marrow transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5adf1b49c8627d3687d7cb9e21e37cde"><gtr:id>5adf1b49c8627d3687d7cb9e21e37cde</gtr:id><gtr:otherNames>Marsh JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>5457aab4683894.97062532</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBAFB516-883B-4927-AD03-70A604264C74</gtr:id><gtr:title>Systematic review of live surgical demonstrations and their effectiveness on training.</gtr:title><gtr:parentPublicationTitle>The British journal of surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebc4da9c11d432d58cf3f380b3c63dc5"><gtr:id>ebc4da9c11d432d58cf3f380b3c63dc5</gtr:id><gtr:otherNames>Brunckhorst O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1323</gtr:issn><gtr:outcomeId>56e046a8cbdce9.20257601</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AC3211B-C753-40AE-A9A6-153ED1484612</gtr:id><gtr:title>The genetic architecture of the human immune system: a bioresource for autoimmunity and disease pathogenesis.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b107a1153776cc2a2267380005b9789b"><gtr:id>b107a1153776cc2a2267380005b9789b</gtr:id><gtr:otherNames>Roederer M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>56df0355dde679.17847906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09FC86D1-8AA1-4126-A66C-7ED8B8A17FE5</gtr:id><gtr:title>Loss of endogenous thymosin ?accelerates glomerular disease.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85373a2da5384ab7e22d24df1461b0f3"><gtr:id>85373a2da5384ab7e22d24df1461b0f3</gtr:id><gtr:otherNames>Vasilopoulou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>58c6b17c580539.86401282</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93F4EDF5-C46D-4DF2-BD40-5F1008909C41</gtr:id><gtr:title>Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6904cf40dbb85f44d1a892dc1482dd03"><gtr:id>6904cf40dbb85f44d1a892dc1482dd03</gtr:id><gtr:otherNames>Ben?tez C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5452131b23f4c5.44940942</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EF50DC9-D040-4D59-90C6-51FDE201FEC3</gtr:id><gtr:title>Regulatory T Cells: Serious Contenders in the Promise for Immunological Tolerance in Transplantation.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5675ebaab260e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>296FD3D7-4F36-4E44-9A72-8A1399A78CD4</gtr:id><gtr:title>Donor specific transplant tolerance is dependent on complement receptors.</gtr:title><gtr:parentPublicationTitle>Transplant international : official journal of the European Society for Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b45355c9a618881be06116dbdce75346"><gtr:id>b45355c9a618881be06116dbdce75346</gtr:id><gtr:otherNames>Bartel G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>doi_13110__tri_12006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4BA5189-94BB-40E8-AAC1-6A7E2277BE1D</gtr:id><gtr:title>Performance of technology-driven simulators for medical students--a systematic review.</gtr:title><gtr:parentPublicationTitle>The Journal of surgical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea439febdd685184acebe5d6813294c"><gtr:id>2ea439febdd685184acebe5d6813294c</gtr:id><gtr:otherNames>Michael M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-4804</gtr:issn><gtr:outcomeId>54579d2c062a78.35205438</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDBB9151-8918-488A-8101-0247F638B68B</gtr:id><gtr:title>Immune Exhaustion and Transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc6207574d1c0261d152ca4d9177b63b"><gtr:id>dc6207574d1c0261d152ca4d9177b63b</gtr:id><gtr:otherNames>Sanchez-Fueyo A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>585d6e1794dd18.05287445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFE6FF55-AE31-4F88-AC02-0A3E4A548A8F</gtr:id><gtr:title>Genome-wide association study identifies three novel susceptibility loci for severe Acne vulgaris.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ea122c6c4d9a15b408bd3b917a5dc5b"><gtr:id>0ea122c6c4d9a15b408bd3b917a5dc5b</gtr:id><gtr:otherNames>Navarini AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5457ac9f437960.71390171</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B95CAD6E-E9D2-4524-BDC2-C9339D9A2DE6</gtr:id><gtr:title>The transcription factor E4bp4/Nfil3 controls commitment to the NK lineage and directly regulates Eomes and Id2 expression.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2bc2daade7204b0c32c705a148fed78"><gtr:id>e2bc2daade7204b0c32c705a148fed78</gtr:id><gtr:otherNames>Male V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>5457ab63ab20b8.66126747</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A770DAF0-2040-4F8B-9707-B5E963407076</gtr:id><gtr:title>Submicron imaging of soft-tissues using low-dose phase-contrast x-ray synchrotron microtomography with an iodine contrast agent.</gtr:title><gtr:parentPublicationTitle>Anatomical record (Hoboken, N.J. : 2007)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53ebda0ef1d5f34531df76cc3306c305"><gtr:id>53ebda0ef1d5f34531df76cc3306c305</gtr:id><gtr:otherNames>Khonsari RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-8486</gtr:issn><gtr:outcomeId>5457a95f09d022.87006566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26442ED3-FBE4-4E33-8AA2-1439C42902E4</gtr:id><gtr:title>Biomarkers in psoriasis and psoriatic arthritis.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d338561644fdd89f5550f2a924a17e4"><gtr:id>8d338561644fdd89f5550f2a924a17e4</gtr:id><gtr:otherNames>Villanova F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>doi_13110_012_203037</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>367621F5-91B3-4999-AF6E-43AD6B3295B5</gtr:id><gtr:title>Instant Blood-Mediated Inflammatory Reaction in Hepatocyte Transplantation: Current Status and Future Perspectives.</gtr:title><gtr:parentPublicationTitle>Cell transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ab3ddf45f9ad26c4812fe499bdfd8ef"><gtr:id>1ab3ddf45f9ad26c4812fe499bdfd8ef</gtr:id><gtr:otherNames>Lee CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0963-6897</gtr:issn><gtr:outcomeId>58c6b17e13f769.69493395</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE4966A6-5A7B-4DD2-AB23-FE006CB7BA75</gtr:id><gtr:title>Molecular markers in acute myeloid leukaemia.</gtr:title><gtr:parentPublicationTitle>International journal of hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f21b0f869744d9177ebf65e1858ab3c6"><gtr:id>f21b0f869744d9177ebf65e1858ab3c6</gtr:id><gtr:otherNames>K?hnl A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0925-5710</gtr:issn><gtr:outcomeId>doi_13110_012_1123_9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A96B079C-9657-4D2D-9A3B-10408FAE886E</gtr:id><gtr:title>Anonymity and live-donor transplantation: an ELPAT view.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9413f2084c871a74507fc204ce76f415"><gtr:id>9413f2084c871a74507fc204ce76f415</gtr:id><gtr:otherNames>Mamode N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>544a6593e88e89.35063270</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F86EF514-742B-4F77-A338-B203E9B3CAF0</gtr:id><gtr:title>Microbiota, immunity and the liver.</gtr:title><gtr:parentPublicationTitle>Immunology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e40ea6a39fae2baf5393f722dd9d371"><gtr:id>3e40ea6a39fae2baf5393f722dd9d371</gtr:id><gtr:otherNames>Vaikunthanathan T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0165-2478</gtr:issn><gtr:outcomeId>56ddac91379e01.65082409</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9933E13D-CEEB-472C-BC50-C96CD5DE2232</gtr:id><gtr:title>Assessment of right ventricular volumes in hypoplastic left heart syndrome by real-time three-dimensional echocardiography: comparison with cardiac magnetic resonance imaging.</gtr:title><gtr:parentPublicationTitle>European heart journal cardiovascular Imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3745fc710f31cf7bcfccfaf4e0d636e"><gtr:id>f3745fc710f31cf7bcfccfaf4e0d636e</gtr:id><gtr:otherNames>Bell A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2047-2404</gtr:issn><gtr:outcomeId>5457b05311e431.33160177</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA1B9880-D359-43B3-8CEB-1B6631188F16</gtr:id><gtr:title>Hepatic artery thrombosis: conservative management or retransplantation?</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16ec70d9b27346a6f70332baf24ec3db"><gtr:id>16ec70d9b27346a6f70332baf24ec3db</gtr:id><gtr:otherNames>Heaton ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>5457af08ea0cc4.71231237</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>357E76DF-D08D-4F2D-AD1B-A1D29A13A276</gtr:id><gtr:title>The role of cognitive training in endourology: a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Actas urologicas espanolas</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3ec6a4c11f8e7c3da8154516355ddc3"><gtr:id>a3ec6a4c11f8e7c3da8154516355ddc3</gtr:id><gtr:otherNames>Shah M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0210-4806</gtr:issn><gtr:outcomeId>5aa7ede9f1d5a4.92588861</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F828857-12CE-47CF-917E-A48BB1189A71</gtr:id><gtr:title>IL15RA drives antagonistic mechanisms of cancer development and immune control in lymphocyte-enriched triple-negative breast cancers.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25b875d50fc4f1dadcca666c746130aa"><gtr:id>25b875d50fc4f1dadcca666c746130aa</gtr:id><gtr:otherNames>Marra P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>5457983f85ce32.32884325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>775385D3-EA45-4328-951C-F3B7B731D18E</gtr:id><gtr:title>Biomarkers of Tolerance in Kidney Transplantation: Are We Predicting Tolerance or Response to Immunosuppressive Treatment?</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43376703a6f3872ef7f7fdad69ee6e06"><gtr:id>43376703a6f3872ef7f7fdad69ee6e06</gtr:id><gtr:otherNames>Rebollo-Mesa I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>585d38ec2cc1d3.72995210</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58373054-38DB-47EA-8AF7-3A50271FA4B2</gtr:id><gtr:title>Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies.</gtr:title><gtr:parentPublicationTitle>World journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3960eee45c3ab2a94ff194c9e8ae4883"><gtr:id>3960eee45c3ab2a94ff194c9e8ae4883</gtr:id><gtr:otherNames>Ukimura O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0724-4983</gtr:issn><gtr:outcomeId>56e046a6686b85.75325023</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>342BC025-0F0B-442E-A2C0-DC1DCBEC01DA</gtr:id><gtr:title>IgG4 subclass antibodies impair antitumor immunity in melanoma.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1ca9da6894e26b6337b69fcd4be667c"><gtr:id>c1ca9da6894e26b6337b69fcd4be667c</gtr:id><gtr:otherNames>Karagiannis P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>doi_13110_2_JCI65579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFC93859-67EF-4069-B77D-DCB198559227</gtr:id><gtr:title>Evaluation of robotic and laparoscopic partial nephrectomy for small renal tumours (T1a).</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28b6c05086685b1ae195244cd718c80b"><gtr:id>28b6c05086685b1ae195244cd718c80b</gtr:id><gtr:otherNames>Froghi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_13110_20_23480733</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E74D086-0A89-457C-9105-24266894063F</gtr:id><gtr:title>New Exploration of Chinese Herbal Medicines in Hepatology.</gtr:title><gtr:parentPublicationTitle>Evidence-based complementary and alternative medicine : eCAM</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89e37983f3278f9c30f6594c27c0aa4a"><gtr:id>89e37983f3278f9c30f6594c27c0aa4a</gtr:id><gtr:otherNames>Feng Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-427X</gtr:issn><gtr:outcomeId>58ca7935d5d612.78076476</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77BD10F9-22FB-4CA2-8C58-52AD38ECF3C5</gtr:id><gtr:title>Difference in outcomes after antibody-mediated rejection between abo-incompatible and positive cross-match transplantations.</gtr:title><gtr:parentPublicationTitle>Transplant international : official journal of the European Society for Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/039435ec9c62b952072970cc24f17401"><gtr:id>039435ec9c62b952072970cc24f17401</gtr:id><gtr:otherNames>Couzi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>561354868af283.77176811</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD775230-84BD-4470-8FF5-98074CFF3F27</gtr:id><gtr:title>Solid organ transplantation for non-TTR hereditary amyloidosis: report from the 1st International Workshop on the Hereditary Renal Amyloidoses.</gtr:title><gtr:parentPublicationTitle>Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/956428c922136c50595c7724e8804929"><gtr:id>956428c922136c50595c7724e8804929</gtr:id><gtr:otherNames>Stangou AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1350-6129</gtr:issn><gtr:outcomeId>doi_13110_012_668503</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEC85E42-0025-4333-A40A-FA5F343A04F4</gtr:id><gtr:title>Serial magnetic resonance imaging in hypoplastic left heart syndrome gives valuable insight into ventricular and vascular adaptation.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/636591188271c2c64096299d0681a773"><gtr:id>636591188271c2c64096299d0681a773</gtr:id><gtr:otherNames>Bellsham-Revell HR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>doi_13110_012_11_016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>087E39EB-FFE1-4365-A3D5-1C3D38B79B7D</gtr:id><gtr:title>Genetic evidence for a pathogenic role for the vitamin D3 metabolizing enzymein multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis and related disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52571622ddf586543c15906e6485b96b"><gtr:id>52571622ddf586543c15906e6485b96b</gtr:id><gtr:otherNames>Ramasamy A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2211-0348</gtr:issn><gtr:outcomeId>5457ac9ee2db61.74242287</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5450A43-9DC8-4B5A-A19E-A6784B35009B</gtr:id><gtr:title>Immune dysregulation in Alagille syndrome: A new feature of the evolving phenotype.</gtr:title><gtr:parentPublicationTitle>Clinics and research in hepatology and gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06c5028c21f247423084aded90093c59"><gtr:id>06c5028c21f247423084aded90093c59</gtr:id><gtr:otherNames>Tilib Shamoun S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2210-7401</gtr:issn><gtr:outcomeId>56bb447b46f835.67989094</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9377F4E2-E4A7-4AE2-8008-2E1958865E79</gtr:id><gtr:title>Loss of endogenous thymosin ?accelerates glomerular disease.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85373a2da5384ab7e22d24df1461b0f3"><gtr:id>85373a2da5384ab7e22d24df1461b0f3</gtr:id><gtr:otherNames>Vasilopoulou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>5aaa692f693805.66841997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>785151CE-B34E-475E-9603-742C3427FE51</gtr:id><gtr:title>CD46 Activation Regulates miR-150-Mediated Control of GLUT1 Expression and Cytokine Secretion in Human CD4+ T Cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4ee94e92f3f3de17f4b3c51ff220d74"><gtr:id>c4ee94e92f3f3de17f4b3c51ff220d74</gtr:id><gtr:otherNames>King BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>56bb447b75af27.67828695</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6249A67-C68F-4656-BD14-2E728E687074</gtr:id><gtr:title>A single autoimmune T cell receptor recognizes more than a million different peptides.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d547e90cc384e09a297316e7446f9b8"><gtr:id>6d547e90cc384e09a297316e7446f9b8</gtr:id><gtr:otherNames>Wooldridge L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>doi_13110_111_289488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0DD03E5-4005-49CB-A920-7D1D0DDA6B73</gtr:id><gtr:title>Clinical-grade multipotent adult progenitor cells durably control pathogenic T cell responses in human models of transplantation and autoimmunity.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7757760750e306c256b60d0266f85451"><gtr:id>7757760750e306c256b60d0266f85451</gtr:id><gtr:otherNames>Reading JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>doi_13110_ol_1202710</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13F4F051-6EAB-4B40-A6F9-4A0557B48733</gtr:id><gtr:title>Research vibrations.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c70b8daadb1f5ec7e394e7e7d240b519"><gtr:id>c70b8daadb1f5ec7e394e7e7d240b519</gtr:id><gtr:otherNames>De Ridder D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e047e7673979.30182945</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B835030-EBB4-4718-A1B6-5334B9C83228</gtr:id><gtr:title>Organ Pretreatment With Cytotopic Endothelial Localizing Peptides to Ameliorate Microvascular Thrombosis and Perfusion Deficits in Ex Vivo Renal Hemoreperfusion Models.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f58f43718dfbc575d7b3f2c5eee78620"><gtr:id>f58f43718dfbc575d7b3f2c5eee78620</gtr:id><gtr:otherNames>Hamaoui K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>58c6b17a0937c9.62451788</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1D62D54-8447-4290-87E8-625A95164400</gtr:id><gtr:title>Regulation, regulation, regulation: Its function and threat to vital transplant research</gtr:title><gtr:parentPublicationTitle>European Society of Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5994cfe1fcc6cb53757f531cf754127"><gtr:id>e5994cfe1fcc6cb53757f531cf754127</gtr:id><gtr:otherNames>Cronin Antonia J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>NHZkAn5m78K</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BD0B61B-82E3-421A-826E-2814AAFFC9E1</gtr:id><gtr:title>Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs&amp;reg; immunomodulatory compounds lenalidomide and pomalidomide.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8246db1023e2f253989e33e5a3ac013"><gtr:id>c8246db1023e2f253989e33e5a3ac013</gtr:id><gtr:otherNames>Henry JY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>pm_13110_20_23374145</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B694CA8-3B77-4C6F-818E-312F49CAC609</gtr:id><gtr:title>Enzymatic Reactions and Detection of C3 Cleavage Fragments.</gtr:title><gtr:parentPublicationTitle>Bio-protocol</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97f2649fc7b89e5df4f4848bcd6d3cea"><gtr:id>97f2649fc7b89e5df4f4848bcd6d3cea</gtr:id><gtr:otherNames>Kemper C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2331-8325</gtr:issn><gtr:outcomeId>5a325c925523a8.65384362</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>430AB24B-5C7A-4F82-A8AB-330482AF7E46</gtr:id><gtr:title>Why is Research on Herbal Medicinal Products Important and How Can We Improve Its Quality?</gtr:title><gtr:parentPublicationTitle>Journal of traditional and complementary medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b755f18956fe2ab70692153c5beea45f"><gtr:id>b755f18956fe2ab70692153c5beea45f</gtr:id><gtr:otherNames>Pelkonen O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2225-4110</gtr:issn><gtr:outcomeId>54ae558573cf48.81950444</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D87874B-0323-41AA-9AE0-868E6390352E</gtr:id><gtr:title>The changing paradigm of prognostic factors in acute myeloid leukaemia.</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa63804623afefe42d3849f6aead48b0"><gtr:id>fa63804623afefe42d3849f6aead48b0</gtr:id><gtr:otherNames>Grimwade D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1521-6926</gtr:issn><gtr:outcomeId>doi_13110_012_10_004</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A06476B7-7E81-4A04-A06A-01D23CEEF6B5</gtr:id><gtr:title>Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6428f92de0bfb11f802069857dd60ce"><gtr:id>f6428f92de0bfb11f802069857dd60ce</gtr:id><gtr:otherNames>Bacchetta R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>545251d6f0f1a1.34063828</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9ABA5073-A07A-4956-BB0A-007F0D5C7D64</gtr:id><gtr:title>A comprehensive cardiac motion estimation framework using both untagged and 3-D tagged MR images based on nonrigid registration.</gtr:title><gtr:parentPublicationTitle>IEEE transactions on medical imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cfb66561e805b522d67b8a104bf0bc2"><gtr:id>4cfb66561e805b522d67b8a104bf0bc2</gtr:id><gtr:otherNames>Shi W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0278-0062</gtr:issn><gtr:outcomeId>doi_13110_12_2188104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C0AEEEF-4B2D-4F44-AA1C-81FEFCF07692</gtr:id><gtr:title>Regulatory T-cell therapy in the induction of transplant tolerance: the issue of subpopulations.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6e9edb77e37799b89623120f1a48661"><gtr:id>b6e9edb77e37799b89623120f1a48661</gtr:id><gtr:otherNames>Edozie FC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>543b98d80013c2.19902003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F7D8342-391E-4B90-8919-FABA934ABFC7</gtr:id><gtr:title>Biophysical modeling to simulate the response to multisite left ventricular stimulation using a quadripolar pacing lead.</gtr:title><gtr:parentPublicationTitle>Pacing and clinical electrophysiology : PACE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e00a205df4c1593666658b6e9822b134"><gtr:id>e00a205df4c1593666658b6e9822b134</gtr:id><gtr:otherNames>Niederer SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0147-8389</gtr:issn><gtr:outcomeId>doi_13110_11_03243_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DA7BD61-B931-455E-8BAD-CEC0BD703B28</gtr:id><gtr:title>Inhibition of thrombin receptor signaling on a-smooth muscle actin(+) CD34(+) progenitors leads to repair after murine immune vascular injury.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ef91a6d242b3418b3065118aa4f2f60"><gtr:id>2ef91a6d242b3418b3065118aa4f2f60</gtr:id><gtr:otherNames>Chen D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>544f5918b45473.27462502</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>807DC342-A8DF-4CBB-A988-4D90B07C810D</gtr:id><gtr:title>Reply</gtr:title><gtr:parentPublicationTitle>Liver Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b05d0a566957a132e2232e304627c5f5"><gtr:id>b05d0a566957a132e2232e304627c5f5</gtr:id><gtr:otherNames>Cherian P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_13110_2_lt_23405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3FAE347-DD01-4F49-9867-F8C8BB0EE6E7</gtr:id><gtr:title>FRA2 is a STAT5 target gene regulated by IL-2 in human CD4 T cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4bd41f5e795706d066b9db464defb69"><gtr:id>d4bd41f5e795706d066b9db464defb69</gtr:id><gtr:otherNames>Rani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5458d80525ee62.36647582</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48D2A803-769F-4001-BD1D-736FABD9B317</gtr:id><gtr:title>Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82e4ce55ad0283b97d594815711ee232"><gtr:id>82e4ce55ad0283b97d594815711ee232</gtr:id><gtr:otherNames>Bierzynska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>5aaa728c5fe1a0.44246401</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F6AA5E4-ED52-4401-9E64-C8E6692295C8</gtr:id><gtr:title>Secretion of shh by a neurovascular bundle niche supports mesenchymal stem cell homeostasis in the adult mouse incisor.</gtr:title><gtr:parentPublicationTitle>Cell stem cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/965fa2e737474be04198ec1e700c3e4c"><gtr:id>965fa2e737474be04198ec1e700c3e4c</gtr:id><gtr:otherNames>Zhao H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1875-9777</gtr:issn><gtr:outcomeId>5457a95e6bfc49.84935341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>287F6AAA-6980-4E19-832C-C0F895210729</gtr:id><gtr:title>Novel en-bloc resection of locally advanced hilar chulangiucarcinuma: the Rex recess approach</gtr:title><gtr:parentPublicationTitle>Hepatobiliary &amp; Pancreatic Diseases International</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df8b311895be1e734affe6e64393aec0"><gtr:id>df8b311895be1e734affe6e64393aec0</gtr:id><gtr:otherNames>Rela M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5457af09853b92.68278245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35E32561-B01E-4281-9765-CAECF6DD9B48</gtr:id><gtr:title>Caspase-7 participates in differentiation of cells forming dental hard tissues.</gtr:title><gtr:parentPublicationTitle>Development, growth &amp; differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04b26ea2752e4b4fd619dec72881e4ef"><gtr:id>04b26ea2752e4b4fd619dec72881e4ef</gtr:id><gtr:otherNames>Matalova E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-1592</gtr:issn><gtr:outcomeId>doi_13110__dgd_12066</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4A8F4AE-B98B-4EE4-8A60-ED22B2979A0F</gtr:id><gtr:title>A novel cadaveric simulation program in urology.</gtr:title><gtr:parentPublicationTitle>Journal of surgical education</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e0b4786411cafcf44ac496e87ec7b61"><gtr:id>6e0b4786411cafcf44ac496e87ec7b61</gtr:id><gtr:otherNames>Ahmed K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1878-7452</gtr:issn><gtr:outcomeId>56e046a6361cc6.50221446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9A2B8E4-6769-4A9B-8F2A-2F49E6FEE99A</gtr:id><gtr:title>VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.</gtr:title><gtr:parentPublicationTitle>Cancer immunology research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a63a52c25ec842dc9d87dc1d2307187"><gtr:id>7a63a52c25ec842dc9d87dc1d2307187</gtr:id><gtr:otherNames>Lines JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2326-6066</gtr:issn><gtr:outcomeId>5458d9610994e3.97456904</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FFFC96C-5458-41E6-971E-F3713883C349</gtr:id><gtr:title>Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure.</gtr:title><gtr:parentPublicationTitle>International journal of clinical practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f98c246289aeff1ca8ff717c5ada8fee"><gtr:id>f98c246289aeff1ca8ff717c5ada8fee</gtr:id><gtr:otherNames>Karsenty G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1368-5031</gtr:issn><gtr:outcomeId>56e047e8921e11.18762995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>861ABFD7-0003-45F4-B0B5-B4E2C5F6C3F8</gtr:id><gtr:title>Usefulness of liver stiffness measurement during acute cellular rejection in liver transplantation.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d13d0c801f737a872b3968e603ce9069"><gtr:id>d13d0c801f737a872b3968e603ce9069</gtr:id><gtr:otherNames>Crespo G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>58c6b17e8dc2d4.86670978</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4D3BCC4-E573-4AC5-8745-2537DA12C139</gtr:id><gtr:title>Cross-validation of IFN-? Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/625f78e63e646ba55438bf4227e9d7f8"><gtr:id>625f78e63e646ba55438bf4227e9d7f8</gtr:id><gtr:otherNames>Bestard O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>doi_13110__ajt_12285</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E88F5790-4833-40BA-895A-0768FDE96CE2</gtr:id><gtr:title>The new face of anaphylatoxins in immune regulation.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a4a3cd997f841d3d0f26f99aa36df9b"><gtr:id>7a4a3cd997f841d3d0f26f99aa36df9b</gtr:id><gtr:otherNames>Zhou W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn><gtr:outcomeId>doi_13110_011_07_016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7901731-9F1B-44AF-A4AA-37C79C5ECD2C</gtr:id><gtr:title>Constitutive expression of the anti-apoptotic Bcl-2 family member A1 in murine endothelial cells leads to transplant tolerance.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/785928b8c34d6342ea641ff5256e80f7"><gtr:id>785928b8c34d6342ea641ff5256e80f7</gtr:id><gtr:otherNames>Smyth LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>58c6b1790a0947.55225752</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC4D2589-9862-4272-B206-5F15C4F69D8C</gtr:id><gtr:title>Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb1c31a807214def85b01c2a66462f0d"><gtr:id>fb1c31a807214def85b01c2a66462f0d</gtr:id><gtr:otherNames>Huda MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>54579ae212f537.43284802</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29AB6FE0-93C3-43B0-B668-3E4B50B2DF24</gtr:id><gtr:title>Diversity of gut microflora is required for the generation of B cell with regulatory properties in a skin graft model.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58ff17d77279e3959684be392b8509a3"><gtr:id>58ff17d77279e3959684be392b8509a3</gtr:id><gtr:otherNames>Alhabbab R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5675e74466e33</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EAF908A-D515-4441-B5B1-38CF1398DA24</gtr:id><gtr:title>Valentine's Day PSA.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e047e825e900.19197835</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F60435A-54A4-4C89-B719-B5BA4A6E9BF6</gtr:id><gtr:title>Resolving the polymorphism-in-probe problem is critical for correct interpretation of expression QTL studies.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52571622ddf586543c15906e6485b96b"><gtr:id>52571622ddf586543c15906e6485b96b</gtr:id><gtr:otherNames>Ramasamy A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>doi_13110_nar_gkt069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA3E9FA5-485D-4308-91B6-279450EE2EF2</gtr:id><gtr:title>Integration of GWAS SNPs and tissue specific expression profiling reveal discrete eQTLs for human traits in blood and brain.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fa0a98b877dd2fe06320fd79e75f4c4"><gtr:id>5fa0a98b877dd2fe06320fd79e75f4c4</gtr:id><gtr:otherNames>Hernandez DG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>doi_13110_012_03_020</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EABFEAB4-DF4D-4EF4-8254-5F5EC5DEC6B7</gtr:id><gtr:title>Effect of early EBV and/or CMV viremia on graft function and acute cellular rejection in pediatric liver transplantation.</gtr:title><gtr:parentPublicationTitle>Clinical transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd9b2d43b55c0b196721a2031f8cba52"><gtr:id>bd9b2d43b55c0b196721a2031f8cba52</gtr:id><gtr:otherNames>Indolfi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0902-0063</gtr:issn><gtr:outcomeId>doi_13110_11_01535_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D6B7056-FF9B-4EAF-AC07-9FE409B86138</gtr:id><gtr:title>Bringing science closer to urologists.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c70b8daadb1f5ec7e394e7e7d240b519"><gtr:id>c70b8daadb1f5ec7e394e7e7d240b519</gtr:id><gtr:otherNames>De Ridder D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_13110_20_23578228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDC1A1F7-585E-4B50-A4C9-1AB4D3E045A0</gtr:id><gtr:title>Scientific impact and beyond.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e0450b561c29.49330063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E7224A8-9AD8-41EA-9688-6866AE2A058D</gtr:id><gtr:title>Targeting C3a/C5a receptors inhibits human mesangial cell proliferation and alleviates immunoglobulin A nephropathy in mice.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d895db59e431e55ec84105d0da4fab0d"><gtr:id>d895db59e431e55ec84105d0da4fab0d</gtr:id><gtr:otherNames>Zhang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>58ca797e78d723.34089574</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A91B25F3-6676-429B-A941-2B0611D25FBD</gtr:id><gtr:title>Origin and biology of the allogeneic response.</gtr:title><gtr:parentPublicationTitle>Cold Spring Harbor perspectives in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a9ca5617c49432b738c2ca1eef57177"><gtr:id>4a9ca5617c49432b738c2ca1eef57177</gtr:id><gtr:otherNames>Lakkis FG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2157-1422</gtr:issn><gtr:outcomeId>doi_13110_ct_a014993</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B97A1360-C3E1-4F30-ACBC-FA69895E966B</gtr:id><gtr:title>Alginate microencapsulated hepatocytes optimised for transplantation in acute liver failure.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3976b2fcb547c6d64b99b80ca1a034c"><gtr:id>c3976b2fcb547c6d64b99b80ca1a034c</gtr:id><gtr:otherNames>Jitraruch S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56e004e50bc105.24036709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1C4917D-1CCB-47DB-8BE4-B2782E1AD9F2</gtr:id><gtr:title>Expression of human tissue factor pathway inhibitor on vascular smooth muscle cells inhibits secretion of macrophage migration inhibitory factor and attenuates atherosclerosis in ApoE-/- mice.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ef91a6d242b3418b3065118aa4f2f60"><gtr:id>2ef91a6d242b3418b3065118aa4f2f60</gtr:id><gtr:otherNames>Chen D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>54e08d4f858e24.56400872</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4DABF9E-560C-448A-A979-B84A47C85F8B</gtr:id><gtr:title>Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/efa521ff6341e9563fe2417fac79c0d6"><gtr:id>efa521ff6341e9563fe2417fac79c0d6</gtr:id><gtr:otherNames>Lucena-Araujo AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5457abfeeaa9d4.45747392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1EABF54-50F2-4672-BBD0-4C56EB26E3E3</gtr:id><gtr:title>Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff1b4f6148da6bc96ac5c5b83d0ded0f"><gtr:id>ff1b4f6148da6bc96ac5c5b83d0ded0f</gtr:id><gtr:otherNames>Kulasekararaj AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>doi_13110__bjh_12435</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0550A11-B784-4BC3-8796-D777E7E71BD4</gtr:id><gtr:title>The estimation of patient-specific cardiac diastolic functions from clinical measurements.</gtr:title><gtr:parentPublicationTitle>Medical image analysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cf655951c3ee15b532584d9bdc2de65"><gtr:id>2cf655951c3ee15b532584d9bdc2de65</gtr:id><gtr:otherNames>Xi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1361-8415</gtr:issn><gtr:outcomeId>doi_13110_012_08_001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A38EB675-3F4F-44D7-9274-0561EDCC23E0</gtr:id><gtr:title>In-silico modeling of atrial repolarization in normal and atrial fibrillation remodeled state.</gtr:title><gtr:parentPublicationTitle>Medical &amp; biological engineering &amp; computing</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aeb4b381e8c48b594ed49f966f319e70"><gtr:id>aeb4b381e8c48b594ed49f966f319e70</gtr:id><gtr:otherNames>Krueger MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-0118</gtr:issn><gtr:outcomeId>5457b05193a095.12577920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>597B51CE-9365-4128-B8E0-2E4667820E73</gtr:id><gtr:title>Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e2571767688cb7c7baf3627feb25a73"><gtr:id>7e2571767688cb7c7baf3627feb25a73</gtr:id><gtr:otherNames>Feliu J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>56e006d582e317.58872342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6262186B-FD8C-4563-88D4-18440A39FF6E</gtr:id><gtr:title>Immunosuppression withdrawal following liver transplantation.</gtr:title><gtr:parentPublicationTitle>Clinics and research in hepatology and gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8537caedf1a7bdbc5f47f9cdcc4993fe"><gtr:id>8537caedf1a7bdbc5f47f9cdcc4993fe</gtr:id><gtr:otherNames>Whitehouse GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2210-7401</gtr:issn><gtr:outcomeId>5452131c2eeae6.78700013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9576A32D-3597-4BE6-83EC-E5B712BA7335</gtr:id><gtr:title>Distinct roles of microRNAs in epithelium and mesenchyme during tooth development.</gtr:title><gtr:parentPublicationTitle>Developmental dynamics : an official publication of the American Association of Anatomists</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a7bc7e97b2be3a83a1cb88cf0b0216e"><gtr:id>8a7bc7e97b2be3a83a1cb88cf0b0216e</gtr:id><gtr:otherNames>Oommen S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1058-8388</gtr:issn><gtr:outcomeId>doi_13110_dvdy_23828</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46C8CAEC-C6A4-4C8E-905E-C5ADFD1A7F87</gtr:id><gtr:title>Carbon nanotubes' surface chemistry determines their potency as vaccine nanocarriers in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c23c308038779d6077fc6d042aea6ae"><gtr:id>5c23c308038779d6077fc6d042aea6ae</gtr:id><gtr:otherNames>Hassan HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>56dda49e4b8058.75166813</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F33F2A84-E25A-451C-B5A3-A55B18A4D07F</gtr:id><gtr:title>Smooth muscle cells in porcine vein graft intimal hyperplasia are derived from the local vessel wall.</gtr:title><gtr:parentPublicationTitle>Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dda8817281a5557ec88ee4eb5459720d"><gtr:id>dda8817281a5557ec88ee4eb5459720d</gtr:id><gtr:otherNames>Jevon M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1054-8807</gtr:issn><gtr:outcomeId>pm_13110_20_20537564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C2C47ED-7D52-427E-920A-1F9308B9F018</gtr:id><gtr:title>International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8799eb123dc0641c7dfcd2bf0856ca67"><gtr:id>8799eb123dc0641c7dfcd2bf0856ca67</gtr:id><gtr:otherNames>Chie WC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>doi_13110__hep_24798</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03B88EC5-1DDF-4E05-AD61-ABAE0DE8F41F</gtr:id><gtr:title>Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0644ad0dc90cfaccfa5695a7f640d47"><gtr:id>a0644ad0dc90cfaccfa5695a7f640d47</gtr:id><gtr:otherNames>Aoyama K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>doi_13110__11_470252</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75128B25-2DDE-47AD-993F-A5F32DBB16CA</gtr:id><gtr:title>Ex vivo study of prostate cancer localization using rolling mechanical imaging towards minimally invasive surgery.</gtr:title><gtr:parentPublicationTitle>Medical engineering &amp; physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad7968d586527c1fd3f76aeabf35ac38"><gtr:id>ad7968d586527c1fd3f76aeabf35ac38</gtr:id><gtr:otherNames>Li J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1350-4533</gtr:issn><gtr:outcomeId>5aa7f0726285c6.80635042</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E7FFD5A-C807-4FE2-BE97-F36EC33F087E</gtr:id><gtr:title>Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b244775c9fbf5525b043c7aab25c663"><gtr:id>9b244775c9fbf5525b043c7aab25c663</gtr:id><gtr:otherNames>Gupta S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>doi_13110_2_JCI45138</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDD53BC2-6574-4633-A3A1-A8CD6536E204</gtr:id><gtr:title>Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/620c32debfab8521e02f0f04add64937"><gtr:id>620c32debfab8521e02f0f04add64937</gtr:id><gtr:otherNames>Mian SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>doi_13110_012_075325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB2A5D1F-DCAE-4313-9789-B63CFFBB2F40</gtr:id><gtr:title>Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0893e8ddad39e952b8d68025a1cfcf13"><gtr:id>0893e8ddad39e952b8d68025a1cfcf13</gtr:id><gtr:otherNames>Dolton G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>5457ad08b7c944.01072004</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C999269-C111-4D51-AF22-39B4B5DCA42A</gtr:id><gtr:title>Immune modulation in humans: implications for type 1 diabetes mellitus.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/388e6573797ca611bb82d8e72a20cf7e"><gtr:id>388e6573797ca611bb82d8e72a20cf7e</gtr:id><gtr:otherNames>Roep BO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1759-5029</gtr:issn><gtr:outcomeId>5457ad431a91e2.19730529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A5ADBEE-23C5-4B34-869F-951E66C3220B</gtr:id><gtr:title>The use of eculizumab in renal transplantation.</gtr:title><gtr:parentPublicationTitle>Clinical transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4de086c273c0c67e49e3b833cb39f230"><gtr:id>4de086c273c0c67e49e3b833cb39f230</gtr:id><gtr:otherNames>Barnett AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0902-0063</gtr:issn><gtr:outcomeId>544a65932db712.46962865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>336EE3B1-E769-4106-AAFD-A65D896E18D1</gtr:id><gtr:title>Robot-assisted vs open radical prostatectomy: the day after.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27d8f8189a89239872f7de9b094df754"><gtr:id>27d8f8189a89239872f7de9b094df754</gtr:id><gtr:otherNames>Ficarra V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>5aa7f0139c7eb3.49485358</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E11BEE1D-3D5F-4A84-9EF1-09DE2AA7E9A8</gtr:id><gtr:title>Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f63fdf10576926ea41cafd72d082d6a1"><gtr:id>f63fdf10576926ea41cafd72d082d6a1</gtr:id><gtr:otherNames>Liszewski MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>544653ad820341.10552468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4618A6C2-7455-41E1-9E11-0030456D1A78</gtr:id><gtr:title>The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2da0d197ccf3f2b68433be172c4e55d"><gtr:id>a2da0d197ccf3f2b68433be172c4e55d</gtr:id><gtr:otherNames>Joshi D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>doi_13110_11_02677_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7DB0661-97D2-419E-9B02-0E59D90D0ED3</gtr:id><gtr:title>Fine-mapping, gene expression and splicing analysis of the disease associated LRRK2 locus.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fc9b26a4f240104f4f5378597d75aff"><gtr:id>0fc9b26a4f240104f4f5378597d75aff</gtr:id><gtr:otherNames>Trabzuni D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_13110_ne_0070724</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08C1F0B8-9A76-405D-81D3-1FCD81AC0CD9</gtr:id><gtr:title>Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill ?-cells.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39b275c4fdd7cbc5392696a76475494e"><gtr:id>39b275c4fdd7cbc5392696a76475494e</gtr:id><gtr:otherNames>Kronenberg D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>doi_13110__db11_1520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA6A9389-A0C9-45B1-B8AF-1B4D326E676B</gtr:id><gtr:title>Mechanisms regulating skin immunity and inflammation.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dd7a0a8111ba811a983255eb990255a"><gtr:id>1dd7a0a8111ba811a983255eb990255a</gtr:id><gtr:otherNames>Pasparakis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>5457a86e1e5a70.24857264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A46677F-AEE4-461A-A98B-19423249872E</gtr:id><gtr:title>Predictors of early graft survival after pediatric liver transplantation.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9035c8e74cd2248306b7fd17e754e1c"><gtr:id>a9035c8e74cd2248306b7fd17e754e1c</gtr:id><gtr:otherNames>Ciria R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>doi_13110_2_lt_23532</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>770131F9-1D9F-4CE6-86A7-F39F00CFBB56</gtr:id><gtr:title>A comparison of left ventricular endocardial, multisite, and multipolar epicardial cardiac resynchronization: an acute haemodynamic and electroanatomical study.</gtr:title><gtr:parentPublicationTitle>Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13ee7b0a284b01d86daa7c5f851c45ab"><gtr:id>13ee7b0a284b01d86daa7c5f851c45ab</gtr:id><gtr:otherNames>Shetty AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1099-5129</gtr:issn><gtr:outcomeId>5457b0542d7ae3.38366579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5805915-4AAA-4AE3-AF8B-E1E889424A41</gtr:id><gtr:title>Human ?-cell killing by autoreactive preproinsulin-specific CD8 T cells is predominantly granule-mediated with the potency dependent upon T-cell receptor avidity.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1657a609ce0055279a33163528fdb4c4"><gtr:id>1657a609ce0055279a33163528fdb4c4</gtr:id><gtr:otherNames>Knight RR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>doi_13110__db12_0315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C68A5A48-F025-465D-BEA3-5FC67D1F4317</gtr:id><gtr:title>The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b45f75b0c7637f862f1b025d4b726505"><gtr:id>b45f75b0c7637f862f1b025d4b726505</gtr:id><gtr:otherNames>Klebe S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>doi_13110_012_304475</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4676A25-E804-4C49-AA5C-37A291B42CFD</gtr:id><gtr:title>Contemporary strategies in the management of hepatocellular carcinoma.</gtr:title><gtr:parentPublicationTitle>HPB surgery : a world journal of hepatic, pancreatic and biliary surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d35a1df08772a9b7e323b19cdf0eb58"><gtr:id>8d35a1df08772a9b7e323b19cdf0eb58</gtr:id><gtr:otherNames>Khorsandi SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0894-8569</gtr:issn><gtr:outcomeId>doi_13110_012_154056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EF52C4B-6E36-4636-AE14-97170E8779D7</gtr:id><gtr:title>Transitional B cell subsets-a convincing predictive biomarker for allograft loss?</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e103252a8160e7ff2d72b21e4bef1aae"><gtr:id>e103252a8160e7ff2d72b21e4bef1aae</gtr:id><gtr:otherNames>Burton H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>58c6b1798268a1.96930323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>229B054A-8105-449F-BE63-7BFBA01A75E8</gtr:id><gtr:title>Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6181309043081124d85172edeeff56ea"><gtr:id>6181309043081124d85172edeeff56ea</gtr:id><gtr:otherNames>Leow JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>56e0450a979df7.96751866</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E469BCE-3CCC-4EC0-965A-CA264395AF1A</gtr:id><gtr:title>Development of a patient and institutional-based model for estimation of operative times for robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e471552c010934f5ba492f2fe94d9202"><gtr:id>e471552c010934f5ba492f2fe94d9202</gtr:id><gtr:otherNames>Hussein AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>5aa7efdb8955b1.18144846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAD57C0C-45A7-415D-871A-C465F9896B5C</gtr:id><gtr:title>Acute myeloid leukaemia with mutated NPM1 presenting with extensive bone marrow necrosis and Charcot-Leyden crystals.</gtr:title><gtr:parentPublicationTitle>International journal of hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb166f172d6376a3795a3a2d84a54351"><gtr:id>bb166f172d6376a3795a3a2d84a54351</gtr:id><gtr:otherNames>Taylor G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0925-5710</gtr:issn><gtr:outcomeId>doi_13110_013_1394_9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25B301B6-F587-4894-851E-1B40A54C3E40</gtr:id><gtr:title>Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient</gtr:title><gtr:parentPublicationTitle>Transplantation Reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/722c4ac63ded662dc422a0a61495e934"><gtr:id>722c4ac63ded662dc422a0a61495e934</gtr:id><gtr:otherNames>Manook M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5aa9340a0e6a96.56336059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F3001A5-9D44-4B99-81DC-3B12B9FC24CF</gtr:id><gtr:title>Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff1b4f6148da6bc96ac5c5b83d0ded0f"><gtr:id>ff1b4f6148da6bc96ac5c5b83d0ded0f</gtr:id><gtr:otherNames>Kulasekararaj AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5457aab43d5b25.93094482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C754F4A7-C791-4CDD-B48E-765718E14079</gtr:id><gtr:title>Patient specific fluid-structure ventricular modelling for integrated cardiac care.</gtr:title><gtr:parentPublicationTitle>Medical &amp; biological engineering &amp; computing</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e8d97a4106a90b455502c0c757d2610"><gtr:id>4e8d97a4106a90b455502c0c757d2610</gtr:id><gtr:otherNames>de Vecchi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-0118</gtr:issn><gtr:outcomeId>doi_13110_012_1030_5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F2F3865-158C-4127-8F68-710FF7680091</gtr:id><gtr:title>Immunological visibility: posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bacf3848666ab7b60efdb7aa1cdab18"><gtr:id>7bacf3848666ab7b60efdb7aa1cdab18</gtr:id><gtr:otherNames>Vantourout P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>5457983f383f85.84029662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EDC396B-E3E2-4C94-AFEE-B2180D425B76</gtr:id><gtr:title>A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/defaa18a89e21eb999004914461c74ef"><gtr:id>defaa18a89e21eb999004914461c74ef</gtr:id><gtr:otherNames>Baron D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>56d81a5ef3b6f7.19567552</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CCDCBED-8351-4DE7-8730-1959A0431EB1</gtr:id><gtr:title>Baseline evaluation of serum markers of inflammation and their utility in clinical practice in paediatric liver transplant recipients.</gtr:title><gtr:parentPublicationTitle>Clinics and research in hepatology and gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70fdba3a9949d997d742526577b4c587"><gtr:id>70fdba3a9949d997d742526577b4c587</gtr:id><gtr:otherNames>Grammatikopoulos T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2210-7401</gtr:issn><gtr:outcomeId>doi_13110_012_01_010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F8057AA-C7EB-404C-BC3C-A5065B49EFE4</gtr:id><gtr:title>Mapping of the CD23 binding site on immunoglobulin E (IgE) and allosteric control of the IgE-Fc epsilonRI interaction.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ab9dd681c7861cbaa73d34677709afe"><gtr:id>4ab9dd681c7861cbaa73d34677709afe</gtr:id><gtr:otherNames>Borthakur S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>doi_13110_112_397059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>764F417A-B3DE-4224-A1B6-213B90017C4A</gtr:id><gtr:title>Eltrombopag: a stem cell cookie?</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5adf1b49c8627d3687d7cb9e21e37cde"><gtr:id>5adf1b49c8627d3687d7cb9e21e37cde</gtr:id><gtr:otherNames>Marsh JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5457aab5652158.37954373</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>591CA581-B705-4217-9B53-EA95082739AD</gtr:id><gtr:title>The effect of bariatric surgery on intestinal absorption and transit time.</gtr:title><gtr:parentPublicationTitle>Obesity surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43df61f2df808029a799865631ab5cf3"><gtr:id>43df61f2df808029a799865631ab5cf3</gtr:id><gtr:otherNames>Carswell KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0960-8923</gtr:issn><gtr:outcomeId>54579ae23e4977.51667687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B14B8E7-9A43-4D37-859D-C6DDCAC28E29</gtr:id><gtr:title>Toll-like receptor 2 or toll-like receptor 4 deficiency does not modify lupus in MRLlpr mice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ff09c7595c7f1b1582e2a909a1edfa8"><gtr:id>7ff09c7595c7f1b1582e2a909a1edfa8</gtr:id><gtr:otherNames>Freeley SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13110_20_24086313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>009016C7-68AE-4651-BA83-6466240E5AD5</gtr:id><gtr:title>AST-to-platelet ratio index in non-invasive assessment of long-term graft fibrosis following pediatric liver transplantation.</gtr:title><gtr:parentPublicationTitle>Pediatric transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d156e85ec78ac1b35dcb7ba8994f412"><gtr:id>7d156e85ec78ac1b35dcb7ba8994f412</gtr:id><gtr:otherNames>D'Souza RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1397-3142</gtr:issn><gtr:outcomeId>58c6b17e64fab3.46858615</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC8E29A6-4BB7-472E-9066-B0847F9DFF76</gtr:id><gtr:title>Steroid regulation: An overlooked aspect of tolerance and chronic rejection in kidney transplantation.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f515e48371db62a4c794f7e505cc5622"><gtr:id>f515e48371db62a4c794f7e505cc5622</gtr:id><gtr:otherNames>Christakoudi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0303-7207</gtr:issn><gtr:outcomeId>5aaa725de49542.80651753</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72252555-46A5-4148-B696-7E5D3A01771A</gtr:id><gtr:title>Effect of mental challenge induced by movie clips on action potential duration in normal human subjects independent of heart rate.</gtr:title><gtr:parentPublicationTitle>Circulation. Arrhythmia and electrophysiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/430dffc1ad1e69cf82fb4afec2616fd1"><gtr:id>430dffc1ad1e69cf82fb4afec2616fd1</gtr:id><gtr:otherNames>Child N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1941-3084</gtr:issn><gtr:outcomeId>5457b05406a402.85214000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4F9362D-BCA2-4391-AF38-922EA23F3CFA</gtr:id><gtr:title>Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13b444623dc74a3be29b74157106537c"><gtr:id>13b444623dc74a3be29b74157106537c</gtr:id><gtr:otherNames>Seth JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_13110_20_23444927</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>522052AB-1603-47AE-BEFA-9C9479231426</gtr:id><gtr:title>Comfort and learnability assessment of a new soft robotic manipulator for minimally invasive surgery.</gtr:title><gtr:parentPublicationTitle>Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a78c111c6b2adff9ca079ee77204aca5"><gtr:id>a78c111c6b2adff9ca079ee77204aca5</gtr:id><gtr:otherNames>Shafti A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1557-170X</gtr:issn><gtr:outcomeId>56e0450ac51226.80841674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA90CD83-8651-4553-83FB-C9776F6A572E</gtr:id><gtr:title>Measuring the surgical 'learning curve': methods, variables and competency.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4565dafaf87d213d5e13e790513349db"><gtr:id>4565dafaf87d213d5e13e790513349db</gtr:id><gtr:otherNames>Khan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_13110_20_23819461</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0254A744-5672-46C7-9CC4-B5D719203194</gtr:id><gtr:title>Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e99419069b860ea088ea32ca81cb26b1"><gtr:id>e99419069b860ea088ea32ca81cb26b1</gtr:id><gtr:otherNames>James LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>doi_13110_012_04_006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC856B31-4FDC-4A58-8CA0-BD08CDFF090B</gtr:id><gtr:title>The clinical spectrum of de novo donor-specific antibodies in pediatric renal transplant recipients.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d75c0bcc9053e9a07e2905e563de2ba8"><gtr:id>d75c0bcc9053e9a07e2905e563de2ba8</gtr:id><gtr:otherNames>Kim JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>544a659186e7b8.69775641</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E29DBF8-CEED-4519-876B-898AA1D81F30</gtr:id><gtr:title>Live surgical education: a perspective from the surgeons who perform it.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa0c0acf3b2630f69a51c5549f4f1b73"><gtr:id>aa0c0acf3b2630f69a51c5549f4f1b73</gtr:id><gtr:otherNames>Khan SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>54579d2df103f4.77056946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBC1F615-F960-460F-832D-171247FF6B8C</gtr:id><gtr:title>The immune cell transcription factor T-bet: A novel metabolic regulator.</gtr:title><gtr:parentPublicationTitle>Adipocyte</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e476949dc4c4ee8bd7d9c756e635262"><gtr:id>1e476949dc4c4ee8bd7d9c756e635262</gtr:id><gtr:otherNames>Stolarczyk E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2162-3945</gtr:issn><gtr:outcomeId>5457ab63862a37.89613955</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BBB2648-FCE0-4A5E-ADFD-6FBC128F9AF1</gtr:id><gtr:title>Delayed trans-septal activation results in comparable hemodynamic effect of left ventricular and biventricular endocardial pacing: insights from electroanatomical mapping.</gtr:title><gtr:parentPublicationTitle>Circulation. Arrhythmia and electrophysiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b35ea001a7fce2c2b01c48f419dfe3e"><gtr:id>8b35ea001a7fce2c2b01c48f419dfe3e</gtr:id><gtr:otherNames>Sohal M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1941-3084</gtr:issn><gtr:outcomeId>5457b0533a00c6.48002130</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2038247C-E087-4E96-A4E8-4C027FFE9360</gtr:id><gtr:title>Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy?</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a6f5d79bbdd361b914b49f67e84ce11"><gtr:id>7a6f5d79bbdd361b914b49f67e84ce11</gtr:id><gtr:otherNames>Boardman D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>585d511e3d62b0.09362090</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6869A3E6-48F9-471F-AD92-21F5867E6806</gtr:id><gtr:title>A case-mix-adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d719223d3cad2a8f78c9f376f99b5016"><gtr:id>d719223d3cad2a8f78c9f376f99b5016</gtr:id><gtr:otherNames>Davis JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>doi_13110_12_11643_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>329B6B8D-F6EE-4C72-93C7-ACB5B82B8812</gtr:id><gtr:title>Enhancement of the immunoregulatory potency of mesenchymal stromal cells by treatment with immunosuppressive drugs.</gtr:title><gtr:parentPublicationTitle>Cytotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39b00748d669559ab52bdc1e8584ee8d"><gtr:id>39b00748d669559ab52bdc1e8584ee8d</gtr:id><gtr:otherNames>Girdlestone J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1465-3249</gtr:issn><gtr:outcomeId>56dee990c2bbb9.97835900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40AACE79-908C-45FB-92F2-79E3792EA4C4</gtr:id><gtr:title>Regulatory T cells: Mechanisms of suppression and impairment in autoimmune liver disease.</gtr:title><gtr:parentPublicationTitle>IUBMB life</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88ce4a32e863de105770d1d6c3b2aab"><gtr:id>f88ce4a32e863de105770d1d6c3b2aab</gtr:id><gtr:otherNames>Liberal R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1521-6543</gtr:issn><gtr:outcomeId>56b488225ebfe4.84590977</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE498947-00DC-4B56-8633-1BAD0DDF073C</gtr:id><gtr:title>Assessment of common variability and expression quantitative trait loci for genome-wide associations for progressive supranuclear palsy.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9daf1044ffaa78c220fa83b15b9c753"><gtr:id>b9daf1044ffaa78c220fa83b15b9c753</gtr:id><gtr:otherNames>Ferrari R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>5457ac9f6d5c08.19355992</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DF7DA8C-65F7-419B-82FA-700815A0A7DD</gtr:id><gtr:title>Diverse matrix metalloproteinase functions regulate cancer amoeboid migration.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f882d9e28887466aecefdcab52008bd2"><gtr:id>f882d9e28887466aecefdcab52008bd2</gtr:id><gtr:otherNames>Orgaz JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5457a86e560623.49733224</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D5C78E3-BB02-455B-BA50-230CC171BED1</gtr:id><gtr:title>Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma.</gtr:title><gtr:parentPublicationTitle>Leukemia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d3f1efde6bd77b48b361870834b1edb"><gtr:id>0d3f1efde6bd77b48b361870834b1edb</gtr:id><gtr:otherNames>Noriega V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0145-2126</gtr:issn><gtr:outcomeId>5457aab5e1d035.37752269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49604708-375B-4D21-9041-C630AE9B4F4D</gtr:id><gtr:title>A psychoeducational program to restore hypoglycemia awareness: the DAFNE-HART pilot study.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e55fa56e4c300e856f6033b5a50ecd73"><gtr:id>e55fa56e4c300e856f6033b5a50ecd73</gtr:id><gtr:otherNames>de Zoysa N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>54579ae1662795.67653628</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65C8F70A-52D6-4F8B-B692-1A3C0C54A3E5</gtr:id><gtr:title>Autoimmune hepatitis.</gtr:title><gtr:parentPublicationTitle>Current pediatric reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e548356ff97da703ae8a04a9207d18f"><gtr:id>3e548356ff97da703ae8a04a9207d18f</gtr:id><gtr:otherNames>Longhi MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1573-3963</gtr:issn><gtr:outcomeId>56b488220084f0.17193901</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E4A2F20-9507-4471-84E5-7793CE196E92</gtr:id><gtr:title>The clinical characteristics at diagnosis of type 2 diabetes in a multi-ethnic population: the South London Diabetes cohort (SOUL-D).</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd16fe1b70bbec3e79e6173d27c3f4bc"><gtr:id>cd16fe1b70bbec3e79e6173d27c3f4bc</gtr:id><gtr:otherNames>Winkley K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>doi_13110_013_2873_5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57A9AEC4-15B9-4910-9F09-D0A403A7CAC0</gtr:id><gtr:title>C1 esterase inhibitor reduces lower extremity ischemia/reperfusion injury and associated lung damage.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fbde246de427536ea9e3f889d2a2937"><gtr:id>9fbde246de427536ea9e3f889d2a2937</gtr:id><gtr:otherNames>Duehrkop C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13110_20_23991040</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CD3383B-6614-4C5D-86F3-463274BDD62C</gtr:id><gtr:title>Increased CD40 Ligation and Reduced BCR Signalling Leads to Higher IL-10 Production in B Cells From Tolerant Kidney Transplant Patients.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a852e087195ad0146102a9de3e4ab8b"><gtr:id>4a852e087195ad0146102a9de3e4ab8b</gtr:id><gtr:otherNames>Nova-Lamperti E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>58c6b17ca87eb1.99695103</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA83A1AD-B11F-4907-A1FD-620E37B0D32F</gtr:id><gtr:title>Identification of Haptic Based Guiding Using Hard Reins.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7371b334f477ce33a42d02d26e98c820"><gtr:id>7371b334f477ce33a42d02d26e98c820</gtr:id><gtr:otherNames>Ranasinghe A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56e046a3b62f81.06218603</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41998237-C6BE-4A51-B111-FCC686CF2DFF</gtr:id><gtr:title>O106 : Therapeutic plasma exchange modulates innate immune activation and improves outcome in patients with acute liver failure</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0342018420be2cbe7f9f5ab7010f8eb6"><gtr:id>0342018420be2cbe7f9f5ab7010f8eb6</gtr:id><gtr:otherNames>Bernsmeier C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56dff5de7a3e36.25258865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED989938-8100-44BA-87F5-D7343F5A55D3</gtr:id><gtr:title>A Method to Standardize Quantification of Left Atrial Scar From Delayed-Enhancement MR Images.</gtr:title><gtr:parentPublicationTitle>IEEE journal of translational engineering in health and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec7e887e5a9d035c7a0a0939b3da640f"><gtr:id>ec7e887e5a9d035c7a0a0939b3da640f</gtr:id><gtr:otherNames>Karim R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-2372</gtr:issn><gtr:outcomeId>5457b053620d89.78167790</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76F116E9-4DAB-4D89-9173-26155738B7FA</gtr:id><gtr:title>Complement--tapping into new sites and effector systems.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a788c06853e465636748c7f0ce3e416"><gtr:id>2a788c06853e465636748c7f0ce3e416</gtr:id><gtr:otherNames>Kolev M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>54466576b69666.15325562</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7FC09D2-7457-40DE-9528-401927A80C4C</gtr:id><gtr:title>APT070 (mirococept), a membrane-localizing C3 convertase inhibitor, attenuates early human islet allograft damage in vitro and in vivo in a humanized mouse model.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2a65dd598c0cffda8550314e8f13a61"><gtr:id>a2a65dd598c0cffda8550314e8f13a61</gtr:id><gtr:otherNames>Xiao F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5649bcd7bfe562.89667577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FC7B0BD-5F30-4D32-8D2A-F2C0F5ABA2E2</gtr:id><gtr:title>CD73 expression on extracellular vesicles derived from CD4+ CD25+ Foxp3+ T cells contributes to their regulatory function.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/785928b8c34d6342ea641ff5256e80f7"><gtr:id>785928b8c34d6342ea641ff5256e80f7</gtr:id><gtr:otherNames>Smyth LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_13110_20_23749427</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A7F9666-5A6E-474D-921D-11903F2109AF</gtr:id><gtr:title>Allospecific CD4(+) T cells retain effector function and are actively regulated by Treg cells in the context of transplantation tolerance.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b047cea4dd83f67871c0c8ee567a171f"><gtr:id>b047cea4dd83f67871c0c8ee567a171f</gtr:id><gtr:otherNames>Chai JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>56d5847e7cf750.61805322</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>582E175A-D035-45FE-9445-C99D4EBB6523</gtr:id><gtr:title>C5aR1 promotes acute pyelonephritis induced by uropathogenic E. coli.</gtr:title><gtr:parentPublicationTitle>JCI insight</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ef586f0ee752b9a48fb0607626bbadf"><gtr:id>8ef586f0ee752b9a48fb0607626bbadf</gtr:id><gtr:otherNames>Li K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2379-3708</gtr:issn><gtr:outcomeId>5aa6587ed2b104.88858719</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5715A9FF-39C4-41FB-A908-B0B0A7B68A94</gtr:id><gtr:title>Regulatory T-cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88ce4a32e863de105770d1d6c3b2aab"><gtr:id>f88ce4a32e863de105770d1d6c3b2aab</gtr:id><gtr:otherNames>Liberal R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5a8ed9156c3ff3.01290389</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E40E866D-5400-4656-95FA-46B4C110BC33</gtr:id><gtr:title>Clinical evaluation of respiratory motion compensation for anatomical roadmap guided cardiac electrophysiology procedures.</gtr:title><gtr:parentPublicationTitle>IEEE transactions on bio-medical engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/417d43a7089aa342f399b24e0f14fc1c"><gtr:id>417d43a7089aa342f399b24e0f14fc1c</gtr:id><gtr:otherNames>Ma Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0018-9294</gtr:issn><gtr:outcomeId>doi_13110_11_2168393</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C6B24A6-BC69-470D-9CDF-A71199BB4796</gtr:id><gtr:title>Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4902b2f8a9b6e0c6975bee82a48c1c1a"><gtr:id>4902b2f8a9b6e0c6975bee82a48c1c1a</gtr:id><gtr:otherNames>Chatzigeorgiou A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5458d9605cfac5.48826632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>869C3652-E174-4203-9266-DA8B42B2E599</gtr:id><gtr:title>Capsaicin, resiniferatoxin and botulinum toxin-A - a trip down memory lane.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e046a5dc5fb0.57597952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DED5D457-9891-4AE7-B6D5-C01883398B88</gtr:id><gtr:title>Personalization of cardiac motion and contractility from images using variational data assimilation.</gtr:title><gtr:parentPublicationTitle>IEEE transactions on bio-medical engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f04c43389c197adfba26bd33468e8596"><gtr:id>f04c43389c197adfba26bd33468e8596</gtr:id><gtr:otherNames>Delingette H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0018-9294</gtr:issn><gtr:outcomeId>doi_13110_11_2160347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20EF8862-B7D4-42E6-B5F7-4EF14991965E</gtr:id><gtr:title>The Effect of Visual-Spatial Ability on the Learning of Robot-Assisted Surgical Skills.</gtr:title><gtr:parentPublicationTitle>Journal of surgical education</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4dd71855c8a51b0bdc370fc4c4a747b2"><gtr:id>4dd71855c8a51b0bdc370fc4c4a747b2</gtr:id><gtr:otherNames>Abe T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1878-7452</gtr:issn><gtr:outcomeId>5aa7eeead8c5c8.96929446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB5DFBDB-587A-4A02-8A65-F1280F8C05D7</gtr:id><gtr:title>Role of P-selectin and P-selectin glycoprotein ligand-1 interaction in the induction of tissue factor expression on human platelets after incubation with porcine aortic endothelial cells.</gtr:title><gtr:parentPublicationTitle>Xenotransplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7593586e84d466eee7964296a9687666"><gtr:id>7593586e84d466eee7964296a9687666</gtr:id><gtr:otherNames>Ezzelarab MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0908-665X</gtr:issn><gtr:outcomeId>5675dce36f192</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAD664E8-5AFA-4031-98AB-2EF0679D9618</gtr:id><gtr:title>Kinetics of mast cell migration during transplantation tolerance.</gtr:title><gtr:parentPublicationTitle>Transplant immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a5436362fdb73cf5e61ed8734e207cb"><gtr:id>9a5436362fdb73cf5e61ed8734e207cb</gtr:id><gtr:otherNames>Bond G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0966-3274</gtr:issn><gtr:outcomeId>54578fb5f04c80.93142059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27E08602-7C7D-4CCF-814D-8DE58A70A4FD</gtr:id><gtr:title>Development and implementation of centralized simulation training: evaluation of feasibility, acceptability and construct validity.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b0a5740de37aded168b01fafb1961dd"><gtr:id>5b0a5740de37aded168b01fafb1961dd</gtr:id><gtr:otherNames>Shamim Khan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_13110_20_22928639</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2F8A9C1-E27E-4EE9-BDD9-1B59ED5E4516</gtr:id><gtr:title>The association of pretransplant ferritin level with waiting list and post-transplant survival. Does ferritin actually predict outcome?</gtr:title><gtr:parentPublicationTitle>Transplant international : official journal of the European Society for Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2dbc1f4474065822759b138c5788db0e"><gtr:id>2dbc1f4474065822759b138c5788db0e</gtr:id><gtr:otherNames>Al-Freah MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>5457af08c7cb90.51318309</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94F5463A-52DE-495D-A67D-06F5807E88F9</gtr:id><gtr:title>Cutaneous manifestations of ESRD.</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d78ff5a3f3074010b886cef06621e7e1"><gtr:id>d78ff5a3f3074010b886cef06621e7e1</gtr:id><gtr:otherNames>Galperin TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>pm_13110_20_24115194</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99BB6FD4-6DE8-4633-B4CD-A0AE59D29EA1</gtr:id><gtr:title>Comparing robotic, laparoscopic and open cystectomy: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2e80a52fa191a5882bf93e9a4c48162"><gtr:id>f2e80a52fa191a5882bf93e9a4c48162</gtr:id><gtr:otherNames>Fonseka T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1124-3562</gtr:issn><gtr:outcomeId>56df038720ad03.51907785</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E70EA1AB-BEF0-485C-9608-F88588053F99</gtr:id><gtr:title>Mutation of duffy antigen receptor for chemokines (DARC) as an indicator of prostate cancer severity in Afro-Caribbean men</gtr:title><gtr:parentPublicationTitle>European Urology Supplements</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c16e043f78ae84a85d84c938e59af5c"><gtr:id>7c16e043f78ae84a85d84c938e59af5c</gtr:id><gtr:otherNames>Galustian C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa7ed840c8ae3.41797001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87D1DC85-ECF7-4E5F-AD78-2CFB237B8253</gtr:id><gtr:title>Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56341cc4eefff6abe2e85c94d290f349"><gtr:id>56341cc4eefff6abe2e85c94d290f349</gtr:id><gtr:otherNames>Seymour JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5457aab5967f97.48940025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C27360A9-D4BA-4366-993C-7BB450D6D9F8</gtr:id><gtr:title>Abstract 1175: Interleukin-15 activates NK and CD8 T cells within the Prostate cancer microenvironment by expanding activatory NK cell receptors and attenuating inhibitory HLA ligands on tumor cells</gtr:title><gtr:parentPublicationTitle>Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/007f557df6feb4f08bff6b0f6d857eaa"><gtr:id>007f557df6feb4f08bff6b0f6d857eaa</gtr:id><gtr:otherNames>Sakellariou C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56e04a5b2b5156.64956917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA7AA414-5F53-4CE1-B81D-9A7E83E20CD5</gtr:id><gtr:title>The role of TNF-a in mice with type 1- and 2- diabetes.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e9820dba35d75da368f8ccb50424b81"><gtr:id>7e9820dba35d75da368f8ccb50424b81</gtr:id><gtr:otherNames>Koulmanda M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_13110_ne_0033254</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3C66D05-260B-4E12-93A9-E043894EDC5B</gtr:id><gtr:title>Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome.</gtr:title><gtr:parentPublicationTitle>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee727a3c3c291dd047d431dadbcc59fc"><gtr:id>ee727a3c3c291dd047d431dadbcc59fc</gtr:id><gtr:otherNames>Potter VT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1083-8791</gtr:issn><gtr:outcomeId>5457aab4b50006.19455579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>635E2DBE-C833-4C97-9446-36190842F973</gtr:id><gtr:title>Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1bc530dea0f047a0508cb343a8ec2de"><gtr:id>c1bc530dea0f047a0508cb343a8ec2de</gtr:id><gtr:otherNames>Kasperaviciute D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>doi_13110_ain_awt233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCEEC7EC-9F73-4B17-9E2D-7C2AA041A0DE</gtr:id><gtr:title>Genome-wide association study of obsessive-compulsive disorder.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dcf1f77d2e1df7ff7feb37ded9568a9"><gtr:id>1dcf1f77d2e1df7ff7feb37ded9568a9</gtr:id><gtr:otherNames>Stewart SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>doi_13110_mp_2012_85</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9822060F-220B-427D-85DE-36328C8946F0</gtr:id><gtr:title>Validation of the RobotiX Mentor Robotic Surgery Simulator.</gtr:title><gtr:parentPublicationTitle>Journal of endourology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9a456f048e3a6a280bc40f401c25021"><gtr:id>b9a456f048e3a6a280bc40f401c25021</gtr:id><gtr:otherNames>Whittaker G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0892-7790</gtr:issn><gtr:outcomeId>56dee59c3fb538.83541143</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E4BF0D4-1A87-41FE-9DD7-43B1A2C97AE0</gtr:id><gtr:title>Guidelines for the diagnosis and management of adult myelodysplastic syndromes.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eae682c909e2ede9e072ba471ecfdd6c"><gtr:id>eae682c909e2ede9e072ba471ecfdd6c</gtr:id><gtr:otherNames>Killick SB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>5457aab5155608.76592077</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05F8F142-AC75-4B3F-AC1A-6B2D8C57C53B</gtr:id><gtr:title>Prolonged survival of allogeneic islets in cynomolgus monkeys after short-term triple therapy.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e9820dba35d75da368f8ccb50424b81"><gtr:id>7e9820dba35d75da368f8ccb50424b81</gtr:id><gtr:otherNames>Koulmanda M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>doi_13110_12_03973_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBBC18E8-1530-4162-8D17-6067A6BBAF13</gtr:id><gtr:title>Face, content, and construct validation of the Bristol TURP trainer.</gtr:title><gtr:parentPublicationTitle>Journal of surgical education</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37f7707194fa120d13e01c91cde34b6b"><gtr:id>37f7707194fa120d13e01c91cde34b6b</gtr:id><gtr:otherNames>Brewin J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1878-7452</gtr:issn><gtr:outcomeId>56e047e7ae2b44.70923046</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F176C2E6-4039-4B34-BCA0-4F8E98B6F87F</gtr:id><gtr:title>Conditional analysis identifies three novel major histocompatibility complex loci associated with psoriasis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccf4169893a11ab3549158dd95501784"><gtr:id>ccf4169893a11ab3549158dd95501784</gtr:id><gtr:otherNames>Knight J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>doi_13110_hmg_dds344</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5639CC02-9914-4FC3-9E98-10FC3ABE870B</gtr:id><gtr:title>Genes and podocytes - new insights into mechanisms of podocytopathy.</gtr:title><gtr:parentPublicationTitle>Frontiers in endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82e4ce55ad0283b97d594815711ee232"><gtr:id>82e4ce55ad0283b97d594815711ee232</gtr:id><gtr:otherNames>Bierzynska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-2392</gtr:issn><gtr:outcomeId>56e006525c3b42.18895936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE23BE8E-3962-4CE8-93F6-59130A742C54</gtr:id><gtr:title>Future of robotic surgery in urology.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0851354012a8b3401603e376dc0a18f"><gtr:id>e0851354012a8b3401603e376dc0a18f</gtr:id><gtr:otherNames>Rassweiler JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>5aa7f0951e1324.53174399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>636664DF-9789-4D91-B2FF-DCAF8CE274FC</gtr:id><gtr:title>Immunological pathways to ?-cell damage in Type&amp;nbsp;1 diabetes.</gtr:title><gtr:parentPublicationTitle>Diabetic medicine : a journal of the British Diabetic Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34a354990b6bc6570b16443e889610ba"><gtr:id>34a354990b6bc6570b16443e889610ba</gtr:id><gtr:otherNames>Peakman M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0742-3071</gtr:issn><gtr:outcomeId>doi_13110__dme_12085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D65AED2F-1801-42BF-8177-92B452D7FD70</gtr:id><gtr:title>Painful bladder syndrome/interstitial cystitis: aetiology, evaluation and management.</gtr:title><gtr:parentPublicationTitle>Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11124ffc1567710d6658831a99dd36ab"><gtr:id>11124ffc1567710d6658831a99dd36ab</gtr:id><gtr:otherNames>Rourke W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1124-3562</gtr:issn><gtr:outcomeId>56e047e73efeb3.94682074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>463E08C3-B158-4E88-8344-D9E0F1592E61</gtr:id><gtr:title>A mathematical model for mechanotransduction at the early steps of suture formation.</gtr:title><gtr:parentPublicationTitle>Proceedings. Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53ebda0ef1d5f34531df76cc3306c305"><gtr:id>53ebda0ef1d5f34531df76cc3306c305</gtr:id><gtr:otherNames>Khonsari RH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0962-8452</gtr:issn><gtr:outcomeId>doi_13110__2012_2670</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14FAE5A3-978C-4CC0-B923-17E234BB7BEF</gtr:id><gtr:title>A U-shaped type II contraction pattern in patients with strict left bundle branch block predicts super-response to cardiac resynchronization therapy.</gtr:title><gtr:parentPublicationTitle>Heart rhythm</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41937a03fd039b41feeaa680c60f6824"><gtr:id>41937a03fd039b41feeaa680c60f6824</gtr:id><gtr:otherNames>Jackson T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1547-5271</gtr:issn><gtr:outcomeId>5457b054c81626.82194428</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E8CEBE3-79EC-41A3-BE5C-5D1B76F86537</gtr:id><gtr:title>Guideline of guidelines.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e046a91c3965.08251495</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A980B42D-D9E5-4589-924F-A4F3DA9AC197</gtr:id><gtr:title>Podcasts made simple.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_13110_20_23444924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A107025-9C33-4C44-84D5-25DAB8C4A88E</gtr:id><gtr:title>Perioperative outcomes of 6042 nephrectomies in 2012: surgeon-reported results in the UK from the British Association of Urological Surgeons (BAUS) nephrectomy database.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72ce3a5e9fc41054c74c1b54418c8f2f"><gtr:id>72ce3a5e9fc41054c74c1b54418c8f2f</gtr:id><gtr:otherNames>Henderson JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e047e7ceca15.50059273</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4C01038-59F6-480B-BB8F-AF479E279BE3</gtr:id><gtr:title>Contemporary practice and technique-related outcomes for radical prostatectomy in the UK: a report of national outcomes.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34f346386c513bb4933b76fee2a584d9"><gtr:id>34f346386c513bb4933b76fee2a584d9</gtr:id><gtr:otherNames>Laird A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e047e6f2f058.17464876</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EF5C8BC-EE36-41D2-BC2F-A50B9B004137</gtr:id><gtr:title>The mechanistic basis for psoriasis immunopathogenesis: translating genotype to phenotype. Report of a workshop, Venice, 2012.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71b18059248a76ceeb0a9d1716bbc0e3"><gtr:id>71b18059248a76ceeb0a9d1716bbc0e3</gtr:id><gtr:otherNames>Bachelez H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>doi_13110__bjd_12347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEE4349F-9418-4AEB-B41F-19A88BD10565</gtr:id><gtr:title>Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling.</gtr:title><gtr:parentPublicationTitle>Cell death discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80404e8d80b50345edfbea7637454854"><gtr:id>80404e8d80b50345edfbea7637454854</gtr:id><gtr:otherNames>Tsai MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2058-7716</gtr:issn><gtr:outcomeId>56b1c37ed3aba6.54510549</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7AB4826-0A0B-4C89-BE4A-0680092678B5</gtr:id><gtr:title>Insights into TREM2 biology by network analysis of human brain gene expression data.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05229e5e9f0a501fa7e63a396d570040"><gtr:id>05229e5e9f0a501fa7e63a396d570040</gtr:id><gtr:otherNames>Forabosco P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>doi_13110_013_05_001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0814C0B7-6F44-4DC3-A038-9B4A678EA68D</gtr:id><gtr:title>Peripheral phenotype and gene expression profiles of combined liver-kidney transplant patients.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82be4209e0074fbacedfe683e20e1e22"><gtr:id>82be4209e0074fbacedfe683e20e1e22</gtr:id><gtr:otherNames>Dumontet E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>56debcfce9b3c0.22516233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B011E0EF-65F2-4F70-A5D6-E74ADE0D4660</gtr:id><gtr:title>Can we vaccinate against Type 1 diabetes?</gtr:title><gtr:parentPublicationTitle>F1000 biology reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34a354990b6bc6570b16443e889610ba"><gtr:id>34a354990b6bc6570b16443e889610ba</gtr:id><gtr:otherNames>Peakman M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1757-594X</gtr:issn><gtr:outcomeId>doi_13110_3410_B4_19</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41AA7FA8-556A-433E-B89B-040A31390A09</gtr:id><gtr:title>Permissivity of primary hepatocytes and hepatoma cell lines to support hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a7463d1f8fa86587b5c95fd20445a75"><gtr:id>1a7463d1f8fa86587b5c95fd20445a75</gtr:id><gtr:otherNames>Wilson GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>56def9abb53019.01646454</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>890D4943-1AF9-4602-97DE-DDFECC45B876</gtr:id><gtr:title>Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A review.</gtr:title><gtr:parentPublicationTitle>Oncoimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95b3edcac0bca152dc2b77a37f322c70"><gtr:id>95b3edcac0bca152dc2b77a37f322c70</gtr:id><gtr:otherNames>Nayar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2162-4011</gtr:issn><gtr:outcomeId>56e04aae8afd35.13271792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BFE8F84-474E-4677-B1A1-21128BA8664C</gtr:id><gtr:title>What Is Direct Allorecognition?</gtr:title><gtr:parentPublicationTitle>Current transplantation reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7a487776927702f0e2714d73f629af4"><gtr:id>c7a487776927702f0e2714d73f629af4</gtr:id><gtr:otherNames>Boardman DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58c6b17a86b889.01559261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4257DD4-B63F-4E57-83F2-1F8D97C5B1CA</gtr:id><gtr:title>Partial-volume effect and a partial-volume correction for the NanoPET/CT? preclinical PET/CT scanner</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3560639b065b63a76e1c9057b6292f20"><gtr:id>3560639b065b63a76e1c9057b6292f20</gtr:id><gtr:otherNames>Szanda I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:isbn>978-1-4673-0118-3</gtr:isbn><gtr:outcomeId>doi_13110_11_6153678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>656555FC-9229-4D85-B063-FF487A8C4A4C</gtr:id><gtr:title>CD46: the 'multitasker' of complement proteins.</gtr:title><gtr:parentPublicationTitle>The international journal of biochemistry &amp; cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43405bdee47846dd21c53267cfab3fd4"><gtr:id>43405bdee47846dd21c53267cfab3fd4</gtr:id><gtr:otherNames>Yamamoto H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1357-2725</gtr:issn><gtr:outcomeId>pm_13110_20_24120647</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>062BD0B5-7163-40B7-9CB0-37258240757C</gtr:id><gtr:title>Analysis of European case-control studies suggests that common inherited variation in mitochondrial DNA is not involved in susceptibility to amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17620dcb0e8d0e59a277bf4f26d4321d"><gtr:id>17620dcb0e8d0e59a277bf4f26d4321d</gtr:id><gtr:otherNames>Ingram CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1471-180X</gtr:issn><gtr:outcomeId>doi_13110_012_654394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52FBA4A0-C5A6-4AAB-BA21-34BF0C74BE76</gtr:id><gtr:title>Clinically significant peripancreatic fluid collections after simultaneous pancreas-kidney transplantation.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f30366d799d746e37175db2afcd1a5d"><gtr:id>2f30366d799d746e37175db2afcd1a5d</gtr:id><gtr:otherNames>Singh RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>544a65935b48d0.69952172</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A417E92-A0B4-4B2B-91C2-747C2CC1B31B</gtr:id><gtr:title>G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bba53bbcc79344baf43824ac1ffb0c19"><gtr:id>bba53bbcc79344baf43824ac1ffb0c19</gtr:id><gtr:otherNames>Munir S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>56e00472219cf8.89618788</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDB6AFDE-2EFD-4692-B44E-7E6473DB4DD2</gtr:id><gtr:title>Inferring separate parental admixture components in unknown DNA samples using autosomal SNPs.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca3d189572208b68949404b00fe09c8f"><gtr:id>ca3d189572208b68949404b00fe09c8f</gtr:id><gtr:otherNames>Crouch DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>doi_13110_g_2012_134</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9FA5F2B-A44C-49D3-8ABB-27CE057AB10C</gtr:id><gtr:title>The variable course of women with X-linked Alport Syndrome.</gtr:title><gtr:parentPublicationTitle>Clinical kidney journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d40b22dd4cfc2356cb939322afdedb49"><gtr:id>d40b22dd4cfc2356cb939322afdedb49</gtr:id><gtr:otherNames>Raju P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2048-8505</gtr:issn><gtr:outcomeId>doi_13110_ckj_sfs021</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1788AA4-DC66-4FB5-9BD1-1B53699F94F6</gtr:id><gtr:title>Increased Fluid Administration After Early Acute Kidney Injury is Associated with Less Renal Recovery.</gtr:title><gtr:parentPublicationTitle>Shock (Augusta, Ga.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d635bdfb4fdcdfe91adfa4598b8d0b18"><gtr:id>d635bdfb4fdcdfe91adfa4598b8d0b18</gtr:id><gtr:otherNames>Raimundo M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-2322</gtr:issn><gtr:outcomeId>56dee59c8d6837.98091991</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>867ECA91-5DCD-4AE4-8FC8-E56798591547</gtr:id><gtr:title>An integrated platform for image-guided cardiac resynchronization therapy.</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f4295deb1b9aa0d8f7c9e9781140361"><gtr:id>2f4295deb1b9aa0d8f7c9e9781140361</gtr:id><gtr:otherNames>Ma YL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn><gtr:outcomeId>doi_13110_57_10_2953</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA47A3C8-E6CA-4ED7-91FF-23BAA85224A2</gtr:id><gtr:title>Phenotypic Complexity of the Human Regulatory T Cell Compartment Revealed by Mass Cytometry.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be4eba9249e5210879c5ba825b58c879"><gtr:id>be4eba9249e5210879c5ba825b58c879</gtr:id><gtr:otherNames>Mason GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5675e98781325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDB25821-0BC2-4BEC-A68E-435D0758DBFB</gtr:id><gtr:title>Optimising long-term graft survival: establishing the benefit of targeting B lymphocytes.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25ee74e60fac27a1dbf2c03b22f0cff8"><gtr:id>25ee74e60fac27a1dbf2c03b22f0cff8</gtr:id><gtr:otherNames>Shiu KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>54818cd6c011b5.32369030</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6A24E70-6FC7-41F7-8273-D8B720DCD964</gtr:id><gtr:title>A tribute to Dr. William D. Steers, 1955-2015.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e046a4d450d9.52493929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF971128-0B91-41E2-A0E4-28A7D92873BA</gtr:id><gtr:title>A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7d47577f7750080fa8e99dbca26188f"><gtr:id>b7d47577f7750080fa8e99dbca26188f</gtr:id><gtr:otherNames>Sunter NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>doi_13110__04_349803</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB2BA55F-9320-4DDA-9E29-457CBF5105E0</gtr:id><gtr:title>Regulatory T cells: tolerance induction in solid organ transplantation.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e40ea6a39fae2baf5393f722dd9d371"><gtr:id>3e40ea6a39fae2baf5393f722dd9d371</gtr:id><gtr:otherNames>Vaikunthanathan T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>5a900e327cb702.40512567</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E590592A-B96A-461A-B9E6-890E0DCB91BF</gtr:id><gtr:title>Multi-fingered haptic palpation utilizing granular jamming stiffness feedback actuators</gtr:title><gtr:parentPublicationTitle>Smart Materials and Structures</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00fdefe91ff283a2134de1284108f187"><gtr:id>00fdefe91ff283a2134de1284108f187</gtr:id><gtr:otherNames>Li M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54579d2c307e05.83785137</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8262E40E-DE65-4E60-B9D4-458511AECF21</gtr:id><gtr:title>Personalization of a cardiac electromechanical model using reduced order unscented Kalman filtering from regional volumes.</gtr:title><gtr:parentPublicationTitle>Medical image analysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f207ced458c8e8ec7ca31d0412a4490b"><gtr:id>f207ced458c8e8ec7ca31d0412a4490b</gtr:id><gtr:otherNames>Marchesseau S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1361-8415</gtr:issn><gtr:outcomeId>5457b051687f90.25895574</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A37396B1-6CD2-4C8F-A5D9-FB9993EA0B71</gtr:id><gtr:title>Transitional-2 B cells acquire regulatory function during tolerance induction and contribute to allograft survival.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d30928ec0a7fef502fb775cd100bb5b8"><gtr:id>d30928ec0a7fef502fb775cd100bb5b8</gtr:id><gtr:otherNames>Moreau A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>5458efcb966595.32774673</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74BCB82B-863C-4524-99EB-C356ADC5AA58</gtr:id><gtr:title>Sialoadhesin - a macrophage-restricted marker of immunoregulation and inflammation.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/243fe4d0f38d033944707f60bc39af22"><gtr:id>243fe4d0f38d033944707f60bc39af22</gtr:id><gtr:otherNames>O'Neill AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>pm_13110_20_23181380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2C615B4-12BC-4F01-9A3A-1F753084F1BE</gtr:id><gtr:title>Motivations, outcomes, and characteristics of unspecified (nondirected altruistic) kidney donors in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/378eac94fd7f33302738833ca4cb3e14"><gtr:id>378eac94fd7f33302738833ca4cb3e14</gtr:id><gtr:otherNames>Maple H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>544a6591e85357.03752656</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E0C5235-3093-4E7F-8B2C-C82F07811FDA</gtr:id><gtr:title>T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78ce7ce6c34651c317706ca694dff341"><gtr:id>78ce7ce6c34651c317706ca694dff341</gtr:id><gtr:otherNames>Kanhere A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>doi_13110_ncomms2260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B480D8C-98E8-4E86-AAD9-C7C226371DAD</gtr:id><gtr:title>Management of acute rejection in paediatric liver transplantation.</gtr:title><gtr:parentPublicationTitle>Paediatric drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9aaa332729f5e0b66bed84ba90757b2a"><gtr:id>9aaa332729f5e0b66bed84ba90757b2a</gtr:id><gtr:otherNames>Thangarajah D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1174-5878</gtr:issn><gtr:outcomeId>54579b722a4108.46316866</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCB9239D-C67F-4589-9E86-0FD6A4466810</gtr:id><gtr:title>Monitoring the efficacy of dendritic cell vaccination by early detection of (99m) Tc-HMPAO-labelled CD4(+) T&amp;nbsp;cells.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fb958eb3535e59307e26530390bd12c"><gtr:id>2fb958eb3535e59307e26530390bd12c</gtr:id><gtr:otherNames>Sharif-Paghaleh E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>543b98d8c33597.35913563</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6667B2BD-9156-4C15-8E9E-5AEC6B877032</gtr:id><gtr:title>Oxford Textbook of Clinical Nephrology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d21ae7bdd9c93b0842383793af69062"><gtr:id>1d21ae7bdd9c93b0842383793af69062</gtr:id><gtr:otherNames>Galperin T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>XuHRoDMvD4H</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C51A0AB3-3BC1-460C-8C8C-CBB96327989F</gtr:id><gtr:title>Myocardial perfusion distribution and coronary arterial pressure and flow signals: clinical relevance in relation to multiscale modeling, a review.</gtr:title><gtr:parentPublicationTitle>Medical &amp; biological engineering &amp; computing</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a5faa4a0c7a85722be9c184be6f37af"><gtr:id>2a5faa4a0c7a85722be9c184be6f37af</gtr:id><gtr:otherNames>Nolte F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-0118</gtr:issn><gtr:outcomeId>5457b051df8182.49094381</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00C7560F-3AFB-4AC9-B06C-A0129D50B0D1</gtr:id><gtr:title>Behavioral characteristics of manual palpation to localize hard nodules in soft tissues.</gtr:title><gtr:parentPublicationTitle>IEEE transactions on bio-medical engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d320a00583e103a9a59efcd91d10f57"><gtr:id>0d320a00583e103a9a59efcd91d10f57</gtr:id><gtr:otherNames>Konstantinova J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0018-9294</gtr:issn><gtr:outcomeId>54579d2dc9f943.42514363</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB39E9DD-0918-4531-BAC7-A05B492C088F</gtr:id><gtr:title>B-lymphocytes support and regulate indirect T-cell alloreactivity in individual patients with chronic antibody-mediated rejection.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25ee74e60fac27a1dbf2c03b22f0cff8"><gtr:id>25ee74e60fac27a1dbf2c03b22f0cff8</gtr:id><gtr:otherNames>Shiu KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>551ee8d2f3ef22.29914698</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E5BDA9A-AD39-4103-B92F-5BD7885908B6</gtr:id><gtr:title>Recurrent urinary tract infections in women.</gtr:title><gtr:parentPublicationTitle>International urogynecology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d56aff527715c429c6f28b0fc7d2c3e1"><gtr:id>d56aff527715c429c6f28b0fc7d2c3e1</gtr:id><gtr:otherNames>Aydin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0937-3462</gtr:issn><gtr:outcomeId>56e046a8614b36.90106912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8E584B0-438D-4F5A-A1EC-36143C2858E4</gtr:id><gtr:title>The Relationship Between Technical And Nontechnical Skills Within A Simulation-Based Ureteroscopy Training Environment.</gtr:title><gtr:parentPublicationTitle>Journal of surgical education</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebc4da9c11d432d58cf3f380b3c63dc5"><gtr:id>ebc4da9c11d432d58cf3f380b3c63dc5</gtr:id><gtr:otherNames>Brunckhorst O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1878-7452</gtr:issn><gtr:outcomeId>5675e4958cc8f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>203F6ADB-3A4F-45DB-AC5C-014B07462FF0</gtr:id><gtr:title>Transplantation tolerance.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4577267b4ebb1f1bc3c7f0e5c1dbae96"><gtr:id>4577267b4ebb1f1bc3c7f0e5c1dbae96</gtr:id><gtr:otherNames>Salisbury EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>56e00471c623f1.83050540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80AC8159-D05C-4AB0-BCFB-75256B556FAF</gtr:id><gtr:title>Acute alcoholic hepatitis and cellular Th1 immune responses to alcohol dehydrogenase.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72ea486058ab809e44864f0c14372d64"><gtr:id>72ea486058ab809e44864f0c14372d64</gtr:id><gtr:otherNames>Blackmore LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56dff8185f9b33.46255958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5238760-E2BB-4BD5-8F7C-DD170B978DEC</gtr:id><gtr:title>Aristolochic acid nephropathy.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b056ebd525a3f82e22b1c43010afc913"><gtr:id>b056ebd525a3f82e22b1c43010afc913</gtr:id><gtr:otherNames>G?kmen MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>doi_13110__bmj_e4000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7905968-D35B-4E11-BAF9-5D778970CBF4</gtr:id><gtr:title>Novel role for matricellular proteins in the regulation of islet ? cell survival: the effect of SPARC on survival, proliferation, and signaling.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73fef5f6f22bbcb7b054ef59c74cab30"><gtr:id>73fef5f6f22bbcb7b054ef59c74cab30</gtr:id><gtr:otherNames>Ryall CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>56e00703c17870.63530941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35C07887-334F-4A36-B199-04D3B1F45D33</gtr:id><gtr:title>Engaging responsibly with social media: the BJUI guidelines.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1071542ecff32da4742fd8971c76b00a"><gtr:id>1071542ecff32da4742fd8971c76b00a</gtr:id><gtr:otherNames>Murphy DG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>54579d2e48d119.57246678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0FA2294-1B8B-494A-A10A-8A8A8D55B02B</gtr:id><gtr:title>Genome-wide regulatory analysis reveals that T-bet controls Th17 lineage differentiation through direct suppression of IRF4.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b056ebd525a3f82e22b1c43010afc913"><gtr:id>b056ebd525a3f82e22b1c43010afc913</gtr:id><gtr:otherNames>G?kmen MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>545251d6ca7ee3.01240075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDC3F2DD-44A7-4427-8872-21471BFEEE27</gtr:id><gtr:title>Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.</gtr:title><gtr:parentPublicationTitle>Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb9e60a537fb36a5280198d63c2749f7"><gtr:id>fb9e60a537fb36a5280198d63c2749f7</gtr:id><gtr:otherNames>Giagounidis A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0008-543X</gtr:issn><gtr:outcomeId>5457aab5ba71d1.59896946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23E92EE9-53F4-4F4B-ACFA-81344D770B8A</gtr:id><gtr:title>A review of the available urology skills training curricula and their validation.</gtr:title><gtr:parentPublicationTitle>Journal of surgical education</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a42221cbbeb6e47fddc8ad97c305d9cb"><gtr:id>a42221cbbeb6e47fddc8ad97c305d9cb</gtr:id><gtr:otherNames>Shepherd W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1878-7452</gtr:issn><gtr:outcomeId>54579d2da6fcc3.42643799</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51BEACCE-8CC7-496F-AC95-B0F8FFC56DAD</gtr:id><gtr:title>Multicenter evaluation of a standardized protocol for noninvasive gene expression profiling.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2a4c87afcedcdfacd62b4cacc594da3"><gtr:id>e2a4c87afcedcdfacd62b4cacc594da3</gtr:id><gtr:otherNames>Keslar KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>doi_13110__ajt_12284</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBEE63AF-DEDD-48F8-83D3-FB33983CD120</gtr:id><gtr:title>Beyond our wildest dreams.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>54579d2b77c298.48600997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7CB367B-9C26-4C07-916D-3294C581967F</gtr:id><gtr:title>Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.</gtr:title><gtr:parentPublicationTitle>Annals of hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb9e60a537fb36a5280198d63c2749f7"><gtr:id>fb9e60a537fb36a5280198d63c2749f7</gtr:id><gtr:otherNames>Giagounidis A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0939-5555</gtr:issn><gtr:outcomeId>5457aab4dd4640.38020981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C853A7B-096D-485B-8E55-AA6BA120F3CA</gtr:id><gtr:title>Quality has no boundaries.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>54579d2d0ff320.66442682</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AC5842B-2DBF-496C-9C75-3E9BAD0B5687</gtr:id><gtr:title>Whole-body imaging of adoptively transferred T cells using magnetic resonance imaging, single photon emission computed tomography and positron emission tomography techniques, with a focus on regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1895b9e88e0dad902266a1805b47a743"><gtr:id>1895b9e88e0dad902266a1805b47a743</gtr:id><gtr:otherNames>Leech JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>pm_13110_20_23574314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E374D60-69F0-4D78-B339-8D7A3645D368</gtr:id><gtr:title>Stress predicts the trajectory of wound healing in living kidney donors as measured by high-resolution ultrasound.</gtr:title><gtr:parentPublicationTitle>Brain, behavior, and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/378eac94fd7f33302738833ca4cb3e14"><gtr:id>378eac94fd7f33302738833ca4cb3e14</gtr:id><gtr:otherNames>Maple H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0889-1591</gtr:issn><gtr:outcomeId>544a659223a218.51875810</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>530E5CF8-BCF2-4605-B999-E213393A700B</gtr:id><gtr:title>Understanding the need of ventricular pressure for the estimation of diastolic biomarkers.</gtr:title><gtr:parentPublicationTitle>Biomechanics and modeling in mechanobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cf655951c3ee15b532584d9bdc2de65"><gtr:id>2cf655951c3ee15b532584d9bdc2de65</gtr:id><gtr:otherNames>Xi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1617-7940</gtr:issn><gtr:outcomeId>5457b0547b1f65.95822908</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62327F44-B6F4-4B4C-A644-44B0C7BC55A7</gtr:id><gtr:title>Redesigning an intensive insulin service for patients with type 1 diabetes: a patient consultation exercise.</gtr:title><gtr:parentPublicationTitle>Patient preference and adherence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4826ab4698623fa53ac015e4b2b61367"><gtr:id>4826ab4698623fa53ac015e4b2b61367</gtr:id><gtr:otherNames>Ozcan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1177-889X</gtr:issn><gtr:outcomeId>doi_13110_PPA_S43338</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD8907B1-60FD-4619-AF68-642BC451B761</gtr:id><gtr:title>Higher dose dobutamine stress MR imaging in repaired Tetralogy of Fallot: observer variance of volumetric assessment compared with normal volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of magnetic resonance imaging : JMRI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09ba51c0443ac9e2c430792d03fa7d67"><gtr:id>09ba51c0443ac9e2c430792d03fa7d67</gtr:id><gtr:otherNames>Parish V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1053-1807</gtr:issn><gtr:outcomeId>5457b0520f8a33.06025910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4BC5415-17F7-4C31-A7D7-B93942B49519</gtr:id><gtr:title>Investigating the utility of human embryonic stem cell-derived neurons to model ageing and neurodegenerative disease using whole-genome gene expression and splicing analysis.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bf41e3616627e43c288596e8b1c932e"><gtr:id>7bf41e3616627e43c288596e8b1c932e</gtr:id><gtr:otherNames>Patani R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>doi_13110_12_07825_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>969CB787-C3D6-4D17-841E-43367F27BBC5</gtr:id><gtr:title>Laparoscopic peritoneal dialysis catheter (PDC) insertion: does it really make a difference?</gtr:title><gtr:parentPublicationTitle>Journal of nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30bf2525ccb62f647d6e51cfb911a3a4"><gtr:id>30bf2525ccb62f647d6e51cfb911a3a4</gtr:id><gtr:otherNames>Bagul A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1121-8428</gtr:issn><gtr:outcomeId>544a659289e0a2.74179320</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2A0E076-73C7-48E7-B0FB-254337834BF9</gtr:id><gtr:title>Wnt signaling regulates pulp volume and dentin thickness.</gtr:title><gtr:parentPublicationTitle>Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/458193cab1cd024212c1e658494d7030"><gtr:id>458193cab1cd024212c1e658494d7030</gtr:id><gtr:otherNames>Lim WH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0884-0431</gtr:issn><gtr:outcomeId>5457a95e964bc4.45946639</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45CE53CD-ACCC-4F61-BDC1-EC39B4B308A2</gtr:id><gtr:title>Patient explanations for non-attendance at structured diabetes education sessions for newly diagnosed Type 2 diabetes: a qualitative study.</gtr:title><gtr:parentPublicationTitle>Diabetic medicine : a journal of the British Diabetic Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd16fe1b70bbec3e79e6173d27c3f4bc"><gtr:id>cd16fe1b70bbec3e79e6173d27c3f4bc</gtr:id><gtr:otherNames>Winkley K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0742-3071</gtr:issn><gtr:outcomeId>54579ae2b94874.43312615</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC30D0E0-C986-4DDF-8611-9F06C70C4E44</gtr:id><gtr:title>Safely targeting autoimmunity in type 1 diabetes: the MonoPepT1De trial</gtr:title><gtr:parentPublicationTitle>Practical Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7c92a675b6502a97a707b04cca69bc1"><gtr:id>d7c92a675b6502a97a707b04cca69bc1</gtr:id><gtr:otherNames>Liu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_13110_2_pdi_1764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>862CB75A-0783-420E-8382-4E6A40BF34C1</gtr:id><gtr:title>Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00223d0cb2f2c2b62ce0eb3ce2a48d21"><gtr:id>00223d0cb2f2c2b62ce0eb3ce2a48d21</gtr:id><gtr:otherNames>Craddock C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn><gtr:outcomeId>doi_13110_u_2012_312</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAF8C55E-0539-4257-8177-0ADDAD4175EB</gtr:id><gtr:title>Humanised mice have functional human neutrophils.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/225398404f1cd0c804bbb1623de3f6f6"><gtr:id>225398404f1cd0c804bbb1623de3f6f6</gtr:id><gtr:otherNames>Coughlan AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>pm_13110_20_22917930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCE8288D-E55F-497A-B603-C84E7014D1EB</gtr:id><gtr:title>Simulation-based training for prostate surgery.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14bc1ac6eea0328f343aef5b9f6dd0f0"><gtr:id>14bc1ac6eea0328f343aef5b9f6dd0f0</gtr:id><gtr:otherNames>Khan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e047e86ccdb4.99322814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2107FC1B-6300-4E83-9E5E-584568ABE291</gtr:id><gtr:title>Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4806f388a6961ee20bcba772f6355d4a"><gtr:id>4806f388a6961ee20bcba772f6355d4a</gtr:id><gtr:otherNames>Bench AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>doi_13110__bjh_12075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6DE8995-2741-4962-AE81-4477CC1D05EE</gtr:id><gtr:title>Surgery: protecting patients during live urological surgery.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2df6cf0e44bda3035674f81d473ebf19"><gtr:id>2df6cf0e44bda3035674f81d473ebf19</gtr:id><gtr:otherNames>Brown M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>56e047e8486469.41541138</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A2EF5CF-4E98-487F-AAC4-2D3FE5B73046</gtr:id><gtr:title>Comparison of depressive symptoms in type 2 diabetes using a two-stage survey design.</gtr:title><gtr:parentPublicationTitle>Psychosomatic medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc8dc5cb2936eccac91b1ef9adab4bbd"><gtr:id>fc8dc5cb2936eccac91b1ef9adab4bbd</gtr:id><gtr:otherNames>Twist K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0033-3174</gtr:issn><gtr:outcomeId>ZeSh4rRJTTj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F048713-B205-46D5-A274-FF0C8E794A59</gtr:id><gtr:title>Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f4afb4ec16786a3c60ea078283f7b17"><gtr:id>9f4afb4ec16786a3c60ea078283f7b17</gtr:id><gtr:otherNames>Aziz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>doi_13110_2_JCI66113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03B80F16-21E7-4F71-B6A8-4C9913B0877F</gtr:id><gtr:title>Licenced to transplant: UK overkill on EU Organ Directive provides golden opportunity for research.</gtr:title><gtr:parentPublicationTitle>Journal of medical ethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d43b0f505fe6b34fb772ce661e3daa0"><gtr:id>4d43b0f505fe6b34fb772ce661e3daa0</gtr:id><gtr:otherNames>Cronin AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0306-6800</gtr:issn><gtr:outcomeId>MbTnY7c98zM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4AFF551-2C2E-44C4-BA1C-D4052EC1C9EE</gtr:id><gtr:title>Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d70f5cc6d40ffce9e6d61932eb5394a6"><gtr:id>d70f5cc6d40ffce9e6d61932eb5394a6</gtr:id><gtr:otherNames>Malde S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e046a6e10622.48688445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>901C9F4D-6996-4CCC-8865-B42BE82A2A16</gtr:id><gtr:title>Toward prediction of immune mechanisms and design of immunotherapies in melanoma.</gtr:title><gtr:parentPublicationTitle>Critical reviews in biomedical engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cbbd22b96b2dc222d62c6279db79e80"><gtr:id>8cbbd22b96b2dc222d62c6279db79e80</gtr:id><gtr:otherNames>Tsoka S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0278-940X</gtr:issn><gtr:outcomeId>pm_13110_20_23140120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F244638E-401B-4F43-B0A3-8E68983424E7</gtr:id><gtr:title>Teamwork Assessment Tools in Modern Surgical Practice: A Systematic Review.</gtr:title><gtr:parentPublicationTitle>Surgery research and practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9a456f048e3a6a280bc40f401c25021"><gtr:id>b9a456f048e3a6a280bc40f401c25021</gtr:id><gtr:otherNames>Whittaker G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2356-6124</gtr:issn><gtr:outcomeId>56e0450ba13b06.26519644</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C503004B-1195-4C8E-8510-9D52F2361AF0</gtr:id><gtr:title>Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97cdb892bd28119895c5dee797659702"><gtr:id>97cdb892bd28119895c5dee797659702</gtr:id><gtr:otherNames>Galleu A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>5a900907e20542.13877548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1675B95C-794F-4FD8-85F1-3886DDCC17B4</gtr:id><gtr:title>Learning from The Lancet.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e046a507c543.81295147</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75BAF5DC-25EE-4933-99F1-D96DD5FD2884</gtr:id><gtr:title>Effector-memory T cells develop in islets and report islet pathology in type 1 diabetes.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ab5f31c06210e007b2edfb35d5bc398"><gtr:id>9ab5f31c06210e007b2edfb35d5bc398</gtr:id><gtr:otherNames>Chee J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5457ad08220a98.12242224</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D8A9FEB-C99A-4284-855F-AF12E4008AAA</gtr:id><gtr:title>The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2eb21ae7e7cf1fa8052620cc52375586"><gtr:id>2eb21ae7e7cf1fa8052620cc52375586</gtr:id><gtr:otherNames>Breen KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>doi_13110_11_08922_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73614F5E-AF49-4C5A-AFBB-D1054AC817EF</gtr:id><gtr:title>Training, assessment and accreditation in surgery.</gtr:title><gtr:parentPublicationTitle>Postgraduate medical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d56aff527715c429c6f28b0fc7d2c3e1"><gtr:id>d56aff527715c429c6f28b0fc7d2c3e1</gtr:id><gtr:otherNames>Aydin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0032-5473</gtr:issn><gtr:outcomeId>5aa7efbd954496.40113930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38CCF764-4115-4518-94D1-87DEE32202E8</gtr:id><gtr:title>Detection of cell membrane-bound CD46 using flow cytometry.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a788c06853e465636748c7f0ce3e416"><gtr:id>2a788c06853e465636748c7f0ce3e416</gtr:id><gtr:otherNames>Kolev M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>978-1-62703-723-5</gtr:isbn><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>544653ae52ebd9.17152691</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F029122C-06A3-4C72-BCCB-AC36DAACDCBD</gtr:id><gtr:title>A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68ae0b5920edebc0579f77ebe7ddbb4e"><gtr:id>68ae0b5920edebc0579f77ebe7ddbb4e</gtr:id><gtr:otherNames>Fogh I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5457ac9f16e971.35318178</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41ACF8CA-8964-4427-BC79-3E86BA6E4C44</gtr:id><gtr:title>Current status of validation for robotic surgery simulators - a systematic review.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd0938c60157f1301ed3eb8e647339c7"><gtr:id>fd0938c60157f1301ed3eb8e647339c7</gtr:id><gtr:otherNames>Abboudi H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_13110_20_22672340</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1C3613E-B6DC-453E-838F-C5990E31CFB9</gtr:id><gtr:title>Three-dimensional late gadolinium-enhanced MR imaging of the left atrium: a comparison of spiral versus Cartesian k-space trajectories.</gtr:title><gtr:parentPublicationTitle>Journal of magnetic resonance imaging : JMRI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f22f54496ae2d0c01f36e42f3dbfa348"><gtr:id>f22f54496ae2d0c01f36e42f3dbfa348</gtr:id><gtr:otherNames>Knowles BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1053-1807</gtr:issn><gtr:outcomeId>5457b052aea9e9.73764176</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>586A2BB4-8F12-4AD6-BD95-B289DC791B65</gtr:id><gtr:title>Critical role for all-trans retinoic acid for optimal effector and effector memory CD8 T cell differentiation.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d862df29bfe1335deda4f8b201d7e620"><gtr:id>d862df29bfe1335deda4f8b201d7e620</gtr:id><gtr:otherNames>Allie SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>doi_13110_ol_1201945</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AC9B488-90BF-4318-B6EA-A13BA0C7D3F9</gtr:id><gtr:title>Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54a4658ef858b411d66e115aaf52aba8"><gtr:id>54a4658ef858b411d66e115aaf52aba8</gtr:id><gtr:otherNames>Tsoi LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>doi_13110_38_ng_2467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2ABC023-505F-43B7-9753-DA5F96A8AF9D</gtr:id><gtr:title>Should we retransplant a patient who is non-adherent? A literature review and critical reflection.</gtr:title><gtr:parentPublicationTitle>Pediatric transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cd6d7723af944acd519ac38c7f1b690"><gtr:id>7cd6d7723af944acd519ac38c7f1b690</gtr:id><gtr:otherNames>Dobbels F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1397-3142</gtr:issn><gtr:outcomeId>doi_13110_11_01633_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>560D2428-3D4D-4EE0-AD28-04E77608C4FE</gtr:id><gtr:title>Active surveillance in prostate cancer: a critical review.</gtr:title><gtr:parentPublicationTitle>Minerva urologica e nefrologica = The Italian journal of urology and nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acfc7d6b478c0e13c64c779f1a4fef31"><gtr:id>acfc7d6b478c0e13c64c779f1a4fef31</gtr:id><gtr:otherNames>Zargar H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0393-2249</gtr:issn><gtr:outcomeId>56e046a4a8c851.00362254</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EC56B04-D3FB-45DC-86EC-1F2E12D05DEB</gtr:id><gtr:title>Spontaneous Operational Tolerance in Kidney Transplant Recipients: Response</gtr:title><gtr:parentPublicationTitle>American Journal of Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52b399dde4cd265ae721d15586d24a17"><gtr:id>52b399dde4cd265ae721d15586d24a17</gtr:id><gtr:otherNames>Brouard S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_13110_11_03967_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83ACD5F3-67EB-4925-84AB-CFC92766E7DE</gtr:id><gtr:title>Management of ureteropelvic junction obstruction in adults.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46ec2f2eef7f2b8509b91be2c570cc0f"><gtr:id>46ec2f2eef7f2b8509b91be2c570cc0f</gtr:id><gtr:otherNames>Khan F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>56e046a8f04109.31155722</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F2C9470-6640-490B-ACAD-D23A627C5AA6</gtr:id><gtr:title>Human complement C3 deficiency: Th1 induction requires T cell-derived complement C3a and CD46 activation.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7140ca04699a825eec70db4f7cfc3903"><gtr:id>7140ca04699a825eec70db4f7cfc3903</gtr:id><gtr:otherNames>Ghannam A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>pm_540e193e193167683</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49DF1A1C-4FE6-4D31-96E2-07960F9FFCFA</gtr:id><gtr:title>Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient</gtr:title><gtr:parentPublicationTitle>Transplantation Reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/722c4ac63ded662dc422a0a61495e934"><gtr:id>722c4ac63ded662dc422a0a61495e934</gtr:id><gtr:otherNames>Manook M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a86da24ce26d6.68265651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A32352D7-37C4-4471-85BC-088E87A55E9A</gtr:id><gtr:title>Single breath-hold assessment of cardiac function using an accelerated 3D single breath-hold acquisition technique--comparison of an intravascular and extravascular contrast agent.</gtr:title><gtr:parentPublicationTitle>Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/824236fef70491b28fea7663e705def9"><gtr:id>824236fef70491b28fea7663e705def9</gtr:id><gtr:otherNames>Makowski MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1097-6647</gtr:issn><gtr:outcomeId>doi_13110_429X_14_53</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DDC4EAD-9373-4AAE-B741-0BCCFE079D8B</gtr:id><gtr:title>Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d338561644fdd89f5550f2a924a17e4"><gtr:id>8d338561644fdd89f5550f2a924a17e4</gtr:id><gtr:otherNames>Villanova F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>5457a86deebcb4.25015778</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B396A642-8F26-4339-84B3-14503AC95517</gtr:id><gtr:title>2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36ac4d44249881fceb9b701144782d9a"><gtr:id>36ac4d44249881fceb9b701144782d9a</gtr:id><gtr:otherNames>Demetris AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>58c9c11f3d3ef7.75833271</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36B1DADB-8B11-483F-BDFF-E598D4397B5B</gtr:id><gtr:title>Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d75c0bcc9053e9a07e2905e563de2ba8"><gtr:id>d75c0bcc9053e9a07e2905e563de2ba8</gtr:id><gtr:otherNames>Kim JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>5a609713add656.60808288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62616E4F-3BC9-4F3A-B2DD-469BE9D4ADD5</gtr:id><gtr:title>Robotic Granular Jamming: Does the Membrane Matter?</gtr:title><gtr:parentPublicationTitle>Soft Robotics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0028dc86b8d9b2b4aea1230ffbfc307"><gtr:id>d0028dc86b8d9b2b4aea1230ffbfc307</gtr:id><gtr:otherNames>Jiang A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54579d2edf3933.68042222</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82F767DC-15DC-414D-B22C-26C5539996BB</gtr:id><gtr:title>Handbook of Renal and Pancreatic Transplantation</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f68854484a6adf46e3d9317b8d8b256f"><gtr:id>f68854484a6adf46e3d9317b8d8b256f</gtr:id><gtr:otherNames>Nizam Mamode</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>BUz2cS1uZ1Y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBA24ADC-3019-49BE-B40B-DAB88785CCA2</gtr:id><gtr:title>Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e67dbb13d97b20d487ae2d74a6d1c64"><gtr:id>0e67dbb13d97b20d487ae2d74a6d1c64</gtr:id><gtr:otherNames>Antoniades CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>doi_13110__hep_25657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDF2CBCC-E080-4006-B01E-33217F53C69A</gtr:id><gtr:title>An assessment of the physical impact of complex surgical tasks on surgeon errors and discomfort: a comparison between robot-assisted, laparoscopic and open approaches.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9a927d1f4660e0a7b04c286f43e4ce9"><gtr:id>d9a927d1f4660e0a7b04c286f43e4ce9</gtr:id><gtr:otherNames>Elhage O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56dff8187f0b25.76609817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DC55BFC-FE67-41A8-8B87-482C974218DE</gtr:id><gtr:title>A novel &amp;quot;complement-metabolism-inflammasome axis&amp;quot; as a key regulator of immune cell effector function.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5da642625a311858b22adc626593801"><gtr:id>e5da642625a311858b22adc626593801</gtr:id><gtr:otherNames>Arbore G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>585d3194281870.09767714</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20261215-A53F-44E8-A9FD-0DF7F3D0DA38</gtr:id><gtr:title>The role of Irf6 in tooth epithelial invagination.</gtr:title><gtr:parentPublicationTitle>Developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f75a8979a27efbec48481bb9dfcacda6"><gtr:id>f75a8979a27efbec48481bb9dfcacda6</gtr:id><gtr:otherNames>Blackburn J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0012-1606</gtr:issn><gtr:outcomeId>doi_13110_012_02_009</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C8BCC04-FCAD-44BE-8D3D-7901D09AD71B</gtr:id><gtr:title>End-stage renal disease: Dual transplantation--the immunological role of the liver.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80a387b7c9213a8a1190296046e23764"><gtr:id>80a387b7c9213a8a1190296046e23764</gtr:id><gtr:otherNames>Martinez-Llordella M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1759-5061</gtr:issn><gtr:outcomeId>5452131c0974a9.05647290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B109E385-1201-4A29-BDF6-FACD60EF3739</gtr:id><gtr:title>Impact of an Early Invasive Strategy versus Conservative Strategy for Unstable Angina and Non-ST Elevation Acute Coronary Syndrome in Patients with Chronic Kidney Disease: A Systematic Review.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23283a6894807530b667f2130a9e6c8a"><gtr:id>23283a6894807530b667f2130a9e6c8a</gtr:id><gtr:otherNames>Shaw C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c6b17d63ac13.44060345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>169FF2D7-E4D1-4ABF-ADD8-B8D92DA1ACF1</gtr:id><gtr:title>Optimising the radiolabelling properties of technetium tricarbonyl and His-tagged proteins.</gtr:title><gtr:parentPublicationTitle>EJNMMI research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9e46450847bc63d817ad16c0a2311cb"><gtr:id>a9e46450847bc63d817ad16c0a2311cb</gtr:id><gtr:otherNames>Badar A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5458d75703eea1.79330895</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>027D1C58-AAFD-473A-900C-35F34A02D2F3</gtr:id><gtr:title>OnabotulinumtoxinA in benign prostatic hyperplasia.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>doi_13110_012_10_051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02A83938-59F8-4599-B4F5-A57F15D2289D</gtr:id><gtr:title>Training in minimally invasive surgery in urology: European Association of Urology/International Consultation of Urological Diseases consultation.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/027c7e8523d542f9c67ef6273823add7"><gtr:id>027c7e8523d542f9c67ef6273823add7</gtr:id><gtr:otherNames>van der Poel H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e0450bcc9875.77124603</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A0242F0-FBB9-4C21-86E2-062D8DFBBEAB</gtr:id><gtr:title>Simulation-based ureteroscopy training: a systematic review.</gtr:title><gtr:parentPublicationTitle>Journal of surgical education</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebc4da9c11d432d58cf3f380b3c63dc5"><gtr:id>ebc4da9c11d432d58cf3f380b3c63dc5</gtr:id><gtr:otherNames>Brunckhorst O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1878-7452</gtr:issn><gtr:outcomeId>54579d2bd3c438.52334066</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD13B4A3-EE28-4416-906D-69495FE63E68</gtr:id><gtr:title>Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/748a917f1a0cb93d6729c6a7a21c09cc"><gtr:id>748a917f1a0cb93d6729c6a7a21c09cc</gtr:id><gtr:otherNames>Veenstra RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>doi_13110__10_387977</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1D62C8F-8D34-494F-B61B-78D86D586BF0</gtr:id><gtr:title>Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d175a0a813140781ea4a2b9dbbcc2eb1"><gtr:id>d175a0a813140781ea4a2b9dbbcc2eb1</gtr:id><gtr:otherNames>McPhail MJW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>585d5408843ef7.95665509</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDD79F1F-8F99-41A5-9D6A-966B49A2E435</gtr:id><gtr:title>Integrative biology approach identifies cytokine targeting strategies for psoriasis.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc10ec43a1dbe3971bd763b8649463aa"><gtr:id>bc10ec43a1dbe3971bd763b8649463aa</gtr:id><gtr:otherNames>Perera GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>5457a86d95f097.28746230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4EB1CC0-ECE6-4F61-A3D1-CD064C916CD4</gtr:id><gtr:title>Reduced TCR Signaling Contributes to Impaired Th17 Responses in Tolerant Kidney Transplant Recipients.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a852e087195ad0146102a9de3e4ab8b"><gtr:id>4a852e087195ad0146102a9de3e4ab8b</gtr:id><gtr:otherNames>Nova-Lamperti E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>5a900c1e093ab7.13421564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>636B4820-F8AB-408D-A112-3CC1B7EA0762</gtr:id><gtr:title>Mental training in surgical education: a systematic review.</gtr:title><gtr:parentPublicationTitle>ANZ journal of surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b71f4ea017c1b0a4a688e904b7edee9d"><gtr:id>b71f4ea017c1b0a4a688e904b7edee9d</gtr:id><gtr:otherNames>Davison S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1445-1433</gtr:issn><gtr:outcomeId>5aa7ef85bddcf7.08332891</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>602178CF-29EB-4D76-9C15-BE72E3870912</gtr:id><gtr:title>Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>56d5858bb8c297.79009955</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0527450-ECE2-4776-83AC-7D8482CDF4A1</gtr:id><gtr:title>Retinoic acid stabilizes antigen-specific regulatory T-cell function in autoimmune hepatitis type 2.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/217e862c10aaef1a63bf86e2391c99dd"><gtr:id>217e862c10aaef1a63bf86e2391c99dd</gtr:id><gtr:otherNames>Holder BS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>54578b5391bbd1.86178905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E99A5DF6-3EEE-4D96-95C1-90EA15A3927E</gtr:id><gtr:title>Minimally invasive cystectomy approaches in the treatment of bladder cancer.</gtr:title><gtr:parentPublicationTitle>Expert review of anticancer therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ab883ce8996eea1e80ef7877f13064d"><gtr:id>0ab883ce8996eea1e80ef7877f13064d</gtr:id><gtr:otherNames>Cheung G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1473-7140</gtr:issn><gtr:outcomeId>doi-13110-10_1586_era_12_52</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09AEB653-7DED-4F54-856E-7CE395A279CD</gtr:id><gtr:title>Perceptions among women with gestational diabetes.</gtr:title><gtr:parentPublicationTitle>Qualitative health research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/852c299558b5639a6f82b2ab3b6f9882"><gtr:id>852c299558b5639a6f82b2ab3b6f9882</gtr:id><gtr:otherNames>Parsons J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1049-7323</gtr:issn><gtr:outcomeId>54579ae1b46a82.46774716</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E19AE232-13C3-4A29-9483-1451A39161D7</gtr:id><gtr:title>The Impact of Ischemia/Reperfusion Injury on Liver Allografts from Deceased after Cardiac Death versus Deceased after Brain Death Donors.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aab3549e3f140ccc891069fed2436660"><gtr:id>aab3549e3f140ccc891069fed2436660</gtr:id><gtr:otherNames>Xu J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c6b17f5667b0.45031315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39C86AB6-0CC8-476A-943B-60072BEFCA7C</gtr:id><gtr:title>Creating a &amp;quot;Transcampus&amp;quot; in diabetes research between King's College London and the Technische Universit&amp;auml;t Dresden: update on islet biology and transplantation.</gtr:title><gtr:parentPublicationTitle>Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1fd0e5fe1c216629fcf28b9a267c24d"><gtr:id>c1fd0e5fe1c216629fcf28b9a267c24d</gtr:id><gtr:otherNames>Bornstein SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0018-5043</gtr:issn><gtr:outcomeId>56dffbab2e3f32.04695148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D9D5CD3-FE4C-4022-B571-3A27CC7A002E</gtr:id><gtr:title>Copper-64 radiolabelling of the C2A domain of synaptotagmin I using a functionalised bis(thiosemicarbazone): A pre- and post-labelling comparison.</gtr:title><gtr:parentPublicationTitle>Journal of inorganic biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3afbce3fd354c1d1ee76c650aab8bbc2"><gtr:id>3afbce3fd354c1d1ee76c650aab8bbc2</gtr:id><gtr:otherNames>Hueting R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0162-0134</gtr:issn><gtr:outcomeId>doi_13110_013_07_017</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9C3E2FE-87EC-4480-857B-BAF38F61172D</gtr:id><gtr:title>Caspase-7 in molar tooth development.</gtr:title><gtr:parentPublicationTitle>Archives of oral biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04b26ea2752e4b4fd619dec72881e4ef"><gtr:id>04b26ea2752e4b4fd619dec72881e4ef</gtr:id><gtr:otherNames>Matalova E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-9969</gtr:issn><gtr:outcomeId>doi_13110_012_06_009</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B79F622D-4DC1-4B34-9271-C909C47A2FC4</gtr:id><gtr:title>Pioglitazone and bladder cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70bb76ba344d3534572d13bbeaffe532"><gtr:id>70bb76ba344d3534572d13bbeaffe532</gtr:id><gtr:otherNames>Warren H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e0450b78b308.65390200</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E5720FA-1AFD-4A20-B331-9DC220D7681A</gtr:id><gtr:title>Continuous Acquisition of MHC:Peptide Complexes by Recipient Cells Contributes to the Generation of Anti-Graft CD8T Cell Immunity.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/785928b8c34d6342ea641ff5256e80f7"><gtr:id>785928b8c34d6342ea641ff5256e80f7</gtr:id><gtr:otherNames>Smyth LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>58c6b17c7d6546.85343013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95FF0218-7339-4EED-924D-D39E6B3F7D2A</gtr:id><gtr:title>The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17c7099b1b184f40f2eaedd0a248f5b6"><gtr:id>17c7099b1b184f40f2eaedd0a248f5b6</gtr:id><gtr:otherNames>Muratori L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>54578b543f22f4.84276745</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EAB6B1D-2CB9-4150-8EB2-6DC21F9F993A</gtr:id><gtr:title>Comparison of regulatory T cells in hemodialysis patients and healthy controls: implications for cell therapy in transplantation.</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a24f02668e536a6d0df0cd985e178d88"><gtr:id>a24f02668e536a6d0df0cd985e178d88</gtr:id><gtr:otherNames>Afzali B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>pm_13110_20_23580782</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58E18F06-AC7A-4432-ADA0-B104E7AAE231</gtr:id><gtr:title>Mutations in TJP2, encoding zona occludens 2, and liver disease.</gtr:title><gtr:parentPublicationTitle>Tissue barriers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c57bb7be0b28cb391f240be3457e5af1"><gtr:id>c57bb7be0b28cb391f240be3457e5af1</gtr:id><gtr:otherNames>Sambrotta M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2168-8362</gtr:issn><gtr:outcomeId>56dff64177e324.97247841</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDFCF175-A50F-4A34-B731-F17193744569</gtr:id><gtr:title>Regulation, regulation, regulation: Its function and threat to vital transplant research</gtr:title><gtr:parentPublicationTitle>3rd Ethical, Legal and Psychosocial Aspects of Transplantation Congress</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6475816f6b88e6a78cc57bdeec3e344"><gtr:id>d6475816f6b88e6a78cc57bdeec3e344</gtr:id><gtr:otherNames> Cronin Antonia J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>dRvmGsXd5mj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49C30CAF-A5AF-48C4-B73A-C8F2D6426BC3</gtr:id><gtr:title>Could abnormal neutrophil-platelet interactions and complex formation contribute to oxidative stress and organ failure in cirrhosis?</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5328ca9d9e8520a9384ed15fa64628d8"><gtr:id>5328ca9d9e8520a9384ed15fa64628d8</gtr:id><gtr:otherNames>Sturgeon JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>585d592bb10625.55433219</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6573556-DD0A-442A-980F-53859F04D5F4</gtr:id><gtr:title>Preliminary specificity study of the Bestel-Cl&amp;eacute;ment-Sorine electromechanical model of the heart using parameter calibration from medical images.</gtr:title><gtr:parentPublicationTitle>Journal of the mechanical behavior of biomedical materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f207ced458c8e8ec7ca31d0412a4490b"><gtr:id>f207ced458c8e8ec7ca31d0412a4490b</gtr:id><gtr:otherNames>Marchesseau S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1878-0180</gtr:issn><gtr:outcomeId>doi_13110_012_11_021</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1C187E2-95AA-451F-8C24-02E98E333F65</gtr:id><gtr:title>International Robotic Radical Cystectomy Consortium: A way forward.</gtr:title><gtr:parentPublicationTitle>Indian journal of urology : IJU : journal of the Urological Society of India</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/521b44172c08c1736638673c71532035"><gtr:id>521b44172c08c1736638673c71532035</gtr:id><gtr:otherNames>Raza SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0970-1591</gtr:issn><gtr:outcomeId>54579d2e230095.55120568</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EB4447C-8F83-41B7-B185-DE60842C09B2</gtr:id><gtr:title>Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development.</gtr:title><gtr:parentPublicationTitle>JCI insight</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1ab6bc223ade8f25eba4d3a76df65cf"><gtr:id>d1ab6bc223ade8f25eba4d3a76df65cf</gtr:id><gtr:otherNames>Popat RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2379-3708</gtr:issn><gtr:outcomeId>58c6b178d16ee9.95060435</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBB6C06D-2D67-45A0-BCF7-FC0986C6299C</gtr:id><gtr:title>Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT.</gtr:title><gtr:parentPublicationTitle>European journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a02ccdc78234d7aa21cb2fcd8f7dca0"><gtr:id>3a02ccdc78234d7aa21cb2fcd8f7dca0</gtr:id><gtr:otherNames>Nagler A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0902-4441</gtr:issn><gtr:outcomeId>doi_13110_12_01811_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22DA5FDE-582B-41C0-8CCC-92D3C86F5DFC</gtr:id><gtr:title>A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035f6ac39e1e0dc2b6df50798858cfc1"><gtr:id>035f6ac39e1e0dc2b6df50798858cfc1</gtr:id><gtr:otherNames>Jakubowski JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>doi_13110__bcp_12042</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99B6A961-5CFE-499F-A0F7-6D497FEF8A15</gtr:id><gtr:title>In vivo assessment of aortic aneurysm wall integrity using elastin-specific molecular magnetic resonance imaging.</gtr:title><gtr:parentPublicationTitle>Circulation. Cardiovascular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6bbd7c93d1201d1dec28b2cd610fa53"><gtr:id>f6bbd7c93d1201d1dec28b2cd610fa53</gtr:id><gtr:otherNames>Botnar RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1941-9651</gtr:issn><gtr:outcomeId>5457b0525f5d70.29059239</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>251159EA-0DB3-4D6D-AC33-EC7EEF4E4B6F</gtr:id><gtr:title>Complement and IL-22: partnering up for border patrol.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43405bdee47846dd21c53267cfab3fd4"><gtr:id>43405bdee47846dd21c53267cfab3fd4</gtr:id><gtr:otherNames>Yamamoto H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>5446637b7ee380.04609543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>057E969E-4177-4002-8002-DA25466C2B1C</gtr:id><gtr:title>Regulatory T-cells in autoimmune diseases: challenges, controversies and--yet--unanswered questions.</gtr:title><gtr:parentPublicationTitle>Autoimmunity reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f73f820f0aa9cc7c43d87294ec7d4ef"><gtr:id>2f73f820f0aa9cc7c43d87294ec7d4ef</gtr:id><gtr:otherNames>Grant CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1568-9972</gtr:issn><gtr:outcomeId>56b48822304d98.13537710</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D139793F-537C-4BC6-B3EC-95CD516F56DA</gtr:id><gtr:title>MAP1B Interaction with the FW Domain of the Autophagic Receptor Nbr1 Facilitates Its Association to the Microtubule Network.</gtr:title><gtr:parentPublicationTitle>International journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86fbf6952dbd9694136a64eb9a9a8195"><gtr:id>86fbf6952dbd9694136a64eb9a9a8195</gtr:id><gtr:otherNames>Marchbank K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1687-8876</gtr:issn><gtr:outcomeId>doi_13110_012_208014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E55E66C9-4702-4748-B5E4-04614C564737</gtr:id><gtr:title>Nupr1 deletion protects against glucose intolerance by increasing beta cell mass.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b481aeec2fb8831a14838a4b25e6128a"><gtr:id>b481aeec2fb8831a14838a4b25e6128a</gtr:id><gtr:otherNames>Barbosa-Sampaio HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>54609f53718559.91988404</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>944DC7FE-3020-4321-8FEC-D2112AE9AFF6</gtr:id><gtr:title>Circulating T follicular helper cell and regulatory T cell frequencies are influenced by B cell depletion in patients with granulomatosis with polyangiitis.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/673680106ade3187f249d2a683028495"><gtr:id>673680106ade3187f249d2a683028495</gtr:id><gtr:otherNames>Zhao Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>5457ad4343e9d4.12851548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>718C250F-C6A6-41B3-B761-542CBDD91001</gtr:id><gtr:title>Improved modelling of tool tracking errors by modelling dependent marker errors.</gtr:title><gtr:parentPublicationTitle>IEEE transactions on medical imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c0254f5b7f14f6e240f08790ae6c527"><gtr:id>4c0254f5b7f14f6e240f08790ae6c527</gtr:id><gtr:otherNames>Thompson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0278-0062</gtr:issn><gtr:outcomeId>doi_13110_12_2216890</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16B6CD90-304D-4E93-BF18-BE24F1C0E129</gtr:id><gtr:title>PREVALENCE OF PSYCHOLOGICAL ILLNESS IN LONG-TERM RENAL TRANSPLANT PATIENTS</gtr:title><gtr:parentPublicationTitle>TRANSPLANT INTERNATIONAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23e101a2ec2154da86f579951d74bebd"><gtr:id>23e101a2ec2154da86f579951d74bebd</gtr:id><gtr:otherNames>Frame Sharon</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>SSuND28ZTtR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30C22DD9-AB90-4BA8-AF3D-2CC113421827</gtr:id><gtr:title>Endoscopic add-on stiffness probe for real-time soft surface characterisation in MIS.</gtr:title><gtr:parentPublicationTitle>Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ec23b4e0f9a048c55b83a1c8f265476"><gtr:id>9ec23b4e0f9a048c55b83a1c8f265476</gtr:id><gtr:otherNames>Faragasso A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1557-170X</gtr:issn><gtr:outcomeId>56e046a68b3483.67978810</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36A45FCD-9CBF-4187-9097-2AB5BB4744CC</gtr:id><gtr:title>Should surgical outcomes be published?</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society of Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fd03ae221b5a58b3177b0b97fb520f8"><gtr:id>1fd03ae221b5a58b3177b0b97fb520f8</gtr:id><gtr:otherNames>Chou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0141-0768</gtr:issn><gtr:outcomeId>56e046a59287c7.44708889</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D895726-23A8-4F36-A1CF-650350B2AD23</gtr:id><gtr:title>The origin of the stapes and relationship to the otic capsule and oval window.</gtr:title><gtr:parentPublicationTitle>Developmental dynamics : an official publication of the American Association of Anatomists</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67b6c590707bce0246a39c0aca3ee5d5"><gtr:id>67b6c590707bce0246a39c0aca3ee5d5</gtr:id><gtr:otherNames>Thompson H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1058-8388</gtr:issn><gtr:outcomeId>doi_13110_dvdy_23831</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DC7B6CC-63C6-4B43-806C-7161F8401972</gtr:id><gtr:title>Elevated Ki-67 labeling index in 'synchronous liver metastases' of well differentiated enteropancreatic neuroendocrine tumor.</gtr:title><gtr:parentPublicationTitle>Pathology international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a35f8880f3a4aee14365b9a3bd7e1bc"><gtr:id>4a35f8880f3a4aee14365b9a3bd7e1bc</gtr:id><gtr:otherNames>Zen Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1320-5463</gtr:issn><gtr:outcomeId>5457af091b52a2.80323450</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFFDE1BD-6F38-418F-BECF-806C2E5CA342</gtr:id><gtr:title>Learning curves for urological procedures: a systematic review.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd0938c60157f1301ed3eb8e647339c7"><gtr:id>fd0938c60157f1301ed3eb8e647339c7</gtr:id><gtr:otherNames>Abboudi H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e047e9087097.43390526</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11DF0DA3-966A-4757-8FB8-08E592657960</gtr:id><gtr:title>Pathophysiological mechanisms of hepatic encephalopathy</gtr:title><gtr:parentPublicationTitle>Clinical Liver Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/573b370842799139ab94933d574a51be"><gtr:id>573b370842799139ab94933d574a51be</gtr:id><gtr:otherNames>Tranah T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>20462484</gtr:issn><gtr:outcomeId>56dff8448515b0.65764774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5F429C4-2F0E-4C5F-84A2-3BD07707B693</gtr:id><gtr:title>Dissecting the role of retinoic acid receptor isoforms in the CD8 response to infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2585257962f19c804855e5920219ec8c"><gtr:id>2585257962f19c804855e5920219ec8c</gtr:id><gtr:otherNames>Guo Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5458d960d56a56.47957317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C958C563-4D98-4E56-B26D-15D6CD316FCB</gtr:id><gtr:title>Inverse finite-element modeling for tissue parameter identification using a rolling indentation probe.</gtr:title><gtr:parentPublicationTitle>Medical &amp; biological engineering &amp; computing</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9b8f6134f2dda035c13e759d60eac1e"><gtr:id>b9b8f6134f2dda035c13e759d60eac1e</gtr:id><gtr:otherNames>Liu H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-0118</gtr:issn><gtr:outcomeId>pm_13110_20_24037385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DB4C249-E0C6-4DA0-8EE4-88A2F7922CDD</gtr:id><gtr:title>Paclitaxel-coated balloon fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous fistulae used for haemodialysis (PAVE): study protocol for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7b5b4299120f20d22551ca04c77f726"><gtr:id>d7b5b4299120f20d22551ca04c77f726</gtr:id><gtr:otherNames>Karunanithy N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58c6b17d8e76b2.91267981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CFBA166-EB02-4B3E-BBA4-51F9FBB8A735</gtr:id><gtr:title>Activation of endogenous anti-inflammatory mediator cyclic AMP attenuates acute pyelonephritis in mice induced by uropathogenic Escherichia coli.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74c7527dc2bbf15fadf582ed815befa6"><gtr:id>74c7527dc2bbf15fadf582ed815befa6</gtr:id><gtr:otherNames>Wei Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>5452489acf7e75.36697302</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>464891DC-84D7-4339-8D23-873EC3614059</gtr:id><gtr:title>Cardiovascular magnetic resonance imaging in congenital heart disease as an alternative to diagnostic invasive cardiac catheterization: a single center experience.</gtr:title><gtr:parentPublicationTitle>Congenital heart disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8aa6012d757a6b82f413fd4ed51c6c32"><gtr:id>8aa6012d757a6b82f413fd4ed51c6c32</gtr:id><gtr:otherNames>Heathfield E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1747-079X</gtr:issn><gtr:outcomeId>doi_13110__chd_12032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEB2E2C2-3A7E-40C1-8B19-8DC3F8D50549</gtr:id><gtr:title>FAT1 mutations cause a glomerulotubular nephropathy.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c60c7f318fcd3925ea7e919341038412"><gtr:id>c60c7f318fcd3925ea7e919341038412</gtr:id><gtr:otherNames>Gee HY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56dda49de2bd48.19502791</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB335C44-AB3D-42C0-AC25-A8EE38D6F3F1</gtr:id><gtr:title>Distinct microRNA profiles are associated with the severity of hepatitis C virus recurrence and acute cellular rejection after liver transplantation.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2da0d197ccf3f2b68433be172c4e55d"><gtr:id>a2da0d197ccf3f2b68433be172c4e55d</gtr:id><gtr:otherNames>Joshi D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>doi_13110_2_lt_23613</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AF48536-6F1F-4EC4-9B7B-2C0CCDA36378</gtr:id><gtr:title>Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation.</gtr:title><gtr:parentPublicationTitle>Transplant international : official journal of the European Society for Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4de086c273c0c67e49e3b833cb39f230"><gtr:id>4de086c273c0c67e49e3b833cb39f230</gtr:id><gtr:otherNames>Barnett AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>544a6592e492e5.66294996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF196577-164B-4BE0-9C5E-296412A67DBD</gtr:id><gtr:title>Immunotoxin Against a Donor MHC Class II Molecule Induces Indefinite Survival of Murine Kidney Allografts.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9bfb181c1926dd7c072e90ee249126c"><gtr:id>f9bfb181c1926dd7c072e90ee249126c</gtr:id><gtr:otherNames>Brown K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>56dead19b542e6.65383296</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8D25BBF-A211-4C35-B0A7-6A2CC4B0CFD6</gtr:id><gtr:title>Hepatic Infiltrates in Operational Tolerant Patients After Liver Transplantation Show Enrichment of Regulatory T Cells Before Proinflammatory Genes Are Downregulated.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21280210dd9638377b3a1032c8525500"><gtr:id>21280210dd9638377b3a1032c8525500</gtr:id><gtr:otherNames>Taubert R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>58c6b17ebf12a6.90951832</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30414A7E-2D6A-40CF-9507-542E6D133FF6</gtr:id><gtr:title>Integration of lyoplate based flow cytometry and computational analysis for standardized immunological biomarker discovery.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d338561644fdd89f5550f2a924a17e4"><gtr:id>8d338561644fdd89f5550f2a924a17e4</gtr:id><gtr:otherNames>Villanova F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_13110_ne_0065485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>679D2B5C-85A2-4D26-8182-75B1DC45203A</gtr:id><gtr:title>Intra-operative tumour localisation in robot-assisted minimally invasive surgery: A review.</gtr:title><gtr:parentPublicationTitle>Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00fdefe91ff283a2134de1284108f187"><gtr:id>00fdefe91ff283a2134de1284108f187</gtr:id><gtr:otherNames>Li M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0954-4119</gtr:issn><gtr:outcomeId>56e047e78fe4f8.19526687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71FE97FD-07CC-4F0C-8938-E414E00F498B</gtr:id><gtr:title>Learning curves for cardiothoracic and vascular surgical procedures--a systematic review.</gtr:title><gtr:parentPublicationTitle>Postgraduate medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11c8935d3911d874df05f5fd9344646d"><gtr:id>11c8935d3911d874df05f5fd9344646d</gtr:id><gtr:otherNames>Arora KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0032-5481</gtr:issn><gtr:outcomeId>585d6e1262c254.73397408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EBD9DDB-EF4E-4FC3-95F5-1D138F0B96FA</gtr:id><gtr:title>Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d6a7ee0f691937e2d7656b89816d236"><gtr:id>3d6a7ee0f691937e2d7656b89816d236</gtr:id><gtr:otherNames>Komarowska I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>56defac5823516.87550697</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F7B15F2-97C8-4FBA-95BA-083FF26966E2</gtr:id><gtr:title>The complement factor 5a receptor 1 has a pathogenic role in chronic inflammation and renal fibrosis in a murine model of chronic pyelonephritis.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56b2d90eb469a207980b8ace0bd12b36"><gtr:id>56b2d90eb469a207980b8ace0bd12b36</gtr:id><gtr:otherNames>Choudhry N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>58c6b5212dd582.48207491</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>809A23EE-EA4F-4DFC-B5FE-7646AB1D9587</gtr:id><gtr:title>Superman and the Swiss Continence Foundation.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fe4e6cc0b93eb94ab03f7dbc1deb00c"><gtr:id>2fe4e6cc0b93eb94ab03f7dbc1deb00c</gtr:id><gtr:otherNames>Dasgupta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>56e046a5b87c88.22745901</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA3A9F81-437D-4662-87B3-E410984CDB59</gtr:id><gtr:title>Treating genetic disease: Expanding the options.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/758a8b8c9a612c9cc5458af828f2d018"><gtr:id>758a8b8c9a612c9cc5458af828f2d018</gtr:id><gtr:otherNames>Thompson RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56defe20ca3a16.19062598</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3751CA6E-8923-4BA3-BE7F-AA4D482E36C5</gtr:id><gtr:title>Face and content validation of the prostatic hyperplasia model and holmium laser surgery simulator.</gtr:title><gtr:parentPublicationTitle>Journal of surgical education</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d56aff527715c429c6f28b0fc7d2c3e1"><gtr:id>d56aff527715c429c6f28b0fc7d2c3e1</gtr:id><gtr:otherNames>Aydin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1878-7452</gtr:issn><gtr:outcomeId>54579d2d5f0902.13802414</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F9A1F53-5F2F-45B9-BF71-376FA9B92499</gtr:id><gtr:title>A genome-wide association study of anorexia nervosa.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4296ae1dc4f3be097c32fd50a800cdb6"><gtr:id>4296ae1dc4f3be097c32fd50a800cdb6</gtr:id><gtr:otherNames>Boraska V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>5457ab635f9971.65021146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6579CC9D-EF24-48B2-8F23-E2160D2E6A1E</gtr:id><gtr:title>Predictive immunomonitoring -- the COST ENTIRE initiative.</gtr:title><gtr:parentPublicationTitle>Clinical immunology (Orlando, Fla.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7305ec09ef822c96713a378098332f6f"><gtr:id>7305ec09ef822c96713a378098332f6f</gtr:id><gtr:otherNames>Popadic D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1521-6616</gtr:issn><gtr:outcomeId>doi_13110_013_01_013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE224684-AB02-40BF-9CC8-9769FB76D1E6</gtr:id><gtr:title>A double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c68d807cc18b764a10aa4b0584215bb"><gtr:id>1c68d807cc18b764a10aa4b0584215bb</gtr:id><gtr:otherNames>Kassimatis T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5aa9328ec52a18.43677100</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D073E05-0EF2-4ACB-B665-621B510A9679</gtr:id><gtr:title>MicroRNAs affect dendritic cell function and phenotype.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/785928b8c34d6342ea641ff5256e80f7"><gtr:id>785928b8c34d6342ea641ff5256e80f7</gtr:id><gtr:otherNames>Smyth LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>543b98d82c5507.17259574</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48E622B6-0135-4CE1-BE34-A77FF62F12C2</gtr:id><gtr:title>Relationship between endocardial activation sequences defined by high-density mapping to early septal contraction (septal flash) in patients with left bundle branch block undergoing cardiac resynchronization therapy.</gtr:title><gtr:parentPublicationTitle>Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9a0f6193b11a33fe2a2a92dc20fde96"><gtr:id>b9a0f6193b11a33fe2a2a92dc20fde96</gtr:id><gtr:otherNames>Duckett SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1099-5129</gtr:issn><gtr:outcomeId>doi_13110_ace_eur235</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C7BFE28-1C53-4533-B4F8-9FC17E375317</gtr:id><gtr:title>Deconstructing the Lectin Pathway in the Pathogenesis of Experimental Inflammatory Arthritis: Essential Role of the Lectin Ficolin B and Mannose-Binding Protein-Associated Serine Protease 2.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f68e3e82549e1f53b6d5a733ebbc51e"><gtr:id>3f68e3e82549e1f53b6d5a733ebbc51e</gtr:id><gtr:otherNames>Banda NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5aa931a0d82529.39065150</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01C61CAA-759A-4025-80A3-6C6ED689BF22</gtr:id><gtr:title>Protease-activated receptor-2 signalling by tissue factor on dendritic cells suppresses antigen-specific CD4+ T-cell priming.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55f40bc5b0102e5288d97d23e4c64c60"><gtr:id>55f40bc5b0102e5288d97d23e4c64c60</gtr:id><gtr:otherNames>Shrivastava S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>pm_13110_20_23347132</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>031C3A6C-4FA4-4DF9-8EEF-918BFC743272</gtr:id><gtr:title>Stem cells and their role in renal ischaemia reperfusion injury.</gtr:title><gtr:parentPublicationTitle>American journal of nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30bf2525ccb62f647d6e51cfb911a3a4"><gtr:id>30bf2525ccb62f647d6e51cfb911a3a4</gtr:id><gtr:otherNames>Bagul A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0250-8095</gtr:issn><gtr:outcomeId>doi_13110__000345731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93209B9D-3A51-40F3-925B-EBDB0A2BBC92</gtr:id><gtr:title>Fibrocytes mediate intimal hyperplasia post-vascular injury and are regulated by two tissue factor-dependent mechanisms.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ef91a6d242b3418b3065118aa4f2f60"><gtr:id>2ef91a6d242b3418b3065118aa4f2f60</gtr:id><gtr:otherNames>Chen D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn><gtr:outcomeId>doi_13110__jth_12198</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFF3C52A-65DB-463A-BEB2-60DF3CBE45C3</gtr:id><gtr:title>Thymic versus induced regulatory T cells - who regulates the regulators?</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2e56aa70edca4379a30f43d2072b4f8"><gtr:id>a2e56aa70edca4379a30f43d2072b4f8</gtr:id><gtr:otherNames>Povoleri GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>543b9b92422529.36104653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF9C9B13-D59E-45DF-B2CB-9C16123ADD3D</gtr:id><gtr:title>Corticosteroid withdrawal normalises the proportion of transitional B cells but does not significantly change gene expression in renal transplant recipients</gtr:title><gtr:parentPublicationTitle>3rd ESOT Basic Science Meeting/13th TTS Basic Science Symposium</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a7dbb6ad6c534ce7d878d1fd2d97148"><gtr:id>2a7dbb6ad6c534ce7d878d1fd2d97148</gtr:id><gtr:otherNames>Smallcombe N</gtr:otherNames></gtr:author></gtr:authors><gtr:outcomeId>545255a1c4e166.40407771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>236D31B1-FC7C-4D99-9F51-D88BBC4C4752</gtr:id><gtr:title>The 24-hour normothermic machine perfusion of discarded human liver grafts.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b19ecfdb9e0fe522baa497187c911194"><gtr:id>b19ecfdb9e0fe522baa497187c911194</gtr:id><gtr:otherNames>Vogel T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>58c6b178a63517.46127402</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C52AD607-B8BA-4225-A6D0-D8D07D5CC017</gtr:id><gtr:title>Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/488e50e2f0ee392a5294cc1d22d0c7ec"><gtr:id>488e50e2f0ee392a5294cc1d22d0c7ec</gtr:id><gtr:otherNames>Blaskovich MAT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5aaa713b7518d0.70812472</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B93DB133-E509-4297-B771-D35935CF0530</gtr:id><gtr:title>Clinical neurophysiology of hepatic encephalopathy.</gtr:title><gtr:parentPublicationTitle>Journal of clinical and experimental hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99a2d6196ec47d83ba076d2ac1a43ad0"><gtr:id>99a2d6196ec47d83ba076d2ac1a43ad0</gtr:id><gtr:otherNames>Amodio P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0973-6883</gtr:issn><gtr:outcomeId>56dff81813d402.18481698</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F110050-0798-45AF-BE37-C632FDEFF5D1</gtr:id><gtr:title>Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f73f820f0aa9cc7c43d87294ec7d4ef"><gtr:id>2f73f820f0aa9cc7c43d87294ec7d4ef</gtr:id><gtr:otherNames>Grant CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>54578b5463fd71.96336793</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>732F4946-6708-4392-9BE4-967614FBC345</gtr:id><gtr:title>Modification of human islet preparation: an effective approach to improve graft outcome after islet transplantation?</gtr:title><gtr:parentPublicationTitle>Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46a95ea71b3ac6c05623a2b6266f179e"><gtr:id>46a95ea71b3ac6c05623a2b6266f179e</gtr:id><gtr:otherNames>Zhao M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0018-5043</gtr:issn><gtr:outcomeId>56dffd4a02b707.65832655</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51ECB530-D69E-49F4-BE0B-30CAEB14EFB9</gtr:id><gtr:title>Tolerogenic Donor-Derived Dendritic Cells Risk Sensitization In Vivo owing to Processing and Presentation by Recipient APCs.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/785928b8c34d6342ea641ff5256e80f7"><gtr:id>785928b8c34d6342ea641ff5256e80f7</gtr:id><gtr:otherNames>Smyth LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_13110_20_23536635</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF1198D0-FBBD-4840-B70F-FF0696C5DF5C</gtr:id><gtr:title>Pilot Validation Study of the European Association of Urology Robotic Training Curriculum.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/919ce2497ec5907ea6bc2d6b0a653065"><gtr:id>919ce2497ec5907ea6bc2d6b0a653065</gtr:id><gtr:otherNames>Volpe A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>56e046a839c773.88082037</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88ED4287-83E3-45A1-88E3-F464FAD1B09C</gtr:id><gtr:title>Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development.</gtr:title><gtr:parentPublicationTitle>JCI insight</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1ab6bc223ade8f25eba4d3a76df65cf"><gtr:id>d1ab6bc223ade8f25eba4d3a76df65cf</gtr:id><gtr:otherNames>Popat RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2379-3708</gtr:issn><gtr:outcomeId>5aaa692fe05fe1.13189515</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B5DBB36-5BA3-4763-AE3E-5B7975B48A96</gtr:id><gtr:title>Towards personalized clinical in-silico modeling of atrial anatomy and electrophysiology.</gtr:title><gtr:parentPublicationTitle>Medical &amp; biological engineering &amp; computing</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aeb4b381e8c48b594ed49f966f319e70"><gtr:id>aeb4b381e8c48b594ed49f966f319e70</gtr:id><gtr:otherNames>Krueger MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-0118</gtr:issn><gtr:outcomeId>doi_13110_012_0970_0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25D148E0-AFB3-4496-9CB1-74B4266DA711</gtr:id><gtr:title>The association between depressive symptoms and systemic inflammation in people with type 2 diabetes: findings from the South London Diabetes Study.</gtr:title><gtr:parentPublicationTitle>Diabetes care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2ca033682ad3db836f611eed53cfb2e"><gtr:id>d2ca033682ad3db836f611eed53cfb2e</gtr:id><gtr:otherNames>Laake JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0149-5992</gtr:issn><gtr:outcomeId>54579ae28eb5e0.96038436</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28158C0F-CE95-4546-AA2F-9E3ABB2DDB94</gtr:id><gtr:title>Human immunoglobulin E flexes between acutely bent and extended conformations.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c4aac35325fe4883693f832ad943db3"><gtr:id>1c4aac35325fe4883693f832ad943db3</gtr:id><gtr:otherNames>Drinkwater N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>5458d7b86b6774.47342180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FA6C1B8-7712-4D96-89DB-7D3039EFCDCF</gtr:id><gtr:title>Chronic Rejection of Cardiac Allografts Is Associated With Increased Lymphatic Flow and Cellular Trafficking.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8fa4fb728601f5057a5f5425dd51a34b"><gtr:id>8fa4fb728601f5057a5f5425dd51a34b</gtr:id><gtr:otherNames>Edwards LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>5a855b0366e738.22358514</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3885615C-4CAC-41BF-AF12-4B46909E14DE</gtr:id><gtr:title>Broadening the translational immunology landscape.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34a354990b6bc6570b16443e889610ba"><gtr:id>34a354990b6bc6570b16443e889610ba</gtr:id><gtr:otherNames>Peakman M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>doi_13110_12_04671_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>329E6A25-8450-4DED-9EC4-8A00FCB7DD59</gtr:id><gtr:title>MicroRNAs, Major Players in B Cells Homeostasis and Function.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf0d24387de302088220770562cdbd47"><gtr:id>bf0d24387de302088220770562cdbd47</gtr:id><gtr:otherNames>Danger R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5675da2c6fdf6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDEB2C32-BFD5-4921-B497-B209C437D94F</gtr:id><gtr:title>Overcoming memory T-cell responses for induction of delayed tolerance in nonhuman primates.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a7c20e452768c9417af546f88a49425"><gtr:id>5a7c20e452768c9417af546f88a49425</gtr:id><gtr:otherNames>Yamada Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>doi_13110_11_03795_x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>429186DB-4CF6-4108-9CAC-DA03D58AC516</gtr:id><gtr:title>Prediction models of donor arrest and graft utilization in liver transplantation from maastricht-3 donors after circulatory death.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb11d32fda9040d76078f4075b739686"><gtr:id>cb11d32fda9040d76078f4075b739686</gtr:id><gtr:otherNames>Davila D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>doi_13110_12_04242_x</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J006742/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>